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PREFACE 
My scientific career as a public health researcher started in 1985 as co-
investigator in the two medical technology assessment stndies described 
in this thesis. The concept of this thesis was born during my application 
interview. Upon a question of the director of the institute of Public 
Health during the application interview, whether I intended to write a 
thesis on the stndies to be conducted, I showed him some reluctance to 
do so: better to judge all the evidence afterwards. 
The judgment tnmed out favourably, but the writing took a bit longer. 
Nevertheless I am happy with the course of events. Since the final 
reports on heart and liver transplantation were published I increasingly 
became aware of the common themes in this type of research. 
Paul van der Maas provided me the opportunity to write this thesis as a 
scientific reflection on medical technology assessment, rather than a 
summary of empirical articles, which of course are relevant for their own 
sake. 
The reader should be warned: the text is rather demanding. Chapter 3 is 
the nucleus, proposing a methodological framework of medical techno-
logy assessment. Any reader who aims at reading at least a part of the 
thesis, should not skip this chapter. Chapter 1 is a prelude and chapter 2 
a reflection on medical technology assessment and health policy. The last 
three chapters on survival, quality of life and need for medical services 
are rather technical. They elaborate on three issues which have consti-
tuted the major part of my empirical work. 
VOORWOORD 
Mijn wetenschappelijke loopbaan startle in 1985 als mede-onderzoeker 
in de twee evaluatie-onderzoeken, die in dit proefschrift zijn beschreven. 
Het achterliggende idee van dit proefschrift werd tijdens mijn solli-
citatiegesprek geboren. Op een vraag van de directeur van het instituut, 
of ik voornemens was de uitkomsten van het nit te voeren onderzoek tot 
een proefschrift te bewerken, reageerde ik afhoudend: verkoop de huid 
uiet voor de beer geschoten is. 
Met die beer kwam het wei goed, maar het schrijven van het proefschrift 
nam meer tijd in beslag. Niettemin ben ik blij met deze loop der gebeur-
teuissen. Sinds het verschijnen van de eindrapporten over hart- en lever-
transplantatie ben ik mij in toenemende mate bewust geworden van de 
rode draad in dergelijk onderzoek. 
Paul van der Maas bood me de gelegenheid dit proefschrift in deze vorm 
te schrijven, namelijk als een wetenschappelijke bezinning op medical 
technology assessment, een term die mijns inziens uiet bevredigend kan 
worden vertaald. 
De lezer zij gewaarschuwd: de tekst is weerbarstig, waarbij de Neder-
landse lezer nog gehandicapt wordt door het feit dat de tekst naar uieuw 
academisch gebruik uiet in het Latijn maar in het Engels is gesteld. 
Hoofdstuk 3 vormt de kern; hierin wordt de methodologische structuur 
van medical technology assessment uit de doeken gedaan. Hoofdstuk 1 is 
een prelude en hoofdstuk 2 bespreekt de verhouding van technology 
assessment tot het gezondheidsbeleid. De laatste drie hoofdstukken over 
overleving, kwaliteit van Ieven en de behoefte aan medische technologie 
zijn nogal techuisch van aard. Zij werken de drie onderwerpen uit waar 
ik mij in empirische zin het meeste mee heb beziggehouden. 
1 INTRODUCTION 
1.1 The general and the specific 
Medical care has changed dramatically in recent decades in terms of 
volume, depth and pace of change. This development may be observed 
from many viewpoints and may be analysed by a variety of methods. 
This thesis concerns a recently developed approach of analysing the 
changes in medical care, known as 'medical technology assessment'. 
Essentially its application should yield information to support decision-
makers at any level in the health care system. The results of om experi-
ence in the development and application of medical technology assess-
ment are presented in two parts. 
The first part gives a general theoretical overview of the subject. It 
includes a description of the particular context in which medical techno-
logy assessment (MTA) is used with an account of the methodology with 
emphasis on three topics of medical interest. The last chapter of this 
part discusses some conclusions and general recommendations. 
The second part is added as an appendix. It embodies the empirical part 
of the thesis and demonstrates the results from practical applications of 
the proposed methodology. Most evidence is drawn from the MTA of 
liver transplantation, which started in 1985 and presented its final report 
in 1988. Many examples in the first part of this thesis are also taken 
from this study. 
Although liver transplantation is a medical technology with modest 
impact on health care and on overall population health, and although the 
MT A was primarily commissioned by health insmance parties to support 
insurance coverage decisions, we assume this case to be representative 
for MTA as a general approach to changes in health care. 
This introductory chapter starts with a general description of the pro· 
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blems related to changes in health care (section 1.2) and the important 
contribution of new technologies to these changes (section 13). The 
search for information on new technologies will be explained as a natu-
ral reaction of all parties involved towards a changing environment 
(section 1.4). It also reflects the growing awareness of the economic 
relevance of this information. 
Special attention is paid to the position of health care authorities (sec-
tion 1.5). There has been a noticeable change in their attitude. Decisions 
concerning the introduction and diffusion of new medical technologies 
are no longer domain of professional interest alone (Freidson, 1972). 
Even the routine application of existing technologies has become a field 
of societal interest, particularly if variations in practice suggest the waste 
of precious resources (Wennberg, 1973; McPherson, 1990). 
In addition an increased awareness of the scarcity of resources may well 
be observed (Reiman, 1988). Health care authorities, hospital managers 
and other decion makers are developing strategies for controlling the dif-
fusion of emerging technologies. This control is usually based on sup-
portive information about various aspects of the technology. 
The response of Dutch health care authorities to the introduction of 
liver transplantation is summarized (section 1.6). Medical technology 
assessment was part of their strategical response. 
In section 1.7 we formulate three key questions which we regard to be 
relevant in the judgment of the current and future value of MTA. 
1.2 Changes in medical care 
On the level of medical science per se, an impressive increase of funda-
mental and applied knowledge can be observed. Scientific progress in 
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immunology and molecular (patho )biology is just one example with high 
public appeal 
Medical practice has changed too, not only with the introduction of 
new drugs, devices and equipment but also with concomitant changes in 
the delivery of medical care. The expansion of knowledge is mirrored by 
the fragmentation of the medical profession into highly specialized sub--
disciplines, with consequences for every level of care. The organizational 
complexity of a transplantation programme is just one illustration of 
these consequences. The hospital has gradually changed from an institu-
tion for supportive care towards an institution for diagnosis and, where 
necessary, acute treatment1• As a consumer, both from an economic and 
a philosophical point of view, the patient has entered medical practice. 
The objectivization of the craft, though essential to success in complex 
treatments, has given rise to alienating effects. This alienation has clearly 
provided opportunities for a growing number of alternative healers to 
cultivate the nostalgia for 19th century paternalistic and ineffective medi-
cal practice with a flavour of naturalism. 
Medical society, too, has been affected by new developments. Inevita-
bly the art to care, cure, detect and prevent has been redefmed, revers-
ing this order of interest Specialists are facing shifts in the borders of 
their territories, ambivalent about the choice between further fragmenta-
tion and only partial mastery of their craft'. The introduction of expens-
ive new technologies has given rise to visible concern about the conse-
quences of limited availability of treatments. 
The medical system has also changed, providing - in Western so-
cieties' - the opportunity for an increasing number of consumers to 
profit from increased medical supply. This change can be observed 
regardless of the system of health care insurance, though different 
distributional effects can be observed from particular systems. 
Chapter 1 14 
The relation between society and medicine has been affected by 
changes in both domains. For example societal developments, like indi-
vidualization and women emancipation, have entered medical knowledge 
and professional practice. On the other hand, the ever-increasing poten-
tial of medical science has given rise to high expectations of the power 
of medical professionals to solve problems of many kinds. 
We should be aware that this description has a critical counterpart. 
Medical science has grown exponentially, but the increased domain of 
'the known' seems to result in a greater domain of 'the unknown'. The 
scientific success of molecular medicine is beyond criticism and bas 
strengthened its paradigmatic position. However, questions remain with 
regard to its blessings for the population at large. Major disease cate-
gories like cardiovascular disease, many malignancies and an array of 
infectious diseases continue to scourge society (Van der Maas, 1989). 
The increased Taylorism within medical practice obviously produces 
efficient care at an optimal level, but its disorienting effects cannot be 
ignored. One of the attractive aspects of alternative healers is their inde-
pendence from fragmented diagnostic and therapeutic modalities and 
their simple definition of pathophysiology of disease, blaming the patient 
if disease occurs or progresses. The eye of God may be preferred to 
blind biological chance. 
Professional developments should also be regarded from a critical 
point of view. Medical training continues to be a rather closed shop. 
Socialization still dominates practical training (see e.g. Fahrenfort, 1985 
[especially p.179-]) and implicit variables are decisive for the acquisition 
of a specialist training position. Even more disturbing is the persistence 
of a modern form of slavery, forcing many in search of a specialist train-
ing position to work under sometimes extremely unfavourable conditions. 
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Some footnotes may be added to the blessings of the medical system. 
The claim of social justice through universal acces to medical care can 
not be upheld. Obviously granting equal rights does not imply automatic-
ally a fair distn1mtion of medical care (Wagstaff, 1989). 
Finally, from a critical point of view, the intrusion of medicine into 
everyday life as a societal hazard should be mentioned. This intrusion is 
only partially covered by the connotations of the word 'medicalization'. 
Maybe Foucault's philosophical vehemence has best described the 
invading potential of medical power (Foucault, 1976 [p.76-J, 1980). 
1.3 Technologically induced changes 
Emerging and changing technologies play a dominant role in many 
changes (Reiser, 1978; Showstack, 1982; Hoffenberg, 1988t Before 1900 
doctors were long on charity and short on science (Jennett, 1986 [p.22]; 
McKeown, 1973), but this pictnre has changed. Below we can only give 
an impression of the role of technologies, applying the same classifica-
tion as in the previous section. 
Medical science clearly benefits from technological advances in basic 
sciences as well as in applied and industrial sciences. Manufactnrers of 
drugs and medical equipment clearly add to the opportunity to dissemi-
nate innovations by their ability to upscale production of succesful 
technologies quickly (e.g. the rapid appearance and spread of several 
cyclosporin determination kits). 
Medical practice has changed the last decades with the introduction 
of many succesful drugs, e.g. analgesics, betablockers, anesthetics, anti-
psychotics, diuretics, steroids and other hormonlike drugs, with H2-
blockers and cyclosporin as two recent and succesful examples. 
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Many devices have changed the hospital environment, e.g. the SMAC, 
monitor equipment, a multitude of diagnostic imaging devices and 
supportive systems which may temporarily replace vital organ functions. 
Many of these devices (e.g. the vena-venous bypass; Slooff, 1989) are 
also involved in liver transplantation. 
Fmally the organization of medical care has been affected by the 
management and the information sciences (Greer, 1977; Jennett, 1986 
[p.19-, 71-]). Traditional organizational settings have been replaced, and 
new organizational solutions are offered to otherwise unresolvable pro-
blems, such as in population screening, but also in organ transplantation. 
Some specific problems within the professional societies caused by 
new technologies should be mentioned. New diagnostic techniques raise 
questions about the specialism most suitable to perform the test (see e.g. 
ultra-sound imaging techniques). Within the medical society questions 
arise when exogeneous factors limit the number of providers of a specific 
treatment modality, as was the case in liver transplantation. 
Related problems formerly sophisticated technologies like ECG, immu-
nological tests, pregnancy tests, infusion devices become available to 
primary care physicians and in some cases laymen. The care of insuline-
dependent diabetics, for example, has been radically changed with the 
availability of recombinant insuline in 'leg'-friendly administration pens 
and the use of autotest devices for self-regulation. 
Technological change, including this development of user-friendly devi-
ces, continues to blur traditional inter- and intraprofessional borders and 
creates new areas of professional interest. Technological advance is also 
partially responsible for a shift in care-delivery towards less structured 
environments. Home care probably will probably show an exponential 
growth, as many supportive systems (drugs, information, transport) have 
become easy to operate and reduced to manageable dimensions. 
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The health care system must find an answer to emerging technologies 
that do not fit easily in its framework. Given national variations in medi-
cal systems, national health authorities and health insurance companies 
do not always face the same problems (McPherson, 1990). However, a 
general pattern in the 'getting noticed' process may be observed. 
Table 1.1 Factors influencing the explicit reaction of the health care 
system to an emerging medical technology 
1. the degree to which national regulations, reimbursement schemes 
and professional conventions determine medical practice with regard 
to the technology concerned (where, for whom, by whom); 
2. the degree of diffusion of the technology; 
3. the degree to which the technology requires new, expensive equip-
ment, or existing equipment to be transferred from routine work; the 
same for human resources; 
4. the degree to which the technology requires a new organizational 
structure or substantial changes of existing ones; 
5. the degree to which the technology is thought to have high societal 
impact (e.g. technologies applied at the beginning and the end of 
life). 
6. the degree to which registration of a new technology is necessary for 
introduction on the health care market. 
An emerging technology will force the current medical system to 
formulate an answer if on one or more of the following reaction-provok-
ing circumstances is relevant (see Table 1.1). Resource scarcity (underly-
ing 1., 3. and 4. of Table 1.1) is not the single important factor. In most 
Western countries registration obligations and ethical considerations (5. 
Chapter I 18 
and 6. of Table 1.1) are important as well5• Most, if not all of these 
factors also pertain to tbe liver transplantation case in tbe Netherlands. 
Fmally tbe society-medicine relation is influenced by tbe diffusion of 
existing and the development of new technologies'. 
Technological advances have redefined social relations. For example tbe 
relation between reproduction and sexual activity has been dissolved, 
exerting influence on partnership at tbe legal, social and individual level. 
Biological and social parentship are no longer tautological. Supportive 
systems for the period of conception and premature birtb are increasing-
ly reducing tbe period of obligatory fetal residence in utero. 
The growing potential of genetic information on the proneness to disease 
will not only affect decisions about reproduction but more generally 
affect decisions about employment, insurance and mortgage arrange-
ments. At the other end of the life span, supportive systems (technical 
and organizational) provoke questions about a suitable living environ-
ment for the elderly. Advanced age is no longer an absolute contra-
indication for complex surgical procedures (e.g. coronary artery bypass 
grafting, liver transplantation) or life sustaining systems (e.g. hemo-
dialysis). Generally technological advances have raised questions about 
tbeir use in terminal patients. 
1.4 Information on changes in medical care 
As technological advances usually induce changes on many levels of the 
healtb care system, they are accompanied by an array of reactions. 
The intensity of this response is primarily determined by the recognition 
of change7 and tbe perception of interests, violated or supported by the 
application of the technology concerned'. 
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In Table 1.1 we already listed some factors contributing to recognition of 
change. The interests involved may range from the financial to the 
ethical, though the former seems the more stimulating. We think that 
simple positive technological changes, which serve the interests of all, are 
uncommon. A mix of positive and negative effects is more likely. Hence 
the reactions will depend on the specific position of the actor in the 
health care system. 
Irrespective of the position involved, infonnation on the new medical 
technology plays a pivotal role in the reactions of interested parties, and 
consequently in the process of technology diffusion (Greer, 1977; 
Casparie, 1989 [p.17-]). As a rule, this information is used as an instru-
ment for decision-making, either directly or indirectly, depending on the 
party involved (IOM, 1985 [p.26, 32-69]). A sample from parties with 
interests in liver transplantation may substantiate this view. 
The liver transplantation team needs information to support patient 
management, to acquire the cooperation of in-hospital workers and of 
the hospital management, and to provide out-hospital colleagues with 
information on process and outcome. The hospital management needs 
information on the resources devoted directly or indirectly to the liver 
transplantation programme, and on the organizational impact and the 
friction problems accompanying its introduction'. The patients need 
information to support their treatment decision and to guide their choice 
for the best environment to receive this treatment. They should e.g. 
know whether the technology involved has been stodied in patients 
similar to themselves. The health insurance company is interested in the 
potential benefits, costs and savings, but also in information on structure 
and process of the programme. Costs and benefits may support the 
decision whether insurance coverage should be extended to liver trans-
plantation; process and structore information provides cues to an effi-
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cient deployment of available resources. This description of the informa-
tional need with a short reference to its purpose can easily be extended 
to other parties (see Table 12). 
Table 1.2 Organizations with informational need on emerging 
medical technologies. 
Government 
Department of Health 
Health Insurance Companies 
Scientific Advisory Boards 
(Other) Health Care Regolating 
Authorities 
Health Care Consumers 
Consumer Organizations 
Patient Organizations 
News media 
Health Care Providers 
Professional Organizations 
Drug Manufacturers 
Equipment Manufacturers 
Hospital Admiuistrators 
Market Research Companies 
Investment Companies 
Medical Schools 
Medical Journals 
Public Health Scientists 
This need may be satisfied in several ways, ranging from a series of 
phone calls to medical opinion leaders or an excerpt of published lite-
rature to a comprehensive empirical study as is described in this thesis. 
We shall focus on the response of health care authorities towards new 
technologies, and on the role of information within this response. 
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1.5 The structuring of the public debate on impendi~~g medical tech-
nologies 
Technologically induced health care changes have given rise to growing 
concern about societal side effects10, some of them mentioned in section 
12. The uncontrolled character11 of these changes have changed the 
attitude of scientists, health care providers, consumers and health policy 
makers (Jonsson, 1990). The unfruitful moral debate about the a priori 
'good' or 'bad' character of technology has gradually been replaced by a 
structured, scientifically and politically more mature discussion between 
the various parties involved 1~13J4 • For an account of this change of battle 
see Cochrane and Jennett (Cochrane, 1973; Jennett, 1986 [p.169-174]). 
Consensus has grown on the desirability to subject some of the new 
technologies to structured, explicit and public decision making15, for 
example by imposing a specific registration requirement. Health care 
authorities have accepted their role in structuring this public debate. 
Although different interests may underlie the willingness to cooperate in 
this process (IOM, 1985 [p.26-30]), this convergence of attitudes can be 
discerned in most Western countries, including the Netherlands ( Ge-
leijns, 1990; Rigter, 1989 [p.39-43]). The process in the different coun-
tries has some national pecularities owing to the structure and the mores 
of the health-care and the political system16• However, a general pattern 
may be observed, and will be described in chapter 2. 
An important feature of this process is the explicit role assigned to 
information, mainly quantitative information, on a number of issues. As 
scientific literature can only partially satisfy this information need, addi-
tional information must be collected. Specific methods for information 
generation usually have to be applied. This systematic information gener-
ation to support societal decisions on medical technologies has conveni-
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ently been called medical technology assessment (see Banta, 1990 for a 
historical review). 
This thesis is dedicated to one modality of MTA, which will be called 
empirical medical technology assessment. 
Next we give a summary. of the response of Dutch health· care 
authorities to the ·introduction of liver transplantation. Empirical medical 
technology ass·essment was a· critical part of this response. As this case of 
MTA will serve as an example throughout the thesis a brief description 
seems justified at this place. 
1.6 The empirlcal.MTA of liver transplantation in the Netherlands 
In the Netherlands empirical MTA as a support to decision-making was 
introduced ·in 1985 by the National Health Insurance Board (NHIB). 
This initiative resulted from the growing concern about the uncontrolled 
extensions of the coverage of the national health insurance scheme17• 
Three technologies were chosen. as. to be subjected to MTA: liver 
transplantation, heart ·transplantation and in-vitro-fertilization. · This 
NHIB initiative was supported by other Dutch health care authorities 
and private health insurance companies. Two research groups were put 
in charge of the required empirical MTA's (Erasmus University Rotter-
dam: heart transplantations, liver transplantation; State University of 
Limburg: in-vitro-fertilization). As the author of this thesis was particu-
larly involved in the liver transplantation MT A, we shall proceed with an 
outline ofover this study. 
In the Netherlands orthotopic liver transplantations have been per-
formed since 1979 at the Academisch Ziekenhuis Groningen (AZG)18• 
The transplantation programme at the AZG started as an experimental 
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clinical programme, funded by general research grants. Despite recom-
mendations of the Consensus Development Conference of the National 
Institutes of Health in 1983 and the favourable development of the 
programme, Dutch health care authorities were reluctant to incorporate 
liver transplantation in regular reimbursement schemes. 
As a result the AZG received supporting grants from the Dutch health 
insurance companies to continue their programme on a larger scale from 
1985 onwards, one of the conditions being that they should participate in 
a medical technology assessment (MT A) by an independent research 
team. This MTA was to yield objective information about costs, effects, 
organizational aspects, donor supply and other topics, which health care 
authorities regarded necessary for a well-founded decision. The final 
report appeared in September 1988, describing the experience of 221 
screened and 73 consecutively transplanted patients (Habbema, 1988). 
The results were used in the subsequent decision process (AI, AlO). 
Baied on the information of the final report it was decided that the 
restrictive regime, limiting liver transplantation to one national centre, 
should be continued while additional research should be done on infor-
mation about long-term results of liver transplantation (NHIB, 1988). 
1.7 The aim and the objectives ofthe thesis 
From the experiences of the Dutch empirical MTA's of heart and liver 
transplantation, it was concluded that empirical MTA may be very 
rewarding as an information generation tool (AIO; Van Rossum, 1990; 
NHIB, 1990). In further elaboration of this conclusion the aim of this 
thesis is to provide answers on the following questions about empirical 
MTA in general (see next page): 
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1. What is the scientific basis of an empirical MTA? 
More specifically, what are the features of survival analysis, analysis 
of health status (or quality of life) and assessment of need? 
2. Which conditions determine the fruitful application of empirical 
MTA results? 
3. How can MTA be developed further? 
The first question is dealt with in chapters 3 to 6. In chapter 3 a 
standard format of empirical MTA is proposed. In chapters 4 to 6 we 
elaborate on methodology for survival analysis, quality of life analysis 
and analysis of need, three of the core issues of an empirical MT A. 
Answers to the second and the third questions are to be found in 
chapter 2, 3 and the appendix. In chapter 7 the answers to the three 
questions are summarized. 
illustrations of the proposed methodology can be found in the appendix. 
Appendix 1 presents the overall approach of the Duth MT A of liver 
transplantation, focussing on the relation between the results and their 
subsequent use. In appendix 2 the results of the application of cost-
effectiveness analysis to the same data is shown. The following appen-
dices are devoted to specific methodological issues of MTA. Appendix 3 
shows the results of a new mathematical technique for estimating survi-
val if transplantation is not applied. Appendices 4 to 8 ali deal with 
different aspects of quality-of-life analysis in MTA. Appendix 4 describes 
the general approach. Quality of life description in liver transplantation 
is demonstrated in appendix 5. Three related investigations on normative 
quality-of-life valuation are shown in appendices 6 to 8. Appendix 9 
shows the results of three techniques for estimating the need for liver 
transplantation. Finally appendix 10 evaluates the burdens and benefits 
of the three Dutch MTA's which started as a test-case in 1985. 
2 THE POLmCAL CONTEXT OF MTA 
2.1 Introduction 
This chapter presents a prototypical description of the political context 
of MTA. This description at least partially fits CWTent health policies 
which aim at information-supported societal decision-making on medical 
technologies (Jonsson, 1990; IOM, 1985)1• The policy process may be 
regarded as a decision cycle, with altematiog phases of definition, mea-
surement, valuation and control (see Table 2.1)2• The roles of health 
care authorities, MTA-investigators, and clinical experts vary accordingly. 
Table 2.1 
Phasel 
Phase 2 
Phase3 
Phase4 
Phase 5 
Phase 6 
The decision cycle on new medical technologies. 
Recognition and selection of technology 
Definition of the decision problem 
Definition of the information need and selection of the 
information generating modality 
Information generation and presentation 
Valuation, decision-making and implementation 
Monitoring and repeated assessment 
This chapter elaborates on these phases and will be ordered accordingly. 
In the notes the equivalents of the proposed phases in the CWTent Dutch 
health care system will be presented. 
2.2 Phase 1 - Recognition and selection of technology 
The initial stage of the decision cycle addresses the following questions: 
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a. how do new and existing technologies which deserve reconsideration 
get noticed (recognition)? 
b. how may technologies which lend themselves for MTA be selected 
(selection)? 
c. who is put in charge of the recognition and selection (execution)? 
Recognition depends on many factors (see Table 1.1). From this table 
follows that passive recognition can be supplemented by an active search 
for technologies to be subjected to MT A 
The process of recognition will also depend on a technology's stage of 
development. New technologies which deserve attention may be detected 
by screening medical literature, by visiting medical congresses and by 
regular consultation of experts. Some have argued in favour of 'early 
warning systems' to obtain timely knowledge of technologies which are 
on their way in (Banta, 1987). The arguments rest on the assumption 
that so far shortage of time bas prevented conscious decisions being 
made and concommittant actions undertaken on further application of a 
technology. We do not think that this assUmption is justified. Besides, 
these systems are likely to take up considerable resources ... 
Existing technologies which deserve reconsideration may be found in a 
similar way. Analysis of geographical variations in medical services is an 
additional possibility (McPherson, 1990; Phelps, 1990; in the Netherlands 
Mackenbach, 1990 and Anonymous, 1990) 
'Getting noticed' does not imply that a technology is automatically a can-
didate for MT A. Additional selection is necessary based on a priori as-
sessment of the relevance of societal decision making and on judgment 
of the additional value of high quality information'. Criteria to judge 
relevance may be developed6• In the Nether lands it would seem appro-
priate to base these criteria on the five boundaries of health care as 
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defined by Dutch health care authorities'. Notwithstanding national 
pecularities, there appears to be an intemationa} consensus on which 
medical technologies should be subjected to MTA'. 
The last issue is the assignment of roles in the recognition and selection 
process. The diversity of interests involved and the- relatively unstructur-
ed appearance of new medical technologies (see chapter 1 ), in our view 
precludes a prescriptive answer to the question of how recognition 
should take place. For maximum sensitivity and involvement, access to 
the recognition process should not be restricted to those parties directly 
involved in the later formal decision process9"10• Selection already 
includes the weighing of societal interests and its realization should be 
treated accordingly". 
Phase 1 concludes with the overall judgement of whether continua-
tion of the cycle is justified12• -
2.3 Phase 2 - Definition orthe decision problem 
In Phase 2 the decision problem is framed". Usually the perception of 
the decision problem is- rather straightforward: should society give a new 
technology legal, fmanciai and organizational support? We think this 
perception is a-simplification whiCh is usually not appropriate. 
A careful definition of the decision problem is thus required, consisting 
at least of the following three parts. 
Frrst, the definition of the subject of the decision". The technology 
should be described and the scope of decision explicitly stated. The 
technology description includes a description of its physical nature, 
purpose and organizational context (see Table 2.2 on next page). 
Chapter 2 
Table 22 Descriptive attnl>utes of a teclmology 
Physical nature 
Drugs and chemical 
substances for other use 
Devices 
Communicative procedures 
Information systems 
Organizational setting 
Home 
General practice 
Outward clinic 
Primary objective 
Prevention 
Diagnosis 
Treatment 
Medical procedures 
Surgical procedures 
Medical support systems 
Organizational systems 
Other 
Hospital 
Specific units 
Other 
Rehabilitation 
Other 
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The scope of the decision concerns questions such as 'To what degree 
should the decision be extended to existing alternatives?', 'Should the 
decision give a simple, unconditional 'yes or no' answer according to the 
above-mentioned perception, or should conditions be included (for 
whom, by whom")?'. The last question will generally be relevant. 
The scope of the decision will differ with the health care party involved. 
A pa.-ticular hospital manager will be interested in whether he should 
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start supportive or restrictive actions within the hospital environment. A 
health insurance company will consider its portfolio of insurance ar-
rangements and reimbursement conditions. The scope of national health 
care authorities is broad, as it not only deals with public health consi-
derations, but also with the interests of other parties involved. 
As a second part, the issues thought to be relevant should be de-
fined. To this description issue-specific criteria to be used in Phase 5 may 
be added". A priori (tentative) definition of criteria should be aimed at. 
The translation of issues, which are usually theoretical concepts like 
'effectivity', 'safety', 'real need', to the language of empirical observations 
is not that simple, as will be shown in the following chapters. 
As with. the scope of the decision-problem, the perspective of the 
decision-maker will influence the issues to be taken into account. 
Fmally, the context of time and place should be described; is the scope 
local, national or even international, what is the timetable of decisions 
and, eventually, implementation and re-evaluation. 
The decriptions in Phase 2 will be used as a base for information 
generation decisions in the subsequent phases. 
2.4 Phase 3 - Definition of the information need and selection of the 
information generation modality 
In Phase 3 the information need must be defined and the preferable me-
thod of information generation determined. 
The information need is theoretically defmed by the aspects and the 
associated criteria distinguished in Phase 2. Intang."bles form a specific 
category of issues, particularly if they are considered to play a major 
role17• The information need may not easily be defined in this case. 
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In some cases definition will be straightforward and information 
sources will be readily available, resulting in a quick generation of infor-
mation. However, in a typical siruation, definitions in Phase 2 and 3 are 
rather vague and information will be patchy. 
Existing sources of information will first be screened for the required 
information. With new technologies, available literature will usually only 
partially satisfy the information need. The institution of a specific 
information generating process like MTA may then be considered. 
Three prototypes of MTA can be distinguished, meta-analysis of lite-
rature, Delphi-techniques and empirical analysis of raw data respectively. 
In the latter case data has to be extracted from a clinical pilot program-
me. Crude data on existing clinical programmes, even if they exist, will 
not be easily made available18• The essential features of these methods 
will be summarized in section 25. 
Available literature shonld be scrutinized first as any additional data-
collection implies considerable investments (Olsen, 1982; AlO). Repre-
sentativeness, comprehensiveness and comparability determine the suit-
ability of existing literature (NHJ:B, 1986 [p56], Bonsel, 1988A). 
With regard to representativeness the disparities between the Nether-
lands and the U n.ited States, the major source of new technologies and 
corresponding literature, will frequently limit the suitability of existing 
information. Clinical practice frequently differs. The role of surgery vs. 
internal medicine (hepatology, cardiology, nephrology) in solid trans-
plantation is but one example. More generally the medical system differs 
for example with regard to referral practice and health insurance arran-
gements. In this context the different economies of health care are quite 
important. See e.g. the remarkable variation in medical purchase power 
parities (Iglehart, 1988). These variations are also likely in solid organ 
transplantation (Kriiger, 1989; Health Council, 1989 [p.124]). 
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· Comprehensiveness pertains to the presence of information on all 
core issues. With new teclmologies attention is usually confined to safety 
and efficacy. Information on other topics is available only infrequently. 
Hence additional research usnally is necessary if a complete MTA as 
defined in chapter 3 is aimed for. 
Comparibility pertains to the use of standardized methods to collect 
and present information. Three examples are given of implicit differ-
ences in definition of methods, defmition of patients and choice of mea-
surement instruments, whlch affected comparibility. 
In liver transplantation the calculated survival of transplant patients 
sometimes apparently excluded 24-hour peri-operative mortality. As peri-
operative mortality may account for about 30% of total (5-year) morta-
lity, comparison of various centres was not feasible. 
In liver transplantation the use of published survival information was 
also limited due to different patient selection criteria. At the start of the 
Dutch MT A in 1985, the literature on survival effects of liver transplan-
tation was limited to reports of survival following liver transplantation. 
Quantitative information on the severity of liver disease at the time of 
transplantation was lacking but it was generally accepted that the centres 
were heterogeneous with regard to pre-transplantation status. Hence the 
net effect of transplantation could not be extracted from the literature 
and different centres could not validly be compared (Bouse!, 1988F). 
The last example is drawn from the heart transplantation study. The use 
of a wide array of unique quality-of-life instruments in previous studies 
disabled the comparison of results on thls issue (Bouse!, 1988A,C). The 
issue of standardization will be further elaborated on in chapter 3. 
If the information need is not fully satisfied by existing literature, an 
empirical MTA should be considered. Justification should take marginal 
information, investigational costs and time constraints into account. The 
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concepts of effectivity space and cost space may be helpful (Drummoncl, 
1987 [p33,34]; AJoy•_ Obviously an empirical does not exclude the use of 
literature and experts to provide ao. reference values and valuations. 
Phase 3 is the starting point of the interplay between health policy 
makers, health care providers and scientists who might be put in charge 
of information generation. If a separate investigative effort is aimed for 
(one of the three MTA-modalities), this phase contains the design of 
that study and of the associated clinical protocol"-". 
2.5 Phase 4 - Information generation (MTA strictu sensu) 
The three modalities of information generation will be summarized next. 
Meta-analysis is the formal synthesis of available information or data 
on a particular topic by means of standard statistical procedures (Van 
Houwelingen, 1989 [p.184-192], IOM, 1985 [p.l25-128]). It has its origin 
in the social sciences (Glass, 1981), but its value in counting the evidence 
of numerous 'small-difference'-trials in medicine is currently acknow-
ledged. Its primary use is in outcome-analysis, enhancing the discrimina-
tive power of a number of comparable trials, while providing information 
on the generalizability of their conclusions. 
The Delphi-method is based on a formal interactive survey process 
(IOM, 1985 [p.130-131], Casparie, 1989 [p.l80, 181]). The method gene-
rates information from the responses of mutually anonymous experts, 
applying controlled feedback procedures. The procedure starts with ob-
taining individual opinions by some formal method (questionnaire, 
structured interview). Next, data-enhancing techniques are applied (semi-
quantification and aggregation). Each expert is confronted with his 
previous response and with the distn"bution and/ or aggregation of the 
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group response. In a cyclic process, convergence or divergence is aimed 
for, maximizing the yield of the exact and intuitive knowledge of all 
experts. The method is used to obtain predictions of events, trends and 
of (quantitative) estimates when empirical data are scarce. The Delphi-
method may be a particularly suitable device if technologies are still too 
immatnre to justify widespread use in humans. 
Empirical MTA is the formal analysis of the effects, costs, and futnre 
impact of a technology based on data abstraction form current cliuical 
research programmes. A standardized methodology is used (chapter 3). 
Meta-analysis and Delphi-studies will not be discussed further. For 
an example of multiple meta-analyses, see Keirse (1988). For examples 
of Delphi-studies, see Van Beeck (1989) and Milholland (1973). 
Policy makers play only a modest role in this phase. In the case of an 
empirical medical technology assessment this role is primarily the 
optimization of conditions to carry out the proposed investigation". 
2.6 Phase 5 -Valuation, decision-making and implementation 
Phase 5 consists of weighing various aspects, the decision and its sub-
sequent implementation23• The political undesirability"' of MTA results 
(e.g. due to expected difficulty with the implementation of decisions) 
should not influence decisions to be taken too much. 
Decision-making in the Netherlands regarding liver transplantation 
has been descnbed (Van Rossum, 1990; AI, AIO). De Charro (1986) 
provided an account of Dutch health policies on transplantations in 
general. From these papers it follows that MTA results usually are 
relevant for all parties involved, supporting various decision processes. 
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2.7 Phase 6 - Monitoring and repeated evaluation 
In tl:ris phase the technology is monitored; tl:ris should take place" in the 
case of one of at least three situations. 
A decision to halt the diffusion of a technology justifies monitoring of 
further scientific advances. The information may be retrieved from the 
literature and from carefully selected experts at regular intervals. 
A conditional positive decision may need reconsideration after some 
time. In tl:ris case monitoring the application of the new technology may 
provide the required information. Reconsideration might result in the 
relaxation of the constraints (by whom, for whom), but also in modifi-
cation of the budget in view of scale and learning effects. 
Even the monitoring of a medical technology with an unconditional 
positive decision on its application may be justified if uncritical extension 
of its application may be expected (Anderson, 1988)26• 
2.8 Summary 
In tl:ris chapter a particular response to technologically induced changes 
was described. A cyclic structure was presented with alternating phases 
of definition, measurement, valuation and control. Although the point of 
departure was the position of health care authorities, this description, 
with some adaptations, might also fit the decision-processes of other 
actors. We are aware that other responses are conceivable. 
In the following chapters the methodology of empirical MTA's will be 
discussed from the viewpoint of societal decision-making. Hence we 
focus on one specific modality of Phase 4 of the proposed decision-cycle. 
3 EMPIRICAL MTA: ISSUES AND CONCEIPTS 
3.1 Introduction 
In this chapter we shall present an outline of the methodology of empiri-
cal MTA (empirical MTA is further usually indicated by MTA sec). 
Section 32 presents a standard format of MT A. 
The same section discusses briefly other aspects of methodological stan-
dardization, particularly the use of randomized controlled clinical trials 
(RCCT's) and the application of quantitative models. The role of the 
perspective of the MT A - so far we have adopted the perspective of 
society at large - is also indicated. 
Five issues are considered essential in MTA: the functioning of the 
health care programme in which the technology is embedded, the effects 
on patient outcome, the costs of the use of the technology or its alterna-
tives, the need for the technology, and current and future uncertainties. 
Sections 33 to 3.7 introduce these issues, with an emphasis on concept-
ual considerations. Each section ends with an indication of how particu· 
lar types of technology affect the empirical task. 
Two of these issues (the effects on patient outcome - survival and quality 
of life - and the need for the technology) are described in more detail in 
chapters 4 to 6. 
The last section of chapter 3 is devoted to two technical features of 
MT A and two additional topics which may be included in an MTA i.e. 
distributional analysis and legal/ethical analysis. Social issues (see e.g. 
IOM, 1985 [p.154-158]) are included in the issues mentioned above (see 
note)'. 
Chapter 3 36 
3.2 Core issues in MTA; other aspects of standardization 
The standard format of an MTA 
From a societal perspective, the following set of issues seem relevant 
(see Table 3.1, derived from IOM, 1985 [p34, 153], Habbema, 1989). 
Table 3.1 Standard format of an MT A from a societal perspective 
Core issues 
Action of the technology 
Effects on patient outcome 
Effects on the use of resources 
Need for the technology 
Current and future uncertainties 
Optional issues 
Distributional effects 
Legal and ethical aspects 
Published MTA's suggest that there is indeed international consensus 
about the issues which are critical to societal decisions on a medical 
technology (see e.g. White, 1982 [p.l58]). Distributional analysis and 
legal and ethical considerations are regarded as optional issues. There-
fore most attention will be given to the five core issues. 
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The need for a standard approach to the issues 
Available methods may provide us with an empirical approach to most 
of the issues in Table 3.1. However, standardization of these approaches 
is needed for four reasons: 
a. to enable comparisons of the same technology applied in different 
circumstances (patients, settings, countries); 
b. to enable comparisons of different technologies for different pur-
poses; 
c. to enable full economic analysis as part of an MTA; 
d. to enable integral forecasts of the health-care programme. 
CompaTibility requires universal concepts, and reproducible and gene-
rally applicable instruments to measure them, with a protocol for their 
standard application. Then the results of an MTA can be compared with 
the results of MTA's of the same or quite different technologies. 
The presence of a standardly derived global set of reference values of 
health care sectors (Koopmanschap, 1991; Health Council, 1986 [p.l22-
123]), makes it possible to select the best health-care programme for a 
given health problem. Moreover, comparability with overall performance 
of other programmes will assist the decision-maker on the global level. 
Full economic analysis (or economic evaluation) is described in section 
3.5. Theoretically it is a powerful instrument for resource allocation in 
health care. Even if resource scarcity is not the main reason for the 
institution of an MTA, economic evaluation is regarded as indispensible 
in MTA to enable an optimal choice. It requires a quantitative approach 
to the concepts and operationalizations of input, throughput and output 
of a health-care programme (Drummond, 1987A; De Charro, 1989). 
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A specific feature is the requirement of rigorous analysis of the target 
programme and of its best alternatives. Finally it usually includes the 
computation of aggregate measures of economic desirability (e.g. the 
cost-effectiveness ratio). 
The requirement of rigorous analysis of the best alternative is con-
ceptually closely linked to the experimental method (in this context 
usually an RCCT) which is applied to get unbiased estimates of relative 
effectiveness of a new technology'S. Although this experimental design is 
not always possible, it is undulty ignored on many other occasions•. 
Forecasting essentially requires a quantitative model, which approxi-
mates the 'real world' with regard to its essential features. In our case 
the model should consist of a dynamic disease model which is linked to 
a technology application model using the same concepts of input, output 
(consequences on among other things the disease level) and time of oc-
currence. A concise report on the key position of quantitative modelling 
in health policy is found in Van der Maas (1986). Eddy lists some tech-
nical essentials (IOM, 1985 [p.153], see also Eddy, 1980). Elaborate ex-
amples are included in Van Oortmarssen (1990) and Van Hout (1990). 
Thus we arrive at the following standard elements of MTA: 
a. a dynamic disease model linking the occurrence and the development 
of disease to survival, health status and other events amenable to 
intervention; 
b. a technology application model, linking the employment of resources 
to the disease model via defined interventions; 
c. an overall structure of the model which allows for comparison over 
time of alternatives; 
d. uniform concepts for input, throughput, output and need, which are 
interchangeable in all the branches of the model; 
e. uniform non-disease-specific measurement instruments for output 
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measurement; uniform non-setting-specific measurement instruments 
for input measurement; 
f. a comprehensive approach to uncertainties. 
The perspective of the MTA 
Other perspectives than that of society may be conceived of (see Table 
1.2, section 23 and Drummond, 1987 [p.7, 19]). Luce distinguishes three 
additional viewpoints: third party payers, health care providers and 
patients (1990 [p.45]). Though some heterogeneity may be found within 
these classes5, this distinction may be useful (see e.g. Weisbrod, 1980). 
A societal perspective is generally regarded as the most comprehen-
sive (Drummond, 1987 [p.39-40]). The structure of an MTA from other 
perspectives may usually be derived from the structure shown above 
(Luce, 1990 [p.4Q-49]; Drummond, 1987 [p39-40]). However, other per-
spectives may imply that the contents of issues will be adapted e.g. by 
changing the emphasis on particular topics, by applying other valuation 
principles or other aggregational techniques. Here the influence of other 
perspectives will not be systematically addressed. 
3.3 Action of the technology 
Relevance 
The relevance of this issue is twofold. First, it provides information on 
the subject of the decision, which also defines the boundaries of the 
MTA. It provides also insight in the process of technology application. 
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A comprehensive description of the action of the new technology is 
usually not available from the clinical protocoL For example, often the 
protocol does not include a detailed description of the selection process 
and of the available alternative options. As a result the decision-maker 
faces a decision problem with apparently one option. Apart from support 
to the decision-maker in that case, a detailed description is supportive 
for the MTA-analysis of other issues. A detailed description of selection 
criteria of patients is e.g. required in the analysis of outcome and of 
need. 
Information from the process of technology application may be use-
ful for evaluation of the functioning of the protocol. It may also provide 
clues to the improvement of e.g. organizational and legal arrangements. 
Methods 
The qualitative part of the description includes: 
a. a description of the technology and its mode of action; 
b. a description of the purposes of its application; 
c. a description of the patients to be subjected to the technology; 
d. a description of the environment of the technology; 
Below we give two additional remarks on b. and c. 
The purposes of application may be defined on the process and the 
outcome level. From an MTA viewpoint purposes should at least be 
stated on a non-disease-specific outcome level (see section 3.4) and be 
related to the patient categories to which the technology applies'. 
Purposes may thus be translated into measurable entities to be used in 
the subsequent quantitative analysis of this issue (flowchart analysis, see 
below) and outcome analysis. 
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From the perspective of an MTA the description of the selection cri-
teria and the selection process within the health care programme is of 
critical importance. The results of all other issues depend on the selec-
tion criteria and their application. 
A systematic approach of these four topics often results in a broader 
description of the technology than might be expected at the onset. This 
is particularly caused by the attention paid to the alternative modes of 
action if the new technology is not or only partially applicable7• In prac-
tice we usually arrive at a description of a comprehensive health care 
programme for a particular patient group (for examples in the case of 
liver transplantation, see Health Council, 1989,AJ, and Bonsel, 1988E)8 . 
The quantitative part of the description of a technology primarily con-
sists of flowchart analysis. Such analysis requires a simplified presenta-
tion of the patients career within the health-care programme related to 
his/her condition and prospects. A quantitative model (see section 3.2) 
of the health-care programme should be defined, representing all the 
essential relations between subjects over time. Good examples are the 
detailed models used in MTA's of screening for breast cancer and 
cervical cancer, of therapy for end-stage renal disease, of heart trans-
plantation and of dental care (Van Oortmarssen, 1990; Habbema, 
1988A; De Charro, 1989B; Van Hout, 1990; Truin, 1982). 
A simpler model was used for liver transplantation (Habbema, 1988B). 
In the model the patient's career should start at the point when the 
new technology provokes change in routine medical practice. A model 
which starts at the stage the new technology is actually applied, usually 
leads to an underestimation of its impact. This is obvious in transplan-
tation MTA's where pre-transplantation activities place a visible burden 
on the programme, but this is less clear in many other programmes. 
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Patient flow (transition probabilities related to time) provides informa-
tion on selection criteria, waiting times, and ultimately programme costs 
and programme outcome. It may also disclose changes over time and 
differences between providers. The transplantation MTA's give numer-
ous examples (see Figure 3.1 and Van Hout, 1990). 
Figure 3.1 Annual inflow of patients in the liver transplantation 
programme, according to stage of selection. 1978-1987. 
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Technology - dependent characteristics 
For preventive and diagnostic teclmologies, health care programme de-
scription will be more complex than for therapeutic and rehabilitative 
teclmologies. For preventive and diagnostic teclmologies selection cri-
teria are usually ill-defined (indeed they often have yet to be established) 
and the paths leading to the ultimate outcome are not easily described. 
3.4 Effects on patient outcome 
Relevance 
Patient outcome is the most important issue in MTA. If the effectiveness 
of a new teclmology is beyond doubt and no alternatives are available, a 
(conditional) positive societal decision on that particular teclmology is 
likely. The reverse is also true: without improved patient outcome com-
pared to existing alternatives, analysis of other issues is justified only in 
exceptional situations•. 
In this section we shall give an introduction to two issues in the 
methodology of patient -outcome analysis: the concepts of outcome and 
the choice of a smtable design. An elaboration of these issues is found in 
the chapters 4 and 5. 
Methods - concepts 
All efforts of those working in the health care system are directed to-
wards the improvement of the health of the population, be it directly or 
indirectly. Few would debate this general statement. Difficulties arise if 
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we try to translate the intuitively appealing notion of 'health improve-
ment' into the language of science. The easy notion in everyday language 
then turns into a concept escaping unambiguous formal definition. 
Our approach to the problem is to start with the scientific context of its 
use (in MTA) in order to arrive at two different concepts: a concept 
from a medical and an economic point of view". Both concepts have 
their own merits and should be used in MTA. 
From a medical point of view patient outcome can be broken down 
into survival, quality of life/general health status (both are disease-non-
specific concepts), and disease-specific health status11• Except for quality 
of life/general health status, these concepts seem unambiguous. 
Besides, in medical research a wealth of biomedical process parameters 
are in use12 e.g. blood chemistry, coagulation status, blood pressure in 
the portal vein in chronic cirrhosis. Depending on the disease under 
investigation, the medical researcher chooses one or more of these para-
meters. Generally, the view has gradually been accepted that the out-
come on the patient level should be decisive in evaluative clinical re-
search. Consequently a shift from the use of clinical process parameters 
towards the use of patient -oriented outcome parameters in the clinical 
evaluation of medical technologies may be observed. This pertains parti-
cularly to the use of parameters of survival and disease-specific health 
status. For obvious reasons, this change applies less to the use of para-
meters of non-disease-specific health status. 
Within the medical concept of outcome in MTA, survival occupies 
about the same position as in clinical research but non-survival aspects 
are treated differently. The emphasis in MTA is on measurement of dis-
ease-non-specific health status: those who decide on medical technolo-
gies are not ouly interested in the disease-specific value of a medical 
technology (compared with its best alternative), but also in its general 
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benefit (compared with other technologies for other purposes). From the 
clinical decision-perspective the use of a disease-specific parameter often 
will snffice. However, the second perspective causes the emphasis in out-
come analysis (based on the medical concept) on standardized, generally 
applicable, quantitative parameters rather tban local, disease-specific 
parameters13• 
If an MTA includes an economic evaluation, an economic concept of 
outcome should additionally be developed, which should fit into the 
frame of economic measures for desirability or preference. 
The natural measure of economic desirability of a good ('commodity') is 
its price. In a well-functioning market, economic theory assumes the 
price of commodities to reflect their actual value and the dynamics of 
demand and snpply will set the price at precisely this value. By compar-
ing prices, we establish the relative desirability of commodities. How-
ever, the health-care system does not fit well to the conventional notion 
of a market (this fact contn1mtes to the existence of MTA). Supple-
mental economic theory is needed to describe and measure the eco-
nomic value (economists often speak of 'utility') of health-care services, 
as their price is not a good indicator (Mooney, 1986 [p.21-33, 64-71]). 
By far the most important economic framework to judge the desira-
bility of the commodities associated with health care (including new 
technologies) have been adaptations of so-called cost -benefit analysis 
(CBA, see Mishan, 1971 for an account). In its usual form, this frame-
work requires the analyst to arrive at monetary units as the one para-
meter of benefits. Keeping the structure of CBA grossly unaltered, 
health economists have accepted other parameters which all are thought 
to represent economic value or utility. The three accepted general para-
meters are life years gained, quality adjusted life years gained and the 
healthy years equivalents gained". 
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If life years gained are used, we speak of cost-effectiveness analysis 
(CEA), if quality adjusted life years gained or healthy years equivalents 
gained the term cost-utility analysis (CUA) is preferred. With life years 
alone an extension of standard survival analysis will suffice to describe 
outcome within the economic concept. If not, complex procedures are 
needed (see chapter 5). 
So far health economists have been reluctant to apply cost -benefit 
analysis ( CBA) in its traditional form, but if we use past decisions on 
health-care and non-health-care investments as revealed preferences, the 
value of life indeed may be estimated and subsequently used. 
Methods - design 
An experimental design is the preferred design of measuring net patient-
outcome differences, be they medically or economically defined. How-
ever, at least two conditions must be met if data are to be suitable. First, 
the control group should receive the best alternative treatment. Second, 
effectiveness should be measured in the long run. These objectives often 
are difficult to achieve. Chapters 4 and 5 deal with technical solutions to 
overcome the problems if the design is not optimal in this respect. The 
individual predictability of the course of disease will appear to be the 
primary determinant of success. 
Technology - dependent characteristics 
The empirical approach to outcome analysis depends on the technology 
involved. With a therapeutic or rehabilitating technology, outcome may 
be easily defined, regardless of the concepts applied. 
If the object is a preventive, or diagnostic or compound technology (e.g. 
47 Issues and concepts in MTA 
screening), measurement at the outcome level is more difficult due to 
the time which bas to pass before effects may be expected. The use of 
intermediate parameters (for example process indicators) may then be 
indicated. 
3.5 Effects on the nse of resources 
Relevance 
This issue forms the counterpoint to patient outcome analysis in MT A. 
Though some doctors still hold the opinion that cost considerations are 
not ethical, the economist's view has gradually gained support. Resources 
are limited; any decision causes changes in resource allocation; igno-
rance of these changes may lead to a larger disadvantage for some un-
specified group compared with the advantage for the patient group of 
the new technology; hence the absence of cost considerations may be 
called unethical. In addition to this ethical argument it may safely be 
stated that cost considerations play a major role in most doctors' deci-
sion making. Fmally, the inclusion of the issue is justified by the level of 
total costs of health care. Modem societies devote a large proportion of 
their resources to the production and distnoution of health care. 
Though cost considerations may sometimes be second to effective-
ness considerations, they form a necessary part of MT A. 
Methods -definitions 
From an economic point of view, cost -analysis should not be restricted 
to the actual resources employed by a new technology. Moreover, eco-
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nomic theory provides an analytical framework to support the decision-
maker, which constructs parameters for optimal resource allocation. This 
framework needs information on input (costs), throughput (process of 
application) and output (consequences, e.g. patient's outcome). 
Following Drummond, such an analysis is called full economic analysis 
(or economic evaluation; Drummond, 1987A [p.8] & 1987B; De Charro, 
1989B). Partial economic analysis is restricted to the input or output 
alone, it takes only the new technology into account, or it applies both 
restrictions. Partial cost-analysis does not yield a criterion of choice, 
hence full economic analysis shonld be regarded the standard approach. 
Full economic analysis may be structured as cost-effectiveness analysis, 
cost-utility analysis and cost-benefit analysis, depending on criterion of 
outcome and the purpose of optimization. 
Within an economic evaluation the determination of economic costs 
shonld be distinguished from an account of the financial costs. 
Economic costs refer to the real input of all resources valued according 
to the opportunity cost principle: what could have been done with the 
same resources in the best alternative way? A perfect market more or 
less guarantees actual prices of the resource input to reflect economic 
costs. The health-care system is not organised as a perfect market due to 
among other things monopolies and the agency function of doctors (see 
e.g. Mooney, 1986 [p.83-87]; McGuire, 1988 [p31-53], Williams, 1978). 
This implies that economic costs in health care have to be distinguished 
from the financial costs"'. Financial costs should preferably be estimated 
too. The decision-maker who commissioned the MTA (but other parties 
too) may need these estimates for other purposes. 
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Methods - design 
Several authors have listed the elements of the empirical part of econ-
omical analyis (Drummond, 1987A [p.22,39-]; Rntten, 1989 [p.lOS-]; 
Luce, 1990 [p.65-{)7]). Once the values of all the elements have been 
established, results are aggregated. Depending on the outcome criterion 
chosen and the purpose of optimization, we arrive at a particular sum-
mary measure (e.g. a cost-effectiveness ratio). As an important economic 
feature of aggregation allowance is made for different timing of events16• 
In this thesis we will not discuss further the empirical procedures 
associated with the monetary part of the table: generally the ten guide-
lines presented by Drummond form suitable anchorpoints (Drummond, 
1987A [p35-38]). The non-monetary part of economic evaluation is 
further discussed in section 3.4 and chapters 4 and 5. Aggregation, for 
example the computation of cost -effectiveness ratios, will be given some 
attention in section 3.8.1. The remainder of this section is devoted to 
some conceptual remarks from the viewpoint of a medical professional. 
Costs of care vs. costs of research; scale effects 
With new technologies it may be difficult to separate resources invested 
in patient care and resources invested in clinical research. In as far as 
final decisions frequently depend on costs considerations, the distinction 
is important. Neglect may lead to the unjustified rejection of a program-
me for its assumed expense or, with the acceptation, to large scale sub-
sidies for clinical research - which are not at issue in this decision-cycle. 
The more immature the technology, the harder it is to make the distinc-
tion17: detailed economic analysis is not very useful if technologies are 
still developing rapidly. 
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This part of economic analysis requires medical expertise, which should 
prefer be provided by the experts themselves. However, some reluctance 
to cooperate may be expected. Even if the circumstances are advantage-
ous, it may be a difficult empirical task. 
The issue of scale effects resembles the issue of distinction of re-
search costs from standard care costs. Scale effects are likely if care is, 
or is to, standardized and if care is, or is to, provided on a centralized 
basis. The estimation of the potential scale effects requires analysis of 
the functioning of the health care programme over time or in different 
settings, supported by information from medical experts. The latter may 
be reluctant to cooperate if they expect their academic and clinical free-
dom to be violated by conclusions drawn from the results. This potential 
conflict of interests may explain the absence of these issues in published 
MTA's. In some cases international comparison of similar programmes 
in different countries may provide clues to scale effects (Bonsel, 1988A). 
Future medical costs 
This issue may be best introduced by an example. Imagine a perfect life-
saving technology which prevents preterm delivery with fatal outcome. 
As a result a healthy child is born. From an economic point of view the 
normally expected life-time medical costs of the newborn should be 
regarded as direct medical costs to be included in the analysis. At first 
sight this inclusion seems just an odd feature of health economics. 
The similarity with an analoguous feature of public health theory is 
remarkable. In the context of judgment of the effectiveness of medical 
care at the public health level it has been suggested that the number of 
diseased and disabled will rise due to the effectiveness of modem 
medicine (the issue is described by Van der Maas, 1989). If this is tme 
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we might be tempted to clisregard the lives of miserable quality saved to 
avoid the conclusion that the balance of sophisticated medical care is 
negative. 
Both paradoxes require carefully devised aggregate measures18• The 
inclusion of postponed negative health effects and medical costs may 
thus be acconnted for (Roos, 1990). 
Technology - dependent characteristics 
As in outcome analysis, the type of technology influences the empirical 
task in cost-analysis (see section 3.4). Due to the multiple ramifications 
of the chain of cost-incurring activities, the empirical analysis of preven· 
tive, diagnostic and componnd technologies may be demanding. 
3.6 Need for the technology 
Relevance 
Determination of the need for a particular technology may serve many 
goals. 
First it allows for an evaluation of the actual performance of the 
clinical pilot programme with regard to its regional or national coverage 
(see also section 33). Secondly it allows for future projections of patient 
flow, provided a forecasting model is available (see section 3.2). Conse-
quently the magnitude of resource use and of the consequences may be 
estimated. Four examples show how need estimates may be relevant to 
the decision-maker. 
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11 an analysis of need suggests impact on the population as a whole, 
as with preventive technologies or technologies for prevalent diseases, 
impact considerations may be recognized as a separate issue. 11 need 
projections suggest that particular constraints will inevitably limit the 
access to the technology, distn'butional considerations may be regarded 
as an important issue. If the projected size is small, centralization of 
technology application may be considered, or, with short term interven-
tions, treatment abroad. If need projections suggest a rapid growth, 
organizational arrangements may be considered to guarantee equity and 
efficiency. 
These examples suggest that from society's point of view need esti-
mates are essential for considerations of efficiency and equity. From a 
supplier's point of view, need estimates may serve similar goals like 
market development and organizational optimization. 
Below an outline of the two main concepts of need is presented. As will 
be explained in chapter 6, general remarks on the empirical design are 
not relevant in this case. 
Methods - concepts 
As with outcome analysis we distinguish a medical and an economic 
concept of need (see also chapter 6). 
From the medical point of view we look for individuals who share 
characteristics which define them as suitable for the application of a par-
ticular technology; i.e. a significant gain of health benefit may be ex-
pected from the application of that particular technology. This concept is 
rather absolute as it excludes other considerations than those related to 
direct patient benefits. Obviously, some extremely effective medical 
services do not need these additional considerations. 
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From the economic point of view the concept of need is a theoretical 
supplement to existing classical theory on demand, supply and function-
ing of the market (Williams, 1978; McGuire, 1988 [p.l50-166]; Mooney, 
1986 [p.72-87]). Need in this view has to do with expected health benefits 
relative to the resources to be employed and to existing alternatives. 
Technology - dependent characteristics 
An empirical analysis of need of preventive and diagnostic technologies 
frequently implies a separate epidemiological study, even if the medical 
concept is applied. Empirical analysis of need in other technologies is 
usually less complex, but data are not abundant (see chapter 6). Lack of 
data is also the major limitation to the use of the economic concept. 
3.7 Current and future uncertainties 
Relevance 
In this section attention will be paid to three related topics: sensitivity 
analysis, trend analysis and policy analysis. They all deal with uncertainty. 
Uncertainty plays a major role in health care decisions and its general 
disutility in the decision process may easily be observed (O'Brien, 
1988)19• The quantification of uncertainties is an essential means to 
reduce this disutility (Drummond, 1987A [e.g. p.7]). Although in a 
teclmical sense these uncertainties are frequently treated in a similar 
way, their significance differs. 
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Definition of sensitivity analysis, trend analysis and policy analysis 
Sensitivity analysis examines the actual uncertainty of the values of key 
parameters which are produced in the analyses described in sections 33 
to 3.6. n may be distinguished into three types. 
Uncertainty about the relation between the distribution of observed data 
and the distribution of the values in the real world (measurement errors). 
We need to know for example what a five year survival rate of 69%, 
based on partially censored survival data of 73 patients, tells us about the 
certainty that a newly treated similar patient will survive the same 
period. Standard statistical approaches, including, meta-analysis are 
usually available to address this type of uncertainty. 
Uncertainty about the distnoution of the values in the real world be-
cause no measurement inst7ument is (J11a/lable ('intangibles'). 
Intangibles refer to dilficulty in counting, valuing or both. For example 
temporary health effects, as encountered in a vaccination or a screening 
programme, are difficult to count. Process effects are intangibles in 
another sense as they are countable but dilficult to value. 
Intangibles may be treated in several ways (Drummond, 1987A [p.l53-
156]). They may be omitted in toto, they may be measured indirectly and 
they may be estimated by a panel. 
If all alternatives share the same intangible, neglecting it may be jus-
tified. Indirect estimation of an intangible may sometimes be a valid 
alternative. For instance patient's behaviour may reveal the disutility of 
traveleing time, the disutility of waiting for treatment given an opportun-
ity to receive treatment elsewhere, etc. Frequently these approaches do 
not satisfy. 'Guestimation' will then be the strategy. Eliciting values from 
experts may be useful, particularly if formal techniques are applied 
(Lammerts, 1987). Scale and learning effects may be estimated this way. 
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Uncertainty about the absence or presence of values in the real world 
due to dissensus about their existence and/or the relevance of their inclu-
sion in the MTA ('imaginables'). 
Imaginables may be found in outcome aoalysis ( qualii']-of-life-effects of 
relatives and friends, life years gained of a future generation, e.g. with 
in-vitro-fertilization, particular process utilities), cost analysis (production 
losses) and aoalysis of need (e.g. abortus provocatus). 
Their treatment rests upon convention. These conventions should prefer-
ably be the result of discussion between MTA-investigators, experts in 
the object field and the decision-maker. A reluctance to this undertaking 
may be observed: the MTA-investigator defines the issue as political, the 
decision-maker as scientilic and the clinical expert wonders what the 
problem is at all. 
Uncertainty about what the real world will look like in forthcoming years 
is another type of uncertainty. Forecasting techniques may be helpful to 
the decision-maker in this case. 
Forecasting the effects of autonomous developments is called trend 
analysis. The technical elaboration is frequently based on the projection 
of the consequences of demographic change ouly, assuming a stable 
relation between the population composition and the technology in-
volved". 
If, additionally, the effects of policy decisions are included, we speak 
of policy analysis. Some options to be included are listed in Table 3.4. 
Many health care decisions are made with policy options in mind. Inter-
play between MTA-parties will make these options more explicit and in 
the favourable case, the effects of these options are estimated a priori. 
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Table 3.4 A selection of policy options to be included in MTA 
Regulatory activities towards technology 
• price/volume/conditions 
• patient/doctor/provider 
Health promoting activities 
• technology relatedfunrelated 
• risk reduction/risky behaviour reduction 
• individual/collectivity 
• optimization of demand/supply 
Activities on the demand for health care (e.g. insurance arrangements) 
Activities on the supply of health care (e.g. man power planning) 
Educational and socio-cultural activities 
Methods of sensitivity analysis, trend analysis and policy analysis 
The basic tool is the quantitative model. Variation of the structure, the 
relations and the data values may mimic real world changes. Micro-
and/or macrosimulation may be used to compute estimated values in the 
future. The type of the model (stochastic, deterministic, mixed) deter-
mines how uncertainty is exactly accounted for. The particular choice is 
based on practice, not on in principle". 
The combined prospective results on all issues within a set of as-
sumptions is called a scenario. The reference scenario combines existing 
technological alternative( s) with trend analysis. The basic or null seen-
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ario the introduction of the technology combined with trend analysis. 
Threshold analysis may be undertaken within the context of sensitivity 
analysis but also within the context of trend and policy analysis. It pre-
sumes a model in which for one or more key parameters - particularly 
aggregate measures of outcome, etc. - values are pre-specified below or 
above which the decision taken will be different. 
In fact these key parameters are the operationalization of criteria formu-
lated in Phase 2 of the decision cycle. In our experience these criteria 
are only infrequently formnlated. Consequently threshold analysis (like 
marginal analysis"') still has limited applicational value in MTA's23• The 
methodology is described elsewhere (e.g. Pauker, 1987/'-
A general feature of the analysis of current and future uncertainties 
is the difficulty in achieving a balance between scientific credibility and 
political suitability, which may be a Procrustean exercise. The different 
approval of the final MTA-reports on the Dutch Heart Transplantation 
Programme and the Dutch Liver Transplantation Programme provide us 
with an interesting example. 
Both reports were conceived and written in a similar fashion by essen-
tially the same research group. However, they differed in how the 
uncertainties were presented. 
The heart transplantation report presented a point estimate of the cost-
effectiveness ratio of 52,000 Hlljlife year gained. This central estimate 
was the average result of 100 microsimulations, substituting values and 
distnoutions of values in the model with, according to the authors, the 
highest likelihood of occurrence. The potential consequences of all types 
of uncertainty was computed by carrying out additional simulations, each 
time changing one (or more) distnlmtion of key parameters25• 
The liver transplantation report did not apply stochastic modelling 
techniques and presented a range of the cost -effectiveness ratios of 
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50,000 - 130,000 Hfljlife year gained. The lower range ali favourable 
ones, the upper range combined ali unfavourable assumptions. 
The point estimate of the heart transplantation report did survive as an 
exact result as opposed to the 'inexact' range results in the liver trans-
plantation report. The apparent exactness in the first case was mistaken 
for certainty. It contributed to a perceived superiority of the first ap-
proach, both in a scientific sense (certainty as parameter of scientific 
skills) and a decision sense (certainty as parameter of suitability). We 
regret the argument, not the conclusion. 
3.8 Miscellaneous issues 
In the final section of this chapter four issues will be addressed: formal 
synthesis, subgroup analysis, analysis of distributional effects, and social, 
legal and ethical analysis. The frrst and second subsection address two 
statistical tools which receive special attention in MT A The third and 
fourth subsection deal with two optional issues (see section 3.1). 
3.8.1 Formal synthesis 
As MTA provides us with information on many topics, the synthesis of 
results from different issues evidently would be useful to the decision-
maker. Several aggregational techniques exist to deal with the problem: 
multicriteria analysis, cost-effectiveness analysis, cost-utility analysis, cost-
benefit analysis (see IOM, 1985). 
Within the framework of economic evaluation, ali but the frrst technique 
may be regarded as standard approaches to integration. Although the 
calculation of these summary measures have been criticized, it should be 
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stressed that aggregation is a basic scientific tool which is also applied 
throughout the analysis of separate issues. 
This subsection starts with a short account on aggregation within the 
issues, followed by an account of 'multi-issue' aggregation. 
Aggregation of results, for example by averaging values and computing 
confidence intervals, may be regarded routine practice in conventional 
methodology. Hence, acceptance of aggregational operations in the sepa-
rate analyses in MTA is obvious. Two exceptions deserve attention. 
First, multidimensional health status concepts have been rejected 
either explicitly or implicitly by redefining the issue of overall judgment 
on health status as an ethical issue (Health Council, 1989 [p.141-]). 
However, multidimensional concepts are ubiquitous in science, medical 
science included; the new thing is statistics and computers providing 
practical means to deal with these concepts rather easily (chapter 5). 
Secondly, counting up health status measures of different persons has 
been rejected (Harris, 1987). Again we regard this position to be unten-
able by the argument that the construction of a survival curve and of all 
other irreproachable aggregate measures of health consequences are 
conceptually no different from aggegrated health status values. 
A second type of aggregation is the combination of (aggregate) 
results of different issues. This type of aggregation is encountered in 
formal synthesis of MTA-results. The aggregation techniques mentioned 
before all are quantitative methods of data-reduction, yielding an overall 
value or judgment. 
Multicriteria analysis is based on a prespecified weighting of out-
comes on an essentially arbitrary set of important issues; operations 
research provides us with various optimization techniques. We are not 
aware of explicit application in health care26• 
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Cost-effectiveness analysis (CEA), cost-utility analysis (CUA), and 
cost-benefit analysis (CBA) are all based on the foundations of welfare 
economics (Drummond, 1987A [p.150-J): their attention is restricted to 
all countable inputs and outputs, relating (usually by division) the net use 
of properly valued resources to net outcome. Essentially the acceptation 
of CE-, CU-, and CB-ratios is based on the assumption of inputs and 
outputs as representation of ends and means and of division (linear 
proportionality) as the most reasonable function rule. 
These reductionistic quantifications of the complexity of a health care 
programme have been particularly prone to criticism (e.g. during the 
transplantation studies, see also VanRossum, 1989). 
Part of the criticism on CE-, CU-, and CB-ratio's probably originates 
from a categorical mistake on aggregation in general, exehanging the 
real world and its abstraction27• 
Another part perhaps arises from misperception of the political signifi-
cance of measures economic desirability. A low cost -effectiveness ratio 
does not necessarily mean the apparently most efficient technology is the 
'best' and consequently should be ehosen (e.g. Keeler, 1987). Caution 
with these ratios is particularly advocated if health-care programmes 
with different targets are compared (see e.g. Leaf, 1989). 
In a technical sense the current lack of cost -effectiveness ratios 
prevents us from justifying the latter type of ehoices on the few available 
data28• In a political sense we must accept that other, often implicit, 
criteria may depreciate what seems to be the optimum from cost-effec-
tiveness considerations alone29• 
In this regard we would cite McGuire, who concisely describes the 
boundary between MTA-analysis and decision-making (1988 [p.99-100]). 
"The decision-makers responsible for the final ehoice of project(s) may 
not, of course, choose the project( s) declared to be efficient. The data 
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on which the analysis was based may be inaCCW"ate and the decision-
makers may feel that, with their more extensive knowledge, some other 
project is more efficient. Or they may disagree with the value judgments 
that the analyst will necessarily have introduoed into the appraisal. ( ... ) 
Or they may decide that a more equitable, but less efficient, project 
should be chosen. Thus the claim of CBA, CUA, and CEA is not that 
they make decisions, rather it is that they assist in the decision-making 
process. Perhaps the chief merits (which should not be undervalued!) are 
that they make health care planning comprehensive rather than partial, 
systematic rather than piecemeal, and value judgments explicit rather 
than implicit." 
In summary it is concluded that aggregation is an indispensible basic 
tool in any scientific activity. Its use in MTA is indicated at the issue-
level and is advocated at the level of formal synthesis. 
3.8.2 Subgroup analysis 
This subsection treats a technical feature of MTA which to some extent 
mirrors the feature discussed above: subgroup analysis. 
As a rule, medical research on the effectiveness of an intervention, 
tries to answer two questions "Does it work?" and ''For whom does it 
work?''. The scope of conclusions of MTA is broader, but they apply the 
same division. 
First we are interested in overall performance of a health care pro-
gramme; formal aggregation techniques as discussed in section 3.8.1. 
may be used to arrive at an answer to the question "Does it work with a 
reasonable employment of resources?" 
Next we are interested in the question on local optima: under which 
conditions (of any kind) performs the programme best? 
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The issue is referred to as subgroup analysis; both statistical and political 
considerations appear to be taken into account. We start with some 
statistical considerations. 
Experiments may be designed a priori to allow for testing the effects 
of selected variables. Usually selection is a posteriori. Analysis a posteri-
ori takes with it the danger of finding 'significant' variables due to 
chance alone, particularly when an impressive number of unknown con-
founders is tested in a less impressive number of patients, as inevitably is 
often the case in MT A. Regardless of the issue involved, prior specifica-
tion of these confounders at the onset of the MT A is preferable". 
A priori specification may also be justified to avoid a posteriori 
objections from e.g. the health care provider or society's representatives 
if results are expected to be in conflict with their interests. Here we 
arrive at political considerations. One fictitious example may illustrate 
the point. An additional one is contained in the note31 • 
A first explanatory regression analysis of the waiting time for a donor 
liver shows that women wait longer than men. Also, the older people 
wait considerably longer. Entering diagnosis in the explanatory model 
appears to decrease the influence of sex and age below significance, with 
primary biliary cirrhosis taking the role of primary explanatory variable. 
When, in the third stage of analysis, severity of disease is added as the 
fourth predictive variable, it removes diagnosis from the list of significant 
variables, and age reappears as a second significant variable after 
severity of disease. Different moral reactions to these three stages of 
analysis may be imagined. 
In our research activities we also encountered these non-statistical 
arguments against the use of a particular explanatory variables". 
We conclude that subgroup analysis may be justified from a statisti-
cal point of view, particularly if empirical data on key parameters show 
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much variation which is accounted for by a priori specified variables. 
Non-statistical arguments may limit the degree of freedom in choosing 
the explanatory variables. 
3.8.3 Distributional effects 
In this subsection the analysis of distributional effects is briefly discussed. 
We start with an explanation of the relevance of the issue which is also 
known as the equity-issue. Next equity is defmed and some remarks on 
the effects of equity considerations in MT A -context are given. Finally we 
reply to the presumed inequity consequences of the use of QAL Y' s. 
In chapter 2 the prior definition of core issues and the criteria to be 
used in decision-making was stressed. If we accept more than one cri-
terion, it will sometimes be difficult to satisfy multiple criteria simultane-
ously. 
Suppose we have chosen as a criterion-variable that average investment 
needed per QAL Y should not exceed Hfl 50,000. Suppose we also ad-
here to a second criterion: health-care programmes directed towards 
rehabilitative care receive priority treatment. It may be expected that the 
complete satisfaction of both criteria simultaneously is impossible. 
More generally stated, health-care programme selection according to 
any primary criterion as meant in chapter 2, will usually result in subop-
timal satisfaction of secondary criteria. The point is raised for the 
assumed conflict of two criteria regarded to be important in health care 
decisions, efficiency and equity. 
Equity is also be discussed because the use of a QAL Y as a unit of 
outcome has been criticized for the presumed deleterious consequences 
towards equity. The selection of technologies based on the cost per 
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QAL Y criterion would unduly favour the young with acute disease; the 
aged and those with chronic disease would suffer the use of this effi-
ciency criterion (e.g. Musschenga, 1987). 
The rationale of an efficiency criterion is in maximizing society's 
benefit as a whole, given limited resources". The use of an efficiency 
criterion originates from utilitarianism. The efficiency of a health-care 
programme is measured by economic evaluation and may be described 
by the afore-mentioned ratios (see section 3.8.1). 
A definition of eqnity in health care is less uneqnivocal (Wagstaff, 
1989; McGnire, 1988 [p.63-73]). Available definitions usually" deal with 
the degree to which the distribution of health-care related goods (here 
the technology or its alternative) satisfies the following two rules: 
a. patients who are unequal according to a criterion (usually: need) are 
treated unequally or, more plainly, the more someone needs health 
care the more he should get it (vertical eqnity); 
b. according to remaining criteria (particularly: income, gender, age, 
race) patients are treated equally (horizontal eqnity). 
Apart from the commodity to be distributed and the criteria to be 
applied, a function rule should be defmed which states how much more 
health commodity you get the more you need it". 
Graphical and computational techniques exist to measure the degree of 
undesirable ineqnity. 
The following six observations (see next page) in our view suggest 
that routine application of distributional analysis within MTA is not 
justified yet. The frrst two observations refer to the concept of equity, 
the latter to the relation of equity considerations with the standard 
effectiveness and efficiency considerations in MT A. 
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1. No standard definition of !he vertical equity criterion 'need' has been 
accepted. The literature provides us with various alternatives: e.g. 
actual health status"', health lost without intervention, potential 
health to be gained with intervention (Mooney, 1986 [p.108]; 
McGuire (1988 [p.l23]). The lack of standards for horizontal criteria 
is less urgent, as age, gender, race (see for transplantation: Kasiske, 
1991) and income appear to be !he most important. 
2. Horizontal equity criteria may correlate with the vertical equity 
criterion. E.g. if age determines health lost without intervention or 
potential health to be gained with intervention (all true in liver trans-
plantation), perfect distribution according to need37 implies !hat !he 
satisfaction of !he horizontal criterion is compromised. This correla-
tion will be encountered often (also with gender and income), hence 
!he overall degree of equity is apparently frequently not defined. 
3. In MTA alternative modalities to solve !he same medical problem 
are compared. Conclusions about !he best choice based on efficiency 
alone may change if vertical equity is taken into consideration. We 
expect !his to be !he case only infrequently: particnlarly if vertical 
equity is defined as "!he more potential health may be gained, !he 
more care you get", conclusions remain unaltered. 
4. In MTA efficiency will be in conflict with horizontal equity consi-
derations if the effects of alternatives differ with regard to their 
relation to !he particular horizontal criteria. As this will be often the 
case, a similar problem as mentioned in 2. arises38• 
5. Discussions about equity seem to focus on the use of MTA-resnlts in 
a broader context: comparison between different health care pro-
grammes in view of resource allocation on the macro level. We agree 
!hat equity considerations with regard to age and other criteria for 
horizontal equity may be relevant in that case (see e.g. Callahan, 
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1990; Levinsky, 1990). In the end the dominant philosophical position 
will determine the primacy of either efficiency, effectiveness, vertical 
equity or horizontal equity. However, if horizontal equity is accepted 
as the primary criterion (to he teclmically achieved by standardizing 
health status or outcome measures according to horizontal criteria), 
medical science would he redefmed39• 
6. The afore-mentioned problems arise with any criterion for need, be 
it health-status or health-improvement related, hence the selection of 
particularly QAL Y's as measure of outcome is not essential to the 
issue. 
3.8.4 Legal and ethical issues 
The position of legal and ethical issues in MTA-reports is not as clear as 
the previous issues (e.g. Luce, 1990 ignores these issues). 
We think that legal issues which are relevant within in an MT A 
should be distinguished from the legal features relevant to the decision 
process which an MTA is supposed to support. For example, within the 
transplantation studies we encountered the issues of brain death criteria 
(Health Council, 1983; id., 1987"') and of legal aspects of acquiring and 
distributing donor organs (Health Council, 1987t'- However, in many 
cases technology-specific legal issues are not at issue in an MTA 
If an empirical MTA is carried out, legal features of medical investi-
gation in general deserve attention, e.g. the use of registration data, and 
of patient data ('Vandenbroucke, 1989). 
Numerous legal issues can be considered before and after this informa-
tion phase of the decision cycle. Their relevance to the consecutive 
phases of the decision-cycle is described in a note42• If selection of 
patients is involved, the legal analysis may he complex". 
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Judging from the contn'butions of legal and ethical experts, legal and 
ethical issues within an MT A frequently coincide and their approaches 
has much in common (compare e.g. Roscam Abbing, 1989 with De 
Wachter, 1989). Country-specific characteristics of the legal system may 
limit the use of foreign legal analyses (compare e.g. in heart transplanta-
tion Evans, 1984 with Health Council, 1988). 
Ethical considerations occupy a special position. 
Moral judgment has been at the core of philosophy for centuries. Medi-
cal ethics have grown only recently to maturity. Its development is close-
ly related to the development of professional medical organization and 
the medical knowledge base (Ten Have, 1988 [p.24]). Traditional deon-
tological professional ethics are embodied in the famous Hippocratic 
oath. At present medical ethics have extended from a science on nor-
mative theories in medicine to an applied science on the process of 
application of these theories (Ten Have, 1988; Beauchamp, 1989; De 
Beaufort, 1989). The former has been called the ethical product, the 
latter the ethical process. 
The IOM lists at least three theoretical principles of medical ethics 
as a deontology (the ethical product): that of autonomy, justice (con-
nected with the issue of equity) and the pursuit of common good (con-
nected with the issue of individual and societal benefit) (IOM, 1985 
[p.l57]). The relevance of analysis of these principles in an MTA will 
vary with the technology involved. Informative technologies, procreative 
technologies, and technologies to be applied in children and psychi-
atrically ill for example are particnlarly relevant to the autonomy prin-
ciple. Ethical analysis may then be indicated. The relevance of the equity 
issue as a subject for ethical analysis is beyond doubt but its analysis is 
uot without difficulty (see 3.8.3). 
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The ethical process concept has been described by Ten Have (1988)44• 
The concept focuses on how we can arrive at an optimal ethical judg-
ment instead of which rules determine whether decisions or conduct are 
ethically justified. The author states two important features of the 
process concept. Moral reasoning depends on the moral rules, which in 
turn are derived from moral principles. "Moral reasoning itself provides 
no criterion for choosing between conflicting principles" (for an example 
see section 3.8.3 on equity). Moreover, "reasoning offers reasons to 
people, but people [and: health-care authorities GJB] are not always 
reasonable". The analysis of Ten Have suggests that the primary import-
ance of medical ethics as a process is in discussing the decision cycle as 
it stands: as with the legal position, its primary value appears to be 
meta-analytical. 
Here we do not give a full analysis of these principles and their applica-
tion. Mooney, an economist, concludes that medical ethics sofar have 
failed to address scarcity satisfactorily (Mooney, 1986 [p.88-106]). This is 
a drawback of medical ethics in the context of MTA. Thus it might be 
too early to advocate the routine participation of a prospectively active 
ethical expert in MTA (Van Leeuwen, 1989). 
3.9 Summary 
In this chapter a standard approach for empirical MTA is proposed. It is 
argued that standardization is of vital importance to MTA: it allows for 
comparibility of results across technologies, diseases, and populations. 
Besides it is required for economical analysis and forecasting. The 
construction of quantitative models which integrate medical and econ-
omic information is a logical consequence. 
69 Issues and concepts in MTA 
Five core issues are considered to be essential in MT A: description of 
the action of the teclmology, the effects on patient outcome, the effects 
on the use of resources, the need for the teclmology and finally the 
actual and future uncertainties. The major part of chapter 3 is devoted 
to conceptual remarks on these five issues. 
In the last section attention is paid to two teclmical procedures: the 
formal synthesis of results applying summary measures like an cost-
effectiveness ratio and subgroup analysis. We end with a short account 
of distnlmtional analysis and legal and ethical aspects. 

4 ANALYSIS OF SURVIVAL 
4.1 Introduction 
1n this chapter some theoretical and practical aspects of survival-analysis 
are cliscussed. From a statistical viewpoint survival analysis is the appli-
cation of a set of tools to analyze the occurrence of an event in time1• 
From the viewpoint of MTA, survival analysis is the cornerstone of out-
come analysis (see section 3.4). 
Section 42 presents some general remarks on survival analysis in 
MTA, clistinguishing between survival as one of the three medical out-
come concepts and survival as an economical outcome concept. Atten-
tion is paid to the estimation of survival consequences of an intervention 
in the absence of any information from randomized controlled clinical 
trials (RCCf's); this absence may be often observed in new technologies. 
In section 4.3 some technical features of survival analysis are shown. 
The technical approach of a method which predicts control-group survi-
val is presented. This method uses prognostic information from each in-
dividual directly preceding the intervention. The predictions may be used 
both at the individual and at the aggregate level (Christensen, 1987). 1n 
the latter case the predicted survival curve, of a group of patients may be 
compared with the observed survival curve enabling judgments of the ef-
fectiveness of the target technology. Also the computation of the number 
of life years galned (or lost) due to the target technology is possible. 
Section 45 shows results from the liver transplantation MTA, pre-
ceded by some historical notes on survival analysis in liver transplanta-
tion (section 4.4). Section 4.6 is a summary. 
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4.2 Survival analysis in MTA 
Two concepts 
In section 3.4 a distinction was made between patient outcome from a 
medical and from an economic perspective. 
The first concept includes survival, quality of life/general health 
status (both are disease-non-specific concepts), and disease-specific 
health status. Survival analysis in this case provides an answer to the 
question whether survival with the target technology differs from that of 
alternatives ( m general or after a fixed interval) and which determinants 
(including intervention) explain observed heterogeneity of survival, using 
cumulative survival percentages as the conventional unit of outcome. For 
example it may be stated that the survival percentage with sclerotherapy 
of oesophageal varices is 80% and 40% after 1 and 5 year follow-up (fic-
titious numbers) and that it does not differ significantly from survival 
with conventional therapy. 
The second concept uses survived years as the primary parameter of 
outcome. If quality-of-life adjustment are not included (see chapter 5) 
survival analysis in this concept follows the same route as above but 
finally integration of the survival curve is carried out. As a result it may, 
for example be stated that patients with oesophageal varices live an 
average 4 years regardless of the therapeutic modality, and that consequ-
ently net benefit of sclerotherapy is zero life years gained. 
Graphica!Iy, the difference between the two concepts is simple: the first 
concept is directed to the level of the graph over time and statistica!Iy to 
the occurrence of terminal events; the second is directed to the size of 
the area below the graph. 
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Shadow survival 
One of the commonest and most difficult problems in survival analy-
sis in MTA (with both concepts) is the absence of experimental know-
ledge on the outcome of alternative options. Too frequently an RCCT is 
rejected because the new technology is believed to be 'much better' than 
any rival option. The same argument was thought to be valid in liver and 
heart transplantation at the stage they were investigated in the Nether-
lands (1985-1988) (Habbema, 1988B; Bonsel, 1989B; De Charro, 1988). 
As was shown by Van Hout in the heart transplantation case and in this 
thesis in the liver transplantation case, differences were not always as 
large as expected (Van Hout, 1990; A3)2• These examples show the 
vuloerability of clinical judgment in the absence of RCCT information. 
In Table 4.1 we present five methods which deal with this problem 
(Bonsel, 1990A). All these methods estimate shadow survival i.e. they 
estimate the probabilities of survival supposing the target technology had 
not been applied. 
Table 4.1 Methods to estimate shadow survival. 
1. Formal expert judgment 
2. Historical control group 
3. Quasi-experimental control group 
4. Intervention delay group 
5. Prognostic modelling 
The characteristics of these methods are discussed below. Examples are 
drawn from the liver transplantation study in which the application of 
these methods was considered (Bonsel, 1988F). 
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Formal expert judgment 
Obviously some expert judgment of survival benefit is already manifest in 
the clinical decision to offer a patient a particular treatment. However, a 
formal quantitative prediction goes beyond this dichotomous decision. 
The strength of expert judgment is its full exploit of human percep-
tive and integrative capabilities. Clinical judgment can take into account 
all patient information, including information escaping formal definition 
such as the change of features like the patient's face, texture, and his 
morale. Hippocrate' s treatise on prognosis already points to their 
importance (Anonymous, 1983B [p.171]). 
The weakness of expert judgment is related to its strength. Human judg-
ment is prone to error, and prone to persist in error. Once a decision to-
wards an intervention is made, all information subconsciously tends to be 
interpreted as a support of the option chosen3• Judgment is also influ-
enced by the social environment. Group judgments tend to converge if 
personal ties or shared objectives place a disutility on dissensus. 
For these reasons clinical judgment by experts of shadow survival can 
only be used within a formal design. For example: in liver transplanta-
tion survival estimation of a sample of anonymous historical controls of a 
liver unit can be used to discover the prognostic evidence used by 
doctors. 
A Delphi-technique (see section 2.6) may subsequently be used to arrive 
at group estimations and wonld-be decisions on these patients. 
Historical control group 
Survival information from similar patients treated in the past (reference 
patients) may sometimes appear to be suitable for direct approximation 
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of shadow survival in current patients (index patients). Nevertheless the 
representativeness of both the patients and their prospects should be 
evaluated. Table 42 lists some sources of decreased representativeness. 
Table 42 Sources of bias using historical control group data. 
Patient 
Patient selection 
Diagnostic changes 
Prospect 
Changes in epidemiology 
Changes in therapy 
A critical problem is how to evaluate the selection of patient data. As 
a rule patient data are not derived from complete registries. We also do 
not know, whether patients presenting their disease or problem now, do 
represent the patients in the past. 
Secondly, diagnostic criteria may change. New technologies may 
induce diagnostic refmements. In this area for example, the development 
of the endoscope contributed to the disentangling of primary sclerosing 
cholangitis, recurrent infectious cholangitis and cholangiocarcinoma. 
Even if criteria are left unchanged the diagnostic and prognostic profile 
may change: refined techniques to discover peritoneal metastases in ova-
rian cancer yields 'improved' survival rates in all stages of the disease, 
without any effect on overall mortality (De Kroon, 1990). 
Epidemiological change is relevant, particularly in infectious dis-
eases'. Even in non-infectious diseases patterns of disease may change 
(Van der Maas, 1988) invalidating the use of old data on prognosis'. 
A common bias in the use of historical data is the underestimation of 
the effectiveness of historical therapy at present. Gradual improvement 
of any therapy may be expected, even if lethality has not decreased. For 
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example, the improvement of resnlts in the medical treatment of cir-
rhosis and in the palliative treatment of liver carcinoma invalidate the 
straight forward use of historical data (as in DeJong, 1990). 
The strength of historical data is their empirical natnre. Their reliabi-
lity and validity can be estimated. Frequently time to follow-up suffices 
to gain a fair impression of average life expectancy with the disease. 
Quasi-experimental control group 
The limited application of new technologies may offer the opportunity to 
compare the survival of the non-recipients of the new target technology 
with those receiving it. 
If the benefit of a new technology is unclear and public appeal is low, 
doctors not involved in the clinical pilot programme will be reluctant to 
refer patients. If additionally there is a clear competing option outside 
the clinical pilot programme and if patient selection is identical, quasi-
experimental data may be validly derived. We made use of this method 
in biliary atresia (see section 4.4). 
Another source of shadow survival data are patients who are referred 
to the intervention programme but who do not receive the target techno-
logy due to withdrawal or deselection. In the case of heart transplanta-
tion accepted candidates, who decided to reject the opportunity for this 
treatment, provided valuable information on shadow survival (Stevenson, 
1986). The same holds for patients rejected for reasons only unrelated to 
survival with transplantation (e.g. psychiatric disorders). Even patients, 
with a prognosis without intervention considered too well to justify inter-
vention, may provide important information on the upper limit of sha-
dow suivival (Stevenson, 1987). In our study the opportunity to use these 
options was limited (see section 4.4). 
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Intervention delay group 
Wailing periods due to scarcity may be another source of information on 
shadow survival Particularly in life-saving teclmologies, much can be 
learned from the waiting-time experience of patients, providing two 
conditions are met6• 
First, patients should be homogeneous with regard to prognosis until 
intervention when they enter the waiting-list. Their entry should only 
reflect suitability to undergo the intervention, be it after minutes or -
without intercurrent change - after months. Particularly if entry selection 
occurs for some additional reason, this generally results in unacceptable 
heterogeneity with regard to survival on the waiting list. 
Second, deselection due to the intervention (the primary censoring 
event) or other reasons (withdrawal, or change of the clinical condition) 
should be aselect with regard to the prognosis without intervention. 
If these homogeneity assumptions are met', several teclmical pro-
cedures exist, both parametrical and non-parametrical, which enable the 
use of this waiting-list experience (Turnbull, 1974). Some of them were 
used in the liver transplantation study (see section 4.4 and AI, A3). 
Prognostic modelling 
Prognostic modelling is a method which may be regarded as a refine-
ment of the three previous methods. Potentially it is the most powerful 
method to estimate control group survival (see e.g. Christensen, 1988). 
The method starts with the application of Cox' proportional hazards 
model (see section 43) to the survival times of a group of subjects 
receiving control treatment in the recent past (for a reference group, see 
the three previous methods). From this analysis a set of prognostic fac-
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tors (patient variables) is derived with their associated weights ( regres-
sion coefficients), and a basal hazard function describing survival in 
absence of these prognostic factors•. 
Next the shadow-survival of each index patient is estimated. The 
actual levels of the prognostic factors of that particular index patient are 
substituted m the prognostic model derived from the reference patients, 
and an estimated survival curve is computed. Thus we use historical sur-
vival information, controlling for all significant prognostic factors distin-
guished in reference patients. 
Three conditions have to be met before this method provides supple-
mental information as compared to the previous methods. 
First, a prognostic model is relevant. If survival of a particular condition 
is rather uniform, e.g. all patients die after 3 months withiD a small 
range, the mdividual prognosis reduces to the average group prognosis. 
However, if the survival times distribution of a particular condition does 
show large variance, this does not gnarantee the existence of a pro-
gnostic model. Survival may be the result of chance only, it may be the 
result of unknown, hence unmeasured, factors or a small number of ob-
servations may simply preclude the estimation of such a model for tech-
nical reasons. If the course of the disease at a particular stage turns out 
to be unpredictable at the mdividual !eve~ average group prognosis again 
is the best estimate of mdividual prognosis. Fmally a prognostic model 
may not exist due to lack of perceived interest. In the majority of diseases 
the ouly available knowledge consists of crude mortality estimates. 
The second and third conditions are those previously mentioned in 
the crude historical control group method: the diagnosis of mdex pa-
tients should be similar to that of the reference patients and the pros-
pects of mdex patients should be represented by the prospect of refer-
ence patients (apart from the prognostic factors of the model). 
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The second condition assumes diagnostic equivalence between the pa-
tients on which the model is based and the patient to which the model is 
applied. Etiological heterogeneity is only a problem if it induces survival 
differences not accounted for by the prognostic factors. This condition 
also suggests that the whole range of variables in index patients should 
fall within the range of these variables in reference patients9·". If this 
condition is not satisfied additional assumptions must be made with 
respect to the effect of outlying values in index patients. 
The third condition assumes no changes in prognosis have occurred 
since the time the reference patients were treated. This applies to 
changes not accounted for by the prognostic factors in the model. If 
independent changes have occurred, model predictions may be too pessi-
mistic. 
At the onset of the two Dutch transplantation MTA's much informa-
tion was available concerning prognosis in end-stage heart and liver 
disease. However, despite many efforts to use this information in the 
case of end-stage heart disease, results were disappointing due to the 
lack of suitable prediction models (Van Hout, 1988; Bot, 1988A). 
In a contrast, analysis of shadow survival in liver transplantation was 
more succesful. At the time of data collection there was a small number 
of prognostic models on cirrhosis (Bonsel, 1988F). Also the second con-
dition of prognostic modelling was satisfied. With regard to the last con-
dition, slight differences between older and more recent prognostic mo-
dels for primary biliary cirrhosis patients suggested a small improvement 
of conventional treatment results. Nevertheless the use of prognostic 
modelling seemed justified in the liver transplantation study. 
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4.3 Technical features of survival analysis 
Purposes 
Survival analysis may serve three purposes: description of survival times 
and terminal events, comparison of survival and prediction of survival 
Description of survival may take different forms, depending on the 
presence of censored observations and the nature of the survival data11• 
Frequently an arithmetic function is derived to approximate parametric-
ally the observed survival-times distn"bution. 
Comparison of survival of different groups is an obvious means to 
evaluate interventions (be they therapeutic or otherwise )12• A number of 
tests are available. Heterogeneity of the survival-times distribution may 
also be investigated using regression techniques. 
The prediction of (individual) survival requires the application of the 
above mentioned techniques, particularly Cox' regression. Because of its 
relevance we shall elaborate on its application. 
Techniques for description 
Survival can be described using S(t),f(t) and '-(t). These functions repre-
sent the cumulative survival function, the probability density function of 
survival and the hazard rate function respectively. If one of these funct-
ions is known, the others can be calculated13• If S(t) is known, LY(t) 
which descn"bes the expected number of years to live after t years of 
follow-up, can also be derived14J 5• Survival analysis from the medical 
point of view uses survival function S(t), from the economic point of 
view the integral LY(t)'6• 
If survival data are uncensored, exact cumulative survival probabilities 
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may easily be calculated for any point of time during follow-up. A spe-
cial case is the reduced sample technique which calculates cumulative 
survival probabilities within a specified period, using ouly data of those 
included in the study for this period or longer. In clinical studies this is 
usually not feasible due to the wide range of follow-up periods17• 
Two methods exist which deal with censored data (see Figure 4.1). 
Figure 4.1 Survival after liver transplantation - two methods . 
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If data are aggregated the actuarial or life-table method is used (e.g. in 
population survival; Cutler, 1958; Benedetti, 1983; Lee, 1980). If individ-
ual survival times are known, the product-limit method is used (e.g. in 
patient survival after liver transplantation; Kaplan-Meier, 1958). 
6 
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The first method presumes intervals to be defined, usually equidistant-
ly18. If each interval contains only one observation, this method is 
reduced to the product-limit method. Obviously in FigUre 4.1 the graphic 
impression of the actuarial method in the first year is too optimistic, due 
to the fact that mortality is not evenly distn"buted along this interval. 
This illustrates a disadvantage of the actuarial method. 
Techniques for comparitive and explanatory analysis 
Two or more survival distn"butions may be compared. Two commonly 
employed methods are the log-rank test (Peto, 1972), the Cox-Mantel 
test (Mantel, 1966) and the generalized Wilcoxon tests ( Gehan, 1965; 
Peto, 1972). These tests differ in how observations are weighted. The 
Wilcoxon tests have more power than the other tests if the hazard ratio 
is time invariant (Lee, 1980 [section 5.1]; Hop, 1981; Benedetti, 1983). 
Comparison may also take another form. Instead of comparing two 
or more survival-times distributions, the effect of several variables on 
survival may simultaneously taken into account. 
If we are interested in the effect of a set of variables on the survival 
at a fixed point in time, 5 year survival, we may use the logistic re-
gression model and the reduced sample of survival times. This model 
does not use information on the time of occurrence of terminal events. 
We did apply the model in analyzing the (potential) effect of donor 
organ quality on graft survival (Pruim, 1989)19• 
If we are interested in the influence of a set a covariates on the entire 
survival-times distribution, the proportional hazards model may be used 
(Cox, 1972; Kalbfleisch, 1980; Hopkins, 1983; Lee, 1980). 
(1) 
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In equation 1 >(t) is the hazard function and >oft) is an unspecified base-
line hazard function. z • z, ... , z, describe the value of each of the p 
covariates of a subject. The coefficients of the model to be estimated are 
b, b, ... , br The coefficients and the base-line hazard function are esti-
mated by means of a maximum likelihood method. 
This proportional hazards model may be further refined. First of all 
the model may be elaborated for stratified analysis when the proportion-
ality assumption is violated". For each stratum i the coefficients are 
identical, nnlike the ""(t): 
>(t) ~ ""(t) • exp (bh + b;h + ... + b_z,) (2) 
An application for transplantation is included in Gilks (1986). 
A related extension is the stratification of the covariates. In the two-
strata case we get (a is the stratum indicator): 
>(I) ~ >o(t) * exp (bh + bz,7, + ••• + /J,_,;zm + bm+~m+l + ••• + bpZp} (3) 
Variable z1 takes the value 1 or 0, and a indicates the stratum. Variables 
z2 to zm are variates with a significant different explanatory effect, hence 
b:~,a. 1 differs from b4a-u Finally variables zm+J to z, are variates in the 
model with an effect independent of the stratum chosen. 
In his analysis of cirrhosis patients treated with either azathioprine or 
prednisone Christensen proved the usefulness of this approach (Chris-
tensen, 1986). Theoretically this method is superior to that applied by 
Neuberger (1989) in estimating survival impact of liver transplantation, 
accounting simultaneously for prognostic factors which influence non-
transplantation survival, transplantation survival, or both. However, its 
data requirements are considerable21• 
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A last extension of the model may be the incorporation of time-
dependent variables. Equation 4 describes its general form. 
The function z(t) may be any function but usually it takes the following 
'switch' form (a=l, b=O, or the reverse) (Breslow, 1975): 
z(t) = 
{ 
z(t) = a; I< z 
z(t) = b; t> z 
(5) 
A refined version of this time-dependent indicator variable approach was 
suggested by Cox (1984 [p.129]). 
A relevant example of this time-dependent application of the propor-
tional hazards model using a 'switch'-variable may be found in Van Hout 
(1990). In cirrhosis no examples seem to exisrz. 
So far we are not aware of any application of the following more 
general elaboration of z(t): 
z(t) = f(t;z) (6) 
Generally, this extension of the proportional hazards model seems 
promising in many pathological processes. It enables to take the change 
over time of prognostic variables into account, rather than using the level 
of a prognostic variable at the onset of the observed survival time (as in 
the common time-fJXed proportional hazards model). For example the 
application in cirrhosis seems particularly justified. 
85 Analysis of swvival 
Techniques for prediction 
The covariates of the proportional hazards model may be interpreted as 
prognostic variables. If the model is estimated and b, b2 ••• ii, and >-o(t) 
are known, for each individual j we may calculate b ;c,i as a prognostic 
index (P~): 
p~ =In (~(t)f~o(t)) = bhi + b;;z2j + ... + bptpj (1) 
Several approaches exist to estimate the variance of P~ (O'Quigley, 1983; 
Andersen, 1983; Christensen, 1981). Van Houwelingen (1990) introduced 
alternative estimates of the error of n;. If P~ and the estimated cumulat· 
ive base-time hazard function A 0(t) are known, the function S (t;PI) of 
patient j predicts individual survival probabilities as follows: 
• c.. c.. • • exp(Pi ·) S(t,P1 j) = exp( -exp(P1 jAQ(t))) = S0(r) J (8) 
We define a prognostic model as a function which includes a basal ha-
zard function and a set of weighted prognostic variables and which to· 
gether predict survival probabilities in an individual case. 
Note that A 0.(t) is different for each prognostic model. (The index k 
refers to the particular prediction model chosen.) Hence when PlAi and 
Pl8i, based on model A and model B respectively, have an identical 
value, this does not imply identical estimated survival funtions23• 
The aggregated survival function S(t)* of a group of n subjects may 
be computed as follows. Suppose a group of n subjects, each subject j 
with an individually predicted survival function S (~PI ki) estimated by: 
So(r) exp(Piki) 
Chapter4 86 
For each subject j, either dead or alive at !he final follow-up date, !he 
maximum possible follow-up time ~ is defined as !he difference be-
tween final follow-up date and date of entry in !he study". 
Maximum possible follow-up times are put in reverse order of date of 
entry, !he most recent first, resulting in an ascending order of~: 
t,_, < ~ < ... < t_.,. 
We define n corresponding time intervals Ic (m = 1, 2, ... , n), with in 
each interval one patient less in possible follow-up, as follows: 
I1 = [0, t"""1 >, I2 = [t_1, t_, >, ... ,I,= [t_.,.1, t_., >. 
Next, !he survival function for each individual j is computed from t=O to 
~· For each time interval Im, !he aggregate nontransplantation survival 
is computed as the average survival of m patients with a follow-up 
including Im, as follows: 
The index m represents the number of patients with~ exceeding the 
upper limit of I= which decreases from n patients in I1 to one in I,. 
Next conditional survival probabilities are derived for each period I= 
each time assuming complete survival at the start of that period. 
The estimate for the group survival function Sk(t)* for the entire interval 
I [0, t_ i·• > is subsequently obtained by multiplication of all condi-
tional period survival probabilities, thus linking all adjacent intervals Im. 
This procedure yields a survival curve which is comparable to !he pro-
duct-limit estimator of observed survival, because expected individual 
survival functions are censored at the date of t_ ;· 
Two alternative approaches were proposed by Neuberger (1986) and 
Markus (1989) respectively. The Neuberger-formula of the aggregated 
survival curve for the entire interval I reads (see next page): 
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(10) 
The Markus-formula of the aggregated survival curve for the entire 
interval I reads: 
(11) 
The Neuberger-formula is particularly erroneous as it denies the expo-
nential nature of Pfi with regard to S(~Pl). The Markus-formula re-
sembles ours, except for a differently defined risk set. We illustrated the 
magnitude of these biases in a PBC-population (A3). 
4.4 Survival analysis in liver transplantation - overview 
During the development of liver transplantation an RCCf bas never set 
up, despite the high mortality of the procedure in the first decade of its 
clinical application. Remarkably, the explicit analysis of the survival 
benefit of liver transplantation as opposed to best conventional therapy it 
not to be found in the literature before 1988, 25 years after its intro-
duction. 
In the pioneering stage little survival information was made available. 
In the early adoption stage of liver transplantation survival analysis con-
sisted ouly of crude mortality figures. Diagoostic categories usually were 
combined, selection of reported cases often was often unclear and stan-
dard survival techniques were employed infrequently (Bouse!, 1988F). 
Since the NIH -conference in 1983, which resulted in diffusion of liver 
transplantation, the quality of reports has gradually improved (Anony-
mous, 1983A & 1984). 
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.Interest in factors predicting survival after liver transplantation has 
also been growing. This is clearly related to the availability of statistical 
packages containing routines for proportional hazards model estimation. 
Despite the awareness of the simultaneous effect of predictive factors on 
the survival with and without liver transplantation - the 'timing' problem 
(Haagsma, 1990 [p.5)) - no formal analysis on the survival gain with liver 
transplantation was published before 1988. 
In 1988 the final report of the Dutch liver MTA appeared, containing 
formal analysis of the net benefit of transplantation with regard to survi-
val and quality of life. In this context we should also mention two articles 
on survival gain of liver transplantation in PBC-patients in 1986 (Neube-
rger, 1986) and 1989 (Markus, 1989) respectively. As these research 
groups in Birmingham (United Kingdom), Rochester (United States) 
and Rotterdam were mutually unaware of their developmental work, the 
coincidence is remarkable. 
4.5 Survival analysis of liver transplantation: a selection of results 
In this section we shall present some results of the Dutch liver transplan-
tation MTA. Description of the programme and the patients as well as 
details about the survival analysis are provided elsewhere (Bonsel, 
1988E,F, 1989B; A3, AJO). 
The use of formal expeTt judgment was discussed with the transplanta-
tion team of the AZG in Groningen. However, this method was regard-
ed to be unfeasible for various reasons. 
The straightforward use of historical data was considered in liver car-
cinoma, but due to the small number of transplanted cases (3), a similar 
analysis already published was regarded to be sufficient (Ringe, 1989). 
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The quasi-experimental approach was used in the analysis of biliary 
atresia. Children with biliary atresia were treated with liver transplanta-
tion in the Dutch centre in Groningen from 1982 onwards. In the follow-
ing 5 years only a fraction of these patients were referred to !he AZG 
for liver transplantation in a as elect way (probably less than 25%). Most 
patients were treated elsewhere with a Kasai procedure only. 
Houwen published the combined Dutch experience in 1972-1987 with 
this treatment strategy (Houwen, 1989)25• Figure 4.2 compares !he Hou-
wen data with resnlts up to 31-12-1989 in !he AZG. 
Figure 4.2 Survival in biliairy atresia - Kasai alone (1977-1987) vs. 
Kasai and LTx (1982-1987). The Dutch experience. 
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Figure 43 Survival after screening for liver transplantation. Patients 
rejected for liver dysfunction (a.) and other reasons (b.) 
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The analysis of rejected patients was also carried out. Patients with 
hepatobiliary malignancies were excluded as the course of their disease 
is different from that observed in chronic cirrhosis. Figure 4.3 presents 
the survival of patients rejected for severe liver dysfunction precluding 
transplantation (a., n=19) and for other reasons (b., n=20)". 
Though a. by definition represents a pessimistic average shadow survival 
of a transplanted cirrhotic patient, it provides us a useful lower boundary 
of non-transplantation survival. In retrospect b. was rather close to the 
predicted non-transplantation survival curves of the group of patients 
with PBC or non-PBC cirrhosis. 
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Figure 4.4 SUIVival from entry on waiting-list. Transplantation period 
excluded ("without LTx") vs. transplantation period in-
cluded ("with LTx") 
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Waiting-list analysis has been rather unsuccesful in the Dutch liver 
transplantation MT A. We investigated waiting-list sum val, with three 
definitions of 10 If t 0 was defined as date of entry in the screening 
protocol or as date of provisional candidacy, the assumption of homo-
geneity at entry clearly could not be met. 
If 10 was defmed as date of appearance on the Eurotransplant waiting list 
for livers, homogeneity seemed reasonably guaranteed, but due to rather 
short waiting times, a valid shadow sUIVival curve could be derived for 
the first year after liver transplantation only (see Figure 4.4). For this 
reason waiting-list analysis in our case was only of limited relevance": 
5 
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Additionally we applied the proportional hazards model, starting at 
the three t,'s mentioned before, and including one time-dependent vari-
able (i.e. transplantation date). None of the models showed prognostic 
significance of transplantation (Bonsel, 1988F). In the case of the model 
with t, defined as date at entry on the Eurotransplant waiting list, this 
result could have been predicted from Figure 4.4. 
Finally we applied prognostic modelling in cirrhotic patients. First we 
shall give some general information on cirrhosis models. Then one ap-
plication in non-PBC cirrhotics will be presented. 
Before the availability Cox' regression model, the prediction of the 
course of cirrhotic disease (particularly of alcoholic origin) received 
already considerable interest. Ratnoff already pointed to the unfavour-
able signs and symptoms of cirrhosis whose influence now has been esti-
mated more precisely (see below; Ratnoff, 1942). 
Until the late 1970's, survival studies suffered from the unavailability of 
suitable statistical tools (see e.g. Garceau, 1963; Hiillen, 1963; Powell, 
1968; Child, 1968 [p.49]). Siegel's multiplicative risk model - in present 
statistical language - was a remarkable achievement (Siegel, 1969), 
though we are unaware of application of its cumbersome calculus out-
side the primary developing centre. 
At present there are many prognostic models for cirrhosis (Porayko, 
1990; Christensen, 1985 & 1989; Llach, 1988; Gines, 1987; Ji-yao, 1989; 
Dickson, 1989; Wiesner, 1989; A3; see also Table 43). Cross-validation 
experience has so far been limited (A3; Grambsch, 1989). 
A striking similarity may be observed. The cirrhosis models contain 
at least one variable related to the hepato-renal syndrome (ascites), one 
related to the synthesis capacity of the liver (albumin, PTT), one related 
to cholestasis (bilirubin) and one frailty variable (age). 
As might be expected, the cholangitis model is slightly different. 
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Table 43 Seven prognostic models for cirrhosis 
Author Diagnosis 
Christensen (1985)PBC 
Dickson (1989) PBC 
Christensen (1986)CAC,Cic,ALC 
Bonsel (A3) PBC,CAC,CIC 
Gines (1987) CAC,Cic,ALC 
Prognostic variables 
AG,AL,AZ,BI,PA 
AG,AL,AS* ,BI,PT 
AC,AG,AL,AP ,AS,BI,GB,NK,PA,PT 
AG,AL,AS,BI,EN,GB,HS,IC,PT 
AG,AP,BI,GG,HS,PT,SX 
Ji-yao (1989) PBC,CAC,CIC, AG,AL,AS,BI,EN,GB,HB,PT 
ALC 
Wiesner (1989) PSC 
AC - alcohol consumption 
AG= age 
AL =albumin 
AP = alkaline phosphatase 
AS = ascites (NB AS* = edema) 
AZ = azathioprine treatment 
BI = bilirubin 
EN = encephelopathy 
GB = g. -i. bleeding or varices 
AG,BI,HB,IB,PA 
GG - gamma-globulin 
HB = hemoglobin 
HV = HBsAg + 
IB = inflammatory bowel disease 
IC =icterus 
NU = nutritional status 
P A = pathology liver 
PT = prothrombin time 
SX =sex 
These empirieal models may be compared with the still universally used 
prognostic Child-Pugh classification (Child, 1968; Conn, 1981). 
The choice of the prognostic factors of the Child-Pugh classification may 
be criticized. The omission of age does not seem to be justified. The 
inclusion of hepatic coma is probably redundant; death usually rapidly 
follows hepatic coma as Hippocrates already observed in his Epidemics 
(1983B [p.136-137]). Hence hepatic coma has little prognostic relevance 
in our case. The efficiency in prediction is inferior to that in the prognos-
tic models for two reasons. The crude practieal interpretation (three cat-
egories instead of weighted real values) implies loss of information. 
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The assumption of equivalence of factors (unweighted summing up 
instead of weighted summing up, or better, multiplication as in Cox' 
model) is empirically untenable (Christensen, 1984; Ji-yao, 1989). 
However, as may be observed with similar rules in other diseases, the 
apparent sophistication of Cox' models (see e.g. Haagsma, 1990 [p5]) 
has not challenged the position of the Child-Pugh classification. 
Next the results are shown which resulted from application of 
Christensen's non-PBC model to 25 transplanted AZG-patients (Figure 
45; Bonsel, 1988F). The results in PBC are published elsewhere (A3). 
Figure 4.5 Observed and model-predicted survival in non-PBC 
cirrhotic patients. Prognostic model of Christensen 
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Particularly in the case of the non-PBC model of Christensen the 
validity of the application was investigated. 
The Christensen model combines experience from alcoholic and non-
alcoholic patients. It assumes no difference in prognostic factors apart 
from the intake of alcohol. At our request, Christensen kindly reviewed 
model estimates for alcoholic and non-alcoholic patients separately: the 
relative importance of prognostic factors appeared to be essentially the 
same, apart from the additional alcohol factor in alcoholic patients (E. 
Christensen, personal communication). 
Histological re-examination of all Christensen's non-alcoholic patients 
was not feasible, hence we do not know the exact distribution of etio-
logical entities (particularly the auto-immune fraction). Our own analysis 
of a (limited) number of Dutch patients (131) with non-alcoholic cirrho-
sis of all kinds did not reveal a separate influence of diagnosis, hence we 
think that potentially a different mix of non-alcoholic cirrhotic patients 
does not violate the diagnostic homogeneity assumption. 
The homogeneity of prospect assumption seems slightly violated. The 
reference population of Christensen's model dates back from the early 
sixties. In the last 16 years Gines and others have demonstrated the 
beneficial effect of rigorous treatment of the hepato-renal syndrome 
(Gines, 1988). Their evidence suggests that a better overall survival in 
decompensated patients may be currently achieved. We expect the 
prediction presented in Figure 4.4 to be the lower boundary of shadow-
survival in non-PBC cirrhotic patients who did reveive a transplant. 
Finally a technical problem in the application of the Christensen-
model should be mentioned. Laboratory methods have changed, so not 
all these type of variables in the model are measured by the same 
technique. Though in some variables companoility appeared to be suf-
ficient, it remained uncertain in others (e.g. serum alkalic phosphatase). 
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4.6 Summary 
Survival analysis in MT A essentially consists of the application of already 
available statistical tools. Supplementary calculations are necessary to 
arrive at life years gained as an economic unit of effectiveness. 
Full exploit of explanatory regression techniques may be helpful in the 
estimation of survival consequences if no RCCf information is available. 
From our experience in liver transplantation we conclude that this 
approach is possible provided one or more of the following conditions 
are met: a. quasi-experimental control group data are available, b. 
intervention delay data are available, c. historical control group data are 
available, d. prognostic modelling is feasible using data from a., b. or c.. 
In all cases homogeneity of reference and index patients with regard to 
diagnosis and prospect should be sufficient, although the last method 
provides opportunities for adjustment. Particularly for prognostic 
modelling extensive data collection is required of both index and 
refemce patients (see e.g. Bonse~ 1988D). 
5 ANALYSIS OF HEALTH STATUS 
5.1 Introduction 
This chapter presents some considerations on the analysis of health 
statns. 
A separate discussion of health status is justified for several reasons. 
At the theoretical level the debate about how to measure health status 
still continues. At the practical level different choices on the design of 
health status measurement hamper the comparison of results, which is a 
major disadvantage in the context of M1'A (see chapters 2 and 3). The 
commercial aspects of health status measurement add a powerful dimen· 
sion to these scientific discussions. Lastly the growing public concern 
about the meaning and the application of health status measurements 
can no longer be ignored1• 
The chapter is divided into two parts, parallel to the two concepts of 
patient outcome distinguished in section 3.4: a medical and an economic 
one. 
The medical concept of patient's outcome consists of three indepen-
dent aspects (see section 3.4): survival, non-disease-specific health status, 
and disease-specific health status, of which the first two usually are the 
most important". Survival was discussed in chapter 4; in the first part of 
this chapter attention will be paid to non-disease-specific health status. 
As explained in chapter 3, the economic concept requires a single 
measure as an expression for the overall value of the outcome (or 
'utility'); generally money as an indicator for value is not accepted, hence 
'Quality of life' and 'health status' have different connotations, 'quality of life' 
being the more general term. In the context of measurement of health-related 
aspects of life we have a slight preference for 'health status', the term which will 
be commonly applied in this text. 
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proxy measures have been proposed such as life-years and QAL Y's. The 
use of life-years alone as a simple extension of conventional survival 
analysis was illustrated in chapter 4. 
In the second part of this chapter composite measures like QAL Y's are 
discussed. These composite measures combine information on survival 
and health status. 
Proceeding along these two concepts, we present a brief account of 
the concept, of the conceptual position of 'time', of the methods of 
operationalization, of the measurement instruments currently in use and 
of the methods of data collection. 
Reference will be made to the investigations undertaken during the 
transplantation MTA's which are largely presented in the appendix (A4 -
AS). We have tried to avoid duplication of information. 
5.2 Description of health statns - the medical concept 
Descriptive health status: a theoretical, unobservable concept 
Health status is a theoretical concept. It is not observable straightfor-
wardly like weight, colour, temperature, velocity or, in the domain of 
medicine, blood pressure and heart rate. As a concept this state like 
'stress', 'frustration', 'self-esteem', etc., defines health status to be an 
abstract mental construct, without a simple unambiguous empirical 
representation. The various words in use to describe its indirect measu-
rement point to this ('indicator', 'index', 'scale'). 
As a result the measurement of health status and the subsequent state-
ments on its value rests upon convention. This convention includes a 
theoretical structure (nomological network) in which health status 
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occupies a specific position. This structure in turn defines relations 
between the included concepts (among other things health status), it may 
prescribe instruments to measure concepts which are defined as measur-
able and lastly it enables predictions about expected relations between 
the collected data. From this follows that the theoretical structure also 
represents what the investigator thinks health status is, and subsequently 
how validity of the data may be established. 
Clinicians usually do not feel at ease if they are confronted with this 
abstract account of the concept of health status. However, they are 
usually unaware of the multitude of such unobservable concepts in clinic-
al practice. Examples are heart function, liver functional capacity, neo-
natal condition'. These concepts have much in common with health sta-
tus from a methodological point of view. 
As with health status, these 'natural' clinical concepts give rise to a 
number of approximating measurement instruments, which have been 
developed parallel to the development of the concept. 
A second parallel is the continning debate about the best operationaliz-
ation of these concepts e.g. about the best indicator of liver function. As 
with health status, the debate is reigned by both a priori scientific beliefs 
and the results of empirical investigations. 
Descriptive health status: a theoretical structure 
We regard health status to be a characteristic of human life, defined by 
aspects such as grief and misery and by satisfaction and happiness. Since 
there is usually no straightforward relation between the theoretical con-
cept 'health status' and particular empirical observations, a theoretical 
structure should be devised. A general form of this structure is presented 
in Figure 5.1 which is derived from Campbell (1976 [p.l6)]). 
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In the centre we find health status, the core concept which lacks direct 
empirical representation. On the left we find the so-called domain part 
(instead of domains some speak of dimensions or aspects), on the right 
there are what we might call expressions. (Refmements of Campbell with 
regard to the domain part are omitted). 
Figure 5.1 A theoretical structure for descriptive health status 
DOMAIN 1 EXPRESSION 1 
DOMAIN 2 t--->- EXPRESSION 2 
DOMAIN n "I EXPRESSION n 
Domains (aspects, dimensions) are thought to determine health status. 
Domains include physical, psychological, social and various other do-
mains. Considerations about their selection are found in De Haes (1985, 
1988) and A4. Domains refer to attributes of an individual which may be 
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determined objectively like walking distance and depressive status (!) 4• 
It is a matter of taste and convention whether or not to include non-
health related (or not unequivocally-health related) domains. Expressions 
are more difficult to define. Usually concepts are used which are thought 
to be related causally to health status. Experienced well-being, both in 
an affective (happiness) or cognitive (satisfaction) way are the most 
common concepts encountered. These two concepts have their back-
ground in psychological theory'. We might also think of a specific beha-
vioural response or more remote consequences of health status changes. 
A clinical example may illustrate the structure. If we read liver function 
instead of health status, 'expression' might be read as (e.g.) hepatorenal 
syndrome and 'domains' might be read as ascites-score, serum-albumin 
and renal excretion of sodium under standard conditions in that case. 
Such a structure may be used to analyze the health status concept in use 
in a particular study and also to analyze a particular measurement in-
strument. 
At this point we must distinguish between two situations encountered in 
health status analysis. 
In the first situation the theoretical structure provides us with 
expressions which may be defined as causal consequences of health 
status changes or as the representation of these changes. In the structure 
proposed by Campbell, the latter type of expressions are formed by the 
particular responses of (healthy) individuals to questionnaires represen-
ting 'happiness' and 'overall life satisfaction'. The responses to these 
questionnaires are thought to represent a direct consequence of the 
unobservable, latent variable 'quality of life'. Other measurable conse-
quences may be thought of. 
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In the second situation expressions are lacking: the concept of health 
status lacks consequences to be predicted (which does not preclude the 
existence of predictive properties). 
The hepatorenal syndrome example may be regarded as a clinical 
representation of the first situation; the NYHA-classification and the 
APGAR-score probably are clinical examples of the second. In both situ-
ations the choice of the domains origin from a priori reasoning (seeA4), 
but in the first case opportunities for validation are better as pointed out 
by Kirschner (1985). For further conceptual discussions we refer to the 
extensive literature available6• 
Descriptive health status: the position of time 
In spite of the fact that 'time' is not a variable or an element in the 
model dsecribed above, it has a definite conceptual position in descripti-
ve health status measurement. The concept of health status, in the sense 
in which it is used in MTA and other evaluative research, is defined as a 
permanent attribute of human life. Thus, descriptive health status mea-
surement aims at efficiently describing a concept which, like body tempe-
rature and heart rate, is defmed permanently but which, unlike these 
examples, lacks continuous monitoring devices. 
Approximative measurement of health status is therefore necessary, 
which usually implies that patients are asked to participate in interviews 
at regular intervals. The frequency of interviewing and the period to 
which health status questions refer are important conceptual choices. 
Overall two schedules may be distinguished, a before-after measurement 
design and a longitudinal desigu7• 
If a unique, lasting change results from intervention, two measu-
rements appear to be sufficient, one before and one after intervention. 
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The post -intervention measurement should be scheduled at the time the 
recovery process may be expected to be finished. This design is tempting 
for two reasons: it is usually easy to implement and standard statistics 
suffice to calculate differences (and e.g. to estimate a priori an appro-
priate sample size). 
This classical experimental schedule is often not justified. 
First, the pace of changes in health status may vary. For example in the 
heart transplantation study the immediate changes in cardiac function 
preceded changes in mobility and energy (return to almost normal levels 
after weeks), which in turn preceded changes in role function and work 
situation (return to normal levels after months to years; Bonsel, 1990B). 
Secondly, information on the course of disease and not merely the status 
at a particular endpoint is of critical value. Measurements during the 
treatment episodes give valuable information about the price to be paid 
for ultimate recovery. Longitudinal information will also shedd light on 
the process of psychological adaptation. 
Thirdly, definite and complete recovery without recurrence or change is 
a desirable but rarely encountered endpoint of a disease process. 
For these reasons longitudinal designs should usually be preferred, al-
though they carry with them specific problems with regard to feasibility 
and type of analysis (particularly the handling of losses to follow up). 
In practice the frequency is not the result from conceptual considerations 
alone: clinical practice and the condition of the patient usually pose 
some limitations. 
Generic health status measurement instruments: conceptual considerations 
Given the health status model, its operationalization (i.e. the construc-
tion of measurement instruments and the data-collection design) should 
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be decided on. Dessens and Janssen (1987) already pointed to the rele-
vance of different operationalization methods for the health status 
model8• Though this may be relevant for the further development of 
health status research, the issue will not be discussed here. Attention will 
be restricted to disease-non-specific ( syn. generic) descriptive health 
status instruments which result from the standard approach'. 
Three types of generic health status measurement instruments may 
be distinguished according to the ascending level of aggregation: a classi-
fication, a profile and an index". A special feature of a proflle is that if 
it claims to be comprehensive an index may be developed validly from a 
profile. Thus we constructed an NHP-index, based on the responses of 
about 100 renal dialysis patients (Bot, 1991 ). 
For a discussion on other features of generic health status measurement 
instruments like the particular dimensions, items and response modali-
ties to be chosen, the reader is referred to current textbooks and recent 
publications on health status measurement in MTA (A4, Bot, 1991). The 
criteria feasibility, internal consistency, reliability, validity, responsive-
ness/sensitivity, suitability to support patient outcome valuation (in the 
context of the economic concept of outcome - section 3.4) and suitability 
for use in the Netherlands enable judgment on current instruments. 
Surprisingly, basic psychometric evidence on the properties of well-
known instruments is rather scarce. 
Measuring health status: practical consideralions 
Basically three techniques are available for data collection: observation, 
questionnaires and interview. Each method has its advantages and disad-
vantages. Indirect measurement by observation should be reserved for 
special occasions (e.g. the very young or the mentally handicapped). 
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The main advantage of questionnaires in this context are their 
modest use of resources and their ability of eliciting response m a 
standard way. A major advantage of the interviewing method is the pos-
sibility of the interviewer to enhance data quality during the interview 
and to record additional data (characteristics of the patient, for example 
the response behaviour). However, patient interviewing is demanding. To 
obtain reliable standard health status scores requires the availability of 
experienced interviewers, a sophisticated interview design, an equally 
well-developed design of the answer scoring and ample resources. Given 
these characteristics we usually prefer patient-based questionnaire data-
collection in MTA. 
Regardless of the data-collection method, a closed and structured de-
sign is required to achieve a standard and quantitative health status-
description. However, sometimes additional research objectives may 
suggest the supplementary use of an open, less structured design. E.g. in 
the MTA of the British Heart Transplantation Programme the admini-
stration of one highly structured questionnaire (NHP) was combined 
with a semi-open interview to ascertain that no unexpected consequences 
of this new teclmology remained unnoticed using the standard question-
naire alone (Buxton, 1985). 
Lastly we should mention computer assisted interviewing (CAJ), a 
technique of data collection which has become available recently. The 
computer may be used by the interviewer or the respondent. 
In the latter case the computer presents a questionnaire to the patient 
on a monitor. The patient uses the keyboard to express his opinion: al-
phanumeric keys to 'write' open answers, numeric keys to choose from 
predefined answers and special keys for special features e.g. the drawing 
of lines (visual analogue scale). Up to now CAJ has proven to be a valid 
substitute for paper and pencil questionnaires. Our own experience with 
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various patient groups has shown CAl to be advantageous in a research 
setting with regular follow-up at a clinical or an outward department 
(Bonsel, 1988). 
Description of health status in MTA's of solid organ transplantation 
Below we give a short account of the strucure of health status analysis in 
the MTA's on which this thesis was based, and of the two predecessors 
of the heart tranplantation MTA, by Evans (1984) and Buxton (1985) 
respectively. 
Campbell's model was completely adopted by Evans in the MTA of 
heart transplantation and the MT A of treatment modalities for patients 
with end-stage kidney disease (both studies took place in the United 
States). In these studies the separate Sickness Impact Pror.Je dimensions 
represented the domains. The so-called Index of Psychological Affect 
scores and the Global Well-Being scores represented the expression part 
of the model11• No evidence was published about the fit of the observati-
ons to the proposed structure. 
Evans adopted a cross-sectional measurement design probably for practi-
cal reasons. This design limited the interpretability of the results (for 
example a 'healthy survivor' effect was likely; Bonsel, 1988). 
Buxton applied the general structure without particular expression 
concepts. A patient interview with specific attention to a priori defined 
domains was combined with a fixed 3-month administration of a health 
status questionnaire (the Nottingham Health Profile). 
In the Dutch MTA's of heart and liver transplantation Campbell's 
model was adopted, adding some of his refmements of domain measure-
ment. As in this particular medical context we regarded the future 
outlook, as perceived by the patient, an essential part of the expression 
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side of the model, a measurement instrument for this concept was 
developed (Bonsel, 1988B & 1988C). 
The fixed 3-month time schedule was identical to that of Buxton, though 
some parts of the lenghty questionnaire were for obvious reasons repeat-
ed at a lower rate (Bonsel, 1988B). Computer asisted interviewing was 
applied. Results are published elsewhere (A4, Bonsel, 1990B). These 
studies too have not reported on the confirmation of Campbell's model. 
5.3 Valuation of health status - the economic concept 
With the economic concept of health status we enter the domain of ends 
and means in health care. The means essentially are the health services 
i.e. the technology under investigation or its best alternative. The ends 
refer to patient outcome. 
As explained in chapter 3, the price of health care services does not 
reflect the economic value of the associated patient outcome. Health 
economists have accepted other parameters which all are thought to be 
relevant outcome parameters: life years gained, quality adjusted life 
years gained and the healthy years equivalents gained12• All are based on 
length of life as the core of patient outcome, which seems reasonable 
from a conceptual point of view (see Richardson, 1990 [p.16-18]). 
The straightforward use of life years alone (in conventional cost-effecti-
veness analysis) requires an extension of standard survival analysis (see 
chapter 4). Below we shall concentrate on the more complex procedures 
for valuation of patient outcome, which are needed in cost-utility analy-
sis. The section starts with a general account of utility. As Richardson 
(1990) has published a highly estimated analytical paper on the subject, 
reference to his paper will be made repeatedly. 
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The economic value of patient outcome: a theoretical concept 
In the preceding text we have loosely used the term 'economic value' or 
'utility'. An indication or, better, a defmition of utility is necessary to 
arrive at a suitable operationalization. This definition is to some degree 
a matter of convention, as utility occupies a specific, but not exactly 
defmed, position within economic theory. Richardson's account of this 
position shows that the following two defmitions (interpretations) are the 
most important in our context: 
1. utility is an index which represents the strength of choice or prefe-
rence, with cardinal properties; 
2. utility is the linear summation of probabilities times quantities that 
are defined by a set of axioms. 
The first definition descnbes the concept and states an important pro-
perty (cardinality) of the index which should be constructed; the operati-
onalization is left open. 
With the last defmition utility is only operationally defined, though its 
meaning may be understood within the context of the Von Neumann-
Morgenstem axioms of rational behaviour: it is regarded to reflect 
preference given axiomatic rationality". 
An important difference between the definitions is the position of 'risk' 
andjor 'uncertainty', which is an essential element of the second defini-
tion. 
Next we proceed with utility, however defmed, in the context of 
valuation of patient outcome. 
First it shonld be stressed that patient outcome in this section refers to 
length of life and to all the attributes of health status that are considered 
to be of additional relevance in decisions (see section 3.4). What we in-
tend to value is an array of outcomes with different lengths of life and 
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varying levels of health status within each 'branch' (see the vector con-
cept of Mehrez, 1989), which altogether represents the expected future 
of a patient given some decision. 
Secondly, the concept of risk underlying the second definition of utility is 
not equivalent to the concept of uncertainty, which is at issue if we state 
that uncertainty exists about patient outcome as reflected by the array of 
possible outcomes (for a detailed analysis, see Richardson, 1990). 
Thirdly, in this context the concept of utility reflects preference as 
defined before. However, the preference with regard to particular 
patient outcomes is unobservable in practice14• As stated before, no 
choice situations exist in which behaviour may be observed which may 
validly be interpreted as revealed preference: we for example do not 
need to buy particular medical services priced according to their as-
sumed effect on patient outcome. The comparison of patient outcomes 
by patients themselves might at least offer a second-best ranking. 
However, the few instances that a patient faces a realistic choice situa-
tion (for examples see the literature on clinical decision making) do not 
yield the preferences we want to know in MTA: the alternatives are for 
example limited to those accidentally imposed by the clinical problem. 
Thus we conclude that, though the theoretical concept of preference 
seems rather simple, it is still unobservable in a straightforward way. 
Patient outcome valuation: the position of time 
Time has a double meaning in patient outcome valuation: 
1. length of survival is an aspect of outcome associated with a probabili-
ty to occur and level( s) of health status. 
2. the ultimate value of an outcome is expressed in time units (QALY, 
HYE). 
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This double meaning is one of the causes of the intricacies of valuation 
studies: time often appears in one way or another in the health scenario 
to be valued and in the valuation procedure itself. 
Measurement procedure and measurement instruments 
A measurement procedure has been accepted for a third-best (see pre-
vious alineas) three-stage measurement of preferences (AS). 
Frrst, a health scenario description is derived from prior information on 
the prognosis (defined as the array of possible survival and health status 
consequences) of the particular intervention. For pragmatic reasons a 
health scenario will usually be reduced to the description of a health 
state with a particular duration and with a fixed particular health status15• 
This predefined duration may reflect complete survival within a particu-
lar branch or a period within this branch with assumed constant health 
status e.g. a year'6• This index health scenario will be valued in the 
following step. One of a dozen available methods is used to arrive at this 
scenario-specific value (amongst others category rating, magnitude 
estimation, time trade-off, standard gamble, see A4, A5)17• All methods 
require the allocation of a value to an index health scenario with particu-
lar length of survival and with a fixed particular health status, by com-
paring it with another reference health scenario or with two other 
reference scenarios. The method of comparison is the assignment of a 
rank, a value-equivalent, or a probability-equivalent respectively (for 
details see Torrance, 1986; Bonsel, 1988C; A6). The value which results 
from the comparisons usually is transformed to a value ranging from 0 
(zero) to 1 (one). Using modelling techniques a multi-attribute utility 
function may be derived18 to predict values of any composition (A6). 
In the third stage the transfonned value is used as an adjustment factor to 
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adjust the life-year value of the predefined period. If the target health 
scenario already has the complete duration of the branch, this will suf-
fice. If not, additional valuations of the remaining periods within the 
branch are necessary. 
Finally summation of the resulting adjusted period values results in a 
branch-value expressed in quality-adjusted life years (QALY's). Multiple 
branches may be summed19 to get an overall value of one path of the 
decision problem (for example a treatment alternative). 
The central assumption of this three-stage procedure is that preferences 
for different outcomes are approximated adequately by the use of qua-
lity-adjusted life year values. As opportunities to test this assumption are 
scarce, some remarks which arise from the measurement procedure it-
self are presented. 
1. To our knowledge until now never a range of branches but only a 
single branch with fixed duration (without further survival-ramifica-
tions) and a fixed level of health status has been valued. It has been 
stated that this reduction disposes the real preference problem of the 
uncertainty aspect (Richardson, 1990). The so-called healthy-years-
equivalent method (see Mehrez, 1989A & 1989B) has been devised 
to adress this problem. This procedure arrives at QAL Y's (which are 
called HYE's) using a standard-gamble based method which has 
been claimed to be able to value a health scenario consisting of 
multiple branches simultaneously. The reported evidence is limited to 
the singular branch case. As there is no clear conceptual difference 
between the two-stage HYE-method and the existing one-stage TIO-
method (see Richardson, 1990), we prefer the latter or any of the 
other valuation methods available for their practical convenience. 
No experience has been reported with the valuation of complex pa-
tient outcome descriptions; we also used the single branch approach. 
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2. An important feature of the method of translating the complexity of 
patient outcome into assessable scenarios is the applied system of 
health status description. Within a the EuroQol-gronp, we were able 
to devise an internationally applicable descriptor system, which 
partially drew on the earlier experience in the Dutch MTA's (Bonsel, 
1988C; A6 -AS). 
3. A last feature of the first stage of the measurement method is the 
choice of an unambiguous method of describing a scenario with a 
particular descriptor system (that of the EuroQol-instrument"') using 
empirical data about the health status. In the Dutch MTA's we adopt-
ed a formal approach for the descriptor system developed prior to 
EuroQol (as described in A4 and A6) but a similar algorithm for 
EuroQol has yet to be established. 
For remarks on the second stage of the procedure we refer to Lipscomb 
(1982), Froberger (1989), Richardson (1990), and the appendix. 
We agree with Richardson that within the context of the second-best 
methods the time-trade-off method conceptually fits best to the use of 
units time to represent preferences. 
The most difficult challenge of the second stage of this procedure was 
getting respondents to perform a valuation task that indeed represents a 
cardinal preference of realistic scenarios. The EuroQol-group showed 
progress in this respect after lengthy experimentation with the measure-
ment procedure (A7). 
The EuroQol·group is a group of collaborating investigatoiS in the field of 
health seiVices research and economic evaluation. Since 1987 the group is 
developing a standardized, non-disease-specific instrument (the EuroQol-
instrument) for describing and valuing health states (for details see A7). 
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The two last remarks are on the third stage of the procedure, the calcu-
lation of QALY's and the aggregation of quality-adjusted life years of 
different branches as an aggregate measure of patient outcome following 
a treatment choice. 
1. An important requirement for the use of the values resulting from 
the second stage of the procedure in QAL Y -calculations is the con-
sensus between respondents on the preference of health states. Using 
the EuroQol-system it appeared that broad consensus existed on the 
preference ranking of the 13 complex health scenarios presented. Of 
course this number should be extended, but the degree of (internati-
onal) consensus was remarkable (A7). 
2. As we pointed out in chapter 3, aggregation is to some extent a 
routine statistical operation. But it may be argued that in this case 
additional requirements must be satisfied if the overall result is 
indeed to represent cardinal preference. We are not able to give a 
full account of this economic problem (see Harsanyi, 1955; Pliskin, 
1980), but in A6 one of the requirements seems reasonably satisfied. 
This observation still has to be replicated with the EuroQol-system. 
Valuation of patient outcome: practical considerations 
Practical considerations of the measurement procedure are to be found 
elsewhere (e.g. Kind, 1986; Torrance, 1986; A6). 
In our experience the operationalization of all aspects of the proce-
dure is demanding, whatever valuation technique is chosen. Standard 
gamble was been particularly difficult to convert into a feasible design; 
the use of visual aids in our view might change the concept of finding 
probability equivalents. 
The use of health economists, public health officials and students fol-
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lowing a course on medical decision making as respondents in many of 
these studies places some doubt on the generalizibility of the results". 
Patient outcome valuation in MTA 's of organ transplantation 
In the American and British MTA on heart transplantation outcome 
valuation is lacking. Particularly in the excellent British study this lacuna 
is regrettable, as all the ingredients were apparently present to arrive at 
a cost-utility analysis. Results of the Dutch MTA's are given elsewhere 
(Bonsel, 1988C & 1988H; A4, A6). 
5.4 Summary 
Though many researchers express their belief in the existence of a 
yet to be developed perfect measurement instrument for health status 
description and a perfect measurement design for outcome valuation, 
none of the solutions so far in use is thought to possess all the defined 
characteristics. Given the cumulative effort of many experts in this field 
we think a perfect measurement instrument and a perfect design do not 
exist. However, we consider the theoretical foundations to be mature 
enough to justify choices on standardization among the measurement in-
struments and designs available. 
The role of choices is different in the description of health status and the 
valuation of outcome. With descriptive health status, a dear predictive 
concept is not available and conventions refer to both the theoretical 
structure and its contents. With valuation of outcome the predictive 
concept is clear, but due to 'limitations of the real world', again we 
depend on conventions on how best to approximate preferences. 
6 ASSESSMENT OF NEED 
6.1 Introduction 
The frequent nse of the word 'need' in health policy suggests that there 
is some real but unobservable quantity, which may act as a normative 
value in decisions and planning activities. In section 3.6 the key position 
of the assessment of need within empirical MTA was indicated. Never-
theless, the scarcity of theoretical and empirical literature suggests that 
the elaboration, operationalization and measurement of this concept are 
still difficult (see Bradshaw, 1972; Williams, 1978; Holland, 1979 [p.57-]). 
This chapter is therefore devoted to theoretical and practical features 
of the assessment of need. Section 6.2 deals with the concept of need, 
distinguishing between definitions based on expected health improve-
ment and defmitions based on other principles. A medical versus an eco-
nomic elaboration of the first type of need definition is discussed in 
section 6.3, followed by an empirical approach to the assesment of need. 
A crude distinction between 'incidence-technologies' and 'prevalence· 
technologies' is proposed. Methodological recommendations are provid-
ed for four major types of technologies (preventive, diagnostic, therapeu-
tic and rehabilitative). Section 6.6 describes our approach of need for 
liver transplantation. Section 6.7 presents a summary. 
6.2 Conceptual choices 
Although we commonly speak about the need for specific health care 
services, it is presumably not health care but improvement in health that 
patients are in need of. Health care is but a means to improve health. 
Even health, though valuable per se, is predominantly a condition to 
Cluzptcr 6 116 
arrive at other goals, like happy personal relations and welfare. 
Further refmement should distinguish 'need for' from 'demand for' 
and 'utilization of health care. We follow Matthew at this stage, keeping 
in mind that Matthew explicitly starts from the individual perspective. 
'A need for medical care exists when an individual has an illness or dis-
ability for which there is an effective and acceptable treatment or cure. 
It can be defined either in terms of the type of illness or disability caus-
ing the need or of the treatroent or facilities for treatment required to 
meet it. A demand for care exists when an individual considers that he 
has a need and 'Wishes to receive care. Utilization occurs when an indivi-
dual actually receives care. Need is not necessarily expressed as demand, 
and demand is not necessarily followed by utilization, while, on the other 
hand, there can be demand and utilization without real underlying need 
for the particular health service used (Mathew, 1971 in Williams, 1978)'. 
Clearly the essential features of need in this quotation are the appa-
rent scientific and ethical merits in the individual case (' ... an effective 
and acceptable treatment or cure.'). Mathew's text (e.g. the expression 
'real underlying need') suggest an objective scientific method to used. 
Furthermore 'demand' is an individual function of 'need' (' ... an indi-
vidual considers that he has a need and wishes to receive care'). Follow-
ing Mathew and others we ground need estimates for a particular health 
care programme or a particular medical technology on the expected value 
of the health improvement to be determined in a scientific way. 
Despite the apparent attractiveness of this concept of need, other 
viewpoints exist. One view starts from the primacy of the judgment of 
the patient. In this interpretation the subjectively felt need or the mani-
fest demand should be the starting point of an analysis of need. At the 
extreme this viewpoint defines the patient as a well-informed, rational, 
sovereign, economic agent acting on a well-priced health care market. 
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As put forward in chapter 3, it is exactly the invalidity of these economic 
assumptions in the health care market which in our view precludes a 
role for the individual patient in the analysis of need in empirical MTA1• 
Other views on the concept of need are visible in the debate on the 
pursuit of equity in health (care). These views do accept the external 
objective judgment instead of the judgments of patients themselves, but 
reject the criterion of expected health benefit. For example it has been 
argued that the condition of the patient, either absolute or related to 
some standard should determine need, apart from the improvement to 
be expected from medical care ("The worse off the patient is, the more 
he should receive help", see also section 3.83.). As this view denies the 
principle of relating ends (health) to means (health care), we think it is 
not acceptable as a guide to a MTA concept of need. 
63 A medical versus an economic definition of need 
Need can be conceptualized from a medical and an economic point of 
view. The expected health improvement is essential to both. Usually the 
expected health improvement is a rather abstract concept: an array of 
outcomes may usually be encountered; certain outcomes are not equally 
likely and comparison between options may be difficult. 
To estimate need on the individual level it may suffice to ask the 
patient's preference. His preference may show different principles of 
valuation of the relation between possible outcomes and their probabili-
ties. Patients may accept high risks of short-term mortality and severe 
morbidity in exchange of a slight chance of complete recovery from a 
chronic relentless disease. The reverse may also be true: risk-averse 
patients may hesitate to subject themselves to 'safe' surgery even if, on 
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average, a considerable health benefit is likely. In the individual patient 
his preferences will be usually be accomodated (Brock, 1990). 
A need estimation at the supra-individual level (e.g. the national 
level) requires a two-stage procedure. First the changes induced by the 
technology (or its alternative) to all potential beneficiaries should be 
empirically derived from a. the characteristics of these beneficiaries, and 
b. detailed knowledge about the prognosis (after treatment) related to 
these characteristics'". Next a uniform valuation principle should be 
applied (see for techniques section 5.3). The resulting values are as-
sumed to represent the individually expected health benefits, which may 
lastly be compared to some criterion value. 
Although the medical and the economic concept share the expected 
health improvement assumption, the concepts differ with respect to: 
a. the nature of need as an absolute vs. a relative concept; 
b. non-medical factors determining need; 
c. the units in which health improvements are expressed. 
Absolute ver.rus relative concept 
Doctors tend to stress the absolute character of medical need. A patient 
is indicated (or not) to recieve a particular treatment. From a legal and 
professional point of view treatment is indicated normatively the very 
moment a positive contribution of treatment to health is expected. This 
on-off defmition based on the provider's judgment drives the economist 
Williams to speak of need as a 'quasi--supply concept' (Williams, 1978 
[p.36,32]). Obviously efficiency considerations do not play a major role. 
Economists tend to stress the relative character of need. Two basic 
assumptions are responsible for this relative concept. 
First, in the economic view health care should be regarded as a commo-
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dity: its consumption depends5 on the expected benefits relative to the 
expected deployment of resources, and, ad libitum, to other (dis)utilities. 
Secondly, the desirability to apply a particular medical commodity de-
pends on characteristics of the target technology relative to alternative 
options for the same resources. Theoretically the opportunities forgone 
by the application of a specific technology may be sought in any health 
care sector, across the boundary of the specific health care unit involved 
in the application of the target technology'. 
From the empirical perspective the operationalization of the econo-
mic view is but an extension of the medical view. However, from a con-
ceptual point of view this 'quasi-demand' concept should be distinguished 
from the 'quasi-supply' concept mentioned before. The economic con-
cept implies that a trade-off has to be made between input and output 
characteristics of the particular commodity which have to be compared 
with those of other commodities. The medical concept implies a judg-
ment on output characteristics alone. 
If decision-making at the societal level is to be supported - as is the 
rule in MT A - the economic view on need is should be preferred in the 
general case. Optimization of the supply of technology is usually an 
explicit goal of societal decision-making on medical technologies. Capaci-
ty restriction is one of the options of decision-makers (see chapter 2, the 
description of Phase 5 of the decision cycle). Therefore we think that 
efficiency considerations require MTA-information on need related to 
the volume and organization of the particular health-care programme. 
Thus the economic concept may provide the opportunity for the optimal 
choice of quantity and quality7 of the health-care programme involved. 
Despite the theoretical preference for the economic "iew, we are aware 
that the medical view on need will suffice on many occasions, viz. if a 
technology shares high effectiveness with neglegible use of resources. 
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Non-medical factors determining need 
From a medical point of view only a few factors are allowed to re-
strict need as defined above8• We can think only of the ethical or moral 
acceptability of a particnlar technology. Acceptability is relevant if we 
try to estimate the need for e.g. abortion pharmaceuticals, neonatal units 
for very low birth weight babies, genetic screening facilities, etc. How-
ever, these examples of acceptability which limit the application of a 
particnlar technology, do not change the general picture: these objections 
function as absolute criteria. Their acceptation implies the complete 
absence of that particular need, their rejection the full presence. 
From an economic point of view all costs and disutilities should be 
taken into consideration. Decreased acceptability in this view is but one 
type of disutility. Need depends on the balance of the input-output cha-
racteristics, the disutilities and the alternatives. 
Units of expected health improvement 
The last difference is related to the empirical requirements of the above-
mentioned concepts. In both concepts the expected health improvement 
should be estimated. The operationalization, however, is different. 
Medical theory does not offer a paradigmatic set of parameters to be 
universally used in the measurement of the medical concept of need. As 
the medical judgment of need depends on the benefits of the target tech-
nology alone, disease-specific parameters are a logical choice to de-
termine need. For example, need exists if at least one expected month of 
life will be free of anginal pain due to the application of technology X. 
Difficulties arise when the predictability of the medical benefit is low 
or when a wide range of outcomes is possible. Depending on the aggre-
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galion principle adhered to10, we arrive at a relatively small need only if 
those included have a high probability of benefit or a neglectable proba-
bility of adverse effects, or a relatively large need if all potential bene-
ficiaries are included11 • 
Problems may also arise if we have to use multiple parameters (e.g. 
pain and mortality). Unequivocal results (e.g. a high mortality-low mor-
bidity pattern versus the reverse, as in some invasive versus non-invasive 
treatment dilemmas) may require the use of constructed multidimensio-
nal measures of benefit (e.g. QALY's). 
From an economic point of view only one parameter should be used 
to express health improvement. Money terms would please an economist 
but a proxy is thought to be acceptable (Drummond, 1987). This para-
meter shonld be interpretable as (gained) 'value' (see chapters 3 and 5). 
Which parameter(s) and whose values (the patient, the clinical expert, or 
society's representatives) has already been discussed. 
Economic theory provides us with various loss functions to deal with 
cases of low predictability of benefit at the individual level (see note 10). 
Need graphs 
The empirical assessment of medical need investigates the epidemio-
logy of specific medical characteristics in the popnlation. For example, in 
liver transplantation data are required on the stage-specific incidence 
and prevalence of non-infectious decompensated cirrhosis. These data 
should be combined with prognostic knowledge described in chapter 4. 
The empirical set-up for the economic assessment of need is not only 
directed at the epidemiology of these specific medical characteristics in 
the population. There is also 'the epidemiology' of expected resource use 
and disutilities. The resulting information should be combined. The 
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calculation of cost-utility ratios is but one method. Other aggregation 
rules may be adhered to (see section 3.8.1). 
The results of both approaches may be presented in a need graph (see 
Fignre 6.1). For convenience we assumed medical need and economic 
need to be measured in units of expected QAL Y's gained. Medical 
need 12 exists if these QALY's gained exceed a threshold (like X 1 and X, 
in Fignre 6.1) u. Economic need exists if the QAL Y I cost criterion 14 is 
exceeded, in the example arbitrarily defmed 1 QAL Y per 500 cost units 
(like X 1 and X_,). These criteria may yield conflicting results (X, and X_,). 
Figure 6.1 Need graph describing medical versus economic need 
0 
w ;;; 
<: (.9 
(j) 
>-
...J 
<: 
0 
15.---------------------------------------~ 
10 
• X1 • X2 
5 ---------------------------
• X3 
• X4 
0~~--~--~---L--~--~--~--L-~--_...J 
0 1000 2000 3000 4000 5000 
MARGINAL COSTS <ARSITRAI=tY LNITI 
123 Assessment of need 
6.4 'lncidence'-technology vs. 'prevalence'-technology 
In our experience the empirical assessment of need in practice can be 
carried out as follows. Attention is restricted to !bat part of the analysis 
which is similar in medically and economically defined need: the epide-
miology of specific medical characteristics in the population related to 
tecimology-specific health benefits. 
We propose a distinction be made between an 'incidence' -technology 
and a 'prevalence'-technology. Incidence-technology is technology which 
will be applied only once in tbe course of tbe medical entity (duration 
independent). Except in tbe case of technical failures repeated applica-
tion will not occur. Recurrence of the medical entity may cause repeated 
application but though related to the initial event it should be regarded 
as new medical entity. Technologies applied in high case-fatality situa-
tions (even with the technology) are a specific type of incidence-tech-
nologies: 'mortality'-technologies. 
Prevalence-technology will be applied more than once in the course 
of a medical entity (duration dependent). Repetition may be periodical 
or continuous. Application is indicated by the existence of a particular 
ill-health state. Discontinuation is the result of death or another definite 
change of tbe health state. 
Some incidence-technologies and prevalence-technologies are listed 
to illustrate the difference - patterns between the extremes may be ob-
served. Examples of incidence-technologies are ccronary angiography for 
anginal pain evaluation, heart transplantation for end-stage heart failure, 
physical therapy after tibial fracture treatment, vaccination for rubeola. 
Prevalence-technologies are for example blood sugar testing in diabetics, 
anti-hypertensive drug treatment, pre-eclampsial monitoring, physical 
therapy in cerebral palsy patients. 
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In our experience the choice of the most suitable empirical method 
to assess need depends on the above-mentioned distinction, the methods 
available and - of course - the available resources15•16• 
6.5 Technology-dependent recommendations 
In view of the incidence-prevalence distinction, the objectives of tech-
nologies (see Table 2.2) and the characteristics of epidemiological 
methods, this section provides some methodological recommendations. 
In all cases we assume detailed17 knowledge on the effectiveness of the 
technology involved. 
In preventive technologies18 need has little to do with states of actual 
ill health. Usually only apparently healthy people are confronted with a 
preventive intervention (a vaccine, a behavioural chaoge, a dietary 
regimen). In most preventive strategies a large number of individuals are 
approached, with only a few beneficaries (who cannot be identified ex 
ante1'). Estimates of need do not depend on this number of beneficaries 
(i.e. the number of diseased prevented) only, but also on medical and on 
economic considerations. Hence an empirical estimate of the need for 
prevention is not possible in a straight-forward epidemiological way. 
A mathematical modelling approach usually is then indicated. 
Diagnostic technologies may be applied in persons in apparently good 
health (as a screening technology) or in patients in ill health. In the 
latter case we assume a diagnostic process starting with a patient with 
complaints of an unknown disease and ending up with a description of 
diagnosis, health status and prognostic factors. Clearly the problems in 
identification of need in the former case do not differ much from those 
engaged in preventive technologies. However, the feasibility of an 
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empirical estimate grows as we walk down the diagnostic path. Diagno-
stic technologies applied in clearcut diagnostic entities give few pro-
blems. 
Need estimation of diagnostic technologies is difficult if a. patients' pro-
files are difficult to define and do not relate to conventional epidemiolo-
gical classifications (e.g. the need for an abdominal cr-scan), and/or if 
b. multipurpose application is likely to result in a multitude of heteroge-
neous patient profiles (e.g. the cr -scan and HBsAg-antigen testing). 
Usually these difficulties prevent a straightforward epidemiological 
approach. Results from experimentation (preferably an RCCT in a 
representative setting), analysis of the health-care programme (see 
section 3.4) and epidemiological analysis have to be combined. 
Treatment usually implies that some diagnostic label has been attach-
ed to the patient. The empirical estimate of need for a specific treatment 
may be relatively simple if this label is closely related to conventional 
epidemiological classifications. Close relation includes the absence of an 
additional set of conditions to be met before treatment is indicated"'. If 
additional patient data are required (for example on severity of disease 
or contra-indications) the estimation of need is more complex. As 
incidence-related data outnumber prevalence-related data, need estima-
tions on therapeutic modalities which are applied once in the course of 
disease are usually more easy to obtain than figures on continuous or 
intermittent therapies. 
With respect to assessment of need, rehabilitative technologies resem-
ble therapeutic technologies. As a rule rehabilitation is directed towards 
the improvement or the prevention of amelioration of functional status. 
Consequently its connection to conventional epidemiological classifica-
tions is rather loose. Health surveys and administrative data may com-
pensate for this disadvantage. 
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6.6 The need for liver transplantation 
The assessment of need for liver transplantation in the Netherlands was 
one of the issues of the empirical MTA of liver transplantation. The ana· 
lysis, finished in spring 1988, is shown in detail in the appendix (A9; see 
also Bonsel, 1988G). Parallel to the assessment of the need for liver 
transplantation in the Netherlands, the need for heart transplantation 
was investigated. Although the meL':!odology was similar, the results, 
whieh are not presented here, were less satisfactory (Bot, 1988A). 
We aimed at the estimation of the need for liver transplantation fol-
lowing the medical concept alone. Considerations of ethical acceptability 
(e.g. transplantation in the very young) were neglected. At that stage the 
application of the economic need concept did not seem possible. 
No longitudinal epidemiological studies of end-stage liver diseases and 
congenital liver diseases were available to allow for direct estimation. 
Thus we applied three indirect methods, partially following the above-
mentioned approach, defining liver transplantation as a therapeutic 
incidence-technology. Previous studies on 'the need for heart trans-
plantation provided some additional clues (Evans, 1984; Buxton, 1985). 
First the use of registry-data was investigated. We concluded only 
mortality statistics to be useful. The use of cancer registry data was not 
considered as malignancies (with only rare exceptions) were excluded 
from the protocol. National utilization registries (hospital admissions) 
could not be used due to classification problems and readmission bias. 
The mortality-based method started from national age and sex·spe· 
cific mortality data. In the case of liver transplantation the clinical syn-
drome (cirrhosis) fits well into a limited number of disease categories of 
the classification system currently in use (the ICD-9; WHO, 1977). 
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Adjusting factors were estimated to express the quantitative association 
between death due to a specific liver disease and suitability for liver 
transplantation. Thus we were also able to estimate the impact of futore 
inclusion of older patients. 
As a second method we used the data from the patient's registry of 
the liver transplantation centre (including all referrals) as a kind of 
utilization data. The conditions allowed for their valid use: 
a. the records of all referred patients were quite detailed, particularly 
with regard to the suitability for liver transplantation; 
b. the centre caught all patients from the Netherlands, being the only 
centre carrying out liver transplants; 
c. geographical variations in the distribution of the prevalence of the 
relevant diagnoses were uniikely"'. 
With this method (in the reports indicated as the practice-based method) 
current transplantation activities were extrapolated. Incomplete referral, 
relaxation of contraindications, inclusion of acute hepatic failure and 
retransplantation were accounted for. 
Finally we revised available epidemiological data on patients with 
specific liver diseases (literature-based method). As these data pertained 
to the incidence of the diagnosis at an earlier stage of the disease, addi-
tional assumptions were necessary. Some of these data originated from 
other countries, particularly from the United Kingdom. 
The three methods yielded corresponding results suggesting an an-
nual need of at least 25 liver transplantations. Without changing inclu-
sion and exclusion criteria, we estimated in 1988 a maximal need of 
about 70 transplantations (5 per 106 inhabitants) for the next, say, 5 to 10 
years. These estimates were close to those of O'Grady (1988) for the 
United Kingdom if we applied the same selection of age-range and 
diagnoses to his results. 
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In heart transplantation we were less succesful, particularly due to 
the fact that clinical heart failure does not match with the ICD-9. Also 
the clinical information on all referred patients was less detailed and the 
coverage of the two Dutch programmes was less clear. Suitable epide-
miological literature was even more scarce than in the case of liver 
transplantation. Hence we could ouly apply the mortality method with a 
low degree of certainty about its precision. 
6.7 Summary 
Conceptual choices and Jack of data dominate the analysis of need for a 
particular technology. In our view any concept of need should start from 
expected health benefits. With regard to the empirical task, we restricted 
our attention to the medical concept of need. The empirical analysis of 
need as an economic concept still awaits elaboration. 
An approach distinguishing incidence and prevalence-technologies is 
proposed. Even if a medical concept of need is adopted, data require-
ments often preclude the straightforward use of existing information. 
Some favourable circumstances allowed for an estimation of the need 
for liver transplantation by three independent method?'. 
Despite this apparent success, this issue urgently needs further 
development. Improved data availability from existing national registries 
would contribute to this development (Vandenbroucke, 1990). 
7 DISCUSSION AND RECOMMENDATIONS 
7.1 Introduction 
Medical technology assessment (MT A) has entered a new era (Reiman, 
1988; Fuchs, 1990). It has been acknowledged as an instrument which 
may have a beneficial influence on health-care policies. Its perspective is 
that of society and its objective is to pursue society's interest by support-
ing decisions on the health-care system. 
Currently at least three major types of MTA can be distinguished: 
meta-analysis, the Delphi technique and empirical MTA. This thesis 
focusses on the latter type of information generation which has shown to 
be a demanding research activity. It calls on the inventivity of the 
researchers to overcome methodological complexities and limitations of 
data acquirement. It calls on the cooperation of health care providers 
without offering them prior certainty about the nature of the results and 
conclusions. Lastly the valid use of it results requires a politically well-
structured decision-process. 
Some have doubted the relevance of empirical MTA-research acti-
vities and have questioned the additional value of empirical MT A above 
clinical research. In their view the current quantitative growth of MTA-
like research should be interpreted as a temporary political affair. This 
thesis defends the opposite position. 
This chapter will subsequently answer the three questions put for-
ward in section 1.7.: 
1. What is the scientific basis of an empirical MTA? 
2. Which conditions determine the fruitful application of empirical 
MTA results? 
3. How can MTA be developed further? 
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Most attention will be given to the first question about the scientific 
basis of MTA, to which the first part of this thesis was devoted. Section 
7.2 gives an annotated account of the methodological features of empiri-
cal MTA-research. 
Availability of a sound methodological approach is but one condition 
to ensure suitable results of MTA-research. The experience from the 
Dutch transplantation MTA's, particularly the MTA of liver transplanta-
tion, provided some conclusions on how to arrive at results which are 
both scientifically acceptable and politically useful. These conclusions are 
presented in section 7 3. 
Section 7.4 casts an eye to the future. The validity of results and their 
subsequent use is only one condition for further development of this 
branch of health sciences. We present an outlook on the additional work 
to be done to settle MTA within the family of health sciences. 
The chapter concludes with an epilogue. 
7.2 The scientific basis of empirical MTA 
The purpose of empirical MTA is the prospective evaluation of a health-
care programme from the true society and true time perspective, compa-
ring it to the available alternatives on the level of aggregation cor-
responding to that of the decision-maker. 
The legitimacy of the claim of a specific MTA-methodology is supported 
by the existence of a number of core issues in MTA which, if dealt with 
in a specific way, indeed make up such an evaluation. These core issues 
are: the action of the technology, the effects on patient outcome, the 
effects on the use of resources, the need for the technology and the role 
of actual and future uncertainties. Particular circumstances may justify 
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the addition of more issues but from the MTA-Iiterature we conclude 
that these issues are complementary to the topics on the effects and the 
future impact of the technology. The general methodological approach to 
these issues is described analytically in Table 7.1. This approach may to 
some extent be regarded as an extension of the economic evaluation 
concept as descn"bed by Drummond (1987). 
Table 7.1 Methodological approach of an MT A from a societal 
perspective 
a. a dynamic disease model linking the occurence and the development 
of disease to survival, health status and other events amenable to 
intervention; 
b. a technology application model, linking the employment of resources 
to the disease model via defined interventions; 
c. an overall structure of the model which allows for comparison over 
time of alternatives; 
d. uniform concepts for input, throughput, output and need, which are 
interchangeable in all branches of the model; 
e. uniform disease-non-specific measurement instruments for output 
measurement; uniform setting-non-specific measurement instruments 
for input measurement; 
f. a comprehensive approach to uncertainties. 
This approach has generally been followed in the Dutch transplantation 
MTA's and its predecessors in the United States and the United King-
dom (Evans, 1984; Buxton, 1985). 
Methodology to analyze the issues separately as a rule already exists 
(see chapter 3). Survival analysis may be found in biostatistics, analysis 
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of health status in clinical psychology and psychometrics, cost analysis in 
economics and the assessment of need in epidemiology. The point of dis-
tinction in Table 7.1 is the multiilisciplinary, quantitative approach. 
All efforts are directed towards an integrated comparison of the conse-
quences of choices. Commensurability of concepts and their operationa-
lizations is therefore mandatory. As the choices are made from society's 
point of view, comparing benefits and burdens, the influence of eco-
nomic concepts and analytical structure in MTA may be explained. 
Empirical MTA thus represents a scientific basis for societal choice 
(Farber, 1982). 
A major alternative to empirical MTA is the informal and/ or formal 
consultation of experts prior to decision-making. Perhaps another is the 
renouncement of specific information generation prior to judgment, as 
removing the veil of ignorance may be costly. Here we shall discuss only 
the first option. 
Some weaknesses are inherent to expert consultation. 
First, qualitative and quantitative knowledge on alternative treatment 
patterns in high-technology settings is limited. Secondly, there is usually 
limited expertise on costs and need compared with knowledge about the 
effects on patient's outcome. Thirdly, it appears to be difficult to express 
opinions on patient's outcome in an intersubjectively quantitative way; 
quantification of opinions on the other issues is even more complicated 
and few experts are capable of making complex integrating forecasts. 
Fourthly, the interests of the consulted experts may blur fair judgment. 
Hence, though a discussion of the results of empirical MTA with experts 
in the field is indispensible, expert opinion may not easily replace empi-
rical MTA-investigations (see also chapter 2). 
Some specific methodological recommendations for empirical MTA 
are given next. 
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In description of the action of the technology we advocate a distinction 
between qualitative health-care programme description and quantitative 
analysis of programme dynamics. The former should pay due attention 
to existing alternatives, including those within the non-teaching hospital 
setting. In the quantitative part we suggest the routine application of 
survival analytical techniques. 
Experience from the Dutch transplantation studies may support this 
recommendation. In the liver transplantation study it was thus possible 
to compare the Dutch programme with the average European experien-
ce (Bonsel, 1988E; AI). In the heart transplantation case the analysis 
was used to predict organizational and outcome consequences of various 
strategies of patient selection (Van Hout, 1990). 
Available evidence (e.g. NIH, 1983; Evans, 1984; Buxton, 1985; more 
generally, the issues of the Journal of Technology Asessment in Health 
Care) suggests that in current MT A -practice this issue usually lacks 
elaboration. From our experience we conclude that a clearcut explicit 
organization of patient flow in the clinical pilot programme with an 
administrative account of decisions is essential for success. 
Analysis of survival and health status is the cornerstone of the 
analysis of patient's outcome. It may be carried out from a medical-
descriptive and from an economic-valuing point of view. In survival 
analysis the consequences of differences between these views are limited, 
in health status measurement they are considerable. 
In survival analysis we advocate the thorough use of the available 
statistical methodology, which is equally useful from both views. Cox' 
proportional hazards model (1972) in particular has opened wide per-
spectives enabling, for example, the analysis of time-dependent effects of 
predictor variables and the estimation of survival consequences of new 
technologies in the absence of information from randomized controlled 
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clinical trials (RCCT's). 
The Cox' model was used for several purposes in the Dutch transplan-
tation MTA's (A4 and Van Hout, 1990). 
Available evidence on survival analysis has shown that the major pro-
blems are technical mistakes (see Bonsel, 1988F for an account of liver 
transplantation literature) and the slow adaptation of powerful statistical 
innovations. On the design level the impopularity of the RCCT in clinical 
practice is more important. Clearly these problems are not specific for 
MTA and their solution should be found in a change in clinical attitude 
and an active responsibility of MT A commissioners for design aspects. 
In descriptive analysis of health status we suggest the use of a general 
model which allows for various operationalizations. The role of the time 
horizon should be explicitly stated, as it directly influences the phrasing 
of items and the scheduling of interviews. Depending on the precise pur-
pose of the description and the style of operationalization chosen, exist-
ing measurement instruments may be chosen or new ones developed. 
An extensive set of criteria for the choice of measurement instruments 
suitable in health status research is available (chapter 5; Bot, 1991). 
In the transplantation studies we arrived at a health status model, 
derived from Campbell and others (1973; chapter 5; Bonsel, 1989A 
{p.115-133]). The choice of suitable measurement instruments and of an 
adequate timing of the surveys was a compromise resulting from theo-
retical, practical and financial constraints. The choice for computer 
assisted interviev.ing of patients turned out to be a lucky one, contnlmt-
ing to high efficiency of the enterprise. Statistical analysis was difficult 
due to right and left censoring of data. 
From our experience we conclude the major conceptual problems in de-
scriptive health status analysis to be the infrequent use of an explicit 
general model, the lack of well-documented questionnaires, the lack of 
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acknowledgement of the disease-non-specific perspective in MTA and 
the conflicts of interests which may easily arise in this issue. Only the 
latter two problems specifically pertain to MTA. Standard methodology 
is available, but incentives are lacking to apply already available know-
ledge from a shared perspective. 
A separate issue is the frequent absence of the experimental design 
which is equally detrimental to this issue as to survival. 
Economic analysis of outcome usually takes the form of a cost-utility-
analysis (chapters 3, 5). Up to now the ideal approach, cost-benefit ana-
lysis, has turned out to escape acceptable operationalization. Cost-utility 
analysis requires the separate outcome parameters (survival and health 
status) to be expressed in one unit. The resulting unit represents the 
'utility' of outcome. Numbers attached to utility should, like money, 
reflect 'value'', hence we speak of valuation in stead of description. We 
advocate the use of so-called Quality Adjusted Life Years as the best 
technique now available to arrive at utilities. The quality adjustment may 
be arrived at by a three stage procedure (see chapter 5). The use of 
QAL Y's or any other measure of utility rests on many assumptions, 
which require for carefully designed measured instruments. 
Within the context of the heart transplantation study we used an instru-
ment for quality adjustment which was particularly suitable for transplan-
tation patients (A6). Later we developed such an instrument for interna-
tional use together with a group of European colleagues (A7, A8). 
This issue, and in particular the use of QAL Y's, is perhaps the most 
controversial in MTA. Some of the controversy is on the use of measu-
res of effectiveness in general, as these are not invariant to age, gender, 
race etc. Both from a philosophical and a pragmatic view we do not see 
any valid alternative: any one-unit estimate will show preference for 
those with the largest potential of loss of healthy years: the severely 
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diseased young with a condition amenable to intervention. If we accept 
the use of effectiveness measures as a reflection of the value of the 
output from the deployment of resources, up to now no alternative to 
QAL Y's exists: healthy-years-equivalents are only an acronym attached 
to a specific variant of QAL Y's (Richardson, 1990). 
In reply to another part of the criticism, it shonld be stated that on the 
popnlation level broad consensus appears to exist on the relative desi-
rability of mnltidimensionally described health states with the same 
duration (A6, A7); agreed this is only one piece of the puzzle, but it 
supports the hypothesis that judgment on the (un)desirability of complex 
health stales is possible. 
Recommendations are directed at a wider application of a standard 
'QALY-toolkil' (the term is from Paul Kind). Choosing one standard 
may appear to be more important than lengthy discussions about which 
standard is best. 
Cost analysis is rather new. The principles formulated by Drummond 
may serve as a first guide. We suggest additional attention should be 
given to costs of care as opposed to costs of research, to the expected 
impact of scale effects, to the relevance of patient costs, and to the issue 
of future medical costs. Admittedly in the Dutch MT A's attention to 
most of these topics has been limited: the empirical task of description 
of direct costs was in itself demanding. 
However, the tendency of making gross comparisons of the cost-effecti-
veness of technologies makes some of these topics urgent For the same 
purpose reference values for broad and small disease categories are 
urgently needed (for an example see Koopmanschap, 1991). 
Additionally the negative consequences of absence of the RCCT-dala to 
cost-analysis should be mentioned. It may be even more difficult than in 
outcome analysis to acquire next-best estimates. 
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With regard to the determination of need the expected benefit from a 
particular technology in our view should determine the degree to which 
the need for a technology exists. This methodological principle connects 
the methodology of need to the methodology of the other core issues 
(see chapter 6) and to the optional issue of distributional aspects. 
Some people have suggested that 'subjective' need (more precisely: 
manifest demand) be accepted as a basis for need estimates. As altruism 
is uncommon, it is unlikely that this approach will yield efficient nor 
equitable results. An economic interpretation of need additionally 
requires specific cost information. 
In liver transplantation medical need could be estimated with acceptable 
certainty due to some favourable circumstances (chapter 6). In heart 
transplantation this was not possible due to lack of epidemiological data 
on heart failure (Bot, 1988A). In neither case did we try to arrive at the 
economically defined need. 
We conclude so far that two major problems exist in the determination 
of need: lack of conceptual clarity and severe underestimation of the 
empirical task. However, the alternative of asking experts incorporates 
serious disadvantages as we experienced in the liver transplantation 
study. Thus we recommend the institution of a feasibility study on the 
routine use of the national hospital admission registry for this question. 
We regard the analysis of uncertainty (scenario analysis) as a separate 
issue. The nature of uncertainties differs considerably but their technical 
treatment may be similar (e.g. by stochastic modelling). 
The liver transplantation and the heart transplantation study showed the 
relevance of thorough scenario-analysis. 
The major problems in scenario-analysis are the technical and political 
requirements, and the difficulty of presentation. All parties in MTA 
would benefit from a shared participation in this part of the analysis. 
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Fmally, we provide some remarks on two issues regarded as optional. 
In chapter 3 it is argned that equity considerations have sofar been of 
limited relevance in MTA. Data requirements are extremely high (parti-
cularly in the elaboration of Rawl's equity rule). Even in the case of liver 
transplantation we do not expect equity analysis to be possible; moreover 
the practical importance may be doubted. 
Legal and ethical issues should not be neglected but we think they are 
important after we have factual knowledge on the abovementioned isues. 
Summarizing section 7.2 we think the question of whether there is a 
specific scientific basis for MTA has to be answered affirmatively. 
7:3 Conditions which determine the fruitful application of empirical 
MTA-results 
The answer to this is twofold. The first part describes the political 
conditions, the second t.':!e investigational conditions. 
The political environment should generate relevant questions and 
should employ explicitly the information supplied. We recommend a 
decision-cycle be instituted as proposed in chapter 2. 
In the Netherlands the National Health Insurance Board proposed a 
decision-cycles of this kind for all new technologies and the decision-
process on heart and liver transplantation may be regarded as an exer-
cise in this respect. Despite this favourable development in the Nether-
lands and similar developments abroad, some features of the current 
political context of MTA could be improved. They are presented in 
order of the phases in the decision-cycle. 
As resources are limited, a rational selection of technologies to be 
subjected to MTA is required. 
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Criteria for selection are suggested in chapter 2 and reflect the potential 
impact of the MTA on health and health care. This is to some extent 
contrary to current policy to institute MTA's for ad hoc budgetary or 
ethical reasons alone. 
MTA requires a clear definition of the decision problem. Relevant 
aspects should be mentioned, criteria be stated, where necessary. 
From our experience we condude that MTA's often· lack a pnor de-
scription of the study objective. Sloppiness in this respect can only 
partially be compensated for afterwards by retrospective tuning of the 
results. 
Given a well-defmed decision problem, the most suitable method of 
information generation should be chosen. As all additional research acti-
vities usually imply considerable investments, the available literature 
should be investigated first. A checklist of criteria for judgment is 
proposed in chapter 2. 
We conclude that the major drawbacks of existing information are lack 
of relevance due to cultural barriers (particularly between the Nether-
lands and the U.S.) and partial coverage of the core issues. However, the 
price of suboptimal suitability of existing information should be balanced 
against the costs of additional investigations and against the disadvan-
tages of delaying the decision. 
The recommendations on empirical MTA, one of the prototypes of 
information generation, were presented above and will not repeated here 
Some considerations on the subsequent political valuation of the 
collected information, the subsequent decision-making and the implementa-
tion of decisions are given next. Quick use of the MTA-results in the de-
cision-making should be attempted. Political inertia after a MTA may 
easily place doubt on the usefulness of MTA's. A clear relation between 
considerations and valuations on the one hand, and the supplied infor-
Chaprer 7 140 
mation on the other will contribute to the credibility of the procedure. 
Explicit relations between MT A and decisions were quite obvious in the 
Dutch transplantation cases (Van Rossum, 1990). Decision-making in 
these cases started during the MT A, though formal decisions were made 
afterwards. The link between the final MTA-results and the decision in 
our view was on average clear. 
In current MTA-programmes we recommend that more attention be 
paid to the anticipation of political decisions. 
Lastly we assume a feedback mechanism usually to be relevant in the 
phase after decisions have been made. Experience with monitoring and 
repeated evaluation is limited. It has recently been decided to monitor 
medical technologies regulated by the Hospital Provision Act (Art. 18). 
Heart transplantation and probably liver transplantation will be covered 
by this decision in the future. 
We expect that the withdrawal of proven dysfunctional technologies and 
particularly of technologies judged to be too expensive will be difficult. 
Irrespective of the status of the technology (accepted, rejected or some-
thing between) the proposed feedback mechanism requires a vivid poli-
tical environment and a receptive attitude of clinical centres involved for 
the required organization of data collection. 
The suitability of MTA-results is not only related to the existence of 
an appropriate political context. Empirical MTA's requires additional 
conditions for investigation to be met. We list five of them. 
First, the MTA-research team should be multidisciplinary, sharing 
medical, economical and mathematical expertise. 
Secondly, standardization of concepts, measurement instruments and 
integration techniques is required to enable comparitive judgment. 
With standardization we enhance both technical and political efficiency. 
A third condition is a good match of the clinical pilot programme(s) 
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to the empirical MTA. This frequently requires a particular set-up of the 
clinical programmes, inducing some change in the particular clinical 
research programmes concerned. In the liver transplantation study some 
questions were difficult to a dress due to partial misfit of the clinical pilot 
programme to the study objectives. 
A fourth related issue is the independence of MTA-investigators. 
Empirical MTA's with potential high impact should preferably be exe-
cuted by independent investigators. Otherwise the magnitude of the 
interests will otherwise create serious risks of bias. Independence also 
implies prior arrangements on scientific publication of results. 
Lastly during the MT A the political position of the parties should be 
kept clear. Policy research like MT A may exert considerable impact on 
the object to be studied and the reverse may also be true. This mutual 
influence is inevitable and may even be frnitfu!. To the extent the 
information exchange between the medical community and health-care 
authorities is stimulated, this intermediate role of the MTA-investigator 
is justified. 
From this section we conclude that conditions may be defined which 
enable fruitful application of empirical MTA results. In the Dutch trans-
plantation studies these conditions were generally satisified. 
7.4 Conditions which influence the future development of MTA 
We are aware that the answer to the third question posed in section 1. 7 
on the further development of MTA implicitly supports the idea of 
independent analysis of medical technologies from a societal viewpoint. 
Our answer on the long-term viability of MT A departs from desirable 
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scientific and policital developments and inevitably includes some specu-
lation. Evidence v;ill be drawn from experience in the Netherlands and 
from developments abroad, particularly in the United States, where 
MTA's were already being carried out in the late seventies. 
On the scientific level the relation of MTA methodology to clinical 
research and clinical practice should be developed further. 
In the pessimistic scenario MT A methods are regarded as a set of 
tools to be included in clinical research to some convenient degree. Its 
inclusion is only to satisfy sponsor's and scientific publisher's demands. 
In the optimistic scenario the clinicians recognize the long-term import-
ance of a 'dialectical' relation with MTA-investigators and their methods. 
A cooperative attitude is also needed for the theoretical and methodo-
logical challenges in MTA2• As empirical MTA's frequently provide op-
portunities for additional research, clinicians and third parties alike 
should be prepared to support these activities'. 
We are observing a growing demand from companies and health care 
authorities for empirical MTA, as piggyback research on already existing 
clinical investigations. Unaltered, the design of these investigations and 
the predefined methods of data collection and analysis give little oppor-
tunity for empirical MTA satisfying the criteria mentioned earlier. Hence 
we recommend prior involvement of MTA-investigators in the design 
phase of these studies. 
The scientific relation to the methodological neighbours, clinical 
epidemiology, biostatisti~ clinical decision making, health economics, 
psychometrics, and operations research should also be established. 
The viability in our view also depends on the self-supporting capacity 
of MTA units. The time involved in creating experienced multidisciplina-
ry teams asks for a consistent grant policy at the national level. We 
expect most benefits from the support of units of at least moderate size. 
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As a last recommendation we suggest that the university manage-
ment adapts to the organizational demands of this type of research. In 
the sector of health care information the environment changes rapidly. 
Flexibility is needed to keep up with the developments as these may be 
observed in the hospital and in non-university research settings. 
On the political level MTA should be increasingly regarded as an 
obvious cost-effective response to particular decision problems (see 
chapter 2)4• The utility of being uninformed is well-known, particularly in 
the health-care market. Hence future developments are difficult to pre-
dict. However, we expect that both health insurance companies and con-
sumer organizations5 will increasingly push health care providers to 
demonstrate the costs and effects of health services supplied. 
At least three scenarios may be thought of (a mix is likely). 
1. an increase of clinical centres incorporating for example a health 
economist on a structural basis to comfort the external demands6• 
2. an increase of trial ·administration and business administration 
offices, offering information technology on a WYW I WYG (what you 
want is what you get) base; information generated thus usually will 
not parallel information from MT A's. 
3. a steady growth of independent MTA-research despite some pressure 
from the health-care market forces and general anti-regulatory 
policies7• 
In the end we expect that the attitude of health insurance companies and 
consumer organizations will be decisive. When these parties recognize 
the adverse effects of a free market of health care8 and when they accept 
that the value of technologies is only loosely related to consumer satis-
faction, the political position of MTA will be established. 
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7 .S Epilogue 
The current technological explosion in medicine has provoked many re-
actions. Sceptical reactions from those judging the scientific advance 
from the net effects on the population's health9• At the extremes both 
averse and supportive reactions may be observed. 
In this thesis medical technologies are considered a priori as morally 
neutral. Critical analysis - MTA - and rational judgment are assumed to 
be possible and to address the ultimate value of medical technologies 
from a societal standpoint of view. This critical position provides us with 
a scientific basis for MT A. 
The assumptions of the quantification of medical benefits and socie-
tal efforts, and the structure of the proposed analytical approach reflect 
an economic interpretation of health care. In our view this interpretation 
does not originate from the assumed budgetary problems in health care 
giving rise to MTA-activities. Moreover the economic interpretation is a 
consequence of a general change of the societal perception of medicine. 
Public awareness of the scarcity of resources parallels the emancipation 
of the patient towards an assertive economic agent, the conscious 
exploration of his agency function by the health care provider and the 
unprecedented competition between health care organizations. This 
metamorphosis from religion to trade implies a change towards a more 
symmetrical relation of patient and provider and ultimately provides us 
with a future political basis for MT A. 
SUMMARY 
This thesis concerns a recently developed method of analyzing technolo-
gically induced changes in medical care. This method is known as 
'medical technology assessment'. Essentially its application should yield 
information to support decision-makers in the health care system. 
The results of our experience in the development and application of 
methods for medical technology assessment are presented in two parts. 
The first part gives a general theoretical overview of the subject. The 
second part is added as an appendix. It embodies the empirical part of 
the thesis and demonstrates the results from practical applications of the 
proposed methodology. This summary is restricted to the first part. 
Chapter 1 starts with a general description of changes in health care 
and the contribution of new technology to these changes. The systematic 
search for information on new technology is explained as a natnral 
reaction of all actors in health care. A growing awareness of the econo-
mic relevance of this information is obvions. 
Health-care authorities have gradually exchanged their passive and 
permissive role for a more normatively active role. The emancipatory 
development of consumer organizations in health-care is remarkable too. 
Both changes breach the traditional monopoly of health-care providers. 
The introduction and diffusion of new medical technology are no longer 
the domain of professional interest alone. 
This thesis draws most of its illustrative evidence from the Dutch 
MTA of liver transplantation, a study instituted by Dutch health-care 
authorities (1985-1988). The history of liver transplantation in the 
Netherlands and the position of this MTA is summarized. 
Three key questions are formulated which are considered to be 
relevant in the judgment of current and future value of MTA: 
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a. what is the scientific basis of an empirical MTA? 
b. which conditions determine the fruitful application of empirical MTA 
results? 
c. how can MT A be developed further? 
Chapter 2 presents a prototypical description of a rational political 
response to technologically induced changes in the health-care system. 
This description apparently fits current health policies in the Netherlands 
which aim at information-supported societal decision-making on new 
medical technology with high impact. The response is analytically de-
scribed as a decision-cycle with six phases: a. recognition and selection of 
technology b. definition of the decision problem, c. definition of the in-
formation need and selection of the information generating modality, 
d. information generation, e. decision-making and implementation, and, 
if appropriate, f. monitoring and repeated assessment. The roles of 
health-care authorities, MTA-investigators, and clinical experts vary 
according to the phase. 
This thesis focuses on the phase of information generation. Three in-
formation-generating modalities to be used in this phase are mentioned, 
viz. meta-analysis, Delphi-study, empirical MTA. The remaining chapters 
are devoted to the methodology of empirical MTA. 
Chapter 3 presents a conceptual description of the methodology of 
empirical MTA ·. A standard format is proposed consisting of five core 
issues: the action of the technology, the effects on patient outcome, the 
effects on the use of resources, the need for the technology and actual 
and future uncertainties. 
Empirical MTA is further usually indicated by MTA sec. 
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Methodological standardization is advocated, particularly the use of 
RCCf's and the synthesis of results by means of quantitative models. 
The arguments for standardization are, in our view, compelling: tech-
nically it enables medical and economic analysis to be combined with 
forecasting, politically it enables the comparison of various MTA-results. 
Some conceptual remarks are presented on the five core issues. 
The description of the action of a technology consists of a qualitative and 
a quantitative part. The qualitative part gives full account of the new 
technology and existing alternative interventions alike. The quantitative 
part applies flow chart and survival techniques to describe quantitatively 
the course of disease and patient's history over time. 
Conceptually the effects on patient outcome may be described from a 
medical and an economic point of view. In the first case survival and 
health status are separate concepts. In the latter case we usually use life 
years gained (with or without quality adjustment) as a comprehensive 
unit of outcome. 
The assessment of costs includes an estimation of both direct and in-
direct costs. The rationale of inclusion of future medical costs is dis-
cussed. The distinction between costs for research and costs for care is 
advocated, particularly if cost estimates of a clinical pilot programme 
serve as a decision-making, planning or budgeting tool. 
As with patient outcome we distinguish a medical and an economic ap-
proach to the need for a technology. In both cases the need as perceived 
by the individual is regarded not to be a reliable and valid instrument for 
the purposes of MTA, particularly not with new technologies. The quan-
tity of expected health benefits to be determined objectively forms the 
basis for both approaches. 
The analysis of uncertainties distinguishes between actual and future 
uncertainties. Actual uncertainties are of various natures: they consist of 
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unknowns due to in complete information, 'intangibles' (measurement 
problem) and 'imaginables' (defmition problem). Future developments 
are uncertain by defmition; usually they are to some extent predictable 
as an autonomous trend. Additional policy analysis provides insight into 
uncertainties due to changes in the environment of the technology. The 
quantitative approach of all uncertainties has much in common and rests 
upon the previously mentioned quantitative model. 
Two technical features of the proposed quantitative empirical approach 
are discussed separately: formal synthesis and subgroup analysis. Aggre-
gational techniques within MTA has received some criticism. We justify 
their application as an ubiquitous statistical technique. Political argu-
ments could be added. The political implications of subgroup analysis, a 
second standard statistical technique, are demonstrated. The last section 
in chapter 3 is devoted to distributional, legal and ethical considerations. 
Chapters 4 to 6 provide backgrounds to survival aualysis, health status 
analysis and the assessment of need. To prevent duplication emphasis is 
placed on methodological backgrounds supplemented with an abstract 
from our experience, shown in more detail in the appendix. 
Chapter 4 describes survival analysis in MTA. It is argued that survi-
val analysis predominantly consists of the enforced application of already 
available statistical tools. Supplemental calculations are necessary to 
arrive at life years gained as an economic unit of effectiveness. The 
challenge of many MTA's is the estimation of survival consequences of 
an intervention in the absence of any information from randomized 
controlled clinical trials (RCCT's); this absence is often observed in new 
technology. Several approaches to the estimation of control-group 
survival ('shadow survival') in this situation are presented, including the 
use of prognostic models. The technical approach of the last method 
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which allows for quantitative prediction is shown. These predictions may 
be used both at the individual and at the aggregate level. Also the 
computation of the number of life years gained due to the target techno-
logy is possible, provided the censored observations are treated appro-
priately. 
From our experience in liver transplantation we conclude that the esti-
mation of shadow-survival is possible if: 
a. quasi-experimental control group data are available, or 
b. intervention delay data (e.g. waiting list data) are available, or 
c. historical control group data are available. 
Additionally prognostic modelling is usually feasible if individual data 
from a., b. or c. are available. In all cases homogeneity of reference and 
index patients with regard to diagnosis and prospect should be sufficient. 
Chapter 5 presents some methodological considerations on health sta-
tus measurement both from a descriptive and a valuing point of view. 
Starting with descriptive disease-non-specific health status, it is argned 
that health status is an unobservable theoretical concept which is similar 
to many clinical concepts. For validity to be established, this state of 
affairs requires a. consensus on a theoretical structure containing the 
particular concept and b. consensus on facts to be predicted from a 
priori specified parallel or related concepts. 
For descriptive pwposes a general structure for the health status concept 
is proposed. If, subsequently, a questionnaire is developed, the choices of 
the exact elements of the structure (e.g. the dimensions) and of items 
and answer modalities, may be gnided by criteria of either statistical effi-
ciency or of interpretative soundness, each having their own virtue. Ad-
ditionally a comprehensive set of criteria is available to judge the feasibi-
lity and quality of descriptive health status measurement instruments. 
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Within health status measurement 'time' occupies an important position: 
the period to which questions on health status refer and the interview 
frequency are closely related and should reflect the underlying concept 
of health status. 
Our experience with health status description in the Dutch transplanta-
tion MTA's is described. Two features of the descriptive analysis appear 
to apply to a general problem in many MTA's: the difficult statistical 
analysis of right and left censored data and - as with survival - the 
difficulty of comparitive analysis in the absence of a control group. 
The second part of the chapter is devoted to health status measure-
ment as part of the economic measurement of patient outcome. Up to 
now the best available technique to arrive at an economic value of 
patient outcome is the calculation of life years gained or, if possible, of 
Quality Adjusted Life Years (QALY's) gained. QALY's require subse-
quent measurement of the patient's health status, construction of health 
status descriptions (vignettes, scenarios) and subsequently valuation of 
these descriptions. The use of QAL Y's in so-called cost-utility analyses 
rests on many assumptions, which ask for carefully designed measured 
instruments. As a result of a collaborative study we were able to develop 
an instrument for health status valuation in this context (EuroQol), 
which is internationally available. With this tool the validity of one 
critical assumption of QAL Y calculations could be confirmed: the inter-
personal consensus about the preference order of complex health status 
situations with a fixed duration. 
The results of cost-utility-analysis in the Dutch transplantation MTA's 
support the feasibility of the QAL Y procedure. 
As a separate issue chapter 5 reports the rewarding experience with 
personal computer-assisted interviewing in health status measurement. 
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Chapter 6 is devoted to the assessment of need for a particular tech-
nology. Conceptual choices and lack of data dominate. Frrst a definition 
based on expected health improvement or one of the available defmi-
tions based on other principles must be chosen. These conceptual 
choices are the same as those encountered in the definition of equity 
(see the end of chapter 3). In our view any concept of need should start 
from the first defmition. Next, a medical and an economic elaboration of 
this need definition is discussed. An empirical approach is offered, 
distinguishing between 'incidence-technologies' and 'prevalence-technolo-
gies'. Consequently methodological recommendations are provided for 
four major types of technology (preventive, diagnostic, therapeutic and 
rehabilitative). Favourable circumstances allowed estimation of the 
medically defined need for liver transplantation. 
Chapter 7 adresses the three questions mentioned in the introduction. 
What is the scientific basis of an empirical MTA? 
From the previous account it will be clear that this thesis defends the 
position this basis consists of a number of core issues, which are appro-
ached specifically. Rigorous standardization, quantitative modelling and 
integration of medical and economic concepts are the ingredients. In 
many issues standard tools are available or, even more important, 
standard methodology exists to arrive at these standard tools. The 
existence of methodological choices is not denied, but in our view these 
choices reflect both a vivid multidisciplinary debate and a close relation 
between scientific labour and societal discourse. 
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Which conditions determine the fruitful application of MTA results? 
The application of empirical MTA results apparently depends on the 
satisfaction of political and investigational conditions. With regard to the 
former a rational and explicit decision-process will clearly add to an 
effective and acceptable use of MTA-information. In the Dutch case the 
National Health Insurance Board (Ziekenfondraad) has proposed a deci-
sion-cycle as described in chapter 2. Though not entirely operational, the 
proposal has already resulted in three pilot MTA's (of in vitro fertiliza-
tion, heart and liver transplantation) and subsequently positively influen-
ced decision-making on these and other new technologies. 
Second to this are conditions for investigation, including the existence of 
independent multidisciplinary MTA institutes, the political support of 
these institutes regarding the application of standard methodology, and a 
match of the clinical pilot programmes to the MTA requirements. 
How can MTA be developed further? 
The answer to the last question on the future development of MTA is 
obviously of a political nature. The previously mentioned conditions will 
of course influence its development but we do not think they are essenti-
al. Moreover we think two other, general developments will be decisive. 
First, the development of scientific relations between MTA institutes and 
both their methodological and clinical neighbours. Secondly, the develop-
ment of a political momentum which acknowledges the permanent ne-
cessity of MTA research, as a natural response to asymmetrical econo-
mic relations in the provision of medical care. We expect this to depend 
on the nature of the emancipation of the medical consumer. 
SAMENVATIING 
Dit proefschrift beschrijft een methode om veranderingen in de gezond-
heidszorg onder invloed van medische technologieen te analyseren. Zij 
wordt wel aangeduid met 'medical technology assessment' (MTA)'. 
Het uiteindelijke doe! van MTA is het genereren van informatie ter 
ondersteuning van besluitvorming in de gezondheidzorg. Onze ervaring 
in het ontwikkelen en toepassen van methoden voor MTA worden in dit 
proefschrift beschreven. Het proefschrift bestaat uit twee delen. 
Het eerste dee! geeft een algemeen theoretisch overzicht over MTA. Het 
tweede dee! is toegevoegd als een appendix en bevat empirisch toepas-
singen van de in het eerste dee! voorgestelde methodologie. Hier wordt 
alleen dit eerste dee! samengevat. 
Hoofdstuk 1 beschrijft de effecten van veranderingen in de gezond-
heidszorg met speciale aandacht voor de bijdrage van technologische 
vernieuwing aan deze veranderingen. De structurele veu_ameling van 
informatie over uieuwe technologieen is een verklaarbare reactie van alle 
actoren in het veld van de gezondheidszorg. Zij zijn zich in toenemende 
mate bewust van het economisch belang van deze informatie. 
De rol van de gezondheidszorgbestuurders (in Nederland kan men den-
ken aan het Ministerie van WVC, de samenwerkende ziektekostenver-
zekeraars, de Ziekenfondsraad, hct Centraal Orgaan Tarieven in de Ge-
zondheidszorg, de Gezondhcidsraad en diverse koepelorganisaties) is a an 
verandering onderhevig. Een passieve en afwachtende rol wordt in toe-
nemende mate ingewisseld voor een actieve medebepalende rol. De 
emancipatie van consumentenorganisaties op dit terrein is evenzeer 
opmerkelijk. Het traditionele monopolie van de zorgaanbiedcrs wordt 
daarmee doorbroken. 
Een bevredigende Nederlandse vertaling ontbreekt. 
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De introductie en verspreiding van nieuwe medische technologieen zijn 
daannee niet Ianger een zaak van de professie alleen. 
Bij de beschrijving van MTA put dit proefschrift voor de voorbeelden in 
hoofdzaak nit de Nederlandse MT A van levertransplantatie, een studie 
die op initiatief van de Ziekenfondsraad en de Gezondheidsraad werd 
nitgevoerd (1985-1988). Om die reden wordt de geschiedenis van lever-
transplantatie in Nederland en de plaats van deze MTA kort beschreven. 
Hoofdstuk 1 besluit met drie vragen, die van toepassing lijken voor een 
beoordeling van de huidige en toekomstige waarde van MTA: 
a. wat is de wetenschappelijke basis van MTA? 
b. welke omstandigheden begunstigen bet gebruik van MTA-resultaten? 
c. hoe kan MT A in de toekomst verder worden ontwikkeld? 
Hoofdstuk 2 geeft een modelbeschrijving van een rationeel-politieke 
aanpak van technologische veranderingen in de gezondheidszorg. Deze 
beschrijving blijkt van toepassing in Nederland. Hier te Iande wordt ge-
streefd naar maatschappelijke besluitvorming over invloedrijke nieuwe 
technologieen op basis van zakelijke informatie. Deze aanpak kan in 
feite beschouwd worden als een besluitvonningscyclus, waarin zes fasen 
zijn te ondcrscheiden: a. herkenning en selectie van de te beoordclen 
technologic, b. definitie van hct beslissingsprobleem, c. dcfinitie van de 
informaticbehoefte en van de informatieverzamelingsmethode, d. infor-
matieverzameling, e. evaluatie, besluitvorming en implementatie, en ten-
slotte, indien opportuun, f. voortgezette controle en re-evaluatie. 
In ieder van deze fasen spelen bestuurders, MTA-onderzoekers en de 
toepassers van de technologic een eigen rol. 
Dit proefschrift handel! over de vierde fase, de informatiever7.ameling. 
Tenminste drie typen worden onderscheiden t.w. meta-analyse, Dclphi-
onderzoek en MTA primair op basis van empirisch onderzoek. 
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De resterende hoofdstukken zijn gewijd aan de methodologie van dit 
laatste type. 
Hoofdstuk 3 beschrijft met name de conceptuele aspecten van MTA-
methoden. Een standaard structuur wordt voorgesteld bestaande uit vijf 
obligate en twee facultatieve onderwerpen. De vijf s!eutelonderwerpen 
zijn: de werking van de techno!ogie, de effecten op de patient, de 
effecten op het middelenbes!ag, de behoefte aan de technologic en 
huidige en toekomstige onzekerheden. 
Methodologische standaardisatie wordt aanbevo!en, met name de toe-
passing van RCCf's en de synthese van uitkomsten door middel van 
kwantitatieve model!en. Er zijn dwingende redenen voor standaardisatie: 
in technische zin is het een voorwaarde voor het combineren van de 
diverse onderdelen tot een toekomstvoorspe!lend model, in po!itiek zin is 
het een voorwaarde voor vergelijkbaarheid van MT A's. 
Hierna vo!gen enige conceptue!e aandachtspunten ten aanzien van de 
voorgestelde vijf sleutelonderwerpen van een MT A. 
De beschrijving van de werking van de technologie bestaat uit een kwa!i-
tatief en een kwantitatief dee!. Het kwa!itatieve dee! beschrift de nieuwe 
technologic en haar alternatieven in vergelijkbaar detail. Hct kwantita-
tieve dee! past zgn. flow chart en overlevingstechnieken toe om het ziek-
tebeloop en de gang van de patient kwantitatief te beschrijven. 
De gevolgen voor de patient kunnen op twee elkaar aanvullcnde manieren 
worden beschreven, namelijk vanuit medisch en economisch gezichts-
punt. In het eerste geval onderscheidt men overleving en ziekte-
aspecifieke kwaliteit van Ieven (gezondheidstoestand) als twee gelijk-
waardige uitkomstmaten. In het tweede geval worden levensjaren, even-
tueel met kwa!iteitscorrectie, als alomvattende uitkomstmaat gcbruikt. 
Voor het vast stcllen van het beslag op maatschappelijke middelen, kort-
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weg de kosten, wordt onderscbeid gemaakt tussen directe en indirecte 
kosten. Beargumenteerd wordt dat alle toekomstige directe kosten moe-
ten worden inbegrepen. Het onderscheid tussen kosten voor zorg en 
kosten voor onderzoek verdient aandacbt, vooral als kostenschattingen 
van een kliniscb ontwikkelingsprogramma worden gebruikt als bulpmid-
del voor besluitvorming, planning of fmanciering. 
Evenals dat bij de gevolgen voor de patient bet geval was onderscbeiden 
we een mediscb en een economische benadering van de behoefte aan een 
technologie. In be ide gevallen wordt beboefte naar bet oordeel van de 
patient zelf als een onvoldoende valide bulpmiddel voor MTA be-
schouwd. De kwantitatief gescbatte verwachte wins! in gezondbeidstoe-
stand, bepaald op een objectieve wijze vorml de basis voor beide bena-
deringen van de bcbocfte. 
De analyse van onzeker/zeden maakt onderscheid tussen buidige en toe-
komstige onzekerbeden. Eerstgenoemde onzekerbeden blijken van ver-
schillende aard te zijn: zij bestaan uit onzekerbeden door onvoldoende 
informatie, uit 'intangibles' (moeilijk te meten zaken) en uit 'imagi-
nables' (zaken die vanuit conceptueel oogpunt moeilijk zijn) . Toekom-
stige ontwikkelingen zijn per definitie onzeker, maar meestal zijn ze 
deels met enige zckerbeid voorspelbaar. Dit wordt wei aangeduid met 
autonome trend. In aanvulling bierop kan analyse van diverse policy's 
plaatsvinden om inzicbt te gcven in de gevolgen van veranderingen in de 
omgeving waarin de tecbnologie wordt toegepast. De kwantitatieve bena-
dering van deze verschillende vormen van onzekerheid is goeddeels 
gelijk en maakt gebruik van kwantitative modcllering. 
Aan twee tcchnische aspecten van de voorgestclde kwantitatief-empi-
rische benadering wordt aandacbt besteed: formele syntbese en subgroep 
analyse. Aggregatie-technieken in hct kader van MTA zijn bckritisecrd, 
meer in bet bijzonder het toepassen van multidimensionele gezond-
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heidstoetand-maten, het rekenen met individuele scores uitgedrukt in 
deze en andere gezondheidstoestand-maten en het berekenen van 
samenvattende maten zoals een kosten-effectiviteitsratio. Aileen al op 
methodologisch gronden is aggregatie als routine data-analysetechniek 
gerechtvaardigd. Daarnaast is zij een politick desideratum. 
De politieke aspecten van subgroep analyse, een tweede routine data-
analysetechniek in empirisch onderzoek, worden aangegeven. 
De hoofdstukken 4 tot en met 6 gaan vervolgens dieper in op de achter-
gronden van overlevingsanalyse, analyse van de gezondheidstoestand en 
de bepaling van de behoefte. Om overlap met de appendix te vermijden 
ligt het accent op methodologische achtergronden, aangevuld met een 
korte beschouwing over de empirische ervaring zoals deze o.a. in de 
appendix wordt gepresenteerd. 
Hoofdstuk 4 beschrijft overlevingsanalyse in MT A. Beargumenteerd 
wordt dat deze in hoofd7..aak bestaat uit sterk doorgevoerde toepassing 
van reeds bestaande technieken. Aanvullende berekeningen zijn nood-
zakelijk om gewonnen (of verloren) levensjaren als economischc uit-
komstmaat te verkrijgen. De uitdaging in meuige MT A wat betreft over-
levingsanalyse is gelegen in het bepalen van de overlevingsgevolgen van 
een interventie als geen informatie beschikbaar is afkomstig uit gerando-
miseerd gecontroleerd onderzoek; deze situatie komi bij nieuwe techno-
logieen dikwijls voor. Diverse benaderingen van de controle-groep over-
leving ('schaduwoverleving') in deze situatie worden beschreven, waar-
onder de toepassing van proguostisch modellen. De technische kenmer-
ken van deze laatste methode, die kwantitatieve voorspellingen mogelijk 
maakt, worden beschreven. De resulterende voorspellingen kunnen 
zowel op individueel als groepsniveau worden gebruikt. Ze maken, mits 
op juiste wijze wordt rekening word! gehouden met zgu. gecensureerde 
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waarnemingen, ook de berekening van de gewonnen levensjaren als 
gevolg van de nieuwe technologic mogelijk. 
De ervaring in de levertransplantatie studie heeft duldelijk gemaakt dat 
schatting van de schaduwover!eving inderdaad mogelijk is als: 
a. quasi-experimentele controle-groep gegevens beschikbaar zijn, of 
b. interventie uitstel (b.v. wachtlijst) gegevens beschikbaar zijn, of 
c. historische controle-groep gegevens beschikbaar zijn. 
Aanvullende prognostische modellering is meestal mogelijk indien de bij 
a., b. en c. genoemde gegevens op individueel niveau beschikbaar zijn. In 
alle gevallen is homogeniteit van referentie en index patienten met 
betrekking tot diagnosis en behandelingsvooruitzicht van belang. 
Hoofdstuk 5 geeft enkele methodologische beschouwingen over bet 
meten van de gezondheidstoestand, zowel vanult een descriptief en als 
een waardetoekennend (in economische zin) gezichtspunt. 
Allereerst wordt aan ziekte-aspecifiek gezondheidstoestand aandacht 
besteed. Betoogd wordt dat gezondheidstoestand een niet direct waar-
neembaar, theoretisch concept is, vergelijkbaar met tal van klinische 
concepten. Het bepalen van de validiteit vereist in dit geval a. consensus 
over een theoretische structuur die bet betreffende concept bevat en b. 
consensus over te voorspellen feiten voortvloeiend ult dit concept dan 
wei voortvloeiend uit gespccificeerde parallelle of anderszins gerela-
teerde concepten. 
Voor de beschrijving van de gezondheidstoestand wordt een algemene 
structuur voorgesteld. Indien vervolgens hierop geente vragenlijsten 
worden ontwikkeld, dan kunnen zowel bet statistische efficientie criteria 
als inhoudelijke criteria hierbij bchulpzaam zijn, b.v. bij de keuze van 
dimensies, items en antwoordmodaliteiten. Beide criteria hcbben hun 
voor-en nadelen. Vervolgens is een aantal criteria bescbikbaar om be-
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schrijvende instrumenten op bruikbaarheid en kwaliteit te beoordelen. 
Binnen de context van gezondheidstoestandbeschrijving in MT A heeft, 
zo wordt aangegeven, 'tijd' een belangrijke conceptuele positie, zich 
uitend in vraagformu!ering en interviewfrequentie. 
Onze ervaring met de descriptie van de gezondheidstoestand in de 
Neder!andse transplantatie MTA's wordt kort beschreven. Twee kenmer-
ken van deze descriptieve analyse lijken binnen MTA van meer algeme-
ne aard te zijn: de moeilijke statistische analyse van links en rechts 
gecensureerde gegevens en - als bij overlevingsanalyse - de problemati-
sche vergelijkende analyse als een experimentele opzet afwezig is. 
Het tweede dee! van het hoofdstuk wordt gewijd aan de meting van 
de gezondheidstoestand als onderdeel van de economische meting van de 
patient gevolgen. Tot nu to is de beste beschikbare techniek om tot een 
economische waardering van de patient gevolgen te komen de bereke-
ning van gewonnen levensjaren, of, indien mogelijk, van kwaliteitsgecor-
rigeerde levensjaren ( ook we! aangeduid met het acroniem 'QAL Y's' 
voor Quality Adjusted Life Years's). Ten behoeve van de berekening van 
QAL Y's zijn a. meting van de gezondheidstoestand 
b. destillatie van gezondheidstoestandbeschrijvingen 
van patienten, 
en vervolgens 
c. waardering van deze gezondheidstoestandbeschrijvingen drie nood-
zakelijke stappen. De toepassing van QAL Y's in zogchetcn kosten-
utiliteits-analyses berust op vele assumpties, die zorgvu!dig ontworpen 
meetinstrumenten vereisen. Wat dit laatsle betreft zijn wij crin geslaagd 
om met buitenlandse collega's een instrument voor gezondhcidstoestand-
waardering te ontwerpen (EuroQol), dat intemationaal beschikbaar is. 
Met dit instrument konden wij de geldigheid van een essenticle aanname 
voor QAL Y -berekeningen bevestigen: de interindividuele consensus met 
bctrekking tot de rangordening naar wenselijkheid van een aantal 
complexe gezondheidssituaties van overigens gelijke duur. 
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De resultaten van de kosten-utiliteits-analyse in de Nedcrlandse trans-
plantatie MTA's ondersteunen de haalbaarheid van de QALY-proce-
dure. 
Als een apart onderwerp gaat Hoofdstuk 5 in op de veelbelovende erva-
ring met het personal computer ondersteund enqueteren van patienten. 
Hoofdstuk 6 besteedt aandacht aan de bepaling van de behoefte aan 
een specifiek technologie. Conceptuele keuzen en dataschaarste ken-
merken dit onderwerp. Allereerst dient tussen een definitie gebaseerd op 
verwachte gezondheidsverbetering of een van de definities gebaseerd op 
andere principes worden gekozen. Deze keuze is dezelfde als die aange-
dnid in Hoofdstuk 3 bij de definitie van rechtvaardige verdeling (' eqni-
ty'). N aar ons inzicht dient het be grip behoefte nit te gaan van de eerste 
definitie. Vervolgens beschrijft het hoofdstuk een medische en een eco-
nomische uitwerking van de eerstgenoemde behoefte definitie. Een em-
pirische bchoeftcbepaling kan vruchtbaar gebruik maken van het onder-
schcid tussen 'incidentie-tcchnologieCn' en 'prevalentie-tcchnologieen'. In 
vervolg hierop worden suggestics gegeven voor de bcpaling van de 
behoefte van de vier onderschciden technologische hoofdtypen. 
Verslag wordt gedaan van de schatting van de behoefte aan lcvertrans-
plantatie. Deze schatting volgcns eerdergenoemde principes was dankzij 
enkele gunstige omstandighedcn goed mogelijk. 
Hoofdstuk 7 keert tcrug tot de drie eerdergenoemde kemvragen. 
Wat is de wetenschappelijke basis van MTA? 
Het zal duidclijk zijn dat in dit proefschrift de Stelling verdedigt dat er 
een wetenschappelijke basis bestaat voor empirisch MTA-onderzoek. 
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Rigoreuze standaardisatie, kwantitatieve modellering en integratie van 
medische en economische concepten zijn de ingredienten voor de 
methoden van MT A. Voor de verschillende onderwerpen zijn standaard-
technieken en -hulpmiddelen beschikbaar, of, minstens zo belangrijk, 
standaardmethoden om deze te creeren. De methodologische keuzepro-
blemen, die soms onmiskenbaar aanwezig zijn, zijn zowel het gevolg van 
een levendig multidisciplinair wetenschappelijk debat als van de samen-
hang tussen wetenschapsbeoefening en maatschappelijke besluitvorming. 
Welke omstandigheden begunstigen het gebruik van MTA? 
Het gebruik van empirische MTA-resultaten hangt van zowel politieke 
als wetenschappelijke randvoorwaarden af. Met betrekking tot de poli-
tieke randvoorwaarden is het duidelijk geworden dat een rationeel en 
expliciet besluitvormingsproces bijdraagt tot vruchtbaar gebruik van 
MTA-informatie. In de Nederlandse situatie heeft de Ziekenfondsraad 
een besluitvormingsprocedure voorgesteld die sterk gelijkt op die is 
beschreven in Hoofdstuk 2. Hoewel ze nag niet volledig geeffectueerd is, 
heeft de voorgestelde werkwijze in combinatie met de drie proef-MTA's 
(over in vitro fertilisatie, hart- en levertransplantatie) al positief bijgedra-
gen tot de besluitvorming over deze en andere nieuwe technologieen. 
Daarnaast zijn de voorwaardcn voor MTA-onderzock van bclang, zoals 
het bestaan van onafhankclijke multidisciplinaire MTA-instituten, de 
politieke steun voor deze instituten waar het gaat om het toepassen van 
standaard methodologie, en een goede aansluiting van klinische ontwik-
kelingsprogramma's aan hct MTA-informatie probleem. 
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Hoe kan MTA in de toekomst verder worden ontwikkeld? 
Het antwoord op de laatste vraag over de toekomstige ontwikkeling van 
MTA heeft duidelijk een politick karakter. De eerdergenoemde voor-
waarden zullen ongetwijfeld haar ontwikkeling beinvloeden, maar ze zijn 
in onze ogen niet allesbepalend. Belangrijker achten wij de twee vol-
gende, algemene ontwikkelingen. 
In de eerste plaats de ontwikkeling van een wetenschappelijke relatie 
tussen MTA-instituten en haar methodologische en klinische buren. In 
de tweede plaats de ontwikkeling van een politiek momentum dat erkent 
dat MT A een continue activiteit dient te zijn, als antwoord op de in 
economische zin asymmetrische relaties in de gezondheidszorg. Wij 
verwachten dat deze laatste ontwikkeling uiteindelijk afhangt van de 
wijze waarop de emancipatie van de medische consument vorm krijgt. 
NOTES 
Chapter 1 
1. This description descn'bes changes in hospital function in this century only (Reiman, 
1988; Foucault, 1975 [p. 54]). 
2. An example of moving borders of professional territoria may be found in gynaeco-
logical surgery. At the end of the 19th century gynaecologists did discuss the 
desirability of including surgery of the female genital tract into their disciplin. The 
answer is known, more than the arguments. Currently the discussion is renewed in 
the question about the prefered surgeon in surgery of the female urogenital tract. 
Technological advances (diagnostics, therapeutics) and professional specialization 
(urology, born from general surgery) gave rise to the current debate (De Kroon, 
1990). 
3. In this thesis the third world countries are excluded from analysis only for practical 
reasons. Their importance is acknowledged (Banta, 1984). 
4. We are aware of other factors inducing or influencing changes in health care. The 
relative impact of technologically induced changes may be quite moderate as is 
illustrated in our study on Future Scenarios of Obstetrics, Gynaecology and Repro-
ductive Medicine (De Kroon, 1990). 
5. Registration may be intentional or casual (e.g. the result from national price lists for 
reimbursement or budget arrangements). It may be the result of a statutory requi-
rement but also the result of initiatives of companies or consumers 
A brief overview of the Dutch state of affairs may serve as an example. In the 
Netherlands a complete drug registration is counterbalanced by the absence of an 
analogous registration of devices and medical equipment (only coming to public 
attention when a particular type of artificial heart valves proved to be unsatisfac-
tory). Health insurance registrations and and hospital administration systems usually 
respond with some delay to new medical procedures. Organisational changes within 
statutory limits are short of registration - as may be illustrated by the "hidden" exis-
tence of transplantation teams (see also Geieijns, 1990). 
Though registration usually ~Jl be pluralistic, even within one country, and will 
apply to particular technologies (e.g. drugs), we conclude that scarcety of resources 
is but one of the factors which may force the medical system to adress the problems 
of emerging technologies. 
6. In this alinea, the emphasis is on medical technologies influencing society. Examples 
of the reverse relation are more difficult to determine, but may be found when 
looking for societally demanded technologies. On a more abstract level Habermas 
(notably in the essay "Technik und Wissenschaft als Ideologic"), and to a lesser 
extent Illich, Foucault and de Swaan have elaborated on this subject (Habermas, 
1968/1976; lllich, 1974/1975; De Swaan, 1984). 
7. See Table 1.1 for circumstancial factors contributing to recognition. 
8. We do not believe - from a historical point of view - this response can precede 
technological change, which is a basic assumption underlying the philosophy of 
societally guided technological change. Organizational arguments could be added 
(Mintzberg, 1979 [particularly p.371-379]). 
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9. As "Will elaborated on later, a new technology is defined as 'new' from the perspec--
tive of the particular organization involved; 'technology' refers to a health care 
programme - in our case for patients with end-stage liver disease from non-alcoholic 
origin. 
10. As in fannacology, 'side effects' as opposed to 'main effects' have to do with the 
intention, not with the comparative impact of the effects. 
11. 'The technological imperative' is sometimes used as a - in our view - theoreticaiiy 
unfruitful concept to describe the autonomous character of occurence and diffusion 
of new technologies. See Reiman (1988). 
12. A similar, analogous change may be observed in the debate on environmental pol-
lution, though the roots of this debate are older (see the history of the American 
Office of Technology Assessment in e.g. Banta, 1990). 
13. The emphasis on the decision process on the the macro level in this section implies 
it to be particularly relevant for the first group of parties of Table 1.2. However, 
with adaptions according to the specific interests, the body of this section also ap-. 
plies to most of the other parties (IOM, 1985 [p. 26-]). Separate attention will be 
paid on this adaptations, particular in the description of the decision cycle. 
14. At this place we will not elaborate on other responses of health care authorities on 
new technologies. 
15. The development of such a rational and intelligible approach of complex problems 
should not only be described as the concerted action of responsible actors in the 
field, but also as a result of the gradual transformation of the former politization of 
(medical) science into scientification of (health) policies - see also e.g. Habermas 
(1968/1974). 
16. This relation is usually neglected when parts of the structure, process or outcome of 
the decision process are held up as an example to another country. 
17. About two thirds of the population is covered by this scheme. 
18. In onhotopic liver transplantation the diseased liver of the reCipient is removed 
(explantation) and subsequently replaced (implantation) by a liver of approximately 
the same size from a donor with the same blood group. Few advocate heterotopic 
liver transplantation in some cases. This technique differs from the previously de-
scribed technique in the apposition of the donor liver, rather than the replacement 
of the diseased liver. 
165 Notes 
Chapter 2 
1. Despite a uniform agenda of topics to be judged, there is a wide array of decision 
processes in Western countries to be observed. Usually the nature of the technology 
and not that of the health care system is decisive for the nature of the process (e.g. 
in most countries new drugs are under the same vigorous control). See also OTA 
(1980), Banta (1982) and Jennett (1986). 
2. In the Netherlands the National Health Insurance Board (NHIB; Dutch: Zieken-
fondsraad) has deviced a similar decision flowchart, combining political and 
informational elements. From 1983-1985 the author as a member of a working 
committee of the NHIB was closely involved in the development of this flowchart 
and its subsequent implementation. 
Though the resulting cybernetic cycle presented here is in some aspects deviant from 
the flowchart of the NHIB, this section owes much to the participation of the author 
in the discussions of the former working committee of the NHIB on this subject. See 
a.o. NHIB (1983, 1986). 
3. A good example in the Netherlands of the lack of impact of early warning on the 
application of a new technology was pointed out by Rigter (1989). The wealth of 
committees and working parties on genetic testing. which exist since 1984, sofar has 
not influenced much the introduction and early adoption of this technology (see 
Rigter 1989 [p.40]). 
Moreover we think, supported by history, that the primary impetus of a decision 
process on the application of a medical technology is the actual effect of a technol-
ogy, not its potential impact. 
4. Maybe these early "lll3ming systems have some limited use for the decision processes 
on budgets for research and development. In that case the decision-cycle should be 
adapted accordingly. 
5. We are aware the judgments on relevance and information surplus require at least 
some information to be available. 
6. We distinguish the following criteria: 
1. maximal cumulative cost per person; 
2. maximal cumulative cost per year of the programme; 
3. minimum cumulative effectivity per person; 
4. minimum cumulative effectivity of the programme; 
S.maximal marginal costs compared to minimal marginal effects (comparison by 
division) per person; 
6. average cost-effectiveness of the health care programme; 
7. direct or indirect consequences with influence on future generations; 
8. direct or indirect consequences which imply interpersonal weighting of different 
interests. 
These eight criteria may serve as a checklist. 
Criteria 1. and 2. are input-criteria. 
The first criterion is related to the end-to-means issue. It compares costs of the 
target technology to the doing-nothing alternative. The second is related to the issue 
of a fixed budget for health care. 
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The first criterion may be simply expressed as total direct costs per person or, 
maybe better, total costs per person. A critical calue will be difficult to fmd from 
history, taking the acceptance of heart transplantation and the existance of units for 
permanent ventilation of patients needing life-long respiratory assistance into 
account. Critical values outside the health care system do exist (Jones-Lee, 1976; 
Mooney, 1977; McGuire, 1988 [p.87, 88]). 
The second criterion may be best expressed as a percentage of health care costs or 
as a percentage of costs within the associated speciality. Note that a criterion of 
total specialty costs of e.g. 1% will not easily be surpassed. 
Criteria 3. and 4. are output-criteria. 
The third criterion is related to what some have mentioned 'medical success'. 
Obviously from a logical position we have to compare the effects 'With the doing-
nothing alternative as we did in criterion 1. with costs. Quantification of the natural 
history 'Will frequently be difficult (See Chapter 4). Again this might be regarded as 
an end-to-means issue. 'Altematieve geneeskunde' will satisfy criterion 3. regardless 
the threshold chosen. 
The fourth criterion relates the importance of an eventually new programme to the 
cumulative t>enefit of the specialty involved or even health care as a whole. 
Elaboration of the second and fourth criterion needs a national cost-of-illness matrix 
together with a national yield-of-health care matrix (Koopmanschap, 1991; Health 
Council, 1986 [p.122, 123]). 
Criterion 5. and 6. are aggregated criteria i.e. they combine information on 
different characteristics. The fifth and the sixth criterion are about end-to-means, 
relating information on ends (criterion 3) and means (criterion 1) and - this is an 
extension of the concept end·to-means in its usual interpretation - relating it to 
similar information on the best alternative action. Thus they are also economical 
criteria, particularly the sixth. 
The last two criteria are ethical. We are aware one may reject the existence of 
ethical criteria which are derived from ethical principles (the ethical products) and 
may prefer the ethical role to be represented by critical reflection on the acceptabili-
ty of new technologies (the ethical process) (fen Have, 1988; see also Health 
Council, 1986, Anonymus, 1988). 
The seventh criterion is about technologies which directly or indirectly produce 
genetic information and about technologies in health care programmes with effects 
on the population at large (e.g. disease eradication programmes). 
The eighth criterion is relevant if technologies implicity or explicity violate personal 
interests of non-diseased. Quarantaine is an example which gained :renewed interest 
during the AID$--epidemic. Vaccination programmes with their inherent victims of 
rare complications are but another. Screening on cancer of various kinds should be 
mentioned but for the same logic the shift from hospital to home care. 
7. Dutch health care authorities speak of five questions, which are of relevance in the 
context of this decision process on the uptake of new technologies in health care. 
Adapted to a technology decision (Anonymus, 1988; Health Council (Gezondheids· 
raad), 1986). These questions are: 
a. Can the technology be regarded as health care? 
b. Is the technology ethically acceptable? 
c. Is the technology effective, is the technology efficient? 
d. Can the technology be paid for? 
e. Does the technology belong to the realm of the constitutional duties of the state? 
Operationalization of these questions has been started on. Answers sofar are tacking, 
which makes us aware of a fundamental void in the decision chain. 
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8. These agendas may be e.g. be derived from the issues of the Journal of Technology 
Assessment in Health Care. We are aware of the different agendas in developing 
and industrialized countries (Banta, 1984). 
9. In the Netherlands the flowchart of the NHIB (Ziekenfondsraad) also starts with a 
recognition phase. The flowchart assigns a prominent role to both health care 
providers and consumers, fotlowed by most of the parties mentioned in Table 1.2. 
See NHIB (1986, [p.!S, 23]). 
10. An interesting example exists in the Netherlands which shQ'.liS the difficulty of 
guaranteeing this type of access. The Steering Committee on Future Scenarios in 
Health Care (Dutch: Stuurgroep Toekomstscenario's Gezondsheidszorg) which 
started in 1983 and is closely related to the Department of Health, acts both as a 
generator and a mediator for investigational projects on future health (care) issues 
(SfG, 1987). A particular generating role for persons and parties outside this 
committee is explicitly stated. Only recently a project has been undertaken, which 
indeed was initiated from outside (Gynaecology, Obstetrics and Reproductive 
Medicine, see De Kroon, 1990). 
11. Within the Dutch system the Health Council and the NHIB (Ziekenfondsraad), 
given the preceding criteria and given their constitutional position in the health care 
system, are the natural agencies to select technologies to be judged (Health Council, 
1986 [p.Sl-84]). 
12. In this context the NHIB (Ziekenfondsraad) flowchart mentions two criteria. 
The first is maturity ("a minimum level of consensus on medical and technical 
aspects of the technology involved"). The second regards acceptability ("no unsurpas-
sable objections from a societal, political, ethical or legal point of view"). 
Surprisingly a criterion of relevance is lacking. This omission avoids conceptional 
difficulties (what is a 'new' technology) and political difficulties (what is an 'import-
ant' impending technology) in the first phase of the NHIB flowchart. We think this 
omission is justified in this case due to the existence of a variety of well-functioning 
sounding boards. See NHIB (1986 [p.16]). 
13. In the NHIB (Ziekenfondsraad) flowchart the framing of the decision problem is 
slightly different from the definition that described here (NHffi, 1986 [p.l6-]). 
In the NHIB a potential shortcut in the flowchart is introduced. after maturity and 
acceptability of a new technology have proved to exceed minimum standards. When 
costs of the new technology seem to be lower than previous technologies and all 
other things are equal, a simple decision is possible, resulting in full support to the 
new technology. If not, comprehensive judgement is necessary. Thus the decision 
process of the NHIB consists of two consecutive decision 'nodes', the first devoted 
to cost balancing alone, the second to weighing of all aspects. In a technical sense 
this implies Phase 3 to 5 to be executed twice, if simple substitution is not to be 
expecte<!. 
We doubt the argument for such a shortcut to be valid, as the expectation of pure 
substitution is not justified both on theoretical and empirical grounds; 
a. lower costs imply extended use; inevitably selection criteria will change (based on 
the fundamental assumption that the health care market is not satisfied and will 
always be subject to economical laws of scarcity); 
b. the utility of ignorance and the disutility of change of medical practice will usually 
keep alive existing technologies: full replacement is an uncommon event, partial 
replacement a more frequent one and parallel or serial application (additional use) 
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the rule; the last rule is especially valid when substitution is an interprofessional 
affair (see e.g. CABG versus PTCA in roronacy artery disease); 
c. all other things are only rarely equal and equality is not easily verified. 
14. Frequently the bringing-under-control (an objective related to the structure and 
process of the technology) has priority over the control itself (an objective related to 
the outcome). 
We will give an example of this change from a public health objective towards 
management objective. Most of the parties, which were involved in the liver and 
heart transplantation technology assessments in the Netherlands, perceived the 
studies as instruments to bring an otherwise autonomous development under public 
control. The freezing of these programmes cannot easily be explained as a necessary 
condition to be met in order to cany out a technology assessment. 
15. For whom refers to indication and selection. By whom refers to profession, setting 
and may be extended to particular persons and/or institutions. 
16. 'Criteria' refer to some critical level, either separately or combined, of these issues. 
A critical level implies measurability. In its simplest form it is absence or presence. 
Most issues should be described more subtle. 
The use of multiple criteria is discussed in Chapter 3. Several formal and informal 
techniques exist to reach a conclusion based on aggregation of heterogeneous issues. 
The choice of the aggregation technique is primarily a political one and should 
ideally reflect major societal values. Aggregational techniques differ with regard to 
principle (outcome or process oriented~ teleological versus deontological), consisten-
cy (if non consistent, the same principle may yield different decisions in the same 
situation) and verifiability (closely related to explicity and measurability). 
17. A description of intangibles is not enough in that case. The development of criteria 
is the core of the problem. To declare these type of issues 'ethical' does not solve 
the problem if explicit valution is aimed at. 
18. We e.g. did not succeed to get access to the data of the European Registry of Liver 
Transplantation. 
19. We can define the effectivity space and the cost space as the estimated difference of 
effects and costs between the introduction of the new technology vs. the null 
scenario for, say, 5 years; with old technologies we can use alternative measures of 
potential cost impact (Phelps, 1990). 
In liver transplantation the MfA-costs accounted for less than 5% of 5-year cost 
space (see AIO). 
20. The NHIB (Ziekenfondsraad) flowchart gives little information on the contents of 
this part of the process. 
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21. The NHIB (Ziekenfondsraad) developed a system of provisional financing of new 
technologies, provided the particular health care providers carried out investigations 
to support a decision of the NHIB in the context of the flowchart ('Ontwikkelings~ 
geneesl-unde'). From the absence of Phase 2 and particularly of Phase 3 in this 
system we conclude the following: 
a. health care authorities are reluctant to take up their political role particularly in 
Phase 2; issues and aspects are not clearly specified and the relevance of projects 
for the health care system at the national level is uncertain; 
b. the managing objective appears to dominate the judging objective; the information 
to be generated in these projects is not clearly defined; this might result in a a 
misfit of need and supply of information at the end of these projects; from a 
managing perspective this misfit is of less relevance. 
22. If medical technology assessment serves other purposes as well (see footnote 21 
about the bringing-under-control objective of health policy makers), this statement 
should be refined. In that case decisions are made during the investigative process of 
Phase 4, and the role of health policy makers is extended accordingly. 
23. The NHIB (Ziekenfondsraad) flowchart clearly fits in this scheme, though two 
decision nodes are involved, the first restricted to cost balancing (note that the cost 
definition is unJ,:nown). See !\TffiB (1983, 1986). 
24. Undesirable according to criteria not specified ahead. 
25. In the NHIB (Ziekenfondsraad) flowchart Phase 6 is lack-ing, which is surprising in 
view of the intention to include already existent technologies in the flowchart. Some 
examples of monitoring do exist. Two wi!l be mentioned. 
The Dutch Hospital Provisions Act includes a section (Art. 18), which enables 
application of specific medical technologies to be restricted and - since 1989 - to be 
monitored. 
In a related field the Dutch Steering Committee on Future Health Care Scenarios 
usually institutionalizes monitoring following a research project on health care 
developments. These projects do not investigate particular technologies but intend to 
forecast on a time horizon of about 15 years developments in broad areas like 
cardiovascular diseases, cancer and accidents (Van Beeck, 1989). 
26. Other reasons may be e.g. extreme scarcity, leading to implicit or explicit selection 
processes, and geographical variations of application, leading to unequal access for 
the patient. 
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Chapter 3 
1. Social issues seem the victim of semantic difficulties. Sofar they have turned out to 
be either a. issues dealt with in sections 3.3 to 3.7, b. ethical issues or c. issues 
outside the realm of MTA related to other phases of the decision cycle or to the 
decision cycle as it stands. 
Social impact of technologies is more conveniently dealt with in sections 33 to 
3.7. The topics 'impact on process of health care delivery at large', 'impact on public 
health', and 'impact on health care expenditures and GNP', etc. have a natural place 
in these sections. 
Sometimes problems are called 'social' when societal values are at issue. In that 
case we would prefer to call these 'economic' or 'ethical', as appropriate. 
Fmally social issues may refer to other phases of the decision cycle e.g. to the 
social process of decision and implementation in Phase 5 of the decision-cycle. 
Though important we regard this elaboration a corpus alienum in the information 
phase. The role of MTA in the preceeding or subsequent phases, the role of other 
factors influencing the decision cycle, or the rationality or desirability of such a 
technocratic system in it own all have their own meta-analytical place. 
2. Randomization in experimental designs pertains to tv.ro aspects in the experiment. 
First a random sample is drawn from the target population. Later, the intervention(s) 
are randomly allocated. Obviously the purpose of randomization is to enable 
generalization and unbiased comparison respectively. 
The recruitment and selection of patient's in clinical trials usually do not satisfy the 
first requirement, limiting the scope of the analysis to statements about within~trial 
differences (Senn, 1990). Apparently this requirement is of limited perceived 
interest. 
The second stage is generally considered to be a neces..<:ary attribute for any RCcr 
worthy of the name. However, pseudorandomization in RCCI"s of new technologies 
is not an uncommon event. In that case one or more of the essential requirements 
of this procedure are compromised. E.g. randomization occurs prior to the doctor's 
request for participating in the trial and the allotted treatment alone is offered to 
the patient with an adapted informed consent. The scientific and ethical problems of 
this adaptation are self-evident. 
One variant of the treatment allocation randomization should be mentioned. A first 
randomization towards a RCCT or a preferred treatment protocol followed, in the 
case of a RCCT, by random allocation of one of the interventions has been 
advocated. 
3. Sometimes it may be difficult to device a control arm which matches ail require-
ments: e.g. complex mimicri-.devices to assure blinding are unsuitable for the 
determination of control cost. 
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4. Only two arguments againt RCCf's seem justifiable. 
First of all practical difficulties may be too difficult to overcome, though 1t lS 
the blinding and not the randomization which frequently is difficult to achieve. 
Problems may arise when one out of several best alternatives can only established 
after some trial and error due to variability of response (e.g. anti-depressive drugs., 
heart failure drugs). 
The other difficulty arises from ethical considerations. The dominant ethical 
position leaves little room for experiments when significant benefit may expected 
from the new technology. As few clinicians would be motivated to undertake 
experiments if this expectation was absent, satisfaction of the ethical imperative to 
give the best to the individual, would result in a moratorium on RCCf's (see e.g. 
Mosteller, 1981). The resulting return to the pre-Baconian era of the alternative 
healers in our view is unacceptable. 
5. The interests of national health insurances only partially parallel those of private 
health insurance companies; the interests of specialist departments do not coincide 
with that of the hospital at large; and the interests of individual patients and 
categorical patient organisations are not identical to the interests of consumer 
organisations. 
The case of the three Dutch MTA's described in this study is interesting as a mix of 
interests may be observed among those supporting these MTA's. 
6. A specific trend is clearly visible in the MTA activities of OI-ITA. The more recent 
the MTA, the more specific are the patients described (IOM, 1985 [p.357~359). 
7. Another reason is the frequent relevance of including organisational aspects in the 
description. Lack of standard methodology in this respect may be observed, e.g. on 
the issue of centralization versus decentralization, the issue of decision-making in 
complex treatments, etc. 
8. A health care programme is defined as the combined professional effort to comfort 
the need for medical setvices for a particular patient group (see also chapter 2). 
A patient group is defined, like the D RG-methodology, as a group of patients with a 
similar pathologic condition and with a rather homogeneous pattern of medical 
consumption. 
9. One exception is the appearance of a new technology being considerable cheaper 
than existing alternatives. Examples are abundant in the field of pharmaceutical 
products. In most cases it is the pricing, not the profile, which is the interesting 
feature of a new drug (me-too preparations and, specifically in the Netherlands, 
FNA~preparations to replace brand name drugs). We are aware of the commercial 
aspects of undertaking CEA's and even full·size MTA's on these occasions. 
10. We disregard an 'essentialistic' approach. 
11. In clinical studies, outcome usually is defined by disease·specific (process) parame-
ters which are derived from the pathological concept of the disease (e.g. ejection 
fraction and cardiac output in cardiac insufficiency, FEV1 in lung insufficiency, blood 
chemistry in liver insufficiency and renal insufficiency, etc.). Parameters reflecting 
the degree to which signs and symptoms exist may be added, when they are thought 
to sufficiently valid. 
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12. As in the exact sciences, these type of parameters may be only defined by means of 
their measurement procedure. 
13. Particularly if clinicians use a carefully designed set of disease-specific parameters 
they put questions on the value of these disease-non--specific outcome parameters, 
which sometimes are quite insensitive from their point of view. 
Obviously these questions are only raised if the choice can be made i.e. if a disease. 
specific technology is looked at. In fact most technologies are applied to patients 
with different disease-categories. In those cases the general level must be chosen, as 
a disease non-specific decision is usually aimed at. Hence we regard disease-specific 
outcome-measurement a special case within the medical concept of outcome analysis. 
The emphasis on disease-non-specific outcome measures easily gives rise to conflicts 
about the design, the operationalization and the publication of the MTA-study as 
they compete with the clinical investigation of the programme from which data are 
drawn. 
14. We disregard other unidimensional parameters for their limited relevance, both from 
a theoretical and practical viewpoint. See also Drummond (1987 [p.lS]). 
The broader concept of outcome, which is adopted in QALY's and HYE's (see 
Chapter 5) may include pain or disease avoided but also reassurance gained by 
information or emotional support and other process utilities; McGuire, 1988 [p.46-
51,92,93,106]). 
15. For analogue reasons consequences have to be valued separately, see section 3.4. 
16. For a brief account of the technical procedure see Drummond (1987 [p.48-53]). 
17. The intensity of patient-monitoring which usually is defined from a research 
perspective should be adjusted to reflect intensity under nonnal conditions. Treating 
the costs of any fixed follow-up routine ~ not depending on patients complaints, 
etc. - as research costs yields an upper bound of treatment costs. 
18. The paradox arises if we aggregate on a cross~sectional base instead of a longitudi-
nal base. 
19. In the typical case the degree of uncertainty determines the decision to be made, 
regardless the actual values of the estimated range of plausible results. 
20. In many cases a clear age-dependency exist which justifies demographical trend 
analysis. If constraints are likely- the relevance may be small. 
21. Here we disagree with Hoogeveen (1989 [p. 122]). 
22. Marginal analysis is an analytical technique which examines the relationship between 
incremental changes in investments in a product (input) and incremental changes in 
output (Luce. 1990 [p.26-28]: examples in Van Oortmarssen, 1990 and Neuhauser, 
1975). 
23. The first step in the NHIB (Ziekenfondsraad) flowchart in (see notes in Chapter 2) 
implies some form of threshold-analysis. 
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24. In practice deterministic models usually are easier in providing thresholds than 
probabilistic (syn. stochastic) models, but feasibility has its price. 
25. Note that this is a socalled stochastic model. 
26. Within the NHIB we remember an analysis of concordance been tried out. 
27. Counting over time however does not necessarily mean one event has the same 
significance for the individual at two occasions. The second anginal attaque may be 
born easier or just the reverse. But for their prevention we treat them equal. 
Counting over different effects does not mean the effects are identical. The only 
share the characteristic that their relative value may be known. If an apple does $ 
0.25 and a pear $ 050 it does not mean two apples are a pear. 
Counting over individuals does not mean they are identical but assumes for the 
aspect chosen, abstraction is allowed. 
28. Available data lend themselves not very wei! for comparison in most of the cases, 
due to departures from the basic rules of cost-effectiveness analysis (Rutten, 1989). 
Even if the analysis has been carried conform these rules it should be particularly 
clear whether marginal or rather average cost-effectiveness ratios are compared. This 
issue is closely related to the choice of the alternative action in the analysis. 
29. For example in the Netherlands these implicit criteria have decided on the institu-
tion of suboptimal policies in cervical cancer screening and the temporacy exclusion 
of liver transplantation in children from the insurance package despite excellent per-
formance as defined by medical and economical figures. 
30. Preferably in the third phase of the decision.-cycle (see chapter 2). 
31. In analyzing the therapeutic effectivity of liver transplantation (parameter: survival) 
the variable 'clinical center' appears an important predictor variable only second to 
'pre-transplantation severity of disease•. As this outcome might result in licensing 
only clinical centers "With best performance, the health care providers do not agree 
with the analysis. 
32. At this place we 'Will not elaborate on study-specific details. Generally the arguments 
may be analytically described as: 
a. an explanatory variable violates professional practice interests; 
b. an explanatoxy variable violates scientific interests; 
c. an explanatory variable violates financial interests; 
d. an explanatory variable violates societal interests, particularly the pursuit of 
equity. 
33. Thus we speak about a consequentialistic approach. 
34. Except for the Rawlsian definition (Rawls, 1972). The nice theoretical operationalisa-
tion of this problem of Blackerby (1977) should be mentioned. However, data 
requirements are immense. 
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35. Usually a linear function combining X and Y is chosen. We prefer the general form 
Y = f(X). This enables for example discontinuous or non-monotonic functions. 
36. Present health status as a instantaneous judgment on mobility, psycho1ogical status, 
etc. appears not to to be a valid measure: for example a disease like AIDS exerts 
little impact on actual health status, but few would support the view that this 
observation implies patients are in little need for care. Prognosis c.q. survival should 
therefore be included. This introduces a QALY-like estimate 'as an aggregate mea-
sure of expected misery' (De Jong, 1983). 
37. The same holds for other operationalisation of need (see chapter 6). 
38. Besides, the quantitative calculation of this relation will be difficult and results may 
be surprising. E.g. in liver transplantation, we found age as a strong negative 
predictor of survival without transplantation, and (within a rather broad range) as an 
irrelevant predictor with regard to survival with transplantation and quality of life 
before and after transplantation. Assuming all other things equal the efficiency 
criterion in this case would even favour the aged as would the vertical equity 
criterion, while horizontal equity considerations would show no preference. 
39. Within economic evaluation the procedure inflates costs at an extremely high rate. 
40. This includes the anencephalic discussion (Harrison, 1986). 
41. Upon the request of health care authorities these issues were dealt with by expert 
committees of the Health Council. The use by health care authorities of information 
on legal issues from the Dutch transplantation MTA's (particularly from the Health 
Council, 1988; id. 1989) has been rather disappointing. The donor card issue still 
awaits elaboration and fruitful legislation. The more general problem of inevitable 
selection still has not been adressed in a satisfactory way. 
42. Phase 1 
Legal considerations are of paramount importance in the selection of technologies to 
be subjected to explicit decision-making. 
Depending on current legislation on the approval of new technologies (Health 
Council, 1987 [p.104]) MTA-like research may be indicated. 
Sofar legal considerations for the selection of technologies to be subjected to MTA 
have been more fundamental (ethical). Attention has been drawn particularly when 
technologies were expected to have impact on either the start or the end of life. 
This interest has some negative effects. 
a. Technologies. which may be defined as important based on other criteria may 
be neglected. Technologies associated with legal or ethical controversies may 
inadvertently be juridified: the euthanasia-question does not need a MTA of 
opiates. 
b. Even if a MTA is needed, the existing variety of fundamental legal positions 
may be projected into the information need, leading to incompatible questions 
and criteria to be used. 
Some have advocated a global judgment of the legal acceptability of a new technol-
ogy, setting intended ends to means. History provides ample evidence for the 
:relevance of this premature judgment, apart from the hazards of judgment of 
intentions. At this stage we think this to be the primary responsibility of professional 
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organizations. Of course this presumes mature professional organizations embedded 
in a consensual Iegai system as in most Western societies. 
Phase 2 
The definition of the decision problem is also related to legal notions but we do not 
agree with the proposed principle of current legislation and jurisprudence defining 
the decision problem. The reverse should be true: the decision problem should 
clearly state the potential relevance of outcomes to e.g. international regulations, and 
to legislation e.g. on the provision of health care. Particularly in new tecchnologies 
the time-lag of legal accomodation, though useful in another way, prevents the legal 
system from a prospective task of defining the decision problem. 
Phase 3 
The information need might or might not include full analysis of aU legal conse-
quences associated with any of the decisions to be made. We reject this broad view, 
preferring Iegal issues in a MTA to be restricted to those pertinent to the techn~ 
logy. 
This preference is based on the following arguments: 
a. The major part of legal consequences is about legal adaptations. Their analysis 
usually can wait. For this part the political decision is conclusive. Though the 
existence of fundamental legal issues should be noticed - see our examples on 
heart transplantation, liver transplantation, in vitro fertilization - these are 
usually part of the ethical issue. 
b. An impressive list of additional externalities to a decision may be formulated 
(e.g. scientific spin-off). Full analysis of all externalities usually is unfeasible. 
We think the legal view does ask for special emphasis on particular issues: descrip-
tion of the health care programme, survival analysis, analysis of need, subgroup 
analysis, equity considerations and legal issues, as defined before. 
Phase 4 
With regard to empirical MTA's we should mention the legal features of clinical 
experiments and the use of registry data. Oinical pilot programmes take with them 4 
legal issues: 
a. free choice of the patient to participate and eventually to leave the pilot 
programme; 
b. limited access to the pilot programme 
c. liability of the provider 
d. confidentiality of patient's data. 
Phase 5 
The decision may call politicians, and legal, ethical and medical experts to arms. 
The first appear to be the legitimate decision-makers. 
Phase 6 
Legal issues in implementation and monitoring are treated in section 2.7. 
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43. The proposition to allow for 'medical' selection criteria only is not a unambigious 
solution. This proposition simply moves back the problem of selection from the legal 
to the medical arena, suggesting the former is of little help. In addition it deliberate--
ly avoids a clear ope-rationalization of the adjective 'medical'. At least three different 
meanings are conceivable. 
If 'medical' means 'to be determined by a medical expert' we arrive at a process 
criterion, ascribing the legal power to select to doctors only. This process-definition 
naturally allows for non-unique explanations. Two examples: 1. the choice for a 
selection criterion is determined by a medical expert or 2. the actual level of a 
predefined criterion is determined by a doctor. 
If 'medical' means 'related to the outcome of the disease', we arrive at an outcome 
criterion. Its ope-rationalization asks for variables predicting the course of disease 
and the degree of succes of treatment. 'Medical' in this sense includes age as a 
justified variable as age usually reigns all aspects of the disease (incidence, progress, 
susceptibility for treatment). Judging from the context of the proposition (medical 
criteria as opposed to the ace criterion) we doubt this meaning of 'medical' has been 
meant. 
Some have proposed a lottery instead of medical selection in case of inevitable 
selection. Though attractive, this usually is not defensible (from the viewpoint of 
equity and the viewpoint of efficiency) when life-saviug technologies are involved. 
Those with the "best' survival without the target technology - unrelated to the net 
benefit - are unduly favoured. 
We conclude a legally acceptable formula has yet to be found. 
44. "By the end of the 1970s there was a gradual change in ethical discussions. The 
importance of general philosophical issues for medicine was recognized, and conse-
quently the need for a philosophical basis for health care ethics. Analysis of moral 
dilemma's inevitably raised questions about the nature of health and disease, and the 
goals of medicine. The moral problems of contemporary biomedicine were in this 
phase linked with a philosophically inspired taxonomy of topics, including autonomy, 
personhood. justice, coercion. Ethical evaluation of the doctor's thoughts and actions 
would be more penetrating when attended by an analytical dissection of hisjher 
presuppositions and by a critical examination of conceptual foundations of clinical 
practice. ( ... ) Once we have chosen a conception of medical ethics as a process, the 
question arises of how moral reasoning proceeds and what purpose it has in medical 
matters. ( ... ) The method of medical ethics [as process GJB] has at least three steps: 
clarification, analysis and recommendation." 
Chapter 4 
1. The technical expression is 'terminal event'. 
2. The present waiting·list experience of heart transplantation patient indeed seems to 
confirm the bold and, according to clinicians, unlikely predictions (in 1988) of about 
25% 1-year survival without heart transplantation. 
3. The phenomenon is well-known in psychological literature. 
4. The pathogenic profile of organisms may change, but also the profile of the host 
may change. 
5. This temporal drift is e.g. a serious threat to the valid use of the Framingham-data. 
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6. We do not advocate wating lists, to be clear. 
7. From the Dutch heart transplantation programme and from the Ef·Newsletter we 
know that these conditions are not ahvays satisfied in organ transplantation waiting 
lists. 
8. Note that this basal hazard function is not equivalent to the hazard function of the 
normal population. It contains observed homogeneity (e.g. the diagnosis of all 
patients; this cannot explain survival differences in this group), observed heterogene-
ity (measured factors not attaining statistical significance in this model) and unob-
served heterogeneity (unmeasured factors which explain survival differences). 
9. This pertains to both significant variables and variables without proven prognostic 
significance. 
10. A particularly important variable is age. If the reference group encompasses only a 
limited age-range, the effect of age may easily be underestimated in extrapolations. 
11. An observation is (right-) censored if no terminal event occured at the end of the 
follow-up. The occurence of censoring should not be related to the occurence of 
terminal events. Usually censoring is due to a short observation period. Other 
reasons are patient withdrawal. unrelated death, etc. 
A particular application of censoring is in survival analysis of primary transplanta-
tions. If we treat retransplantation as terminal event we describe graft-survival; if we 
treat it as a censoring we describe patient survival of primary transplants; if we 
ignore the event we descnbe survival of transplanted patients, regardless of the 
number of retransplantations. 
12. Note that statistical significance is about the vertical distance of two or more survival 
cu:rves; clinical relevance is about the horizontal distance. 
13. >.(t) = f(t)/S(t) 
14. The reverse is not true. 
15. LY(C)) of a health newborn usua!Iy is approximated with life tables resulting in 
about 74 year for males and about 80 year for females. 
16. In statistical work .A(t) frequently is preferred as it shows more clearly the changing 
pattern of the force of mortality (syn. hazard rate function). 
17. Milani (1985) published a reduced sample regression analysis of sutv:ival cirrhotic 
patients. However, for unknown reasons he excluded all patients alive at the end of 
follow-up which makes the stated resemblance of his results with that of e.g. 
Christensen rather accidental. 
18. For the actuarial method the usual (also in liver transplantation reports) 3-month 
interval was chosen. 
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19. This model seems more appropriate than the proportional hazards model as for 
biological reasons the duration of the effect of donor organ quality 'Will 'oe :rather 
limited. Indeed we obsexved decreasing explanatory power of logistic regression 
models the later we defined the dependent variable, graft survival at x years. 
20. This assumption requires the ratio of the hazard rates >..;(t) for i different levels of 
an independent variable to be constant. Proportionality may be i~ed by plotting 
the log minus log survival function for i specific strata: ln. (-ln S(t,zJ) versus t (see 
also Kalbfleisch, 1980; Hopkins, 1983). Tests are available (see e.g. Moreau, 1985; 
Lancaster, 1985). 
21. This model requires two groups of othe:rwise comparable patients, one which is 
engaged in transplantation programme, and one that is not. From both groups data 
are drawn at a comparable stage of their disease, e.g. the occurrence of decompensa-
ted ascites. These data should cover the three types of variables mentioned: those 
which only influence prognosis without transplantation (also from the transplant 
group!), those which only influence prognosis with transplantation (also from the 
non-transplant group!). and those which affect both prognoses. 
22. The time-dependent model as described by Christensen in 1986 treats each set of 
the observed values of prognostic variables of one patient at consecutive occasions (3 
month-intervals) as separate cases in a time-fixed model (Christensen, 1986). Hence 
it is, strictly speaking. not a time-dependent model. 
23. tn computation of S(t) it may be convenient to approximate the stepfunction 'S..0it), 
A Ok(t) or S0k(t) by polynomial, Weibull or other functions. 
24. For computational convenience t=J may be rounded. 
25. One of the main conclusions of this article is based on a common mistake in clinical 
survival analysis. Survival differences are explained by the occurrence of cholangitis 
in the course of survival. This is an obvious mistake: survival is stated to be 
predicted from birth onwards, hence the value of all covariates should be known at 
birth, the start of survival time (t0). 
A similar error may frequently be found in analysis of survival after liver transplan-
tation (Bensel, 1988A). Operative blood loss (or an equivalent variable) is frequently 
included in the set of prognostic variables predicting survival after transplantation. 
As t0 starts before surgery, Mpostdiction" rather than prediction is the case. 
These incorrect applications of survival techniques may have serious conse-
quences when clinical policies are based on their outcomes. 
26. Other reasons were (absolute numbers) cardiopulmonal contra-indication (3), severe 
osteoporosis (1), other surgical alternatives (5). miscellaneous (11). 
27. For applications, see Buxton (1985) and especially the excellent analysis of Van 
Hout (1990). 
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Chapter 5 
1. We think of the issue of length of life versus quality of life, care versus cure, priority 
setting based on health measures (survival, health status), etc. 
2. For details see section 3.4. 
In most specialties there exist classifications or descriptive systems which may serve 
for disease-specific health status measurement purposes (e.g. NYHA-dassification, 
CCS-classification, AIMS classification). 
3. One might even wish the application of the measurement instruments in the latter 
case to be as explicit and efficient as it is usually in the first case. 
4. The empirical observations are not logically conferred to responses of the individual 
him/herself. 
5. E.g. Andrews (1976) developed a refined classification of these concepts. 
6. Berg (1973), Veit (1982) and Kane (1982) are stilt classics, which pay attention to 
valuation and description. They are rich of thoughtful considerations and little new 
has been put forward since. 
With regard to description alone we could mention McDowell (1987), Spilker (1990), 
a recent supplement of Medical Care (1989, March) and the more technical and 
unconventional text of Streiner (1989). The evaluation of three important American 
instruments is interesting for its considerations (Read, 1987 and the discussion of 
Bergner, 1987). 
De Haes (1985), though focussing on the cancer literature alone, demonstrates 
amongst other things the relevance of the distinction between objective versus the 
subjective (see A4) and elaborates on validity and design. Many of the theoretical 
considerations which can be found in her thesis on quality of life of cancer patients 
(De Haes, 1988) apply to decriptive measurement in general 
The classics to our opinion reveal more of the conceptual considerations related to 
application on the macro level as opposed to the more recent works, which • under-
standably - focuss on the empirical work of the last decade. 
The monograph of the Institute of Medicine (1989), though useful as a bibliography 
on the subject, also emphasizes applications rather than the theoretical conside-
rations that may underpin the choices in each of the studies which is described. An 
extensive bibliography is published as a supplement of Medical Care (1990, Decem-
ber issue). 
7. For a detailed treatment of the subject see for example Campbell (1976). 
8. We distinguish the classical test theory, the latent trait theory and Gutman's theory 
on facet design. We agree with Dessens (1987) that operationalisation with a facet 
design as an addition to the classical approach would be worthwhile. 
9. Based on the classical test theory. 
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10. A classification is defined as a measurement instrument with one or more items a, b, 
.•. , p, each with a 1 - 1 correspondence to domains a, b, ... , p with a nominal or 
ordinal measurement level. An individual is classified as having a nominal or ordinal 
score on each of the domains. 
A profile is defined as a measurement instrument with one or more items a1 _ n• b1 
_ :J' ••• , p1 -n' each with a correspondence to domains a, b, .•. , p by means of 
wetghting and summing up of the empirical observations. Each individual has a score 
on each of the domains with a presumed interval or ratio measurement leveL 
An index finally, does not differ from the profile except for a final, usually weighted, 
summing up of all separate domain scores to one score, usually between 0 and 100. 
In this case an individual may be characterized by only one score with a presumed 
ratio measurement level. 
11. The weighted sum of IPA and GWB yielding the Index of Well-Being does not add 
a new expression and hence is not regarded as a new expression. 
12. We disregard other unidimensional parameters for their limited relevance, lx>th from 
a theoretical and practical point of view. See also Drum:nond (1987 [p.lS]). 
The broader concept of outcome, which is adopted in QALY's and HYE's may 
include pain or disease avoided but also reassurance gained by information or 
emotional support and other process utilities (McGuire, 1988 [p.46-51,92,93,106]). 
13. Utility as defined by deftnition 2. not necessarily complies with the requirements of 
definition 1 (Weber, 1987; Richardson, 1990 [p.12]) hence we may not regard it as a 
specific operationalisation within the general concept of definition 1. 
14. Provisionally we assume that the sum of individual preferences equals societal 
preference (this might not be true as in some cases of vaccination). 
15. This is not necessarily true: for good reasons it could consist of multiple branches 
and multiple levels of health status within a branch. To our knowledge there have 
been no attempts to use e.g. a two-branch health scenario. This is surprising in the 
case of the use of standard gambling as valuation method: a two-branch scenario is 
already included as calibration device. 
16. Variation of the assumed duration only may provide insight into value of time. From 
our experience in a pilot study we conclude this requires extremely carefully defined 
calibration scenario's. 
17. The willingness-to-pay method apparently is a surrogate for the first-best method, 
revealed preference. However, it is of little use for the insurmountable confounding 
effect of income and wealth. Moreover, we met a considerable number of adverse 
reactions of laymen respondents upon introduction of the method. 
The equivalence method could be added, but we think this method does focus to 
much on the distribution problem - being aware this remains a problem. 
18. Either an additive model or a multiplicative model. 
19. Weighted by their probabilities or otherwise (McNeill, 1982) 
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20. After we established the feasibility of the EuroQol-system, we took a sample from 
health politicians (about 70). Apart from a higher response values were about the 
same. 
Chapter 6 
1. Technologies for diseases which are primarily defined by patient's complaints may 
give rise to empirical difficulties (e.g. CABG in angina pectoris). 
2. From an economical point of view 'medically-defined need' does not exist as a sepa-
rate entity. Scientific and political practice, in our view, justifies to speak of two 
viewpoints. The concepts of 'indication' and 'contra-indication' clearly refer to a 
medically defined need concept. 
3. 'It can be defined either in terms of the type of illness or disability causing the need 
or of the treatment or facilities for treatment required to meet it.' We prefer to 
speak about 'and' instead of the second 'or'. 
4. Hence there is a strong relationship between need estimation and patient outcome 
analysis. 
5. Particularly in this case we should say 'should depend' due to obvious market 
imperfections. 
6. In practice the first question to be adressed will regard alternative modes to solve 
the same medical problem. 
7. A sovereign consumer choosing rationally the commodity that fits best his preferen-
ce is not representative for the patient saving and receiving medical help. A supplier 
deciding to enter the market, calculating the optimal mix of quantity and quality of 
commodities (health care services) as to gain maximum profits usually is not 
representative for a health care provider. 
8. Thus we accept a subjective feature of the real but unobservable quantity. 
9. See the adjective 'acceptable' in the definition of Matthew. 
10. These aggregation principles may be derived from the loss functions well-known in 
economic theory (maximin, minimax, maximax, expected utility). Different principles 
may yield entirely different results. 
11. Prevention is the extreme case. But also heart transplantation for some diagnostic 
categories (arrythmia's). 
12. Qinical language speaks of 'an indication to' rather than 'the need for' treatment. 
13. In the ideal rational system this threshold does not depend on the disease involved. 
14. A QAL Y ;cost criterion may be chosen if a linear relation is accepted. 
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15. We think of case-control study, cohort study, sample survey, registry analysis 
(incidence, mortality, prevalence), mathematical modelling. case report, observational 
study, RCcr and expert opinion. 
16. The assesment of need is an uncommon objective of medical research. If underta-
ken, it usually is 'piggyback' research, i.e. an investigational effort additional to an 
already existing design. 
17. 'Detailed' refers to the distribution and the predictability of benefits. 
18. Screening, as a complex of diagnostic, therapeutic and sometimes preventive, 
technologies is not regarded as a preventive technology in this classification. 
19. They cannot be identified ex post either in primary prevention. Anonymity of the 
beneficiaries is a major source of the disrepute of prevention. The 1 in 10.000 who 
experience some adverse effect of prevention may succesfully blame the system; we 
shall experience the wrath of the 20 in 100.000 who die from preventable disease 
only at the other side. 
20. E.g. minimal severity or absence of concurrent diseases. 
21. Note that alcoholic cirrhoisis and hepatitis B were excluded from liver transplantati-
on by the pilot programme protocol. These diseases probably will demonstrate geo-
graphical variation. 
22. These favourable circumstances were a. the relevance of the mortality method 
combined with suitable mortality data, b. no competing treatments and no competing 
centres, and c. an excellent referral database. 
Chapter 7 
l. In fact 'utility' this way us a second best alternative: outcomes valued in currency 
units should be preferred. 
2. Nothing so practical as excellent theory. 
3. A tentative programme of MTA~methodologies needing further elaboration should 
include the following items. It is clear the nature of these methodological problems 
is quite divers. However, standardization (preferably at the international level) 
should be aimed at in all cases, despite the arbitrariness of some choices. 
The methodological issues are: 
1. non-experimental outcome analysis, 
2. quality-of~life measurement related to time, 
3. utility analysis, 
4. indirect costs, 
5. analysis of objective need, 
6. distributional analysis, 
7. ethical analysis. 
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4. The measurement of quality of care is but a straightforward extension of the MTA-
concept (the reverse is also true). 
5. We emphasize that consumer organisations have little to do with organisations 
representing the interests of patients with particular diseases. Sine nomen est omen. 
6. Depending on the budgetting regime and the relation between the hospital manage-
ment and the medical staff, economical expertise may be drawn from the hospital 
administrative staff or from outside. 
7. This pressure curtailed MTA-activities from e.g. OTA and OIIT'A in the United 
States. Similar synergism may be expected in Europe, particular when 'Europe 1992' 
carries through. 
8. Admittedly this is a paradox. 
9. The erroneous expectation of impressive numbers reflecting scientific advance clearly 
originate from era of the succesful eradication of (most) infectious diseases (in 
Western. countries). Mackenbach demonstrated the small number approach needed 
to demonstrate probably larger improvements really due to medical care in modern, 
and prosperous, hence healthy societies (Mackenbach, 1989). 
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Summary 
In 1985 Dutch health care authorities and health insurance companies Initiated a 
large--scale technology assessment {TA) of liver transplantation (LTx) In The Nether-
lands. The 10-year experience of the existing programme in the University Hospital 
Groningen was investigated. Topics included were patient flow, selection policies, 
survival, quality-of-life, costs, need, supply of donor organs and organisational as-
pects. Estimation of the consequences of a non-transplantation scenario allowed for 
the execution of a cost-effectiveness analysis. Results showed clear improvement 
by LTx of survival and quality-of-fife, though to a lesser degree than expected. Costs 
of the first transplantation year amounted to Dfl 180,000 (approx US$ 90,000). The 
cost-effectiveness ratio ranged from Dfl 47,000 to Dfl 133,000 per life year gained. 
No overt Imbalance between need and donor supply existed or was expected in the 
near future. The Impact of this study Is related to the informational value and to the 
contribution to the declsion-process. Even at Its appearance in 1988, the final report 
provided health policy makers with new Information. Health polfcy concerning LTx 
was considerably influenced, as a rule in agreement with the study conclusions. We 
conclude the Dutch case study to be an example of a useful and efficient TA. 
U-1er transplantation; Cost; Survival; Quality of life; Health policy; Technology as-
sessment 
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Introduction 
In The Netherlands orthotopic liver transplantations have been performed since 
1979 in the Academisch Ziekenhuis Groningen (AZG) [1,2], In onhotopic liver 
transplantation the diseased liver of the recipient is removed (explantation) and 
subsequently replaced (implantation) by a liver of approximately the same size from 
a donor with the same blood group. Few advocate heterotopic liver transplantation 
on some occasions. In this procedure the diseased liver is left in situ and part of 
a donor liver is additionally placed in the abdomen below and behind the diseased 
liver. In this case the donor liver is connected to the biliary and circulatory system 
by seperate anastomoses. 
The transplantation-programme in the AZG staned as an experimental clinical 
programme. funded by general research grants. Despite the recommendations of the 
Consensus Development Conference of the National Institutes of Health in 1983 
and the favourable development of the programme, Dutch health care authorities 
were reluctant to incorporate liver transplantation (LTx) into regular reimbursement 
schemes [2,3]. As a result the AZG received supporting grants from the Dutch 
health insurance companies to continue their programme on a larger scale from 
1985 onwards, one of the conditions being participation in a technology assessment 
(TA) by an independent research team. This technology assessment should yield 
objective information about costs, effects, organisational aspects, donor supply and 
other topics, which health care authorities regarded to be necessary for a well-
founded decision [4]. The final report appeared in September 1988, describing the 
experience of 221 screened and 73 consecutively transplanted patients [1,5]. The 
results of this technology assessment were used in the subsequent decision-process. 
Based on the information of the final report it was decided that the restrictive 
regime. limiting LTx to one national centre, should be continued whilst additional 
research should be conducted towards information about results of LTx in the long 
run. 
In the first part of this article the general results of the LTx -technology assessment 
are summarized (programme description. survival. quality of life. costs. donor 
supply). Also the main features of the resulting decision process will be described. 
In the second part two evaluative questions will be addressed as far as the state of 
affairs in The Netherlands in February 1990, i.e.: 
1 Did theTA generate knowledge and information which might justify the research 
effort? 
21'o what extent has the process of decision making been influenced by the 
information from the TA? 
Finally we will discuss some critical aspects of this TA in view of future 
application of this policy tool. 
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Data and methods of the TA 
Data 
Medical data were provided by a clinical database describing pre-transplailtation 
status and follow-up status of transplanted patients at regular intervals (before, and 1 
week, 1 month, 1 year, 2 years, 3 years, 5 years and 10 years after transplantation; 
about 1100 variables per patient with complete follow-up). Medical data were 
complete for 76 transplantations (68 patients); from 5 patients no (sufficient) data 
could be obtained. Additional medical data were abstracted from medical records 
of chronic cirrhosis patients who were rejected for LTx to enable estimation of 
non-transplantation survival (131 patients) [6]. 
Administrative data and socio-demographic data were available for all referred 
patients, including vital status at !he closing of follow-up September 1987. The 
following stages were distinguished: screening. waiting list. operation - 3 months, 
4-12 months and every consecutive year. 
Quality-of-life was measured applying computer assisted interviewing [7,8]. 
The interview was presented to the patient before LTx and at regular intervals 
afterwards, and consisted of several questionnaires representing !he full spectrum 
of dimensions of quality-of-life [9]. 
Cost volume data were retrieved from the hospital administration system. which 
registers the majority of clinical activities (in hospital stay. physician services. lab 
services etc.) on a per patient per diem basis. The input volume of key specialities 
was determined separately on a real time basis. Other cost units counted separately 
concerned blood products, operating room facilities, drugs, social work and out--of-
pocket patient costs. Prices (1987-level) for each cost unit (time, product or service) 
were derived from the financial adminstration. 
Donor data were collected at Eurotransplant, an organisation which is responsible 
for optimal distribution and excbange of human donor organs in Western Europe. 
Data on the need for LTx were derived from three different sources: national 
age- and sex specific mortality statistics, epidemiological literature and !he afore-
mentioned administrative system whicb included medical details for !hose referred 
patients which were regarded temporary or definitely unsuitable for LTx. 
Literature on all topics was collected extensively to provide a full reference for 
!he case results of !he AZG. 
Methods 
Flow chan analysis and life-table teclmiques were used to describe !he patient 
flow from !he referral to post-LTx status [11]. Conventional statistics were used to 
compare characteristics of different patient-groups and to compare characteristics 
over time. 
Survival analysis included Kaplan-Meier estimates of survival and Cox-regression 
analysis on determinants of success of !he transplantation [10--14]. A new sta-
tistical technique was developed which enabled a comparison between observed 
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survival curves (Kaplan-Meier) and model-predicted non-transplantation survival 
curves [15,16]. 
Quality-of-life analysis included comparison of both one-dimensional and aggre-
gate quality-of-life indicators over time [17-21]. A utility estimate was arrived at, 
based on multi-attribute utility theory [22,23]. 
Cost analysis followed methodological guidelines on economical cost-analysis 
[10]. Estimates of quality-of-life and costs in the hypothetical absence of the LTx-
programme were derived from the waiting list period. of the patient (on average 
3 months). 
Potential donor supply was extrapolated from existing trends on renal organ 
donation and multi-organ donation. We assumed an increasing fraction of multi-
organ donations to be used for liver transplantation in the future due to relaxation 
of relative contra-indications and a decrease of organisational waste as a result of 
better preservation techniques. 
Finally the need was estimated in three independent ways, combining a variety 
of sources on tile suitability of potential patient groups (deaths or diseased with 
specific liver disease) with demographic trends. 
An economical cost-effectiveness analysis was carried out separately, combining 
results on costs, survival and quality-of-life [24]. 
For tile statistical analysis we used tile BMDP-statistical software, release 1985 
[25]. 
Results 
Description ollhe LTx programme 
The treatment protocols regarding patient selection. timing, infection prevention, 
surgical techniques are published elsewhere [26] and will not be discussed here. 
From a clinical point of view the most important identifiable innovations during 
tile study period were the introduction of a vena-venous bypass technique and the 
change to a triple drug immuno-suppressive scheme [27, 28]. At the start indications 
were limited to adult patients with chronic cirrhosis, a clinical entity which is the 
final common pathway of a wide array of chronic diseases of the liver and of the 
biliary tracL Diseases witll a high probability of recurrence (malignancies, infectious 
hepatitis) were excluded. Indications were gradually extended to retransplantations 
(1982), paediatric transplantations (1982) and, more recently, transplantations in 
patients with acute hepatic failure and HBsAg-positive cirrhosis. due to hepatitis B 
infection [5]. Gradually patients with more advanced disease were transplanted [15]. 
In the first I 0 years of the programme, 221 referred patients satisfied criteria for 
fu..1:her examination. About two thirds of them, 145 patients, were regarded to be 
suitable candidates. The difference with the number of patients transplanted at the 
end of data collection (Summer 1987) (73) may be explained by the large number 
of patients whose condition was considered to be too good for transplantion at 
acceptation date. Patient-referral attained a stable level in !986, but the prediction 
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Fig. 1 Flowchart of the nver transplantation programme of the AZG 1985-1988 (01...01-198$). 
was that transplantation frequency would stabilize later (about 1990). 
Until 1988 the major part of accepted patients consisted of chronic cirrhosis 
patients (see Fig. 2). Detailed analysis of medical characteristics for primary biliary 
cirrhosis (PBC) and other types of chronic cirrhosis revealed some change over 
time: referral was more adequate (fewer rejections) and transplantation was carried 
out later in the course of the disease (e.g .• higher O:rild-Pugh score, which indicates 
a higher degree of liver dysfunction). 
International comparison was not possible for the flow-chart and the medical 
characteristics, but results from the European Registry for Liver Transplantation 
showed the Groningen patient population to be comparable to the average European 
patient with regard to age [5,29] and diagnosis (see Fig. 2) [29]. 
Only acute hepatic failure, biliary atresia (an infrequent congenital malformation 
of the biliary tract. characterized by interference of bile drainage. cholestasis. and. 
if untreated. death after weeks to months) and tumours were relative infrequent 
diagnoses. Overall-survival after LTx appeared to he 64% at one year and 53% at 
five year. Clearly this gives no good impression of the effect of LTx, as survival is 
strongly related to the nature of the pre-existent disease. In a Cox-regression model. 
characteristics of the recepient (age. liver function. renal function). the donor (renal 
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function) and the surgical procedure (blood loss, related to haemostatic factors) 
appeared to predict survival significantly. 
At the start of the study no empirical information was available about the 
improvement of survival by LTx. The effectiveness of LTx was usually related 
to survival after LTx per se, assuming survival without transplantation to be 
negligibly low. Publications about heart transplantation (HTx) showed considerable 
differences between clinical predictions and empirical evidence about the prognosis 
in absence of HTx [30]. We therefore tried to support the clinical assumption 
by empirical evidence. In the absence of randomized controlled clinical trials 
we estimated non-transplantation survival for three diagnostic categories (primary 
biliary cirrhosis, chronic cirrhosis (excl. PBC) and biliary atresia) by two different 
methods (Fig. 3). For the two cirrhosis groups we used two published prediction 
models and a new model, based on the medical data of 131 non-transplanted patients 
in the AZG. In the case of biliary atresia we assumed the simultaneously published 
national experience with the Kasai-procedure, which is the therapy of first choice 
in the Netherlands, to provide the best control survival curve [31]. 
The differences in the cirrhosis-groups using the Christensen-models were 
smaller than expected but on the long term LTx appeared to contribute positively 
to survival (PBC 1 year and 5 year survival with LTx: 62 vs. 55%; without LTx: 
35 vs. 26%; non-PBC-cirrhosis I year and 5 year survival with LTx: 60 vs. 51%; 
without LTx 46 vs. 21 %). Patients in Child-Pugh class B and C (most deteriorated 
liver function) benefitted most from the transplantation, despite increased operative 
risk [5, 16]. The model based on non-transplanted AZG-patients yielded slightly 
better net effects of LTx. In the case of biliary atresia, differences appeared to 
be fairly large, indicating LTx (usually preceded by a Kasai procedure) to be far 
superior to the Kasai-procedure alone (I year and 5 year survival 100 vs. 62% 
and 100 vs. 47%). 
Results of quality-of-life analysis are shown in Table l. Pre-transplant scores 
suggest major limitations on all domains of life, the most predominant feature 
being severe lack of energy. After transplantation all objective indicators show 
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Rg. 3 Observed survival with LTx compared to expected survival without LTx in PBC, non-PBC 
cirrhosis and biliary atresia. Obs-PBC, observed survival with LTx In PBC; Obs-C!R, observed 
survival with LTx In Non--PBC cirrhosis; Obs-BLA, observed survival with LTx in b!llary atresia; 
Exp-PBC, expected survival without LTx In PBC (cf. Christensen model}; Exp-CIR, expected 
survival without lTx In Non-PBC cirrhosis (cf. Christensen model); Exp-BLA, expected survival 
ytithout lTx In biliary atresia (cf. national Kasai-experlence). 
improvement. although the level of the general population is not always attained. 
Subjective quality-of-life attains levels which in the first year exceed the level of the 
general population, maybe due to euphoria of surviving the most critical surgical 
phase. Psychiatric morbidity was seen rarely. Until recently only few indicators of 
quality-of-life have been studied. usually from selected survivors after LTx. The 
few systematic studies available in 1988 showed conflicting results though they 
shared our findings of sharp improvement of subjective quality-of-life contrasting 
to moderate and gradual improvement of objective quality-of-life indicators [32,33]. 
The serious psychiatric morbidity reported by others [34-37] could not be replicated 
in our series. These discrepancies may be the result of a different patient selection 
policy or the effect of the thorough mental and social support programme in the 
AZG. 
Costs of the programme are shown in Table 2. Clearly the first three months after 
transplantation are the most expensive from the perspective of cost per unit of time. 
However, the impact of cyclosporin (CyA) maintenance therapy to cumulative costs 
is impressive. For comparison we added an hypothetical CyA-conversion scheme, 
converting the patient to azathioprine/prednisone after one year. If we assume a 
survival of 20 years costs decrease with 26% (undiscounted) or 19% (discounted). 
respectively. Decomposition of total costs in the first year after transplantation 
(Dfi. 180,000, US$ 90,000) shows net costs of transplantation (25%) and hospital 
care (30%) (immune-suppression and medical services excluded) contributing mosL 
Drugs account for another 12%. 
Limited reference values were available in September 1988 on the costs of 
LTx. Reports from the U.S. showed charges for a one year surviving patient 
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Table 1 
Ouality-of~life beiore and from 1 year after liver transplantation 
Questionnaire Range* Normal 
value 
Pre l+Yr 
Karnofsky Performance Index 0--100 >90 67 87 
State-Trait Anxiety Inventory 80--20 < 37 41 32 
Self-rating Depression scale !00-25 < 33 51 44 
Index of Psychological Affect 1-7 > 6 45 6.4 
Overall Life Satisfaction 1-7 > 6 3.8 6.7 
Nottingham Health Profilc-I !00--0 <10 
-Mobility 25 14 
-Pain 23 5 
-Energy 52 6 
-Sleep 39 14 
- Emotional reactions !6 6 
- Social isolation !4 5 
Nottingham Health Profile-TI** 
Present staie of health causes problems for. 
-Job of work (% yes) 33 17 
-Looking after the home (%yes) 67 41 
-Social life (% yes) 67 13 
- Home life (% yes) 50 0 
-Sex life (% yes) 50 9 
-Interest and hobbies (%yes) 67 22 
-Holidays (% yes) 100 41 
Symptoms and complaints** 
-Abdominal distension (% yes) 46 21 
-Itching (% yes) 46 13 
-Icterus (% yes) 61 21 
-Bone pain (% yes) 38 43 
-Low pcrfonna.""lce capacity(% yes) 78 17 
* Theoretical range, from worst (left value) to best (right value). 
**The healthy population is assumed to give the answer ~no" in all instances. 
ranging from $ 230.000 to $ 340,000 [38]. Additional years of survival would 
cost between $ 10,000 and $ 20,000 per year. These values had little meaning in 
the Dutch case because (a) charges are different from economical costs and (b) 
even applying purchase power parities, surgical costs in the U.S. are incomparably 
high in comparison to most other Western countries [39]. An unpublished repon 
of the hospital administration of the AZG estimated total cost for the procedure 
includi.."lg five year of follow·up at least being the double of our empirical results. 
The cost-effectiveness ratio ranged from Dfi 47,000 to Dfi 133,000 per life year 
gained. depending on the severity of disease at transplantation date [24]. About the 
same range of costs per QALY was obtained [24]. 
The need for transplantation is clearly related to many factors. Generally the 
epidemiology of relevant end-stage liver diseases, detection and referral, and 
clinical selection are the most important ones. Estimations for the Dutch case 
showed consistently a need of 2 to 5 per 106 inhabitants, given a protocol which 
excludes active Hepatitis B-infection, alcoholic cirrhosis and patients aged 60 years 
and over (see Table 3). Also the vigorous screening of candidates with a primary 
hepatic tumour excluded the larger part of these patients from transplantation. 
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Table 2 
costs (Dutch florins) of one liver transplantation patient per stage including 20 years of 
follow~up (n::76) 
Transplantation stage 
Screening/provisional 
candidacy 
Waiting list 
Operation - 3 months 
4-12 months after LTx 
Each consecutive year 
-with Cy-A 
-without Cy-A 
Cumulative costs (20 year survival) 
-with Cy-A 
-without Cy-A 
Undiscounted costs 
15.514 
3.646 
132.860 
46.318 
28.099 
12.050 
732.219 (100%) 
427.288 ( 74%) 
5% Discounted costs 
17.104 
3.828 
132.860 
46.318 
CF X 28.099* 
CF x 12.050* 
539.695 (100%) 
345,738 ( 81%) 
* The costs for each consecutive year are equivalent tO the annual costs. corrected for the time 
they are incurred with the following correction factor (CF): CF = ( l.~S) YR 
Estimations of donor organ availability did meet these need-projections on an annual 
base (Table 3), but this does not preclude the occurrence of actual donor shortage 
(especially in the case of children). 
Alternative estimates of need did exist. ranging from 4 to 20/106 and 20 to 
250/10', respectively [40,41]. Only the first range is suitable for comparison as it 
is based on a similar epidemiological approach and on a country with about the 
same epidemiology of liver diseases [42]. The difference between O'Grady and our 
study is explained by different inclusion criteria: in the English case patients of all 
ages and all alcoholics were regarded potential LTx-candidates. With our inclusion 
criteria the estimates of need were identical for the United Kingdom and The 
Netherlands, given a comparable epidemiological profile of chronic liver diseases. 
At the time of decision (1988) information on donor supply was only partially 
available. Little was known about the preventable organisational waste of organs 
and the potential increase of liver donation due to relaxation of suitability criteria. 
Table 3 
Transplantation need and donor supp!y in The Netherlands on an annual base 
Need Supply 
Min Max Min Max 
Number provisional 
candidates ('84-87) 20 20 Number of MUD* (86-87) 60 60 
Acute hepatic failure + 2 + 5 Improved donor acquirement X 1.00 X 1.40 
Inclusion of HBsAG .. + 2 + 10 Change legal system X 1.00 X 1.20 
Optimal referral X 1.0 X 1.9 Suitable liver donors X 0.75 X 0.90 
Rerransplantation X 1.1 X 1.2 Improved utilization X 0.90 X 1.00 
Crude total 26.4 79.8 Crude total 40.5 90.7 
Standardized total 2/106 6110' Standardized total 3/106 7/106 
* - multi-organ donation. 
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Description of the decision process 
ln this section the judgement and decisions on LTx made by the Dutch health 
care authorities will be described. Before 1985 LTx was excluded from regnlar 
reimbursemenL During the study-period (1985-1988) decisions of government and 
health insurance comparties were deferred_ which a_o. implied competing liver 
centres could not start a LTx-programme. 
Before the TA started in 1985. two national advisory boards were asked to 
prepare advices on LTx to be released in 1988. The National Health Insurance 
Board (NH!B), which unites the insurance interests of premium parties (health care 
providers, employers. employees. insurance companies) set up the above--described 
TA to provide for the required information on costs. benefits and potential future 
impact The Health Council (HC), which was primarily asked to report on the 
scientific state of the an of LTx. instituted an expert committee consisting of liver 
disease experts from all Dutch liver centres. A simultaneous appearance of both 
advices was aimed at 
Generally, the NHJB accepted all the empirical evidence of the study [43]. 
However, a clear decision was considered to be difficult for several reasons. 
First, long term results (i.e., beyond a 5-year-torizon) were still unknown, though 
available evidence suggested no additional risks for long term complications. 
Second. clear definition of selection and timing criteria seemed critical but difficult 
to achieve. Third. need projections were based on epidemiological data combined 
with rather crude estimates on the distribution of disease severity. Without data on 
this distribution, the size of even a clearly defined patient group seemed difficult 
to project. Finally, treatment policies of paediatricians with regard to biliary atresia 
suggested dissensus, with an unknown probability of future convergence. 
Given these uncertainties and an unfavourable cost-effectiveness ratio compared 
to e.g., heart transplantation, the NIDB advised to postpone a definite decision 
for the LTx-programme as a whole. Furthermore, the TA should be continued 
to provide answers on the questions left. In view of the projected need and the 
potential capacity of the AZG-programme, the number of LTx-centres should not 
be extended. 
The Health Council regarded theTA-results as only one piece of evidence [44]. 
The publications of the Pittsburgh centre were regarded as equivalent sources of 
information, though it was recognized that important views expressed in these 
articles sometimes lacked empirical evidence. From a scientific point of view it 
was concluded that LTx had left the realm of experimental care, although the 
expert committee acknowledged the same uncertainties as the NHIB. The critical 
criterion as stated in the HC-repcm was the survival benefit. Survival gain was 
regarded proven in PBC-patients and most likely in patients with other types of 
chronic cirrhosis and biliary atresia. Implicitly this view suggested conditional 
inclusion of LTx in the reimbursement schemes, as the status of LTx as an accepted 
and acceptable therapy could no longer be doubted. On some important clinical 
issues (timing of surgery, the acceptance of patients with active hepatitis B. acute 
hepatic failure and the preferred therapeutic strategy in biliary atresia) no statements 
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were made. As did the NIDB, additional research was regarded useful (e.g., on 
heterotopic LTx and on the need for LTx) but not mandatory for an answer on the 
status of the therapy. One organisational issue received much attention: the possible 
increase of the number ofliver transplantation centres. The HC comntittee favoured 
extension of the LTx-programme to two, maybe three centres, primarily to set up 
a trial comparing orthotopic liver transplantation with the heterotopic procedure, 
which has been advocated by the Dutch liver centre in Rotterdam [ 45]. 
Both advisory reports and its conclusions - though not always concordant -
were accepted by the Minister of Health in the summer 1989. In a letter to the 
parliament on the rationing of health care and more specifically on the control of 
new technologies as heart transplantation, in vitro fertilisation and LTx. LTx was 
subjected to the regimen as proposed by the NHIB. TA -research was continued and 
the financial and legal arrangements were kept unaltered, preventing other centres 
to start their own LTx-programme. The projected TA research was restricted to the 
questions about timing and long-term benefits. An analysis of the need for LTx 
was regarded unfeasible by the expected refusal of registration offices to enable 
analysis of death certificates and hospital records of diseased due to chronic liver 
diseases. Unexpectedly and still poorly understood the biliary atresia problem was 
regarded not important enough to justify further research. 
Evaluation 
Informational value 
Justification of the TA of LTx in The Netherlands should be primarily related 
to the informational value. An important criterion in this context is the degree to 
which the study generated new information. New information may be defined as 
information which fills an information gap. challenges existing information or adds 
information to existing data (as e.g .. in meta~analysis or cost-effectiveness analysis). 
Appropriate reference dates are the beginning of the study (July 1985) and the 
appearance of the final report (June/September 1988). In 1985 information about 
LTx was printarily devoted to survival after LTx, and to clinical aspects (surgery, 
immune-suppression). Even in 1988 comparative information on other topics was 
scarcely available. despite the widespread application of LTx. The greater pan of the 
reports originated from the large LTx-centre in Pitrsburgh (U.S.A.). However. many 
of these were of limited use either by national specifity (need, supply, costs) or by 
methodology (costs, quality-of-life, survival without LTx). It should be added that 
particularly on the subject of estimation of non-transplantation survival and qualil)'-
of-life much has been published since [16,41]. We therefore conclude the study 
generally satisfied the above mentioned criterion of informational value. In 1988 
the informational value was not primary the result of the filling of an information 
gap but the result of providing independent information on several topics on which 
divergent views existed. 
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The contribution oithe TA to ihe decision-process 
The description of the policy impact of this TA should not be limited to 
the contribution of the final report to the explicit decision process. It should 
be noticed, that the research programme exerted considerable influence on the 
diffusion process of LTx during the study period. E.g. detailed analysis of medical 
characteristics of the patients, organisational characteristics of the programme 
and preliminary survival results were published as interim~reports in 1987. These 
provided justification of the continuation of the restrictive approach of LTx in only 
one centre. 
At least three contributions of the final report may be distinguished. The NHIB 
adopted the entire contents soon after its appearance and the HC judged LTx to 
be acceptable and accepted therapy. based on the same evidence predominantly 
with regard to survival benefit The report also convinced many in the periphery 
of the decision-setting of the good quality-of-life of the great majority of surviving 
transplanted patients. In view of tile provisional acceptance of LTx one migbt 
conclude that the TA contributed to the decision that LTx was an accepted form 
of therapy. 
Second. tile analysis of the need for LTx left little room for a second LTx-centre 
in The Netherlands, from a health care point of view, given the fact that even an 
excentrically located unit has good accessibility due to the small size of the country 
and excellent tra...1sport facilities. The continuation of restrictive legislation on the 
number of centers was clearly based on this information. 
Third, the final report provided some suggestions on improvement of the referral 
and selection process. which clearly influenced the practice of LTx in the AZG. 
Discussion 
An appropriate judgement of the resui!S and impact of the TA of the Dutch 
LTx-programme should consider some important aspec!S of TA beyond the infor-
mational value as such. These aspects are equaUy decisive for the viability of future 
application of this policy tool. Five of these aspects will be discussed. 
In the section above it was concluded that the information on survival and -
maybe- quality~of-life contributed to the provisional acceptance, thus proving the 
informational value. But the provisional character deserves attention. The NHIB 
suggested to postpone decisions until uncertainties had been clarified. The particular 
uncertainties involved (selection. need. long~term effects) will exist at any time 
with any recent technology. The requirement of certainty may be regarded as a 
process-criterion, not a mere outcome~criterion, which neglects the inherent value 
of the technology sofar demonstrated, as in the case of LTx in children with biliary 
atresia. The emphasis on process-criteria is related to the use of TA as a process 
management tool (usually a •freezing tool') rather than as a decision supporting 
tooL This use illustrates a yet immature decision process. 
From a health insurance perspective another undesirable aspect of the decision~ 
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process is the lack of information on cost-effectiveness of other health care pro-
grammes. LTx was apparently less cost-effective as compared to heart transplan-
tation (HTx) but due comparison would include interventions for other chronic 
diseases as well, notably malignancies. This implies a balanced cost-effectiveness 
analysis research programme on a larger scale, and a continuous decision process in 
the context of an increased awareness of the necessity of rational choices in health 
care [32]. This should be preferred to an accidental comparison of two health 
care programmes (Hfx and LTx) which mainly share public appeal as banners of 
medical progress and golden standards of increase of medical expenses. 
Next, the societal or public health perspective usually ignores the scientific inter-
est of a health care programme. Regulations which aim at optimization of capacity 
usually conflict with maintenance of professional autonomy and the freedom of 
scientific research. The subtle differences between the HC-advice and the NHIB-
advice clearly originate from this difference. In our opinion patients interests should 
guide the decision-maker, which implies a tendency to centralization of complex 
procedures of the number in centers with a capacity guaranteeing scientific and 
economic effeciency. 
The uncertainty of the need estimates may be criticized. In our view this is not 
primarily a specific feature of TA methodology but a characteristic of descriptive 
population epidemiology. Population data on the incidence of many adult diseases 
are scarce. a result of the cost-intensiveness of this type of epidemiological research. 
Even more scarcely available are population data on stage or severity of disease. 
Monality data or clinical admission data sometimes may be a good proxy for data on 
severely ill patients, but in many countries reliable nation-wide registrations do not 
exist or data are not available for case-by-case exploration. The development of a 
feasible approach of this recurrent problem is a major challenge for epidemiologists. 
notwithstanding the fact that one aspect of uncertainty will remain in the context of 
TA. Projections of future need will always be prone to changes due to developments 
in the technology involved and its alternatives, i.e .• in this case transplantation and 
conventional medical therapy. 
Finally, the deployment of resources and the inconvenience involved by a large 
scale TA should be explicitly valued as a diswility. No standards exist about the 
appropriate maximum of resources devoted to a single TA. From an economical 
perspective these may be related to the economical decision space, given a time 
horizon of 5 to 10 years. In our case the lower bound of the decision space was 
determined by a liver programme without LTx and with conventional therapy. The 
upper bound of the decision space was the execution of abcut 40 LTx each year. 
follow-up included. Using a short 5 year time horizon, theTA-costs made up only 
3-4% of the differential costs of these two options. From the clinician's perspective 
the intrusion of the TA on the clinical programme was regarded with suspicion at 
the stan. It was valued positively in the end, probably because inconveniences were 
balanced by scientific spin-off and an improved position on the Dutch market. 
The TA of the Dutch LTx -programme taught us many lessons. one of them being 
that high impact technologies may be fruitfully analyzed this way. 
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Cost-Effectiveness Analysis of the Dutch Liver 
Transplantation Programme 
G.J. Bonsel, I.J. Klompmaker, M.L. Essink·Bot, J.D.F. Habbema, and M.J.H. Slooff 
L IVER transplantation (LTx), though never assessed in a controlled clinical trial. is performed in growing 
numbers in centres all over the world.' As the costs of the 
procedure including follow-up tre::ttment arc impressive, 
health insurance companies have been reluctant to incor-
porate LTx into their insurance scheme.z""' 
In The Netherlands, orthotopic liver transplantations 
have been performed since 1979 in the Academhch Zie-
kenhuis Groningen. ~ 
In view of the unknown costs and effects of the liver 
transplantation programme in The Netherlands. the Dutch 
government and the National Health Insurance Board 
(Ziekenfondsraad) agreed in provisionally subsidizing the 
AZG-progmmme. In 1985 the AZG was provided with a 
3-ye;.li' grnnt. on the condition that the hospital would 
participate in a medical technology assessment by an 
independent research te<un. This study should aim at an 
empirical description of the costs. effects. organi:>ational 
impact and other aspects of the AZG-progmmmc to sup-
port a decision about incorporation in the Dutch health 
insurance scheme (Table 1). 
Legal and ethical issues and the concluding health policy 
recommendations were dealt with by two national advis-
ory boards. The final report of the study appeared (in 
Dutch) in September 1988. describing the experience of 
221 screem:d patients and 81 transplantations (including 8 
retranspl:mtations) between 1978 and 1987.6 This :lftic!e 
presents a cost-effectiveness analysis based on the data of 
this study. 
PATIENTS AND METHODS 
Treatment Protocol 
Treatment protocob regarding patient selection. timing. infection 
prevention. surgiQll technique. and immuna-uppre:,sion are de· 
:.cribed el~where. 7 Changes in the study period included the 
introduction of a modifi<:d vena-venous bJ'PU"s technique (!981)" 
nnd rhe ctJ.anse to a triple drug immunosuppres._,ive scheme 
(l%$).° Cost calculations were based on u treatment protocol 
inducting cyelosporin A. 
Table 1. Topics of the Dutch Orthotopic uvor 
TranspLantation Assessment 
Survival with and wltholll L Tx 
Qul)llty of lifO with and Without LTx 
Costs woth and without lTx 
COst-effoctlvonoss of l Tx 
Need lot LTx and supply of donor IIV(li'S 
Patloot cmorla 
Process of referral. 
scroonlng. timong 
Orgarusatlonal aspectS 
Changes ovor t1mo 
Medical Data 
A medical databa:.c (lTlllX I 100 variuble~ per patient) d~ribed 
pretransplantation statu~ and follow-up ~tutus of tran~planted 
patient' at regular intervals. Medic:U data were complete for 76 
tran~plantation~. 
Admini~trative and ~a<::io-demographic data were available. 
including the vital ~tutus ut the dosing offollow•up (;>.utumn 1987). 
The following ~t:lge~ were distinguished: '-Creening; waiting list: 
operation to 3 month~: 4 to 12 months. ~econd year. third year. 
etc.). 
Additional data were abstracted from mcdiQll records of 
chronieeirrho~ patien~ who were rejected for LTx to ennble the 
modelling ofnontran~pluntat.ion ~urvivul by means ofCox-regres-
'ion unalysb (1! ~ 131).'0 
Quality of Ufe Data 
Quality of life und heo..lth ~tutus were me~ured applying comput-
er·a~sisted interviewing. The time 'ehedule induded an interview 
before LTx (waiting list) and at regular intervals after LTx (3 
month,. !-year. 2·yeur. and eon~ecutive yc:m.). 1' ·"The interview 
eon,isted of several que,tionnaires representing the full 'peetrum 
of objeaive :md subjective measures of quality of life." Children 
were excluded (age limit 16 yc:m.). 
Cost Data 
Cost volume data were ab:.traeted from the ho..pital administra· 
tion ')"item. which registmte.. the mnjority of clinical aetivitie~ 
(admissions. physician service... laboratory service~. ete.) on a 
per patient per diem ba"". 
The input volume of key speeialtie.. (hepatology. paediatrics. 
wrgery. anaesthe..iology) was determined separately, ba..OO on 
real time devoted by the medical staff to various tu.~k.' (clinical. 
outpatient,. overhead). Other ea-t unit' counted were blood 
product,. operating room facilities. donor procurement, drug:;. 
social work. and out-of-pocket patient costs. Capital outlays were 
estimated on n annual programme base by data provided by the 
flnaneial administration of the hospitaL Prices (1987-levell for 
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eru:h cost unit (time, product, or ~rvice) were denved from the 
fin:mcial adnlinr;tmtion of the hospit.ll.l. 
Mothods 
Conventional de>.Criptivc stntistic' were computed with the 
BMDP-,oftw:rrc package. •~ All values presented are averages. 
The dat:J.justified a time horizon of 5-y= follow-up after tmns-
plll.ntation. 
Cost-effectivene5S analysis W'..S carried out according to the 
guidelines set out by Drummond et n.l." One of the requirements 
is the estinmtion of key par.unet""' (survival, quality oflife, coR~) 
in the absence of a liver tmn'plll.ntntion programme. 
Observed ~urvival curves after gmfting wen: ca.lculmed using 
tbe Kaplan-Meier estimate.:::: Two models published by Christen-
sen were used to predict nontransplantntion survival of PBC and 
noo-PBC chronic cirrhosis pati::nL~ sep=tely. '""'"The combined 
actual tran$plantntion survival wa~ compared with the combined 
expected nontrnnsplantntion survival.'""" For a check of validity 
n third. model was developed ba-;ed on Cox-regression analysis of 
the survival experience of those patients with PBC and non-PBC 
chronic cirrhosis, who were not uccepted for tmnspluntntion."' 
Quality of life ~ummary data were c.n.lculnted following the 
guidelines of each questioMuire involved.:;,.;~ An :w=se utility 
index for pre- and posnrunsplantntion bealth statu' wa;. ca.lculated 
bused on health scenario valuation_~ by a snmple of the gener.ll 
public.:oo For tbe cost-effectivene>.s analy,;~ it was as'umed qunl-
iry of life in absence of liver tmnsplantntion could be represented 
by pn:transplanration W'..Uting li't value>.. 
Cost wen: cnleuluted both a~ undiseounted cost.~ per ~rage (eg, 
=nlns period, waiting list period) and "-' costs per patient 
tmnsplanted. Stage cost.~ enuble, for exnmp)e, the compnri:.on of 
the impact ofv:uious stage:>. Costs per transplantation arc useful 
for planning purposes and necessary for calculatioo of a cost-
effectiveness ratio.'~ In tbi~ca-;e, cost>. lncum:d by patients firuilly 
not trunsplanted are added to the =plantation cost:., weighted 
for their frequency relative to one tmnsplo.nted putient. Tbe 
transplantation date was chosen as the point in time for which the 
so-called ·•present value" of cosu; per transplanted patient wu:, 
ca.lculated," Thus a negative discount rate wa~ a.•5igned to cost:. 
pertrunsplanted patient before tran,plWltation (screening, waiting 
list). An o.nnual discount rate of 5% wa_~ chosen, foUowing 
nationnl guidelines. 
For the cost-effectiveness analysi~ pretransplantation cosl' 
were restricted 10 those cost>. pertinent tO tmnsplantation (eg, 
exduding conventionnl treatment cost.~). Costs in absence of 
transpl:mtation wen: estimated by multiplication of the predicted 
nontr:~m;plantntion survival time (in days) with uvernse per diem 
costs for conventional treatment during the waiting li~t period. 
RESULTS 
On December 1, 1987, a total of22I patients were accepted 
for screening. About two--thirds were provisionally ac-
cepted for transplantation: 73 patients were transplanted. 8 
of them twice. Primary biliary cirrhosis (n "'25) and other 
chronic cirrhoses (n "" 29) together accounted for 74% of 
the primary transplantations. 
Survival analysis of cirrhosis patients showed a signifi-
cant improvement due to transplantation (log rank P < 
0.01: see Fig 1). A positive net benefit of average years 
survived emerges after about I year, as the surgical risks 
------ .';~to>d WithOut L TX 
----... 
·----
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Fig 1, Survival wlth and without transplantation of all chronic 
cirrhosis patients (n ~ 54. 1978-1967, AZG). Model-predicted 
nontransplantatlon survival. X·UXls: tlmo since date of tmrl$plant 
(years): y-axis: cumulative survival probability. 
outweigh the nontransplantation mortality in the first half 
ycru-. Subgroup analysis showed no benefit for patients in 
Child-Pugh class A and a clear benefit for Child-Pugh 
class B and C patients (see Fig 2). 
Pretransplantation quality of life dn.ta showed moder-
ately impaired functional performance, severe anxiety Md 
depression Md many symptoms of chronic liver disease, 
e~pe:<:ially fatigue and Jack of energy, Three months after 
transplantation, quality of life of the survivors showed an 
impressive improvement; funher improvement to normal 
or slightly affected v:llues is seen after I year (see Tuble 2 
for a selection of outcome variables). Two rrwjor psychi-
atric episodes were encountered {1 suicide). 
Cost analysis of the various tr".msp\antation stages (non-
discounted) showed the first 3 months after u:msplantation 
accounting for about Hfi 133,000, assuming a 15% rctrans-
pl.antation rote (Table 3; 1 Hfl- 0.5 US$). 
The surgical costs (donor procurement, hepatectomy, 
Flg 2. Survival with and without transplantation of clrrhosJs 
patients according to Child-Pugh class (A ~ 2:2, 8 and C .,. 29, 
1978-1987, AZG). x-u.-:ls: t1"1Q sinco dato of transplant (yoars): 
y-axls: cumula~vc survival probability. 
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Table 2. CWIIIty ot U!o Belore and After UIICr Transplantation (n = 23) 
Kamolsky ?orlormanee Index 
State-Trait An:dety 1nve1110ry (anxiety) 
Symptoms and complaints 
NoWngham Health f>rofile-1 
mobility 
"''" energy 
•ooo 
omo~onaJ r<Jactlons 
social lsola~on 
Index of well-being 
U~lily lnde;o; 
'"'" ().tOO 
,., 
,_, 
"0-<l 
2.1-14.7 
o.o-1.0 
Range • !heom!lcaJ rnngo, rrom _,. (t(lft vllluo) lO IX!S1 {right valoo). 
implanTation and additional perioperative procedures) ac-
counted for Hfl39.000. Follow-up costs from I year after 
LTx onwards accounted for Hfl 28,000, to which cyc!o-
sporin contributed Hfl16.000 (about 60%). Totrl.l costs per 
transplanmtion including5-yearfollow-up amounted to Hfl 
250.000 (see Table 3). Costs without transplanution were 
estimated to Hil60,000. yielding net costs of Hfi 190.000 
per transplantation. [n view of patient 25% variability 
mn.rgins seemed justified, resulting in Hfl !42.500 to Hfl 
237.500. 
As reliable data about survival probabilities after 5-veur 
survival were lacking, we assumed a range of 2.5 t~ 20 
additional life years gained for those patients surviving 5 
years.:n After discounting and multiplication with the 
proportion surviving 5 years, 1 to 5 additional life years (at 
the expense of Hfl 28,000 to Hfl 140.000) are gained per 
transplantation, which should be added to 1 life year 
gained in the first 5 years {per transplantation, discounted. 
child B and C). 
Combining the unfavourable assumptions and the fa· 
vourable assumptions yielded a cost-etTectiveness ratio 
ranging from (237.500 + 28,000)1{1 + !) to (142.500 + 
140,000)/(l + 5) which is Hfl133.000 to47,000 per life year 
gained. When quality of life adjusting was applied results 
"--
,~. P....t.Tx '~- , ... y_ 
,90 87 
" 
87 
~"' " "' " 0 
' 
2 2
<" 
2$ 
" " Zl 8 5 
52 
" 
6 
39 5 
" 
" 
3 
" ' 
5 
S.> ,,,
'"' 0.55 0.80 0.85 
were similar: Hft 133,000 to 51.000 per Quality Adjusted 
Life Year gained. 
DISCUSSION 
This article presents the results of the first cost-etTective--
nes.'> analysis of liver trnnsplantation. As no controlled 
clinic.al trial has been perfonned, we could not dispose of 
an unbiased estimate of control survival. quality of life. 
and costs. However. restricting our analysis to adult 
patient.'> with chronic nonalcoholic cirrhosis we were able 
to approximate the nontrunsp\antation ca..;;e. 
As we are aware of methodological flaws inherent to 
each of the approximations. vclidity was checked if possi· 
ble. We compared the Christensen models with the AZG 
general cirrhosis model {rejected patients) and, for PBC 
patients, with the recently published Ma.yo--model.:o.:<o As 
for PBC patients, the two alternative models predicted 
nearly identical nontrunsplantation survival curves. which 
were slightly more favourable than estimates from Chris-
tensen's model. Comparison of Christensen's model for 
non-PBC cirrhosis with the AZG·model showed a small 
difference in the same direction. These differences are 
Table 3. Costs at 1967 Prices per Transplantation Stage and perT..,nsplantatlon (n"' 76, 1978-1987, AZQ) 
T"-'r'l$tllallta~"" Und~c= 01SCCost5' Pa~ori!Y 
""'" 
-
"'"~ -~ ""'' ""'" Scroonlng 15,514 17J04 '.30 = WaJtlngllst 
'·"" 
3,924 ,20 4,316 
Oporo.non---:3 months 13.2,860
'"'""' 
1.00 
'"'""' 4-12 months al1er LTx 46,318 46,316 0.75 
"'·"" 2nd yoar alter LTx 28,099 26,761 0.60 16,057 
3rd y(lar alter LTx 28,000 25,487 0.55 14,016 
4th year after LTx 28,099 24,273 0.55 13,350 
S!h year after L Tx 28,099 23,117 0.55 1.2.714 
Total costs por transptantatlon al transplantabon dato- H!l 2$0000 
Undlo costs~pliotago ~ costs por ~~"'" por stogo. r.ot ~lscountod 
O.r.c COS!SipVstago - W$15 por I)$""' por stage. 5% d•:ICOuntcd rol~Wo 10 transpl<;ntatoon da!<l 
Prices In 0\ltcl\ 110rlns; t H!l - 0.5 US S. 
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maybe caused by improved conservative treatment since 
the time of Christensen's study.~' 
Our assumption of control quality of life may be over-
estimated. but while waiting list patients are genemlly in 
poor health. potential long-term survivors without trans-
plantation might experience temporary improvement. as 
we observed in some patients leaving the waiting list for 
this reason. The hospitn.lization rate underlying our non· 
transplantation cost assumptions may be an underestimate 
in as far in a non transplantation scenario patients might be 
subject to heroic treatment efforts, for example. for gas· 
trointestinal bleeding. However from the pas~ we know 
that many cirrhotic patients die suddenly. without prior 
hospitalization. 
The transplantation survival curves show early mortn.l-
ity to be an important limiting factor for survival gain. 
Optimal timing combined with a decre:c;e in perioperative 
mortality can further improve cost--effectiveness. 
Application of our results requires outcome and cost 
estimates to be comparable with other reports. Though we 
did not find major differences with regard to the outcome. 
a striking difference occurs between Dutch and American 
cost figures.~' This is probably caused by the fc.ct that the 
frequently used financial costs (based on a.o. charges) and 
the real economical costs used in this study are not 
interchangeable concepts.'~ Also. the American price level 
of medical services b relatively high.~~ 
Cost--effectiveness analysis is currentlY recognized as an 
additional tool for societal decisions about the choice or 
rejection of pOlrticular technologies."" Our study shows 
liver transplantc.tion to have an acceptable ratio. with a 
lower range comparnble to, for example. the eost--effe<:· 
tiveness ratio of heart transplantation. which in a re<:ent 
Dutch study w:l$ estimated to be Hfl 50.000 per life year 
gained.34 
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Use of prognostic models for assessment of value of 
liver transplantation in primary biliary cirrhosis 
GoUKE].BONSEL lDS].KLOMP,'AAKER FR.EDVAN"TVEER. 
]. DIKF. HABBEI.\1A MAARTENJ. H. SLOOFF 
To examine 'the effectiveness of liver 
trunsplantation (LTx) for the 'treatment of primary 
biliary cirrhosis( (PBC) 'the actual survival of 30 
PBC patients y..ho received liver grafts was 
compared wi't:h predictions of what survival would 
have been witho~'t:'t:r<msplantation. Three models, 
based on Cox' regression analysis, were usod. Two 
models were derived from survival of PBC 
patients in drug trials and the third from cirrhotic 
patients whp did n_ot receive't:runsplants. 0 bserved 
and ,expected surv1val were compared for a follow-
up time of 7 years. After 1 year the difference in 
favoJr of LTx was small, but after 5 years survival 
with LTx exceeded all predicted survival 
probabilities without L Tx. After 3 years every year 
of follow-up added about 0·3 years to expected 
Survival gain per transplanted patient, resulting in 
1·5 to 2·3 life-years gained at 7 years' follow-up, 
depending on the model used. The benefit was 
greatest for patients in Child-Pugh classes 8 and C. 
The consistency between 'the th reo models in 'their 
predictions supports the validity of the use of 
predictive models in the indirect assessment of 
lTx. 
L:mcet 1990: 335:493-97. 
Introduction 
Although never assessed in a =domised clinical trml., liver 
tt:msplant:ttion (L Tx) is supposed to beeff<:etivein patientS 
with end-stage liver di.scase'""' und may now be rer:;u:ded "~ 
<l=Pted therapy for non-alcoholic liver diso::ases, including 
primary biliary cirrhosis (PBC).45 
Without info=tion on eost-clfectiveness of the 
proeedure, national authorities tend to control the 
application of L Tx, by financial or other restrictions, as 
occurs in the Netherl:mds, for example. 
In the Acad=iseh Ziekenhui.~ Groningcn (AZG) 
orthotopic liver t:r::msphntations have been done s:inee 
1979,"'' :md these arc subsidised. by the Dutch Goven=ent 
und the National He:l!th Insurance Board 
(Zieken:fondsraad). From 1935 to 1988 liver-
=spl:mmtions underwent a comprehensive medical 
technology assessment by an independent research group, to 
estimate empirically the costs 3lld the effects of the 
procedure :and the future need for LTx. •·• 
This article presents our assessment of the value ofL Tx 
in prolonging ~-urvival of patients with primacy biliary 
cirrhosis. In Europe this dise:lSe aecounts for 20% of liver 
transplants, in AZG for about 30%.'° For non-tranSplant 
patients three models were used to predict pa.tient-specll"i.c 
survival. 
Patients and methods 
Patient population 
Between the 'u.--c of th~ L TJ<·progrn.rn.m~ in 1978 and March, 
1989, 30 pati<:nt:; (23 wom<:n, 2 m<:n) with PBC roccived liver 
transplant:;. 12 {40%) pati<:nn; were in Orild-Pugh d:t.<S A, 11 
(37%) i.n da::.~ B, :ood 7 (23%) in cl= C"""' The mean age at 
trno:lpiantation "":IS 49·6 yc:crs (SD 4·7). 
T rotm<:nt protocols '""l:'U'ding patient selection, timing, 
infection preva1tion, surgical t~que, and llll!llunosupprcssion 
h:lv~ ~ dcscnbed elsewhere." Ow!gcs in th~ study period 
i.ncluded the introduttion of a modified Vc:l.()--vrnous bypass 
tec::h.n.ique (1981)" :tnd th~ clmnge to a triple-d..--ug 
immunosup~ve sc:home including cyclo:;porin A (1985). '' 
Forth~ medical technology ==a'lt in 1988 we !"oct up a 
compreha!Sive database containing elinical, bioc:hanical, 
hi.tological, and other pa.tient d:!c, including surgical procedure 
:md donor. Premmspianmtion dac accounted for about 100 
differau wriablcs:md. included d:!ta n=ru;• for the3pp!iCl.tion of 
the tlu= prognostic models. Prc=,pianmtion =tus wa.' defmed 
m; the st:J.te of the patient nt the time of transplantation. 
Median follow-up after tra.n.'pl:lnt:J.tion was 2·5 y=, m:JXimum 
9·9 Y=· Fum! follow-up date was M.ireh I, 1989. 
Prognostic models 
The Ouistensen model was based on d.ac of a multicemre tri:U 
=.mini.""!g the effectiveness of azathioprine.'" The AZG modd was 
developed m; p= of our study o.nd 1.1/U:". b~•-'ed on non-=spl:lntc:d 
patients w:ith cither-PBC or non-alcoho~ccirrhosis." The third, the 
Mayo-model,'" 1.1/U:". 00..-;al on~ study •imil.ar to Q.ri,;tensen\. All 
three smtistiCl!. models were bar.cd on OJJ<• proportional h:>z:lrds 
modd. Eaeh of the model:; on be used to calcul:ue 3 prognostic 
indo: (PI) for nny patient. Th~ hi~er b th~ vnlue of the PI, the 
~oner the o:pcct.ed survivnl. Combined with the so-allied 
underlying eumub.tive hn=d function, th~ probability that 3 
patient with a given set of values of the progn~tic vatl:lble. at to will 
suniveto a given tim~t can be estimated. 
In th~ Ouist=""'-·model sb: prognostic variables nrc combinc:d 
tO give~ prognostic indo: (PIJ a:; follO\>o-s:'" 
PI0 <!·51 (log,0 serwn bilirubin, filllOI/1) + 0·0069 o;p ([age, yr, 
-20]/10) -0·05 (serum albumin, g/l) + 0·88 (cirrhosis. 
l/0)+0·68 (his1ologic:~l ehol=ffi. 1/0)+0·52 (no 
=thioprine = I, azathioprine = 0). 
TheAZG·modelstar!ed with all131 patients\\ithnon·alcohol.ic 
cinho<,is o.nd pri.mary biiWy cirrhosis who, for variou:; reasons, 
were o:cluded from the LTJ< progr:mtmc or who were still under 
investigation. Nine varin.bles were significantly rebted to prognosi& 
nnd were ,;elected to yidd a prognostic indo:'' as follows: 
PI,= 0·0065 (serum bilirubin, fill'OI{l)+0-0605 (age, yr) -0·0517 
(serum albumin, rJI)+l-1817 (HBsAo:J+2·0849 
(neurological complications, 1}0)+1·2804 (vari= 1/0) 
+ 0·1866 (Quick-time prolongation, s) +0-9183 (llScitcs, 
1/0) +0·7468 (elinicalict=. 1/0). 
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In the Moyo-modeJ five indep=dent variables were used for t1 e 
prognostic indo; (PI,) as foUmv:o:" 
Pt., "'-0·871 (lor., serum bilirubin, mg/dl) +0{)39 {age, yr)-2·53 
(log. serum .albumin, g/dl)+2·38 (Quick-time nbsolute, 
s)+0·859oedonas=, 1/0·5/0), 
where oedc:rna s= is 0 if no diuretic thcrnpy was needed fo• 
oed= OI" no oedc:ma Wll.~ pre;ent, 0·5 if oed= resolved with 
diuretic thernpyo•if nodiurtticthc:mpy was J>=Cribcd forced=, 
nnd I if oedema was present despite diu=i.:; therapy. 
Model-specific S\lt'Vivor cwnull!tive h=d functions were: 
estimated with polynomial or Wcibull functions. 7 y= was the 
mmcimum time for which the predictions were valid. 
Statistical methods 
Obsaved. survival time was !he interval betw= primary liver 
tr:111Splanmtion and deaTh or fiil.Gl follow-up (M>lrch 1, !939) n.o.d 
CJJ.cub.ted by use of the K:lpl:m-Mcio:r cstimo.te. Rctranspl:mction 
was~ beatuse we= iru=ted in p::ttia~t, not g:mft, 
survivaL 
To CJl.cub.te ccpected. survivnl time for norHransplant pntients 
the estinlmed aggregnte non-tr:msplantntion survival function was 
computed (method nvaibble from author). Y= nlive with and 
without =splant:ttion were calcuJ::\ted as the integrnl of the 
survival function, rhenumc:riCJl. equivnlcntofthesurfaceofthe= 
below the :<WVivnl curv~:. Two stD.tistie:.>.l =• the one-=p!e 
log-r:mk :mel a simplified version of the acruarial prediction test,,. 
wae applied to the diff= betwc:eo. ob&a'Ved and ocpecred 
surviv::ll.. 
To oaun.ine the relation between the severity of prc-o;isting liver 
disease and the guin in rmrvival w:itb =splantation, th<: patient 
grocp w:l:l split into rwo npproximntdy equa.l-sizcl sub= 
belonging tO low (A) or high (B and C) Oilld-Pugh class. 
~ :m:J.Iysis w:l:l used tO :find out whether, at 110me time 
during the =spl:mmtion prog:r:unme, th= vros an ndvaoo: in the 
smge of dis= at which patients were: offered L Tx. 
The rd:ltion between the prognostie models w:l:l te=d by 
pairw:i:l<: and overall rnnk corrclntion of patient's ptO&l'Ostie 
indic:lton; (Spc::trm:lD's rnnk cocrdm:ion andKend:ill'sCOI:fficicnt of 
ccnoordllna:). 
Results 
At the final follow-up date 19 of the 30 patients were alive 
{table I). Death usually occurred within the first year after 
grafting. The wide differences between patients in clinical 
variables and prognostic indices reflect variations in hepatic 
dysfunction at the time ofmmspl:mtation but, as expected, 
the subgroup with Cilld-Pugb class A had better values for 
the variables :md indices than did patients in cluss B or C. 
TABLE-PATIENT DATA 
Child-Pugh Child-Pugh 
~' ,_, ,_, Group (n-30) (n•12) (n•18) 
Char~>c/eristicr 
Albumin (gil) :H·9 (to·Z) :3M (4-5) ::8·5 [4-8) 
Billrubin[mmol/l)t 216 [166) 10::: (101) 292 (19:2) 
""-' 
4% (4-6) 
Prognostic indicbs· 
47·8 [4-1) 50-8 (4-6) 
,, 5-t.:>(l~) ~33(1-51) &49(1{)5) 
"· 
4-51 (2·ZS) 2·5Z(M2) S·$3(1·86) 
"· 
7-45(1·67) 5·84(1<:~3) 8·52(0-90) 
Vital status 
Alivo (O<Man:h I, !9SII) 
" ' " O.::.d, surglco.J complk:ltion 
' 
• 
' Deod, bcpatk nnay po!hology • 
' 
• D""<!,cl>oleswls • • 
' •FondJ 
·--
0 <>g g '""'" cs ). 
TMO<II.en: 223 (All). 45 (ChJid-Pugh S-7). 279 (CMd-Pu~h 8-15) 
Appendix 3 
Comparison of the observed :lnd predicted survival 
probability curves indicate that LTx conferred a survival 
advantage from about 12 months after the operation, even 
though the three non-transplantation survival curves are not 
identical (fig 1). Cumulative survivul probability with L Tx 
at 1 yearaftertransphntation was 0·65 (SE0·09), whlch was 
simi.bl- to the .Mayo prediction (0·63) but better than 
predictions from the Otristeilsen or the AZG model (0-43 
:md 0·52 respectively). 5 y=' survival with LTx evidently 
was superior to all predicted survivnl prolxlbilities without 
L Tx (0·58) versus 0·19 (Christensen), M9 (AZG), :md 0·29 
(Mayo). After 3 years every year of follow~ up :added about 
0·3 Y= to expeaed survivul gain per transplanted patient. 
The differences between observed :md expected survivul 
curves were signific:mt in all three cases-by the one-sample 
Iog~r.:mk test (p= 0·001 [Christensen]; 0·014 [AZG]; 0·047 
[Moyo]), and by the actuariul prediction test (p<O.C)QI 
[Ol.ristensen];0-002 [AZG]; 0·006 [Moyo]). 
;: 
,,,---------------.., 
~ eo 
<>--. 0~, 
~~;::=:~~~''":~~-·-
o~,-~--1--c,--o,--c,c--c,c--c---l 
Tom~ ~once date 01 transplant (yoar5) 
Fig 1-0bs<.orvod and oxpoctod surv'oval of PBC patients. 
Ol>!i~ob<orve<O ~urvlval after LTx (IC:optan-Mcocr). Mod-c. Mod-a. 
Mod-m~prcdlctod without LT~ (from Chnstcnscn. AZG. ond Moyo 
models) 
Survival without tr:msplantntion for Child-Pugh class A 
patients (fig 2, uppa) was dose to that for survivul after 
tronsphntation (p for difference from po~lt-tr:msplantation 
survival > 0·1 for all models), whereas pn.tients in Child-
Pugh dasses B and C (fig 2, lower) dearly benefited from 
L Tx (p < 0·001 for each of the three models by log-r.:mk f' 
and Turnbull st:mdnrd nornml test statistics). The 
diffcrcn<X between th= two subsets in survival gain is 
explained by the large differences in survival without 
mmspla.utation; the subsets did not differ in surv:ivul after 
transplantation. 
If the incr<:;lSing experience gained by the transplant team 
was partly re:;ponsiblc for the apparent independence of 
transplantation survival from prett:msplantation severity of 
disease, there should have been an increosein ptetransplant 
diseuse severity with stnge of transplant, without change in 
tr:msplantation surv:ivnl. Our data s= to sup!Xlrt this 
supposition. Survival curves for the 15 pa.tients who 
received: tr:li!Sphnts in the :fum: half of the progrnmmewere 
the smne ns for the 15 in the second half, even though 
prognostic indices were higher for those entered later in the 
progrmnmc, irrespective of the PI dlosen. Also the SD fell, 
which suggested: ::1 decreasing: variation in the stage of the 
di5c:ase ::It which the patient underwent mmspla.utation. 
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Fig 2-0bs<;lrvad <>nd O)(P<>Ct<>d survival of P8C pati\lnts 
according to Child-Pugh score. 
Upp.:r: Ch•ld-Pugh class A. 
Lower: Child-Pugh eta= B ~nd C 
Regression analysis with the three prognostic indices for 
euch patient os the dependent vnriable and LTx-serial 
number as the independent vnriable showed that, whichever 
of the tb.ree modeL~ used, prognostic indices were greater the 
Later the patient cntero:d the L Tx programme; this was 
presumably due to ovcrrcprescntation of patients with 
relatively good liver function at the start of the progr:mune 
(fig3). 
"r '""""M~M "' MAYO 
" o0 o o' 
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LTx-Mnal number 
Fig :>--Prognostic indicators related to LTx serial number. 
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Most r<::>ults show a firm rcl:ltion between prognostic 
models. We investigate the rel:ltion between the prognostic 
indices as a teSt for validity of the prognostic models.. The 
Child-Pugh score (ranging from 5 to 15) vr.JS included os a 
separate prognostic indicator (not index). Only r.Jnk 
correl:ltion ~t:ttisics nmy be used because absolute survival 
probnbilities are not directly represented by the PI or the 
Child-Pugh score. Pairwise comp:uison of the four 
prognostic indicators resulted in highly significant rank 
correlations, all exceeding r, = 0·80. The ov=ll ngrcement 
of prognostic indicators vr.JS high, Kendall's coefficient of 
concordance being 0·93 (p <0·001). 
Discussion 
Our fmdings show that LTx significantly improves the 
long-term survivnl of patients with PBC of Qilld-Pugh 
cl.::ts5es B <md C. Although L T x nmy sometimes be justified 
for improving the qwlity of life for pntients with class A 
primnry biliory cirrhosis, it will probnbly not lengthen 
:.urvivnl. Predictions beyond 7 y= are limited by both the 
time horizon of the prognostic models (survival without 
=splantation) mtd by the limited follow-up time for 
=splant patients (transplantation survival). Over:ill the 
conclusions are in agreement with thoscofNeubcrgcr"" and 
Markus/' although their studies diller from ours in the 
nwnber of progn~"tic models used, the stati~-tical method of 
arsregation of individual prognostic information, and the 
patient group. 
Neuberger's and Markus' studies each apply only one 
prognostic model, the a.rucensen-modcl and the Mayo-
model, respectively. A disadvantage of the use of these 
models for prediction of survival without transplantation is 
their derivation from a patient popub.tion in an early stage of 
the disca:>e. Thus, application of these models requires 
cxtrapol:ltion to more severe stages, whicl1 could lead to 
biased estim:nes. The AZG-modd = :tdded to counter 
this unccrr::tinty, but the limited number of patients on 
which the final model vr.JS b:t5cd (n""76) means that its 
St:Jtisrical reliability is poorer than that of the Christensen 
and Mayo models. However, thr: validity mny be better 
because, compared with the patients on which the 
Christensen and .iv[uyo models are based, those for th~ AZG 
model are more rea:nt (year of entr:m.ce from 1978 to 1985) 
mtd have a distribution of Se\-"erity of dis= (Oilld-Pugh A 
54%, Crild-Pugh B 27%, Qilld-Pugh C 19%) that 
encomp= that oftr:m.splanted patients. 
A.nother difference concern;; the aggregation tedmique 
applied in the respective studies. To arrive at n curve for 
gtoup survival without tr:m.splantation for comparison with 
the Kaplan-Mciert:rnnsplant:ltion survival curve Neuberger 
computed the arithmetical mean of the individwl 
prognostie indices of his 29 patients. The corrc::>ponding 
non-transplantation survival function = :lS!.lJlllcd to 
reflect the group's ~-urvival without transplantation. This 
assumption is not justified from a matbem:~tical point of 
view, since particular prognostic indices for individwl 
patients have an exponential rel:ltion to the ~-urvival 
function. Unpredict:1ble bi:l.s will result (fig4). 
The nggregation technique of 11arkus implies averaging 
all individwl predkted survival curves. This procedure mny 
be justified when there is little variation bctw= individual 
prognostic indices over time. When non-random time-
dependent vnriation exists, the comparison with Kaplan-
Meier estim:nes of mmsplantation survival may be seriously 
biased, since patients with rea:nt transplants have 
only shon-tcrm influence on tranSplantation survival but 
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Fig 4-Aggrog.atod prodictod survival curvos. Example with 
Mayo-model .ond all AZG-pntionts (n ~ 30}. 
Ag-n. Ag-n. Ag-m-Qggregotlon by N~ubcrgcr. AZG. Jnd MJyo. 
respeCtively, 
full-t= iniluenc.: on c:.timat~ of ~urvivul with 
tr.msplnntarion. If, for o:a.mple, sevcriry of 
pretranspl:murion smrus increases over time, the gain of 
survival with LTx will be overestim.o.ted (fig 4). 
Fm.:ill.y we comp:Jred the balrulce of trnnspl:mmrion 
survivn.l ::md survival \\ithout =pl:mtat:ion in the AZG 
with Neuberger's result (PBC patimt:; who received 
tr:lllSpl:mts in C:unbridgc, Engl:md, until April 1984) and 
with those of lv1m:kus et a1 (161 PBC-pmients who re<:civcd 
transpl:mts in Pittsburgh and the .M.ayo-dinic bcrwo:en 
March, 1980,andJune, 1987). 
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Neuberger and oolk<J.gues' p<ltients were gencr::!lly <lt :1 
btcr st:lgeof!he dis=e (av=ge PI, 6·76 [SD 0·75]) !h:J...'l 
w~'l'e the AZG-paticnts (avernge Pic 5·63 {1·64.]); other 
indic~-s wcre not uv:lilabk. Surv:iV<ll :llter tnlr.~pl:J...'lt:ltio::~ 
{especi:illy in the pcri-operotive period) .md .:lso the 
estimated g;lln in surv:iv;:U with trnnspl.motion ·.vu~ =nller 
th:i . ''l. that for the AZG-po.tien:~ in Child-Pugh classes E :md 
C. This findin£: suggests <l limit to which the opc:mtion c::m 
be postpOned. 
Our results for short-t=1 n=spl.motion survival s=· 
inferior to those of lviurkus :md colleagues, who report 
vil.'tU<l!.ly no peri-op=tivede:n.bs .. This discrepancy mlly be 
due to differences in definitions of patients includOO in the 
=lysis, or it nuy reflect !he greater experience of the 
Americ::m centres. 
The consistency bet>vcen the three independent models 
in predicting surviv;:U '.'.-ithout =splanta.tion h:.lve both 
methodological and clinical implications. They show th::r.t <l 
specific applic::ttion of Cox' proportional h=rds model is 
;:,bk to provide predicted surviV<ll curves which =Y be 
validly compared with observed K:!plan-Meier survival 
curves. J\ia:ny :~pplico.tions of the :~bove described procedure 
:lre concciv::~ble. 
This <tudy wa' fll!MCed by oi'J< D~tcl>. Nntio=l Bc:>!th ln>ur-..nce BoMd 
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Abstract 
Medical technology assessment (MTA) is a type of policy research whicb supports 
decisions at the macro~level on the allowance of medical technologies at the health 
care market. MTA puts a high value on the quantitative analysis of the multiple 
effects of medical technologies on patients. Analysis of survival and quality of life 
(OOL) are the core of this outcome analysis. 
In this context QOL methodology consists of methods for description and methods 
for valuation. These methods share the application of standard psychometric tech-
niques for operationalization and measurement. An example of description and 
valuation is drawn from the Dutch MTA of heart transplantation. 
Criticism on QOL-research may partly be explained by its developmental stage and 
by the cultural differences between the three disciplines involved. 
1 Introduction 
Psychology is currently an acknowledged discipline within clinical medicine, and 
psychologists are to be found in many positions within the medical system. Its area 
of application is still growing and is not restricted to mental health care alone. 
Clinical psychologists, but other professionals too, routinely apply psychological 
methods of diagnosis and treatment in every day medical care. Additionally, clinical 
research currently includes the use of psychological methods of data collection 
(structured interviewing, questionnaires) and analysis. This paper on quality-of-life 
research (QOL-research) presents a recent example of this general development. 
Generally speaking, QOL-research is directed towards the measurement of health 
status. Depending on the particular nature of the research, health status may be 
operationalized as the perceived well-being of the patient, as rather objective 
characteristics of health itself, or as specific or global determinants of (perceived) 
health. The boundaries of QOL-research are rather vague, and theoretical and 
empirical problems are abundant. The latter for example include the definition of 
'health' and the measurement of QOL in severely diseased patients. 
Last decades has showed an impressive growth of QOL-research (Knippenberg, 
1988), particularly in two areas: the medical treatment and support of cancer 
patients (decisions on the micro level) and the societal decision-making on the 
Appendix 4 230 
introduction of new medical technologies (decisions on the macro level). The latter 
policy research, which is usually initiated by the national government or health care 
authorities, has been denounced as medical technology assessment (MTA) (Boose! 
1990). 
This contnbution to of the Dutch Journal of Psychology will be dedicated to QOL-
research in the context of MTA and therefore on decisions on the macro level 
(Habbema, 1990). We start with some theoretical considerations on MTA and 
QOL, followed by the presentation of a case-study which illustrates the theoretical 
and empirical approach. Finally a (partial) reply will be offered to critical questions 
which has been rised by both investigators in the field and people involved outside. 
2 Medical technology assessment 
MTA systematically investigates the consequences of the application of a medical 
technology from a societal point of view. 
In this context a comprehensive definition of medical technology is adopted, 
including pharmaceuticals, diagnostic imaging devices, surgical procedures and 
organizational provisions. One, or rather a complex of technological innovations 
may be concerned, which is applied within a particular health care programme 
dedicated to patients with a specific disease or health-related problem. Thus an 
MTA of heart transplantation is not restricted to the cardiac surgery alone, but also 
includes the extensive health care programme for these type of patients (usually 
suffering from severe heart failure). The surgery is only a modest part of this pro-
gramme. The care which is offered after the transplantation operation, and offered 
to those rejected or awaiting a donor organ, they all are subject to an MTA of 
heart transplantation. Thus an MTA and the related policy decisions have to be 
placed in a wide conte,.1:: not a single medical service but a comprehensive health 
care programme is at issue. 
In MTA consequences too are rather broadly defmed. They encompass desirable 
and undesirable effects on patient outcome, effects on patients which are not 
accepted for the technology under investigation, and they also indude the employ-
ment of resources, the impact on the health care system at large, and the ethical 
and legal consequences. Those consequences with refer to the perceived well-being 
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of the patient and his performance are designated as quality-of-life effects'. 
Systematically points to a. the comprehensiveness of the consequences, b. the 
formal synthesis of empirical results (multi-criteria analysis, cost-effectiveness 
analysis, cost-benefit analysis)', and c. the generalizability of conclusions from the 
empirical research. 
The societal viewpoint is represented by many specific features of the design and 
methods of investigation (Habbema, 1989). One particular aspect of the societal 
viewpoint is the emphasis on the analysis of the health effects in general, rather 
than on the analysis of biomedical parameters (like the pumping capacity of the 
heart in heart transplantation patients). Another specific feature of outcomes 
measurement in MTA in this respect is the valuation of health outcomes addi-
tionally to their description. Descriptive methodology is rooted in psychology 
(sc.aling techniques, classical test theory). Methods for valuation are derived from 
economic theory (on the utility of commodities) and psychometric decision theory. 
An elaboration is presented in the next paragraphs. 
3 Concepts in the description and the valuation of health status 
The point of departure in any type of QOL-research is the choice of a particular 
concept of health. If we abandon a negative definition of health3, then various 
strategies exist to define the concept of health: 
L a philosophical strategy: according to a particular religion or conviction, the 
(most) important dimensions of health may be defmed. One example is the 
WHO-concept of health, which distinguishes between a physical, a mental and 
a social dimension (Breslow, 1972); 
2. a democratic strategy: according to the results of population surveys, those 
dimensions are selected which are regarded to be essential for health. Several 
1 If the emphasis is on performance and other 'objective' characteristics. we prefer the designa-
tion 'health status' instead of 'quality of life'. (In this paper quality-of-life and health status as a 
rule are regarded to be synonyms). 
2 Apparently some form of standardisation is needed. 
3 I.e. health as the (degree of) absence of disease. 
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health. status questionnaires have been devised according to this strategy (e.g. 
The Notthingham Health Profile; Hunt, 1986). 
3. a discriminative strategy: according to prior knowledge on the specific effects 
of a technology, those dimensions are chosen which are expected to record 
the largest changes. Usually this strategy restricts the attention to one 
dimension or aspect which is strongly associated to a specific biomedical 
parameter (e.g. the aspect 'body image' if a psychological mutilating surgical 
procedure is compared to a more conservative one). 
Regardless the strategy, all concepts share the premise that health is a theoretical 
construct which should be operationalize<f, rather than an empirical notion, which 
can be measured straight forwardly. If the choice of the health concept is explicitly 
accounted for, the first strategy appears to be the more common one, though the 
result often will resemble that of the second strategy. Usually the construct health 
is assumed to be covered by different 'aspects' or, in a non-statistical meaning by, 
'dimensions'. Frequently, the dimensions of the WHO-defmition constitute the nu-
cleus, supplemented with, for example, the dimension work. 
The operationalization of the dimensions makes up for a second stage of decision-
making on the design of QOL-research. The operationalization may be accom-
panied by preparatory investigations. After this stage, we are able to classify and 
consequently to descnl>e health status or changes in health status. 
Being aware that the description of health status takes with it some arbitrary - but 
not random - choices, we admit that the valuation of health status requires even 
more decisions to be made. This part of QOL-research aims at assigning value(s) 
to health status in an economic interpretation of the word 'value'. The ultimate 
goal of this enterprise is to relate societal investments directed at health improve-
ment (as expressed in monetary units), to the value of changes in health which are 
actually observed (as expressed in units yet to be defined). See for details Torrance 
(1986). 
4 Here we ....;u not elaborate on theories of operationalization and particularly not on the 
relevance of a nomological network. 
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One might expect that the subjective judgment of the patient with regard to his 
own health or health improvement, may suffice for such a valuation5• However, 
despite its occasional application in MTA, this method may be challenged funda-
mentally. The perceived well-being depends on many circumstantial factors. The 
majority of these factors is unrelated to the actual level of health, even in diseased 
persons. Particularly we should mention the influence of the personal set of 
reference values and the potential effect of 'coping' on patient judgments of their 
O\\-n well-being. If we intend to apply the results in societal decision-making on 
medical technologies, these health-unrelated factors should be regarded as confoun-
ders (Drummond, 1987; Campbel~ 1976). Biased responses may also occur if a 
patient uses his response as a messenger for promotion of the treatment or as a 
mean to express his discontent with the doctor or his treatment. Thus the use of 
subjective evaluations of the patients in MTA is limitcd6• 
An example, which is taken from the MTA of liver transplantation, may support 
the argument (Bonsel, 1989). In this study patients, who were alive three months 
after transplantation, reported a level of experienced well-being which exceeded 
that of the normal population. In due time this level attenuated, despite the fact 
that the medical condition was still improving. Feelings of gratitude and relief for 
the provisional success of this risky procedure apparently rivalled the role of actual 
medical improvement. Experienced well-being thus appears to be an invalid 
measure of outcome in economic analysis in the context of societal decision-
making. 
After this argument on the relative unsuitability of patient's valuation of his own 
health, we proceed with an account of methods thought to be more appropriate. 
They all are explicit valuation techniques, which are derived from economic and 
decision analytic theory. (Fanshel, 1970; Torrance, 1976A & 1976B, Pliskin, 1980). 
These techniques explicitly elicit value judgments on health status, either in a direct 
or an indirect way. The direct way offers the respondent one or more response 
modalities to value health states (Kaplan, 1979). The indirect way asks the respon-
dent to indicate his behaviour in a projected health situation. 
5 We prefer to define a change in health (status) as the difference of two health (status) 
measurements rather than one measurement post hoc of the difference as such. 
6 Their use as a support to individual decisions. 
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The respondent should choose between either certainty of no change in a subopti~ 
mal health state or a probability of improvement with a complementary probability 
of worsening or death. Patients themselves are not primarily engaged in this valu~ 
ation process. 
The description and valuation of health status in the context of an MTA \Vill. be 
illustrated with an example in the next two paragraphs. The example is dra\VD. from 
the Dutch MTA of heart transplantation which was carried out between 1985 and 
1988. This MTA was instituted to provide answers on many questions about heart 
transplantation, for example the effects on patient's survival and quality of life, the 
costs and the need for heart transplantation in view of limited donor organ avail-
ability (Charro, 1988). At this place we confine ourselves to the investigation of the 
quality of life effects of health transplantation (Bensel, 1988). 
4 The Dutch MTA of heart transplantation: the description of quality of life 
effects 
As a randomized controlled clinical trial appeared to be ethically unacceptable and 
unfeasible for practical reasons, the study design was observational. A control 
group of patients was lacking. For analytical purposes we assumed that in absence 
of transplantation quality of life of patients would remain stable at best. 
As a concept of health we adopted the WHO-definition. Standard-questionnaires 
were selected on psychological functioning (State Trait Anxiety Inventory (Ploeg, 
1980], Self-Rating Depression Scale [Zung, 1965], Psychological Questionnaire for 
Patients with Heart Disease [Erdman, 1982]) physical functioning (questions 
derived from the Dutch National Health Survey, disease~specific questionnaires), 
social functioni..,g, work and sexual functioning. 
As a separate issue experienced well-being was measured on a global and a specific 
leve~ applying the Index of Well-Being (Campbell, 1976) and Life Satisfaction 
questions from the Dutch National Study on Living Conditions respectively. 
It appeared that the number of QOL-measurements and the precise timing of the 
interview implied a choice on the conceptual level. Three considerations will be 
presented. If an experimental design is adopted in clinical research, the measure-
ment instruments and the measurement schedule are deliberately chosen in order 
to maximize the probability to demonstrate differences between alternative actions. 
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In treatment evaluation the resulting schedule usually consists of two measure-
ments, one just prior to a treatment cycle and one shortly afterwards. This type of 
schedule may induce statistically significant differences without clinical or societal 
relevance in the long run. However, as MTA should support far reaching decisions 
at the macro level, due attention should be paid to ultimate effectiveness rather 
than to temporary or short term effects. 
The second conceptual consideration on the time schedule follows from the 
phenomenon that the changes in each dimension only infrequently coincide. For 
example in heart transplantation we observed. a resumption of elementary daily 
activities (washing, dressing, etc.) within a week after transplantation. Psychological 
recovery at least took some weeks, and the social recovery process and the 
restoration of full employment even lasting months or longer. 
The last consideration takes the length of treatment into account, which in many 
cases is life~long. In the example of organ transplantation this is clearly visible by 
the permanent immuno-suppressive treatment following transplantation. 
For these reasons in the heart transplantation study a longitudinal design was 
adopted resulting in quarterly interviews after transplantation and one interview 
just prior to transplantation. 
Table 1 and figure 1 show some results from the descriptive QOL·analysis of this 
study. The table shows average scores from questionnaires on performance status, 
anxiety, depressio~ experienced well·being and work Results represent the health 
state at three important points in time: just prior to transplantation, 4 months after 
transplantation and 13 months after transplantation. Four months after transplanta· 
tion a dramatic improvement may be observed. Further improvement, though pre-
sent, is rather modest. The depression·scores and other data (not sho\VIl) demon· 
strate the presence of psychosocial problems. Due to intensive professional support 
these problems usually appeared to be temporary (Bonse~ 1990). Multivariate 
analysis did show age, diagnosis, gender and education not to influence results 
significantly. If this influence had been demonstrated • as was the case in an 
analogue American study • the societally relevant question might have been raised 
whether the explaining variable(s) should be taken into account during the selection 
of patients. (Selection is inevitable, due to the discrepancy between the availability 
of donor organs and the prevalence of patients with end-stage heart failure). 
This type of consideration is a specific feature of MTA: many choices, which other· 
wise should be made from an academic point of view, should de made prudently. 
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Table 1 Quality or life before and following heart transplantation 
Question.naire Nonnal Before Tr: 4 Mnths 13 Mntbs 
Post Tx Post Tx 
Kamofsky Performance Index >90 53 89 94 
State-trait Anxiety lnventoty 
(STAI-Spielbergc:r) < 37 46 35 Z9 
Self-rating Depression Scale 
(SDS-Zung) <38 ss 43 41 
Index of Well-being >12 7 13 14 
Work/Regular Activities 
if 2:. 2 hr/d ? > 90% 23% 60% 63% 
Figure 1 Nottingham Health Profile before and following heart transplantation 
100r--------------------------------------------, 
90 
eo 
pre-HTX 
n = 48 
4m post-HTX 13m post-HTX 
n=33 n=20 
111111 mobility 
~pain 
~energy 
~sleep 
~social 
isolation 
r==l emotional 
reaction 
normal: <10 
237 Appendix 4 
5 The Dutch heart transplantation MTA: the valuation or quality or life effects 
The following account of valuation of quality of life effects distinguishes between 
four stages. Eacb stage will be supported by some empirical evidence from the 
transplantation study. We assume the effect of- in our case heart transplantation-
on survival is kno~ which implies knowledge on the survival probabilities with 
and without transplantation. 
Stage 1 The health state of patients is measured empiricaily by means of standard 
questionnaires (our choices have been described in the previous paragraph). A 
longitudinal design is adopted, accounting for nine measurements, one before and 
eight at quarterly intervals following transplantation. 
Stage 2 For each interval 'health scenario's' are derived from these empirical data 
by means of a formal algorithm. A health scenario consists of a standardized 
description of a health state. In this case four dimensions were regarded to be 
essential for sucb a description: mobilityfself.care, psycbological state (anxiety, 
depression), symptoms/complaints (loss of energy, shortness of breath) and 
intensity of medical care. 
Figure 2 An example of a four-dimensional health scenario 
Somebody 
is at home 
is rather quickly short of breath, at times in pain 
is able to care for himself, though limited in walking around 
has no psychological complaints and having trust in the future 
Figure 2 is an example of a health scenario based on our four dimensional system. 
If the questionnaire data did approve of heterogeneity of health states within a 
particular period, more than one health scenario was abstracted from the data. In 
our study this procedure yielded well over 20 health scenario's. 
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Stage 3 A value is attached to each health scenario by means of a specific valuation 
method. Usually the standard-gamble method is regarded to be the superior 
method from a theoretical point of view7• However, the operationalization of the 
standard-gamble method is hampered by several problems. A simpler method is 
preferable, e.g. visual analogue sealing (VAS), provided a fixed, mathematieally 
defined relation may be assumed between the VAS values and the standard-gamble 
values. In our study the about 20 health scenario's were presented in a random 
order to a panel of laymen. The VAS-method was applied. Despite the apparent 
complexity of the valuation task, the panel ranked and valued the health scenario's 
quite unanimously. Next, values were indexed using a 0-1 scale and the average 
value of each health scenario was calculated. Fmally we arrived at a value for each 
interval or period by weighted averaging of health scenario values. The weights 
were derived from the frequencies of the partic-ular health states in a given period 
as observed in Stage 1. In this example the pre~transplantation period value was 
about 035, the first average value in the year after transplantation was about 0.75 
and the subsequent year this value was about 0.9. 
Stage 4 Survival consequences were adjusted with the above~rnentioned values, 
resulting in so called Quality Adjusted Life Years (QALY's) as measure of 
(economic) outcome. Once again the heart transplantation study example: if we 
assume survival to be on average three months without transplantation and ten 
years with transplantation, and if we assume the health state to remain stable after 
two years, the next benefit of heart transplantation may be calculated as follows: 
(0.75 x 1 + 0.9 x 9) - (0.25 x 035) = 8.76 QAL Y's. This outcome may be formally 
related to net costs in a so called cost-utility analysis (De Charro, 1988). 
7 Essentially standard gamble compares two health states., A and B respectively. The respondent 
is offered the following alternatives. Alternative 1 includes certainly (probability = 1.0) that 
the respondents remains in (suboptimal) health state A for the remaining pa:rt of his life. 
Alternative 2 offers a treatment modality for health state A with two possible outcomes: either 
the patient recovers to full and permanent health (health state B) which has a probability of 
Q, or the patient dies instantaneously with probability 1-8. The valuation process consists of 
an iterative procedure which varies probability Q, until the respondent expresses indifference 
to the two alternatives. The utility of health scenario A follO'IVS from the following equation: 
UA = Q* U8 + (1-Q)* Udeath." Us is usually set to 1. U death to 0. Note that reference health 
scenario's U8 and U death may be chosen otheNiise provided that Us .2:,.. Us .2:_, Udealh 
holds. 
6 The position of QOL-research in MTA: internal and external criticism 
Obviously the analysis of effectiveness to which QOL-research belongs, is the 
nucleus of most MTA's. The balance of positive and negative effects frequently is 
the fundamental issue in health policy decisions at the macro level (like it is in 
individualized decisions on the micro level). This key position does not protect us 
against many practical problems (in the example the absence of a control group, 
the shortness of follow-up, the selective losses to follow-up), nor does it preserve us 
from theoretical problems. The latter type of problems may be distinguished into 
tensions between scientific cultures ('criticism from outside') and problems due to 
unsolved theoretical questions ('criticism from inside'). 
6.1 Criticism from outside 
The analysis of effectiveness brings the independent MTA-researcher and the 
clinical investigator together. Usually part of the effectiveness analyses within the 
conten of a MTA does not appeal to the clinical investigator, despite a sincere 
interest in clinical outcome of the latter. However, the objectives of effectiveness 
analysis, though related, arc not identical and the research environment frequently 
is quite different. Some examples of these differences follow. 
1. From the viewpoint of the MTA-investigator the health care programme is the 
unit of analysis, from that of the clinician it is the patient treated. Consequen-
tially, differences may be observed with regard to the attention paid to a. non-
treated patients who are involved in the programme, and b. to the patient's 
environment. The latter difference points to a question yet to be solved, i.e. 
whether the current primacy of patient's interests in individual decisions 
necessarily implies the neglect of effects on patient's environment if decisions on 
a health programme at large are concerned. 
2. The MTA-invcstigator prefers disease-non-specific, generally applicable scales as 
measurement instruments. The emphasis is on the level of scores and on the 
amount change observed. These are related to levels and ranges which are 
known from the general population. The :MTA-investigator collects patient's 
information on the process of medical care too. As a contrast the clinician 
prefers medical parameters as a measure of outcome, occasionally supplemented 
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with disease-specific questionnaires. Apparently the main interest is in showing a 
significance between the target intervention and some alternative at a given point 
in time. Process information usually is not regarded to be scientifically interest-
ing. 
3. Differences are not confined to the specific study objectives and the set of 
outcome parameters chosen. Additional methodological differences do exist. The 
MTA-investigator applies the full range of methods and techniques which are 
regarded standard tools within the social sciences (for example scaling tech-
niques). The clinician prefers medically based techniques, which do not depend 
(much) on the 'unreliable' response of the patient. Unobservable variables and a 
high measurement level which is achieved by the application of scaling tech-
niques, are distrusted at best (Meer, 1988). The request from the heart trans-
plantation centres to skip all the superfluous items from the SDS1 ST AI and 
other questionnaires and to select 'a few meaningful questions' is a good 
example of these intercultural differences. 
4. Different views on the time schedule of measurement provide us with a last 
example of these differences. 
6.2 cn·ticism from inside 
This paper on the position of QOL-research within MTA finishes with an indica-
tion of acknowledged scientific problems in this field. According to some authors 
these problems seriously affect the position of QOL-research in the context of 
health policy decisions on the macro !eve~ resembling discussions which dominated 
the social sciences for tens of years. 
The first problem in the context of health status description is the lack of consensus 
on a standard repertoire of generally applicable, disease-non-specific question-
naires. An important ruling principle is the selection of originally English-language 
questionnaires. This principle, which dates back to the strong incentive to publish in 
English-language scientific journals, severely curtails the opportunity to apply 
additional scientific criteria for the selection of questionnaires. A second problem is 
the limited availability of reference data from the normal population, even if the 
source version has not been constructed elsewhere. 
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A third barrier to comparability of results is caused by the presence of rather 
inflexible local research policies and by the silent influence of substantial economic 
interests. Even in a small country like the Netherlands, standardization appears to 
be a long way going. 
More complex problems are encountered in the valuation of health status. This 
hybrid of medical, psychological and economic theory is bristling of pitfalls. The 
assumption that a QAL Y conceptually may be regarded as a measure of utility, 
theoretically implies empirical observations which yet have to be established. We 
especially think of the independence of the adjustment index and the time dimen-
sion (Torrance 1976A). 
The multitude of valuation methods makes up for a second theoretical challenge. 
We already mentioned two of these methods, standard gamble and visual analogue 
scaling. All methods share that little is knovm on the internal validity, and even less 
on the external validity. Additionally, feasibility and validity are counteracting 
criteria which necessarily require a compromise of design features of the Stages 2 
and 3. This compromise is by no means standard. 
Thirdly, the aggregation of individual utilities to arrive at a substitute for society's 
utility has been disputed. Despite their complexity, a collaborative group of Dutch 
and other European investigators has demonstrated that the latter two problems 
may be solved. Continued integration of medical, psychological and economical 
theories is a prerequisite for this progress, which in our view could benefit even 
more from existing psychometric evidence (Kind, 1982). 
7 Epilngue 
This paper has provided an outline on a research area in medicine which owes 
much to psychological theory. This area, indicated by 'QOL-research', concerns the 
description and the valuation of (changes in) health state. The apparently grov.ring 
interest in QOL-research is caused by the acknowledged contribution of psychologi-
cal experience and theory to the individualized treatment of patients - e.g. suffering 
from cancer - who face trade-offs between quality-of-life and survival. This 
contribution currently is extended to the field of decisions on medical technologies 
on the macro-level, particularly by meat".s of its undeniable influence on QOL-
research in MT A. 
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The challenge of QOL·research to any scientist regardless his academic background 
and his main interest - empirical or theoretical - in our view is evident. Beyond 
doubt further integration of social sciences in this type of research is relevant for 
future progress. We expect that this integration will enhance the arousing aware-
ness of clinical scientists of the usefulness of this body of knowledge to medical 
research. Current developments in many medical specialties (besides oncology we 
think of rheumatology, cardiology, surgery and primary care) support this expecta-
tion. 
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Abstract 
Analysis of the quality-of-life effects is part of the current technology assessment of 
the Dutch orthotopic liver transplant-programme. 
Data are collected by means of computer-assisted interviewing, including one 
interview before transplantation and annual follow-up interviews. Data on 
psychiatric morbidity are obtained from medical records. 
This article shows preliminary results of a cross-sectional analysis of data collected 
from 1987 to 1989. Eighty-eight measurements were obtained from 46 adult 
patients (response rate 82 %). 
Pre-transplant scores suggest major restrictions on all domains of life, especially a 
low amount of energy. After transplantation all indicators show improvement, 
although the level of the general population is not always attained. Improvement of 
subjective quality of life is more marked, maybe due to euphoria at surviving the 
hazardous procedure. Psychiatric events occurred only infrequently. 
We conclude that orthotopic liver transplantation contributes positively to the 
quality of life of surviving patients. In addittion, computer-assisted interviewing 
proved to be a feasx"ble survey technique, even when very ill patients were involved. 
1 Introduction 
Though never assessed in a randomized clinical trial, orthotopic liver transplanta-
tion is accepted aS an effective therapy for patients with end-stage liver disease (1). 
The considerable claim on fmancial resources and the uncertainty about the 
balance of harm and benefit have given rise to many investigations of its overall 
effectiveness. Results on the gain in length of survival of patients treated with liver 
transplantation have recently become available (2-4). 
However, studies assessing the gain in quality of life as a result of liver 
transplantation are few (5-6). Most studies on the effect of liver transplantation on 
the quality of life have studied a few non-comprehensive indicators of quality of 
life, e.g. days spent in hospital, work, activity status, and growth in length (children) 
(7-13). In addition several reports are available on psychiatric morbidity, focusing 
primarily on neuropsychiatric symptoms of end-stage liver disease (hepatic en-
cephalopathy) (14-16). A more comprehensive assessment of quality of life in liver 
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transplantation patients was reported for liver transplant recipients only after the 
operation, probably due to considerable difficulties in obtaining measurements 
from pretransplant patients (17-20). The study of Lowe (20) is of particular 
reference since it applied a quality of life instrument (the Nottingham Health 
Profile) which was also used in our study. Only the study published by Tarter in 
1988 has a longitudinal design (21); preliminary results indicated a sharp 
improvement in quality of life after liver transplantation, although the pre-morbid 
level of quality of life usually was not attained. The present article describes the 
design and the first results of a study on the changes in health-related quality of life 
in adult Dutch liver transplant patients. The study is part of a medical technology 
assessment of the liver transplantation programme in the Academisch Ziekenhuis 
Groningen in the Netherlands, which analyzed effects of liver transplantation on 
survival. quality of life and various resources (3.22). 
2 Patients and methods 
2.1 Patients 
The protocol of patient selection, timing of transplantation and support during 
follow-up has been described before (23-25). The nationally accepted protocol 
states overt psychiatric morbidity, including active alcoholism, to be a contra·indica-
tion (3). Intensive support by a specialized social worker is a regular part of the 
clinical programme. 
A longitudinal study de,Ogn for the quality of life study v.ith pre- and post 
transplant measurements was aimed at. Until the start of data collection for the 
quality of life study in June 1987, 63 patients received a transplant, 38 of whom 
were still alive 1 month to 8 years post-transplantation. These 38 patients 
constituted the group that was only eligible for post-transplant measurements (the 
cross-sectional group). for obtaining information on the long-term quality of life. 
Eight patients under 18 were omitted; additionally 4 adults were omitted for 
practical reasons as they lived abroad. The remaining 26 Dutch adults living with a 
transplant in June 1987 were included in our study and completed a questionnaire 
once a year. 
249 Appendix 5 
The longitudinal group consisted of all adult Dutch-speaking liver transplantation 
candidates who have entered the programme since June 1987 as defined by the 
formal request for a donor liver from Eurotransplant. Collection of data for the 
present report was terminated on July 1st, 1989. By then the longitudinal group 
consisted of 26 patients, 6 of them still awaiting transplantation. 
2.2 Questionnaire 
It is generally recognized that health-related quality of life (or "health status") 
constitutes a comple;.; multi-.d.imensional construct (26). According to present 
standards objective and subjective components are discerned (27). Objective quality 
of life usually refers to observable phenomena which can be compared with ex-
ternal standards (e.g. walking distance). Subjective quality of life refers to expe-
rienced well-being. We selected a set of general and specific questionnaires which 
addressed objective and subjective of quality of life. If possible, validated Dutch 
questionnaires were used. The left-hand columns of table 3 show the questionnaires 
used as well as their ranges of scores and reference scores for the general 
population, if available. 
The Nottingham Health Proflle (NHP, part 1) is a comprehensive measure 
designed to measure perceived health on 6 specific domains of life, as shown in 
table 3 (28). The NHP consists of 38 items with a yes/no answering format and has 
been used by Lowe in his assessment of post-transplant status of liver transplan-
tation patients (21). The Karnofsky-index is a global one-item measure for health 
status, often used in oncologic research (29). It covers domains like intensity of 
treatment and ability to take care of oneseJf. The Index of Well-being is a global 
measure for experienced well-being (24), consisting of 11 items. The other 
questionnaires mentioned in table 3 concern more specific indicators. The State-
Trait Anxiety Inventory (STAl) and the Self-rating Depression Scale (SDS or 
Zung), are 20-item questionnaires to measure anxiety and depression respectively 
(30-33). The questions on Activities of Daily Life were derived from a Dutch 
national survey on health-related problems. For nine activities, ranging from 
dressing to shopping, patients were asked whether they performed these activities 
independently; and if they did, at what effort. The questions on physical complaints 
and working capacity were designed for this study. Inquiries were made about the 
following complaints by means of a three-point scale (absent/sometimes 
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present/always present): lack of appetite, abdominal cramps, swollen belly, itching, 
jaundice, bone pain, backache, haematomas, drowsiness. The questions on 
satisfaction with aspects of life originate from the Dutch health survey mentioned 
above. 
The resulting questionnaire consisted of .±. 250 items. 
Stand-alone computer assisted intervie'Ning was used as method of presentation of 
the questions and registration of the response (34). This technique was succesfully 
applied earlier with ambulatory as well as bedridden patients in a similar study of 
heart transplantation patients (35). 
In addition to the self-reported quality of life, medical records of all patients were 
abstracted for the pre.sence of psychiatric events. A psychiatric event was defmed as 
clinical or outpatient treatment by a psychiatrist and/ or the prescription of 
psychiatric drugs (excluding temporary prescription of benzodiazepine-derivatives). 
3 Results 
3.1 Response 
Of 57 theoretically possible measurements among the 26 cross-sectional patients, 42 
(75 %) were actually realized. From all of them at least one measurement was 
obtained. Fourteen measurements were missed (including 2 refusals) from 12 
patients due to initial organizational reasons unrelated to the physical condition of 
the patient. 
In the longitudinal group 22 of 26 possible pre transplant measurements (85 %) 
were obtained. Impaired physical condition of three patients prevented them from 
participation. From the 20 patients meanwhile transplanted, five died. From the 
survivors all 24 possible post-transplant measurements were obtained. 
A total number of 88 (42+22+24) measurements was obtained from 46 patients 
(overall response rate: 82 %). The number of measurements related to the time of 
completion is presented in Table 1. As for paired observations (i.e. measurements 
obtained from the same patients before and after liver transplantation), 14 pre - 3 
months pairs could be obtained. 
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Table 1 Number of questionnaires completed 
pre 3m 7yr Syr IOyr Total 
22 18 13 8 5 3 4 5 4 4 1 1 8S 
3.2 Patient characteristics 
Socio-demographic and medical characteristics at the time of transplantation are 
summarized in Table 2. Only one of the interviewed patients showed clear signs of 
hepatic encephalopathy preceding liver transplantation. She completed half of the 
questionnaire with considerable assistance. There was no significant difference in 
severity of disease, diagnosis. or other patient characteristics between earlier or 
later transplanted patients in the study--group; liver function of those alive at 1 year 
follow-up or more was good (data not shown). 
3.3 Quality of life 
The interview results are summarized in Tables 3 and 4 and Figure 1. 
The results shown in Table 3 represent a cross-sectional analysis. This implies that 
average values of measurements relate to groups of partially different composition. 
For reasons of presentation the results for the cross-sectional group of patients 
from 2 years after liver transplantation onwards were combined into two groups, 
resp. 2 to 5 years after liver transplantation and 6 years or more after liver 
transplantation (including only one measurement per patient per follow-up group). 
The results of the longitudinal analysis are shoVIIl in Table 4. 
Fmally we addressed the question whether physical complaints were related to 
restrictions on particular domains of quality of life. The severity of the self-reported 
complaints was correlated with the dimension scores of the Nottingham Health 
Profile and with the Index of Well-being. Only correlations (r) exceeding 0.55 arc 
mentioned. 
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Table 2 Sodo-demographic characteristics of the study population (n=46) 
n % 
Gender 
female 31 67 
male 15 33 
Educational level 
minima] education 10 22 
intermediate education 30 65 
high education 6 13 
Diagnosis 
cirrhosis excl. PBC 12 8 
primary biliary cirrhosis 17 37 
prim. sclerosing cholangitis 6 13 
re-transplantation 2 4 
other 8 17 
Child-Pugh classification at transplantation* 
A 12 26 
B 24 52 
c 10 22 
Child-Pugh score 
X (SD) 8.1 ( 2.1) 
Age (years) at liver transplantation 
X (SD) 42.6 (11.1) 
. 
minus 5 patients not yet transplanted 
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Table 3 Quality of life before and after liver transplantation (reference values, 
mean patient values and standard deviations; 1987~1989, n=46, cross-
sectional analysis) 
Nottingham Health 
Prome -1 
Kamofslcy-lndc;x 
Index of Well-Being 
State-Trait Anxiety 
rnvel'loto~ 
Self-rating 
Range •• 
""'-
G~=> 
Population 
0-100 ,2:.90 
2.1- 14.7 :> 12 
80-Z<l 
Dep=ion Scale (Zun&) 100- 1S 
Activities of daily 
life 
Physic:a! complaints. 
Working" activity 
(ho ... rs/day) 
Median va)u<: 
S.:.tistaction with 
..health 
..leisure time 
.dally aajvjtio:s 
..life as a whole 
1- 10 
10-
0- l'l 
s-
s-
s-
s-
< 2.6 
< 2.6 
< 2.6 
< 2.6 
p:ud and 1,1npatd work (e.~; housework, study) 
Waiting 
"'' (n=22) 
64. (18) 
9.5 (2.9) 
41 (11) 
so (11) 
8.7 (1.7) 
5.6 (2.0) 
1.9 (3.0) 
0.0 
4.1 (1.0) 
3.2 (1.6) 
3.1 (lS) 
3.0 (1.1) 
3 Months 
post LTx 
(n=18) 
71 (15) 
135 (1.1) 
:34 (10) 
43 (S) 
9.2 (lA) 
JA (L9) 
1.7 (1.8) 
1.0 
2..2(1.1) 
2.3 (1.3) 
2.3 {LO) 
2.2 (1.2) 
wo~ P=ible :;core on the left. best possible scoro: on the ri!,;hl 
&ee figuro: 1 
lY= 
post LTx 
(n .. lJ) 
~ (13) 
13..2 (2.0) 
Z9 (7) 
39 ( S) 
9.3 (1.9) 
2.6 (1.9) 
3.3 (2.3) 
,_o 
1.6 (0.8) 
1.7 (0.8) 
1.7 (0.9) 
1.5 (0.7) 
2-S Yts 
post LTx 
(n=lS) 
85 (16) 
13.4 (2.3) 
30 (7) 
" ( 7) 
9.4 (1.4) 
3.4 (1.8) 
4..1 (2.6) 
'-0 
1.6 (1.0) 
1.7 (0.9) 
1.8 (1.1) 
15 (0.8} 
6-10 Yr.:: 
pogt: LTx 
(n"lO) 
9.6 (S) 
13.4 (2.0) 
3.2 (S) 
43 (6) 
9.8 (0.6) 
z.s (1.9) 
'"(2S) 
s.o 
1.4 (0.7) 
15 (0.7) 
2.0 (LO) 
1.4 (05) 
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Table 4 Quality of life before and 3 months after liver transplantation 
(n=14, longDtudinal analysis, t~test) 
Questionnaire Waiting 3 Months p-value 
List after LTx 
General indicators 
Nottingham Health Profile - 1 
Mobility 42 27 > 0.1 
Pain 24 12 > 0.1 
Energy 73 19 0.00 
Sleep 47 16 0.01 
Social Isolation 17 8 > 0.1 
Emotional Reaction 23 8 0.07 
Karnofsky-Index 57 71 0.02 
Index of Well-Being 8.9 133 0.00 
Specific indicators 
State-Trait Anxiety Inventory 39 34 > 0.1 
Self-rating Depression Scale 51 43 0.04 
Activities of daily life 8.4 9.1 > 0.1 
Physical complaints 6.0 3.4 0.01 
Satisfaction with 
. .health 4.4 23 0.00 
. .leisure time 3.7 2.4 0.02 
.. daily activities 3.4 23 0.04 
.Jife as a whole 3.4 2.1 0.01 
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Figure 1 Nottingham Health Profile part 1: mean scores before and after liver 
transplantation. 1987-1989. 
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Restrictions on the Mobility-dimension correlated most with the presence of bone 
pain (r ~ 0.57), on the Pain-dimension with the presenee of bone pain (r ~ 0.61) 
and backache (r ~ 0.67), on the Energy-dimension with a swollen belly (r ~ 0.60), 
on the Sleep-dimension with itching (r = 057), on the Emotional reaction-
dimension with drowsiness (r = 059). None of the complaints correlated 
sufficiently with the score on the Social isolation-dimension. A low Index of Well-
being correlated most with the presence of drowsiness (r = 059). 
Only three patients needed psychiatric treatment. One patient underwent psychi-
atric consultation preoperatively because of a suicide attempt in the past. One 
patient needed anti-psychotic medication during the postoperative period. The third 
patient, who was actually transplanted for primary biliary cirrhosis, had a history of 
alcohol abuse. As anxiety to move hampered her remobilization, she was prescribed 
anxiolytic medication postoperatively. 
4. Conclusion and discussion 
In this article preliminary results of a study assessing the influence of liver 
transplantat.ion on quality of life are shown. The pretransplant state can be 
characterized by a rather low Karnofsky index, psychological distress, many physical 
disturbances and a low level of experienced well-being. Three months after 
transplantation patients show a considerable rise of the quality of life level. Further 
improvement in the first post-operative year results in a quality of live level similar 
to or slightly below the level fo the general population. This level appears to 
stabilize in the following years. Obviously the low frequency of long tenn complica-
tions adds to this favourable picture. Experienced well-being shows an impressive 
favourable change following liver transplantation, the level exceeding that of the 
general population. The posttransplant NHP-scores resemble those reported by 
Lowe (20) closely, though the comparison should be made with caution as the 
latter study combines data from patients shortly after transplantation (43% < 1 
year) with data of patients at more than 2 years follow-up. 
We are aware that our conclusions depend on some assumptions especially with 
regard to the absence of a control group of nontransplanted patients and the effect 
of selective non~response. 
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In this study, liver transplantation patients were used as their own controls. As gra-
dual deterioriation of quality of life in the nontransplantation case is likely (36), a 
comparison of quality of life-values before and after liver transplantation may give 
a conservative estimate of the positive effect of liver transplantation. 
Selective (non-)response is another threat to validity. High severity of disease 
precluded three patients, who can be expected to benefit most from liver trans-
plantation, to complete the prctransplant questionnaire. Measurements from 5 
posttransplant patients were missed as a result of mortality. The overall result of 
this selective non-response might be a slight overestimation of average pre- and 
posttransplant quality of life. 
Some results deserve attention. Firstly, the fairly good activities-of-daily-life score 
preceding liver transplantation seems to contrast with the limited scores on work-
status and Karnofsky-index. Liver transplantation candidates are able to perform 
independently most daily activities only with great effort. Following liver trans-
plantation these activities can be performed with little if any effort. 
Secondly, the scores after liver transplantation on the SDS-Zung scale for 
depression seem rather high, i.e. in the range of Dutch non-depressive psychiatric 
patients (34,37). As reported by Smith, a high score does not necessarily mean the 
presence of a clinical depression following DSM-III standards (38). Although the 
SDS-Zung scale is an accepted and validated questionnaire for depression, its 
interpretation for somatic patients remains to be established. 
Thirdly, psychiatric morbidity occurred apparently only infrequently. The support by 
a specialized social worker probably contributes to this favourable outcome. 
Surman reported frequent episodes of pre- and postoperative anxiety and depres-
sive disorders, and considered psychiatric consultation an essential support to the 
transplant programme (17). 
These results strongly suggest that liver transplantation not only improves survival, 
but also significantly improvements in quality of life. These findings should be 
validated by a longitudinal study, for which data are currently collected now. 
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Abstract 
A computer assisted interview schedule was developed for the valuation of health 
states.. After minor modification of standard techniques, the interview was used to 
elicit value judgments of a laymen panel on a large number of different health 
states. This article presents the results of two subsequent investigations. The first 
study adressed fca5l"bility and reliability of the procedure. Health state descriptions 
turned out to be too long and some valuation methods obviously were too difficult. 
In the second study a simplified version of the questionnaire was used. Forty health 
states were evaluated in interview sessions taking on average 25 minutes. Judg-
ments consisted of scores on a fixed interval scale, which appeared to be reliable 
and internally valid on an individual level. Moreover, high consensus was found be-
tween individuals with respect to the ranking and the valuation of the health states. 
The application of the results in cost-utility analysis is discussed. We conclude that 
computer assisted interviewing may be a useful method to collect value judgments 
of the general public on different health outcomes. In this setting, line production 
turns out to be the valuation method of choice. 
1. Introduction 
Governments and health insurance companies increasingly have to decide on the 
incorporation of new medical technologies into existing insurance schemes. Cost-
benefit analysis, cost-effectiveness analysis and cost-utility analysis are methods 
which can be of aid to the required decision-process. The authors are involved in 
the cost-utility ana1ysis of the Dutch heart and liver transplantation programmes1.2 
These studies formed the impetus for the studies described in this paper. 
Cost-utility analysis is regarded as a special form of cost-benefit analysis, in which 
benefits arc represented by the change of life expectancy, weighted for the level of 
quality of life3• These benefits are referred to as QAL Y's (quality adjusted life 
years). The construction of QALY's was proposed by Fanshel and Bush first and 
implies the weighting of years of survival by means of an index representing the 
quality of the years survived4 • The quality-index should be a cardinal value ranging 
from 0 for the worst possible health state to 1 for the best health state5• The deter-
mination of the quality-index in the context of CUA implies a valuation process 
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involving many theoretical and practical choices. Theoretical considerations for the 
construction and application of QALYs are given by e.g. Pliskin6.7.8..9Jo •• Some 
examples exist of the application of empirically based QAL Ys11Jm_ 
This paper presents the results of two subsequent studies which aimed at the 
determination of the cardinal values of health states using a computer assisted 
interview. Two questions were to be answered: 
is there a feasible, reliable and valid way of determining these values given 
the usc of computer assisted interviewing? 
can the results be applied in cost-utility analysis? 
In the second section some of the methodological concepts involved are discussed, 
followed by the description of the interview design and the study population 
chosen. Next the results of a pilot study (referred to as Study I) are presented, 
particularly on feasibility and reliability of the measurement instrument. The final 
sections present the results of the main study (Study ll) including data on the 
degree of consensus between the respondents. We finish with a general discussion 
on the applicability of methods and results of these studies. 
2. Methods 
2.1 General approach 
Direct valuation of health states appears to be a complex procedure from a metho-
dological point of view. This valuation procedure essentially consists of the 
following steps: 
1. the conception of an operational definition of health status and the estimation of 
the impact of a health programme on health outcome according to this defini-
tion (health state discn"ption) 
2. the construction of health scenarios and estimation of the economic value of 
these health scenarios (health state valuation) 
3. the application of the results in cost-utility analysis (implementation) 
Each of these steps involves many choices for which literature offers different 
options (see Table 1 on next page for details on the first two steps). In most cases 
a 'perfect' choice is not possible due to the fact that optimization of conflicting 
properties of the measurement instruments is required. 
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Table 1 Methodological choices in the description and valuation of quality of life 
Measurement of the patient's health state 
1. concepts of a health outcome measure for utility anaJysis 
"QALY 
2. dimensions of health 
physical 
medical (symptoms) 
psychological 
future outlook 
social relations 
3. measurement level within a health dimension 
nominal 
ordinal 
4. data collection 
observors 
Valuation of health Slates or 'scenarios' 
standard gamble utility 
age 
= 
work status 
marital status 
duration (time) 
interval 
ratio 
patient questionnaire 
5. relation of patient's health state measurement with description in valuation procedure 
implicit (expert opinion) explicit {algorithm) 
6. jury 
doctors 
nu<= 
patients 
7. subject of health state description 
'f (first person) 
8. presentation style 
short hand 
9. valuation method 
magnitude estimation 
standard gamble 
10. interview situation 
written interview with/without support 
oral interview 
11. sample technique 
22 Health state description 
'experienced' laymen 
random sample of laymen 
health services researchers 
'He' (third person) 
narrative style 
time trade-off 
willingness tO pay 
computer assisted 
interview 
The description and valuation of health states depend much on their underlying 
concept14• This concept is characterized by the dimensions which are distinguished. 
In spite of the growing literature on the measurement of health states, little infor-
mation is available about the influence of health concepts and of the dimensioning 
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on reliability and validity of the resultsJ.S.I6.,l7. Additionally, the selection and opera-
tionalization of dimensions show much variety. Most authors use scaled categories 
within a dimension. The resulting structure is used to measure health outcome con-
sequences at the patient level. 
2.3 Health state valuation 
From these observations we must derive formal health state 'summa..-ies' or 
'scenarios'. The same health concept and dimension-structure will usually be 
chosen, though simplification maybe needed. 
If the resulting scenarios have to be valued for economic purposes it should 
additionally be made clear whether a health scenario is to be considered by the 
judging subject as applying to him/herself - 'first person' - 14'18J9.2!l or to someone 
else - 'third person' - 2!.22.23.24 • Health scenarios can be written in a shorthand style 
2l.22.2S or in a narrative style, including or excluding statements on duration 14.20.26. 
Regardless the method of presentation there exist many methods to elicit utility-
judgments on these health scenario?.28.29JO.:H.32.33.34_ The methods vary a.o. with 
respect to the resulting measurement level In cost-utility analysis a cardinal scale is 
required to construct QAL Y's33• Consequently the rather easy method which ranks 
health scenarios on an ordinal scale (category rating) can not be used3S. Below four 
other methods are considered: magnitude estimation, standard gamble, time trade-
off and vr.illingness to pay. More methods are described in the above mentioned 
reviews. 
Magnitude estimation was originally developed by Stevens in 195836."37. Respondents 
express their judgment about a health state directly in numbers. The assumed scale 
usually has two fixed endpoints, one end representing the least preferable health 
state - usually death - and the other end representing optimal health. This 
procedure yields a relative scale. Its usefulness in measuring subjective judgments 
has been demonstrated (see e.g. BohrnstedfS) and its application in medicine is not 
limited to health state valuation39• Although the instructions of a magnitude estima-
tion scale aim at a ratio scale, the obtained scores may have a loginterval level40A1• 
Other response modalities than numbers are possible e.g. visual analogue scales. 
Standard gamble also yields cardinal values. Essentially the respondent has to state 
which probability p of immediate death combined with probability (1-p) of life-long 
optimal health is equivalent to the certainty (p= 1) of a specific non-optimal health 
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state with 'infinite' (life-long) duration". This method cannot easily be applied, 
since the cognitive task of comparing probabilities and different outcomes appears 
to be difficult, especially when small probabilities are involved 14,43. Sometimes a 
visual aid for standard gamble is applied, bridging the difference between mag-
nitude estimation and standard gamble. In addition standard gamble does not 
satisfy a constraint imposed by the construction of QAL Y's, i.e. not to include a 
time dimension. Therefore we did not use the standard gamble method. Tz.me 
trade-off was developed specifically for the use in health care. Like standard gamble 
it is an indirect technique as it derives the preference for a particular health state 
from the respondent's response to a decision situation. The respondent is offered 
two alternatives. Alternative 1 implies being in health state A for a defined period 
(t1) as opposed to alternative 2 which implies optimal health for a shorter time (tA; 
tA < t1). Time tA is varied until indifference between alternative 1 and 2 is reached. 
The preference value for A is easily calculated (vA = tA/t1 * v1; v1 being the value 
for optimal health, which is usually set 1). The time trade-off method fits well to 
the constraint on the quality index in CUA with respect to the time dimension, 
which is an advantage as compared to standard gamble. Like standard gamble time 
trade-off involves a rather difficult process of determining respondent's indifference 
betv.>een alternatives with different probabilities. 
Willingness to pay can be regarded as another trade-off method. Essentially the 
respondent is asked how much he would be willing to pay to get a well~defined gain 
in health44• Although from an economic point of view several authors have claimed 
this method is superior, its position is yet not well established30.44,45.46. 
As compared to the time trade-off method, the heterogeneous attitude of 
repondents towards money may be a disadvantage. Money is not a very good yard~ 
stick if respondents put very different values on money45.46. 
The choice of the appropriate jury or panel to obtain the values from, is influenced 
by the ultimate goal of the valuation study. Judgment is sometimes by expert panels 
consisting of doctors or nurses25.47• If results are implemented in a CUA, health 
states should be valuated from a societal point of view, suggesting a sample of the 
population to be the best panel, as in our studY8.25.JJ. 
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2.4 Criteria for evaluation 
We regarded the following criteria to be important: feasibility, reliability and 
validity48.4?. A measurement procedure is considered feasible if it is acceptable to 
the respondents. if it is easy to interviewers and to data~analysts, if it enables to 
measure a substantial number of health states, and if it can be performed at low 
costs. Reliability is related to the question to which extent the same phenomenon 
can be measured a second time with the same results. Reliability depends partially 
on acceptability to the respondents. A measurement procedure is valid if actually 
measures the phenomenon it claims to measure. This presumes a comprehensive 
health state description, including all relevant aspects. Consensus ber.veen respon-
dents and the possibility of assuming a ratio scale can be regarded as specific 
aspects of validity in the context. 
25 Interview design in Study I & II, and study population 
Usually a structured and strongly supported interview situation is chosen for the 
valuation task. This approach involves lengthy (1.5 to 4.5 hours) interviewi".sl. 
Although this approach to a certain extent guarantees adherence to the judgment 
task, judgments may be biased by the influence of supporting interviewers and by 
fatigue of the respondent?'. A related disadvantage is the limited number of 
scenarios which can be valued this way. In our studies health states were presented 
and valued by means of a personal computer (computer assisted interviewing, 
CAI)52• Advantages of this method are the short response time, the option of incor-
porating special features (e.g. individual random presentation of questions, 
conditional presentation of questions) and generally good quality of data. All res-
ponse modalities are possible e.g. categories, numbers and lines. Automatically the 
time required for each separate judgment task is recorded. If an elaborated 'help 
menu' is provided for, an unbiased supported interview situation can be ap-
proximated. 
In both studies the same panel of respondents was involved, which consisted of a 
sample of households in the city of Amsterdam. 
Each adult member of the household voluntarily participates in answering 
interviews using CAl on a monthly base. As a reward the panel members are given 
a home-computer in loan and occasionally some new software. 
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The home computer is loaded (survey questions) aud unloaded (respondenfs ans-
wers) automatically using the telephone communication line. Information on back-
ground variables is described in Table 2. 
Table 2 Age, sex, education and income of study population (income in Dutch 
florins 1 Hll = 0.3 £) n=72 
n % 
Age 
16- 20 yeatS IS 21 
20- 30 yea<$ 13 18 
30- 40 years IS 21 
40- 50 years 12 17 
SO- 60 years 9 16 
60- 70 years 7 10 
> 70 years 1 
Sex 
Male 35 49 
Female 37 51 
Education 
Primary school 
Lower vocational 
Secondary school 
Middle vocational 
College 
Higher vocational 
University 
In(:orne if employed 
<1000 
1000- 1500 
1500- 2000 
2000- 2500 
2500- 3000 
3000- 3500 
>3500 
n 
4 
14 
16 
5 
13 
IS 
5 
5 
4 
4 
8 
5 
3 
4 
% 
6 
19 
22 
7 
18 
21 
7 
IS 
12 
12 
24 
IS 
9 
12 
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3. Study I 
3.1 Design -additional features 
In Study I 21 different health scenario's with 6 dimensions were constructed. The 
health concept was partially based on the early work of Patrick and Bush21 .22. The 
following dimensions were used (in order of presentation): physical functioning, 
medical symptoms, social relationships, psychological well-being, time spent in the 
health state and intensity of treatment. The psychological dimension was included 
according to the W.H.O.-defmition of health53JO, and to the recent literature on 
quality of life measurement (see e.g. De Haes and Kat7?x). The intensity of the 
medical treatment was added because in the posHransplantation phase there is 
often a striking discrepancy between apparent health state and the need for medical 
treatment. Fmally a statement about the duration of the health state was incorpo-
rated. No information was included about the name of the particular disease or 
medical condition. A disease label introduces in fact extra information which might 
influence respondents in an uncontrolled waY.8• 
Other infonnation e.g. on the patient's social status and work status was not 
included. Since we restrict ourselves to the question whether different health states 
can be valuated as a contribution to rational health care resource allocation 
decisions, only aspects of the healrh situation itself seem relevant. If distributional 
effects of resource allocation decisions should be taken into account too, other 
aspects of the health situation may be included, e.g. age. 
In a modified factorial design 21 health states were defined, after exclusion of some 
too unrealistic health states. The interview started with an introduction on the topic 
and with a presentation of the standards i.e. the best and the worst state within our 
classification. Next the respondent valued the health states in blocks, each block 
comprising of one valuation method. Only a selection of health states was evaluated 
by the time trade off and willingness to pay method. 
3.2 Feasibility 
In this case non-response is not a good indicator of acceptability of the judgment 
task as members of this panel cou1d be expected to accept the task even if they 
consider the task too difficult. Four other indicators of the feasability seem more 
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appropriate: incomplete response, answer patterns, comments of respondents and 
interviewing time. 
Few respondents broke off the interview, but on the answer patterns both trade-off 
tasks turned out to be too complex. About half of the respondents clearly gave 
nonsensical responses and 20% refused to answer. The small number of interpret-
able answers appeared to be inconsistent as nearly identical responses were given 
for different stimuli, while different responses were given on very similar stimulus. 
Respondents were given the opportunity to comment at the end of the interview. In 
study I most respondents commented on the interview. Descriptions were consider-
ed to be too long and too similar, particularly the willingness to pay method was 
regarded to be unethica.,4 notwithstanding a comprehensive introduction preceding 
this valuation method. The trade-off tasks (time trade-off and willingness to pay) 
prolonged the interview unacceptably. The whole interview in Study I was complet-
ed in about 45 minutes. The trade-off tasks accounted on average for 20 minutes, 
although they constituted 19% of the questions. 
With regard to other aspects of feasibility (e.g. interviewers-acceptability, flexibility 
to change, data quality, cost) the interview method appeared to be satisfactory. 
3.3 Reliability 
Reliability can be estimated by repeated measurement provided that the design 
guarantees that correlation cannot be due to memory effects and variation cannot 
be due to change in time of the phenomenons:2. Memory effects seemed not likely 
to have occurred in our studies. Scenarios were randomly presented and 
respondents revealed concern about consistency when they commented on the 
interview. Standard test-retest reliability, repeating some questions v.rith the same 
measurement method, was satisfactory. In addition a second test -retest procedure 
was applied, based on the assumption that magnitude estimation using numbers 
and magnitude estimation using line production are parallel instruments. Applica-
tion of this type of test-retest procedure in Study I resulted in a median of cor-
relation of only 0.67. This disappointing value was probably the result of too 
complex health scenarios. 
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3.4 Relation between dimensions and health state value 
With linear regression we estimated the relation between the different dimensions 
and the total health scenario scores. For convenience log transformation \VaS 
applied to the time dimension, which originally consisted of the categories '2 
weeks', '6 weeks', '3 months', '1 year', etc. The other dimensions were scaled fol-
lowing their logical ordening, assigning 1 to the best category, 2 for the second best 
category, and so on. The assigned ordinal number of each category was conve-
niently regarded as a variate. Without interaction terms the model explained 88% 
of the total variance. The attribution of each dimension was fairly uneven, social 
relations and medical symptoms attributing insignificantly to the variance explained 
(data not shown). 
4. Study II 
4.1 Study design - additional features 
The design of Study II was modified according to the results of Study I. Social 
relations as a dimension was excluded. The dimension time was also omitted for 
methodological reasons (QALY-construction). Finally some categories were 
reformulated. 
Table 3 presents the operationalization of the four remaining dimensions, each con-
sisting of five categories. Twenty-six health state descriptions were formulated by 
combining one category from each dimension. The combinations were partially 
based on empirical patient data from the heart transplantation study and partially 
constructed to achieve maximal variation. 
The interview task started with valuation of all health states by line production. 
Next a selection of eleven health states was valued using number assignment. 
Within each block the order of presentation was random on the individual level. 
The trade-off tasks were omitted. 
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Table 3 Heallll state dimensions and categories of Study 11 (translated)' 
A. Intensity of treatment 
1. at home 
2. at home, but having regular medical check-ups 
3. at home, under intensive out-patient control, taking powerful drugs 
4. temporarily hospitalized 
5. in hospital, intensive treatment 
B. Medical symptoms 
1. no complaints or disorders 
2. some small complaints, but not in pain 
3. rather quickly short of breath, at times in pain 
4. at the smallest effort short of breath and tired, in moderate pain 
5. constantly in severe pain and out-of-breath 
C. Physical functioning 
1. able to do everything both at home and outside 
2. able to do everything at home, but restricted outdoors (e.g. unable to cycle 
or do the shopping) 
3. able to care for him/herself physically, though limited in walking around 
4. difficulties with getting in/out of bed needing help with self-care 
5. restricted to bed, unable to do anything 
D. Psychological well-being and subjective medical prognosis 
1. no psychological complaints, and having trust in the future 
2. feeling down now and then, but having trust in the future 
3. under stress having trust in the future, but without looking too far ahead 
4. depressed moderate trust in the future, does not look far ahead 
5. tense and depressed, living day by day, and fearing the worst 
1 One specific health scenario can be indicated by four digits, representing the category·number of 
dimensions A, B, C, and D respectively. Thus optimal health is health scenario lllL 
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Table 4 presents the line judgments of the panel on 26 different health states. 
Health states are indicated by a 4 digit number, each digit representing the 
respective category of a dimension. The dimensions and categories are ordered as 
in Table 3. Scores are transformed from a 1 - 39 to a 0.0 - 1.0 scale. 
Table 4 Line judgments of 26 health states. Health states ordered according to 
the arithmetic mean (n=65). 
Health Aritm. S.D. 95% Coni. Geom. Median 
State Mean Interval Mean 
1111 0.97 0.06 0.95-Q.98 0.96 1.00 
3111 0.60 0.19 055-Q.64 056 059 
= 0.49 0.18 0.45-Q.54 0.45 0.49 2232 0.47 0.20 0.42.()52 0.42 0.46 
1331 0.46 0.19 0.42.()51 0.42 0.43 
2322 0.43 0.16 0.40-Q.47 0.40 0.41 
4222 0.43 0.19 039-Q.48 038 0.43 
3114 0.40 0.19 035-Q.44 034 0.41 
1323 039 0.16 035-Q.43 035 038 
3321 036 0.15 032-Q.40 032 032 
4432 036 0.17 032.().40 030 035 
2224 036 0.16 032.()39 031 038 
3323 033 0.17 0.29-Q37 0.28 030 
3333 0.32 0.15 029-Q36 0.28 030 
5232 0.30 0.18 025-Q34 0.24 0.27 
2442 0.29 0.16 025-Q33 0.23 0.27 
3343 0.27 0.14 0.24-Q31 0.23 0.27 
2434 0.27 0.15 0.23-Q31 0.22 0.27 
4434 0.25 0.15 0.22-Q.29 0.20 0.24 
4444 020 0.13 0.17-Q.23 0.15 0.19 
4553 0.18 0.11 0.15-Q.21 0.14 0.16 
5443 0.15 0.11 0.12-Q.17 0.11 0.11 
4454 0.14 0.10 0.12-Q.17 0.11 0.14 
5543 0.13 0.11 0.11-Q.16 0.09 0.08 
4545 0.11 0.10 0.08-Q.l3 0.07 0.05 
5555 O.Dl 0.02 0.01-Q.01 0.01 0.00 
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The modifications of the interview improved the acceptability of the interview. 
Nonsense answers were absent and comments of the panel were predominantly 
positive. The average interviewing time, instruction time included, was reduced to 
25 minutes. Shorter interviewing time should not be expected as this type of 
judgment is cognitively and emotionally difficult. 
4.2 Reliability 
With the same test-retest procedure as in Study I, regarding the different answer 
modes as parallel instruments, the median correlation rose to 0.92, which may be 
regarded as a very satisfactory result (see Table 5). 
Table 5 Correlation between line judgments and number judgments on the 
individual level 
Study I median of correlation 
mean of correlation 
Study II median of correlation 
interquartile-distance 
mean of correlation 
4.3 Validity 
.67 
.66 
.92 
.89- .95 
.89 
Four types of validity can be distinguished according to the Recommendations of 
the APA Committee on Psychological Tests56: predictive validity, concurrent 
validity, content validity and construct validity, the first two taken together as 
criterion validity. Criterion validity would require the prediction of particular health 
behaviour or health care expenditures depending on stated values for different 
health states. Sofar, this type of validation seems to involve too complex 
methodological and empirical problems. In fact this is exactly the raison d'Ctre of 
the second best methods described. Content validity seems not relevant in our case 
as health states arc not regarded as psychological construct but as a commodi~. 
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To our opinion in this study only construct validity can be determined. This type of 
validity is involved whenever a test is to be interpreted as a measure of some attri-
bute or quality which is not itself •operationally defined,:x;. Construct validity is ob-
tained deductively and involves a process in which evidence from different sources 
is integrated. In this section we consider 5 different indications for construct 
validity: order effects, scale distribution, logical consistency, independency of 
dimensions and results from linear regression after rescaling the categories. 
No effects due to the order of dimensions in the health scenario should e;cist. We 
varied the position of the time dimension in Study I. Some evidence in support of 
an internal order-effect was found, but no definite conclusion could be drawn due 
to the low reliability of Study I. One might expect that this phenomenon will occur 
when the list of dimensions is long resulting in predominance of the· first dimen-
sion. We repeated this experiment in Study II. Two health scenarios were presented 
twice with different ordering of the dimension statements. As no order-effect was 
found it may be tentatively concluded that respondents attached a value to the 
health state as a whole. 
Another criterion of construct validity is the distn"bution of values on the response-
continuum57, both individually and on the group level Categorical answers were 
found in Study I due to apparent difficulties with the judgment task. No such 
response behaviour was found in Study TI on the individual level. On the aggregate 
level mean values were equally distributed along the response continuum except for 
a 'gap' between optimal health (state 1111) with value 0.97 and the next-best health 
state (state 3111) with value 0.61. The same result was reported by Patrick~ but 
Rosser and Kind showed a great majority possible health states was given a value 
between 0.9 and l.OSO. Torrance3, using multi-dimensional scenario•s like those 
presented in this article, reported mean values which were more equally dis-
tributed. Furthermore we obtained the mean judgments about different health 
states expressed both in lines and - independently - in numbers. When individual 
reliability is high the coefficient of identity between both group scale~ can be 
computed as a measure of internal validity of such a group scale. This coefficient 
was equal to 0.98 and the aggregated group scales are thus exchangeable. 
Logical I consistency provides us with a third validity criterion. If two health state 
scenarios A and B are compared and for aU dimensions the respective category of 
A has a higher Oower) or equal rank compared to B, then the expressed value of A 
should be at least (most) equal the value of B, assuming no interaction of dimen-
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sions. E.g. the value of state 1323 should at least equal the value of state 3323; no 
logical ordering exists between e.g. 1323 and 3114 and as a consequence no 
prediction is possible about the order of their respective values. Inconsistent 
response behaviour can be related to the 'distance' between two logical ordered 
states. We define 'distance' conveniently as the sum of category-rank differences of 
all (4) dimensions. This sum ranges from 1 (e.g. states= and 2232) to 16 (states 
1111 and 5555). 
The 26 different health states accounted for 206 logically ranked pairs. Respondents 
expressed in 92 % of all logical pairs consistent values and expressed in 8% 
reversed preference. Relating inconsistent response behaviour to distance between 
a pair of health states showed a strong association: the majority (78%) of 
inconsistencies occuring when the distance was less than 5 (see Table 6). 
Table 6 Consistency according to category - rank difference between pairs of 
health states 
Distance Pairs Consistent order Reversed order 
Better Equal Worse 
1 7 55.4% 14.7% 29.9% 
2 13 69.1% 103% 20.6% 
3 20 785% 6.9% 14.6% 
4 33 81.1% 5.8% 13.1% 
5 Z7 88.6% 3.9% 7.6% 
6 17 88.4% 3.7% 7.9% 
7 22 92.5% 2.7% 4.8% 
8 25 95.4% 2.1% 25% 
9 15 97.1% 13% 1.5% 
10 7 97.1% 1.1% 1.8% 
11 9 98.5% 0.9% 0.7% 
12 5 99.7% 03% 0.0% 
13 3 100.0% 0.0% 0.0% 
14 2 100.0% 0.0% 0.0% 
16 1 100.0% 0.0% 0.0% 
Total 206 '012% 43% 8.5% 
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The response behaviour turned out to be consistent, inconsistencies being related 
to resemblance of health states. 
In the context of a multi-attribute utility function each dimension should prefarably 
independently attnDute to the resulting overall health state value. If the attnbution 
of dimensions does not show interaction, a change from e.g. category 1 to category 
3 in one dimension should result in about the same difference between the scores, 
regardless the level of the other dimensions. Four pairs of health states could be 
selected which allowed such a check of validity (see Table 7). 
Table 7 Interaction between dimensions 
Dimension 1 
1 1 1 1 versus 3 111 037 } difference 031 
1323 versus 3323 0.06 } 
Dimension 1 
2222 versus 4222 0.06 } difference 0.04 
2434 versus 4434 0.02 } 
Dimension 3 
2222 versus 2232 031 } difference 0.20 
3323 versus 3333 0.11 } 
Dimension 4 
2222 versus 2224 0.14 } difference 0.03 
4432 versus 4434 0.10 } 
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The first two rows of this table show that a change rise from category 1 to category 
3 in dimension 1 shows a difference of the total score of 037 and 0.06 respectively. 
Only a minor difference should be expected as is e.g. the case in the second and 
the fourth pair. We conclude that the attribution of each dimension to the total 
score is not always independent from the level of the categories in the other dimen-
sions. One might argue this interaction should be expected, assuming that simple 
additivity of the disutilities of suboptimal health aspects does not exist". 
The relative contribution of each dimension to the group scale was estimated, 
applying ordinary lineair regression. The mean score of a health state was the 
dependent variable and the corresponding categories of each dimension, scored as 
a variate from 1 to 5, acted as the explanatory variables. This model explained 83 
% of total variance. As the numeric scale from 1 to 5 is arbitrary, we investigated 
whether higher order models could improve the model. Frrst we normalized the 
categories between 0 and 1. The best category was indexed 0 and the worst was 
indexed 1. The remaining three dimensions were supposed to be on a line: 
f(i) = i""', i=0.25, 0.5, 0.75 
Table 8 presents the results of this rescaling procedure. 
Table 8 Original and rescaled category values 
Dimension A B c D 
Category Rescaled category value 
1 0 0 0 0 
2 0.49 0.65 0.11 0.21 
3 0.86 0.81 033 0.46 
4 0.70 0.91 0.63 0.72 
5 1 1 1 1 
Note that this procedure lead to an category-order reversal (A3 - A4). Using the 
rescaled category-scores 91 % of total variance could be explained. 
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The estimated model is (A, being the rescaled category-score on dimension A, etc. 
and T-values between parenthesis): 
Y = o.so- 0.21'A;- 02S'B;- o.os•c.- 0.20'D, 
(-4.2) (-5.0) (-1.4) (-4.1) 
The product moment correlation between the observed mean values of the 26 
health states and the predicted values was 0.96, which is an acceptable value. This 
model enabled us to estimate the values of all possible health states within our 
classification. 
4.4 Consensus 
In this section we address the question whether a common scale of health state 
values does exist. Without the application of the resulting values for QALY-
calculations in CUA, the issue of consensus would be of merely academic interest. 
However, implementation in CUA depends on consensus. The argument runs as 
follows. Suppose we have derived a period-dependent quality index, from the 
cardinal values created in the valuation process described before. I.e. the cardinal 
value of the quality-index is based on some measure of central tendency applied to 
the values of the respective health scenario(s) which apply to that period. Usually 
the aritmetic mean is chosen, but other measures of central tendency may be 
appropriate from a statistical point of view, for example the mode, median of geo-
metric mean (see Table 4). Each measure of central tendency implies some rule 
for aggregation of preferences "With an assumption about the measurement level. In 
the case of the aritmetic and geometric mean, this level is supposed to be cardinal, 
in the case of mode and median nominal and ordinal respectively. 
It is important to be aware of the non-statistical assumptions of this aggregation. 
All measures of central tendency presuppose commensurability of the individual 
sca1es60, which is a prerequisite for an empirically based social welfare function61• 
Assuming commensurability, the degree of dissensus should be defmed according 
to the measurement level involved (standard deviation, inter-quartile-distance). If 
consensus appears from the data, application of the group values seems justified. 
However, dissensus causes serious problems. Suppose a health care program for 
the treatment of disease A is evaluated. The CUA yields the costs and benefits, the 
latter expressed in QAL Y's. Ultimately QAL Y's are derived from the mean (or 
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median, etc.) of value judgments of the health scenario(s) before and after 
treatment. For a future group of consumers of the treatment, or for society as a 
whole, these group values do not provide us with useful information if dissensus 
exist. Some will regard the cost per benefit, whirh results from the judging panel on 
the health scenarios to be rather low and they will consequently benefit from a con-
sumer surplus. Others will experience a consumer loss, as consumption will have a 
more or less obligatory character. 
Each aggregation principle in fact implies some rule for counting these benefits and 
losses. It can be argued that if no common rule for counting benefits and losses 
exists, the QAL Y construction is not justified when dissensus exist. Examination of 
our data for the existence of a common scale presupposes: 
sufficient reliability and validity of the answers on the individual level 
- the assumption of commensurability of the individual scales 
- a satisfactory aggregation technique for the individual answers 
Assuming these conditions to be sufficiently fulfilled and assuming a cardinal 
measurement level, we estimated the degree of consensus between individuals. The 
line-answers were used of 65 respondents for whom which sufficient demographic 
data were available. The arithmetic mean was chosen to compute values of the 
group-scales. Fl.rst individual scales are compared to the group-scale. The effect of 
outliers is shown. Finally the existence of subgroups according to three background 
variables is investigated. 
The co"elation between the individual scales and the overall group scale was 
estimated. For this association to he high, both a high intra-reliability and a high 
consensus are required. In Study TI the mean correlation between the individual 
line scores and the group scale was 0.86. Presumably laymen agree to a large extent 
about the degree of severity of different health states. Additionaly we investigated 
the hypothesis whether respondents' individual scale - group scale correlation 
depended on three background variables: age, education and a variable 
representing the respondents' experience with health problems or health care. We 
did not find any significant association (Kendall's tau b insignificant in all three 
cases). Although these results seem sufficient on aggregate level, they do not 
exclude the possibility of substantial individual variation. The observed standard 
deviations of the valuations were about 0.16 on the 0.0 - 1.0 seale (see Table 4). 
This might be due (1) to respondents with a low intra-respondent reliability, (2) to 
respondents with a different opinion compared to the group-scale or (3) to 
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variation in response behaviour. Excluding the scores of the 13 respondents with 
the lowest intra-respondent reliability, the scores of the 4 respondents with the 
greatest deviation of opinion and the scores of 4 respondents with variation in 
response behaviour, the mean standard deviation only decreased 0.03. We thus 
concluded that no group of deviators could indicated this way. 
Because of conflicting reports in literature, which sometimes showed characteristics 
of respondents influencing judgments1s.62 we tested in more detail the potential 
influence of background variables. The panel was dichotomized according to 
educational level, age and health care experience respectively. Subgroup scales were 
calculated and compared applying the coefficient of identity" - reflecting the degree 
to which two scales have the same mean, same dispersion and same distribution. 
No differences between subgroups could be demonstrated this way. 
5. General discussion 
Medical, psychological and economical science meet in the valuation of health 
states. The implementation of results in cost-utility analysis requires good technical 
qualities of the measurement instrument and unequivocal results. 
After a pilot study we arrived at a four-dimensional health concept, each dimension 
consisting of five ordered categories. In the pilot study we could not replicate the 
results reported in other studies when we applied the willingness to pay and the 
time trade-off valuation technique. This may be caused by the fact that our panel 
was selected from the general public. Also the fact we applied a computer assisted 
interview, which limits the possibility of technical support of the respondent, has 
contnOuted to our selection of two magnitude estimation techniques. The results of 
Study ll were satisfactory, showing reliable, consistent and homogeneous answers. 
With regard to the requirement of a cardinal measurement level a definite answer 
is lacking, as no formal criterion exists with respect to this aspect of validity. Based 
upon comparison of different valuation methods (e.g. in Torrance33) one may 
assume a 'true' cardinal utility function which is a monotonic transformation of the 
empirically determined value function. Not knovving the exact relationship between 
our value function and the 'true' cardinal utility function, sensitivity analysis should 
be carried out if the results are applied in CUA 26.41• 
Ultimately this study aimed at application of results in the medical technology 
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assessments of the heart and liver transplantation in the Netherlands. We derived 
health state descriptions (health scenarios) from survey-answers of patients who 
participated in the Dutch transplantation programmes. Tne earlier shown model 
was used to estimate health state utilities. Subsequently, sensitivity analysis was 
carried out as previous described. The difference between the mean of the estimat-
ed values of the health states before and after transplantation was 0.4D - 055. Thus 
also costs per QAL Y could be estimated1•63• 
6. Conclusion 
We conclude computer assisted interviewing is a rewarding technique in valuation 
research. Despite some technical limitations, it turned out to be a feasible, reliable 
and valid measurement instrument. Application of the results in cost-utility analysis 
seemed justified. In this setting line production (linear analogue scaling) turned out 
to be the valuation method of choice. Certainly the next future will show the 
combination of audio-visual devices with a personal computer as interview instru-
ment. This will enable the incorporation of other valuation techniques in the 
interview schedule which are indispensable for more information on the validity of 
the various valuation techniques. 
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Summary 
In the course of developing a standardised, non-disease-specific instrument for 
describing and valuing health states (based on the items in Table 1), the EuroQol 
Group (whose members are listed In the Appendix) conducted postal surveys in 
England, The Netherlands and Sweden which indicate a striking similarity in the 
relative valuations attached to 14 different health states (see Table 3). The data were 
collected using a visual analogue scale similar to a thermometer (see Table 2). The 
EuroQol Instrument Is Intended to complement other quality-of-life measures and 
to facilitate the collection of a common data set for reference purposes. Others 
interested in participating !n the extension of this work are invited to contact the 
EuroQol Group. 
EuroQol Group; Health status Index; Quality of life measures 
Background 
During the past decade there has been a burgeoning interest in the measurement 
of health-related quality of life, some of which has been motivated by a desire to 
widen the range of outcome measures used in clinical trials or other evaluative 
studies [12], some for auditing the performance of groups or individuals [1 0], and 
some for monitoring health levels in whole communities [4]. 
For these purposes a wide variety of methods has been used, depending on the 
interests of the measurers, their disciplinary background, the resources available 
"'The tenn 'EuroQor is the copyright of the EuroQol Group. 
"'"The 23 members of the EuroQol Group are listed i."I the Appendix. 
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to them, the context within which the measurements were to be made and used, 
and the level of accuracy required. For some, measurement simply meant accurate 
description. whilst for others it embraced also explicit valuation. 
This diversity is both understandable and justifiable, since it will never be 
possible in such a broad field for one single all-embracing insuument to capture 
in an economical manner everything that anybody might want in any conceivahle 
situation. 
But so crowded is this field of endeavour becoming that there are a great number 
of rival approaches aiming to do very similar things, with little or no attempt at 
systematic comparison of their respective strengths and weaknesses either at a 
conceptual or at an empirical leveL Moreover, such systematic comparison would 
be a formidable undertaking, for a mere half-dozen such instruments wpuld generate 
15 possible pairwise ccmparisons. 
One obvious solution to this problem would be to compare each instrument only 
with the • gold standard' amongst its class. But the trouble is that in this field there 
is no such gold standard. because initial decisions on structure and content made 
at the design stage were guided by the specific purpose of each insuument and 
compatibility with other instruments was not usually given any consideration. 
The EuroQol Group 
It was to create such a compatible common core of quality--of-life items that a 
small group of researchers from centres in five European countries, who shared a 
common interest in the valuation of health-related quality of life, met for the first 
time in May 1987 to draw together their respective expertise and experience. 
Aims 
The principal aim of what became known as the 'EuroQol Group' is to test 
the feasibility of jointly developing a standardised non-disease-specific instrwnent 
for describing and valuing health-related quality of life. It was intended that the 
instrument should complement other forms of quality of life measure, and should 
facilitate the collection of a common data set for reference purposes. Of particular 
importance to the group was the capacity to generate cross-national comparisons 
of health state valuations. It was envisaged that this in tum would facilitate the 
exchange of data on methods, and lead to standardisation in the collection and 
reporting of quality-of-life data. 
Membership ol the group 
The EuroQol Group has a multidisciplinary membership (drawn from the fields 
of economics, mathematics. medicine. nursing, philosophy, psychology and soci-
ology). and is made up of researchers who are actively engaged in practical ex-
perimentation. They share a common research interest in the evaluation of heaHh 
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care services and meet on a regular basis. The present membership of the group is 
listed in the Appendix to this paper. The existence of the group has become widely 
known through personal networks and we feel that it is now time to disseminate 
some of the early fruits of our collective endeavour more generally. Hence, this 
paper aims to record both the objectives of the EuroQol Group and to report on its 
prelim~ary findings after some 3 years of successful collaboration. 
Development strategy 
It was recognised from the stan that a common core data set would not of 
itself be a comprehensive measure of health-related quality of life. but it would 
need to cover (in a selective manner) most of the different domains or dimensions 
which are frequently featured in such work. There was evident tension from the 
beginning between the desire to cover all the things that other people included. and 
the recognition that the more comprehensive the common core became, the less 
likely it was that collaborating research groups would have the resources available 
to collect the data in addition to whatever else they were doing. 
We have also been motivated by another irnponant strategic consideration. 
Within the field of health-related quality of life measurement there are two (often 
opposed) schools of thought. Both agree that quality of life is a multidimensional 
phenomenon, but they disagree about the implications of this. For one school of 
thought. this multidimensionality is held to imply that the measurement of quality 
of life must necessarily be multidimensional, so that the best we can hope for is the 
creation of a quality of life profile, in which measurement is only possible within 
a dimension or domain. Adherents to this way of thinking hold that measurement 
between dimensions or domains is not possible [3.11]. The second school of thought 
notes that since people have to weigh up the very diverse attributes of health to 
determine which. on balance. seems best. it should be possible to elicit such overall 
valuations by some suitable investigatory method which generates a single index 
value for each health state [2,9]. 
The EuroQol Group is grounded firmly in the second school. A multidimensional 
profile can be very useful in specific circumstances, for example in clinical trials 
where detailed information may be required. However. there are situations in which 
a profile is less useful and a single index is required. This is especially so in 
evaluative studies. for example in assessing cost -effectiveness. The same is true a 
foniori when outcome measures are needed to help establish priorities across a wide 
range of health-care activities which bear on quality-of-life in very different ways. 
The final general consideration which influenced our development strategy was 
ease of data collection. Health-related quality of life data is sometimes collected 
by highly skilled research teams, who are able to spend a great deal of time with 
each subject. On other occasions data is acquired by less sophisticated means. 
for example by postal questionnaires where interviewer follow-up is not feasible. 
Thus any supplementary data required for comparative purposes as pan of our 
'common core· must be capable of being collected under those (least favourable) 
circumstances. 
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Extract from the EuroQo.l questionnaire 
- No problems in walking about: 
- No problell!S with self" c~ 
-Unable to pc~form main activitY 
(e.g. work. st,dy, housCWOr'k) 
- Able to p"rsuc family n.nd 
leisure activitio,o 
- ~odC'r'ate pain or discorofOr't 
- Not n.n.xioun or- deprensod 
- No problems in walking about 
- No problems with self-c~ 
- Able to pcr-f'orm main activity 
(eg. work, study, housework) 
- Able to purnuc family and 
leisure activities 
- No pain or di.o:coDfort 
- Not anxious or- dcp:resscd 
- No problems in walking about 
- No problems >dth self-en~ 
- Unable to pcri'orm wain activity 
(cg work. st,dy, housework) 
- Unable to pursue f"nwily nnd 
leir.ui'C actiVJ.ties 
- ~oder'ate pain or discomf"ort 
- Anxious or dept'Cssed 
- Unable to walk without n ::;tick. 
crutch or walking fr11111c 
- Unable to d~ss self" 
- Unable to perform tcain sctivity 
(Cg work, StUdy, hOUS<;'WOrk) 
- Unable to pursue family and 
leisure activities 
- Ext4'Cme pain 0~ d.iSCOtcfOt't 
- Anxious or depressed 
BEST IMAGINABLE 1-fE:!..LTH STATE 
- wo 
95 
90 
65 
eo 
75 
65 
60 
55 
so 
45 
40 
35 
30 
20 
WORST lMACIN,\BL£ HE:ALT~ STATE 
- No problems in wo.lking about 
- No proble= with self-c~ 
- Able to ))Ct'form main activity 
(e.g. work, study, housewot'k) 
- Able to puro.uo family and 
leisure activities 
- (')oderate pain or discomf'ort 
- Anxious or depressed 
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- Unnble to wo.lk abo"t •d. thout a 
stick, crutch or walldng f'rWlle 
-No proble= with sclf'-co.rc 
- Unable to perf'orm m.:Un activitY 
(cg work, study, houscwo!'k) 
- Unable to pursue family a.'"ld 
leisur-e activities 
- Extl'cme pain or discomfort 
- AnxiOUS Ot' dep...;:,s~ 
- Being Dead 
- Conf'ine<:l to OOd 
- Unable to f'ced self 
- Unable to pcr-forw mnin activity 
(eg work, study, housework) 
- Unable to pur:::ue family nnd 
leisure activities 
- £:-:trcmc pnin or discomfort 
- 1\nxiou::: or dep~,;sed 
What then were the properties which this new instrument needed to possess? lt 
was decided early on that the instrument should be capable of being used in large-
scale surveys of the community and that this necessarily meant that the instrument 
had to be designed as a self-completed questionnaire, probably for use in postal 
surveys. It needed to be sufficiently short so that it did not present a significant 
experimental burden on subjects and thereby jeopardise completion and/or return. 
(especially when it is being used as an additional item in an already demanding 
research design). Since the ability of subjects to make consistent valuations of 
health states was not known. some form of test-retest was included in the design 
of the questionnaire. The single most significant property which was designed into 
the instrument by the EuroQol Group was a capacity to yield a single index value 
for any given health state. 
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- No problems in walking about 
- No problems with scli'·c~ 
- Able perform main activity 
(e.g. work, study, housc,.ork) 
- Able to pursue family a.nd 
leisure activities 
- Moder-ute pain or discomfort 
- Not uro:ious or depressed 
- No problems in wo.lking about 
- No problems with self-cat"':> 
- Unable to perform main activity 
(cg. work, study. housework) 
- Unable to pursue fo.mily and 
leisure activities 
- Extreme pain or discomfort 
- Anxious or- dcprcascd 
- Scing Dead 
- Confined to Jx,d 
- Unable to dress self 
- U<'lablc to JX)rform main nctivit.V 
(eg work, study. housework) 
- Unable tP pursue f'011lily :md 
lciS\lr<:' activities 
- Extr'e<llC pain or discoofort 
- Anxious or dcpress<:-d 
BEST l.'tACIKA3l.£ HEALT'! STATE 
wo 
95 
90 
85 
80 
75 
65 
60 
55 
50 
45 
40 
35 
30 
20 
10 -
5 
0 t_ 
WORST Iii'>AOl:\AlJLE HEALTH STATE 
Appendix 7 
- No problc<!ls in walking about 
- Ko problems wit.h self'-curc 
- Unable to perform mJ.in act.ivity 
(e.g . ..,ork. study. hou~=ork) 
- Able to pursue f=ily und 
leisure o.ctivitics 
- Extreme pain or discorofort 
- f;ot nnxious o:- dcpr.;:sscd 
- t>o problems in wulkins: o.bout 
- ~lo proble"'s with self-cure 
- .;ble to perform main activity 
(cg work. study. housework) 
- Able to pursue fun:ily and 
le::.sure activities 
- No po.i.n o:- discomfort 
- Anxious or- dcpr-c~.:;~cd 
- No problems in wo.lking: about 
- No problems "'ith sclf-cor<: 
- Uno.blc co pcrfOt'<ll main J.ctn·~ty 
(og wor-k. study. hou::>cwork) 
- Uno.blc to pur-sue f=ily and 
le-isure o.ctlvitics 
Moder-o.t.c pain or discomfort 
- Anxious or deprossod 
- UnJ.blc -co "'nlk '-"lthouc c :JCick. 
crut.ch or "'o.lking frUl:lc 
- Unable to feed self 
- Unable co per-fo= :na~n o.ct.ivltY 
(C'.O: wor-k. study. housewor-k) 
- Uno.blc to pursue fo.:nily o.nd 
leisurC' <J.Ctivitics 
- Extreme pain or dl$COrnfort 
- Anxious or depr('sscd 
Fig. 1 Please Indicate how good or bad these health states are, by drawing a 
line from each box to a point on the scale. 
The EuroQol instrument 
During the development phase we have been using a descriptive system which 
embraces six distinct dimensions or domains, with two or three categories within 
each. These dimensions were selected following a detailed examination of the 
descriptive content of existing health status measures including the Quality of Well 
Being Scale [6], the Sickness Impact Profile[!], Nottingham Health Profile [5] and 
the Rosser Index [7]. Additional measures currently being used by members of the 
EuroQol Group were also included in this meta-analysis. The resultant descriptive 
system is set out in Table 1 and defines a theoretical universe of 216 health states. 
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Table 1 
EuroQol Oeseriptlve Ciasslflc.atlon 
Mobility 
1. No problems walking about 
2. Unable to walk about without a stick, crutch or walking frame 
3. Confined to bed 
Self-care 
1. No problems with self-care 
2. Unable to dress self 
3. Unable to feed self 
Main activity 
l. Able to perform main activity (e.g .• work. study, housework) 
2. Unable to perform main activity 
Social relaJUmships 
I. Able to pursue family and leisure activities 
2. Unable to pursue family and leisure activities 
Pain 
l. No pain or discomfort 
2. Moderate pain or discomfort 
3. Extreme pain or discomfort 
Mood 
1. Not anxious or depressed 
2. Anxious or depressed 
296 
In choosing this panicular set of descriptors we were anxious to cover as many as 
possible of the domains frequently covered by others. We also wanted to cover a 
wide range of degrees of severity within each domain, so that the common core 
would offer scope for application to many different populations, from fairly healthy 
people living in their own homes and going about their usual activities, to severely 
ill patients in hospitaL 
In the preamble to the valuation task, subjects were given the following guidance: 
"We are trying to find out what people think about health. We are going to describe 
a few health states that people can be in. We want you to indicate how good or bad 
each of these states would be for a person like you. There are no right or wrong 
answers. Here we are interested only in your personal views." 
Each subject was asked to rate 16 states, which were presented in two groups of 
eight across successive pages of the questionnaire (as shovvn in Fig. 1). 
The choice of 16 states from amongst the2161ogically possible ones was dictated 
by the following considerations: 
(a) We wanted some check on internal consistency, so we repeated two states from 
the first page on the second page. It will be noted that one of these was the state 
of 'being dead', so this left us with 14living states to selecL 
(b) We wanted to include states which we knew (from earlier work) were likely to 
occur fairly frequently in practice. 
(c) We wanted to include states representing a wide range of degrees of severity 
(which clashed to some extent wirb (b). since the more severe states are not amongst 
those that occur most frequently). 
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Methods and Results 
The detailed work carried out during the developmental phase will be reponed 
by individual researchers within the EuroQol Group in due course. It concerned 
variations in the instrument itself, alternative ways of eliciting valuations for the 
state dead. and comparisons with other valuation methods. However. one set of 
results emerging from this phase is of such intrinsic interest that it is worth 
disseminating immediately. 
As noted earlier, one of our objectives has been to generate data on a comparable 
basis in different countries. so that we can check whether people have similar health 
experiences and whether they hold similar values about what it is like to be in 
various health states. We have devoted a great deal of attention to this laner issue. 
All collaborating centres have piloted the EuroQol questionnaire and collected data 
on health state valuations using a visual analogue scale based on the thermometer 
shown in Fig. 1. This form of scaling has been used elsewhere to derive values 
for health states [8]. 
Three somewhat more extensive studies were conducted in the U.K. (York), in 
The Netherlands (Bergen op Zoom) and in Sweden (Lund). In August 1988, 1321 
questionnaires were mailed to a random sample of the adult patients of a GP group 
practice in Frome (U.K.). The return rate was 39% (n=522), of which 59% (n=310) 
provided- fully usable responses. The Bergen op Zoom survey was conducted in 
December 1988 among a random sample of 200 heads of household. Sampling was 
based on postal codes. The return rate was 57% (n=112). of whom 66% (n=74) had 
fully completed the questionnaire. The third study was conducted in Lund among 
1000 individuals selected at random from the general Swedish population. The 
Table 2 
Results of three pilot studies conducted with the EuroQol Instrument in Lund (Sweden, 
n=20S/1000), Frome (U.K., 11:310/1321) and Bergen op Zoom (The Netherlands, n=74/200) 
Note: The health Stale codes are descnDed in Table 1, and the dimensions (mobility; self-care; etc.) to which 
each digit refers are in the same order as stated there. 
Health state Median valuations Mean valuations Standard deviation 
Lund Frome BoZ Lund Frome BoZ Lund Frome BoZ 
111111 100 99 95 93 95 93 13 10 13 
111121 86 84 86 83 81 81 16 14 19 
111112 75 70 75 69 67 71 21 18 22 
111122 70 68 70 64 65 69 20 17 21 
112121 65 70 65 61 67 63 22 18 23 
112131 50 59 60 51 56 56 21 19 22 
112= (a) 35 40 43 36 41 43 20 17 21 
112222 (b) 39 40 40 38 40 41 19 16 21 
112232 35 35 33 36 36 37 20 17 23 
212232 22 25 20 26 26 26 20 16 20 
2=2 10 !0 7 !4 12 12 19 12 15 
232232 7 5 6 12 8 10 19 9 16 
3=2 4 2 5 9 5 10 18 7 18 
332232 1 1 4 8 4 7 19 6 12 
being dead (a) 0 0 3 lO 10 19 24 20 25 
being dead (b) 0 1 2 10 10 18 23 21 25 
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retwn rate amounted to 35% (n=349). of which 60% (n=208) were fully usable. 
In general. there seems little danger of selection bias as valuations vary little with 
background variables or response times. 
The results of the three studies are summarised in Table 2. lt can at once be 
seen that values for the majority of states are closely related, both in terms of 
their absolute values and in terms of their relative position within the samples. If 
the values are treated as ordinal data tben Spearman's rank correlation coefficient 
can be used to quantify the pairwise relationship between the ordering of states in 
each study. In each case Spearman's rho was close to 1.0. Kendall"s coefficient of 
concordance. W, for the rank ordering of states across all three studies was high 
and sigrtificant (W= 0.984, p < 0.001), indicating broad agreement regarding the 
ranking of states. 
If the data are treated as cardinal values, then a regression analysis can be 
conducted. Where dependent and independent variables correspond perfectly the 
gradient of the regression line would be 1. with a zero residual constanL Regression 
analysis of the mean values in the BoZ and Frome studies yields an X coefficient 
of 1.06. and a constant of -4.80. The corresponding values for Lund/Frame are 
1.04 and -2.04, and for BoZ/Lund are 1.01 and -2.37. The value for R' in all 
three cases is very close to 1. 
These procedures were repeated using the median valuation as measure of central 
tendency and yielded the same results. We therefore conclude that whether treated 
as ordinal or cardinal data. the results of the three studies were strikingly similar. 
Conclusions 
We have been greatly encouraged by the progress we have made so far in 
achieving our principal ahn of testing the feasibility of developing a new instrument 
for describing and valuing health-related quality of life, to serve as a linkage tool 
in a variety of different circumstances. We are also encouraged by the immediate 
spin-off benefits, such as the empirical data reported above. There is still some 
distance to go. however, and our system is not yet in its final form, since we 
are still experimenting with the form of the thermometer. with the descriptors. 
and with the treatment of 'being dead'. We have also not yet finally resolved the 
precise interpretation of our numbers in relation to other indices of health, derived 
by other means for other purposes. And although we already have our existing 
instrwnentation available in Dutch. English, Finnish, Norwegian and Swedish, we 
are conscious of the fact that these cou•·1tries do not constitute the whole of Europe 
and that our existing findings may not stand up if tested on populations with 
somewhat different cultural backgrou.1Jds (such as the Mediterranean countries). 
Each of us has financed our own research input. and we have shared our empirical 
data freely with each other, and we propose to continue on this same collaborative 
basis. We would be pleased to hear from :interested researchers in this field who 
would be willing to help us to extend this work in a practical way, and especially 
by offering 'test-bed' facilities whereby data. such as that reported here. could be 
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generated from other populations. Such contacts may be channelled through any 
of the members of the EuroQol Group, but preferably through one of the liaison 
officers, who are marked thus a in the list of members in the Appendix. 
Appendix 
Membership of the EuroQol Group 
Health Economics Research Group 
Brunei University 
Uxbridge, Middlesex 
England 
Ma...-tin Buxton* 
Moira O'Hanlon 
Julia Rushby 
Academy of Finland 
Markku Pekurinen• 
National Public Health Institute 
Elimaenkatu 25 A 
SF-00510 Helsinki 
Harri Sintonen 
University of Helsinki 
Mannerheirnintie 172 
SF-00300 Helsinki 
Swedish Institute for Health Econom-
ics 
PO Box 1207 
S-22105 Lund, Sweden 
Stefan Bjork* 
B join Lindgren 
UlfPersson 
Richard Brooks 
National Institute of Public Health, 
Geitmyrsveien 75, 
0462 Oslo 4, Norway 
Erik Nord* 
Department of Academic Psychiatry. 
Middlesex Hospital 
Mortimer Street. 
London, WIN 8AA, England 
Richard Allison 
Carole Butler 
Rosalind Rabin* 
Rachel Rosser 
Caroline Selai 
Erasmus University Rotterdam 
P.O.Box 1738 
3000 DR Rotterdam, 
The Netherlands 
Gouke Bensel* 
Marie-Louise Essink-Bot 
Ben van Hout 
Institute for Medical Tecirnology 
Assessment 
Deparunent of Public Health and 
Social Medicine 
Frank de Charro 
Department of Economics 
Faculty of Law 
Centre for Health Economics, 
University of York, 
York, YOl SDD, England 
Claire Gudex 
Paul Kind* 
Alan Williams 
*EuroQolliaison officers for each research group. 
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VALUATION OF HEALTH STATES BY THE GENERAL 
PUBLIC: FEASIBILITY OF A STANDARDIZED 
MEASUREMENT PROCEDURE 
MAR!E·LoUISE EssL'lK·BoT, 1 GoUKE J. BoNSEI}~ and PAUL}. VANDER MAA.$1 
1 Department of Public Health and Social Medicine and ~Institute for Medical Technology Assessment, 
Erasmus University Rotterdam, P.O. Box 1738, 3000 DR Rotterdam., The Netherlands 
Absml.ct-In the context of an international collaborative study we tested the feasibility of a utility 
measurement procedure in the Dutch general population. A postal questionnaire was sent to a random 
sample of 200 households in a town in the Netherlands (±50,000 inh.). ResPQndents were requested to 
v:Llue \4 six-dimensional health states by means of visual analogue scaling (II AS). The response was 
satisfactory (57%}, though about a fifth of those willing to complete the questionnaire did not manage 
to use a VAS to express their opinion. Inconsistent answers occurred relatively seldom. Generally 
consensus existed with regard to relative (ranking) and absolute values of different health states. 
Th= first results encourage us to go on with the development of this international instrument for the 
valuation of health states.. We conclude the present instrument to be a feasible tool for valuation research, 
although questions relating to its measuring properties. as well as its reliability and validity remain to be 
answered. 
Key words-utility measurement. valuation of health states. quality of life 
INTROOUcnON 
Cost-effectiveness ::malysis and cost-utility analysis 
:tre currently recognized as sources of information for 
decisions about the incorporation of new medical 
technologies in health insurance schemes [1, 2], e.g. 
governmental decisions about the reimbUI'SCDlcnt of 
hean tr:lnsplanution in the United States, the United 
Kingdom and the Netherlands were made utilizing 
the results of national studies on the costs and effects 
of this intervention [3-5). 
Despite a still growing interest in the measurement 
of costs and effects in health c::rre and the appearance 
of standard textbooks, currently published studies 
still display large disparities regarding conceptual 
background and operational design. especially for 
measurement of effectivity [1. 6]. In cost-utility analy-
sis, the measure of effectiveness consists of a factor 
representing length of survival and an index regard-
ing health related quality of life. A way to find values 
for this index is by means of measuring health state 
preferences [6]. 
With regard to the measurement of utilities, at least 
two aspects contribute to observed variations in 
theory and practice. First. cost-utility analysis is an 
analytical tool derived from economic science. This 
leads to the implicit assumption of health being a 
commodity like other goods. to be acquired on a 
market [l. 7]. In fact. health does not fit perfectly into 
the definition of a commodity. Until now, health as 
a commodity is only operationally defined, using, e.g. 
the concept of quality adjusted life years (QAL Y's) or 
the more refined healthy-years equivalents [8]. 
In addition, the operational designs of various 
emptrical techniques to determine the quality adjust-
ment index show many differences. 
One rnight argue that these disparities are a charac-
teristic of an immature branch of science; the lack of 
a paradigm would be only temporary [9]. Even if this 
is true. there are several undesirable consequences of 
this situation. 
The lack of standards hampers scientific judge-
ment, especially of aspects of validity (1]. Incompara-
bility of results also prevents governments, health 
insurance companies and others from setting priori-
ties among different technologies. based on infor-
mation from cost-effectiveness analysis or cost-utility 
analysis. Finally, the application of different methods 
lirnits the possibility to benefit from studies already 
conducted in other countries. 
Following an initiative of Professor Alan Wt!liams 
(York) in 1987, several Eu:ropean research groups 
joined their research efforts aiming at two goals: first. 
development of a common con: of methods and 
practical devices to measure health state preferences. 
and second, establishment of a common set of data 
collected with these instruments in different European 
countries. Details on the aims and the development 
of this research group are to be published elsewhere. 
Based on the shared experience and on intermediate 
results of pilot-studies, consensus was reached about 
a prototype of a common utility measurement instru· 
ment in 1988. An international pilot-study with this 
measuring instrument was conducted since. 
This article describes the first results of the Dutch 
part of the international pilot-study, addressing the 
following questions: 
1. Do the results of this pilot-study indicate possi-
bilities to develop the present instrument into a 
feasible instrument for large scale surveys? This 
question should be focused on the follov.'ing 
aspects: 
-the feasibility of the valuation of complex 
multi-dimensional health state descriptions. 
The method that is used here consists of six 
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dimensions. This is opposite to, e.g. the ap--
proach of Rosser and Kind who use health 
state descriptors composed of two dimensions. 
i.e. disability and distress [10]. The Rosser and 
Kind approach simplifies the task of valuating 
health states. but may oversimplify the con-
cept of health: 
-the feasibility of the valuation of health states 
by the general public. as opposed to the 
usually well-educated subjects in the literature 
[10, 11]: 
-the feasibility of the valuation of health 
states by means of a postal questionnaire, 
as opposed to the common interviewer-
supported designs [12]. 
2. What is the actual value of health states. r.l.Ilg:ing 
from the health state of, e.g. heart tra.nspla.n-
t:ltion candidates to that of the healthy popu-
lation? 
3. Do the results of this pilot-study indicate the 
existence of consensus about the rating of health 
states among respondents to a degree justifying 
future research to be directed at application of 
the results in cost-utility :ma.lysis? 
Questions concerning the influence of background 
variables (including nationality) on the valuation of 
health states, validity of the measurement procedure 
and use of the results in cost-utility analysis will be 
addressed more extensively in later papers, combining 
the results of several national studies. 
METHODS 
Design of a utilitv measurement procedure 
Utility measurement consists of four consecutive 
steps: 
I. health status measurement of the target 
population. usually patients subject to some 
intervention; 
2. translation of resulting health state data into 
verbal descriptions of the health states in the 
target population, sometimes called 'scenario's' 
[II. 13]: 
3. valuation of these 'scenario's' by a panel consist-
ing of representatives of the general public. 
experts or patients [11, 13]: 
4. implementation of the results into a cost-utility 
analysis. preferably combining effects on 
survival with that on health status (a procedure 
yielding. e.g. QALY's) [II]. 
The concept of health used 
Defining health status, a multi-dimensional ap-
proach was adopted in order to take the complexity 
of the concept of health into account. A concept of 
health status, defined by six dimensions {apart from 
survival state), to be used in step 1-3 was agreed on. 
, CMCo~bi:::l~~:~b~~o.;1~c· ~~,~i~~o~oo~o~M~ofc<~h0o !'O>I:::!l<h""o'~"~oo>"'-' __ 
Daily activities and self care (3 lc:v~ls) 
Work p:rforma= (2 levels) 
Family and ldsure performance (2 level5) 
Pain/dis<:omfon (3 lc:vds} 
Present mood (2 lc:vds) 
Table Z. Exampl~ of a complete o;ccnario 
State 112232: 
No problems in walkillg about 
No problems with 5df-can: 
Un.D.ble to pcrfonn main activity 
Un.D.blc to pursue fanu1y/leisure activitie. 
Extr=ne pain or di:scomfort 
Anxious or depressed 
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The choice of dimensions was suggested b)' 
existing health questionnaires such as, e.g. the 
Nottingham Health Profile and the Sickness 
Impact Profile. and by the health concepts used b)' 
Patrick and Bush and by Rosser and Kind 
respectively [11.12, 14.15]. Within each dimension 
the State of a patient should be described by one out 
of a set of dimension-specific descriptions. Three 
dimensions were subdivided into three categories. the 
other three into two categories (see Table 1). Thus a 
complete health state descriptor or 'scenario' consist:> 
of six dimension-specific statements ('items'). 
Theoretically this set of dimensions and items allows 
for 216 (2) x 3") permutations. Each possible 
scenario can be characterized by a string of the values 
of the item-levels on each dimension. 'I' representing 
the optimal level, '2' respectively '3' representing the 
worst leveL One example of a scenario is shov.n in 
Table 2. 
The questionnaire 
A questionnaire was developed for the valuation of 
scenalio's (step 3 of the aforementioned procedure) 
by members of the general public. 
For our study 13 scenarios were selected both on 
empirical grounds (counting health state frequenci~ 
in patient data from other studies) and on theoretical 
grounds [16, 17]. The state of'being dead· was added 
[18]. Two states were presented twice, resulting in 16 
health states in the questionnaire. The scenarios were 
presented on two pages of the questionnaire. A 
rectangular box was drawn around each scenario and 
four boxes were placed on either side of a vertically 
placed visual analogue scale 01 AS) in a r.l.Ildom 
sequence, as illustrated by Fig. 1. The endpoints of 
the scale were marked with the words 'worst imagin-
able health state' {0) and 'best imaginable health 
state' (100). No additional information about the 
interpretation of the scale was added. The duration of 
each state was supposed to be 1 year: what happens 
afterwards was stated not to be known. To avoid 
misinterpretation a detailed instruction paragr.:tph 
was added. including illustration of the method of 
valuation by a non-health-problem-related example. 
Also the lay-out of the questionnaire was carefully 
designed. 
The main task of valuating the health states was 
preceded by the task of classifying and valuating 
one's own health state at the time being. Questions 
about characteristics that might influence the rating 
of health states (a.o. age, educational level, experience 
with illness. own health state) were presented at the 
end of the questionnaire. 
The sample 
The questionnaire was mailed to a random sample 
(n = 200) of the general population in December 
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He,.lth state Health ntate 
l!o.,lth st"'to Uoalth state 
Ho;o.lth state Health s~te 
Health state Health sbto 
Fig. 1. 
1988, followed by a reminder 2 weeks later. Sampling 
was based on postal codes. 
RESULTS 
Response was obuined from 112 persons. The 
response rate (excluding 4 dead persons) was 57%, 
assuming all addresses were provided correctly. which 
is obviously optimistic. Background data of the 
respondents are sho"MI in Table 3. Comparison with 
data from the sampled population shows some differ-
ences in age and sex distribution. The relative over-
representation of men among the respondents may be 
due to the method of sampling, as the questionnaire 
was directed to the administrative bead of each 
household. 
Five respondents returned their questionnaire 
blank. Twenty-one (20%) of the remaining 107 
clearly had not understood the task, i.e. the use of 
VAS to express their opinion. This response was 
chiefly found among the older and less educated 
respondents [chi-square: age (2 strata) P = 0.003, 
eduC:J.tion P = 0.001]. These respondents were left 
out of further analysis. Five of the remaining 86 
completed only one of the two pages on which the 
valuation task was presented. overtly because they 
thought the second one to be a double from the first. 
Data from these five were included. 
To assess aspectS of the feasibility of the 
questionnaire, respondents were questioned about 
the difficulties they experienced answering it. 
Forty-three percent of the respondents judged 
the questionnaire as being very (6%) or rather 
(37%) difficult, while 57% reported it to be fairly 
(45%) or very (12%) easy. The mean time required 
to complete the questionnaire was 20.3 min (SD 
12.4 min, n = 86). 
Respondents rated their own health status on the 
VAS (range: 0-100) with a mode of 85, a median 
of 85 [interquartile range (IQ) 8) and a mean of 
81 (SD 18). Indeed, those who classified themselves 
on all predefined dimensions as being in the best 
category (111111) (n =52), attributed a significantly 
(P < 0.01) higher value to their own state of health 
(mean 89, SD 7) than those who reponed a subopti-
mal level on any dimension (n = 40: mean 70. SD 22.L 
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Table 3. Background data oi =pondents (n = 86). cxe!uding 
inapproprnne• rcspon;e: >Orne background data of the sampled 
popu!auon {age ~IS) 
Sampled 
Approprm.te population 
Vanable =oo= (%) 
""' 15-29 16(19%) 
30 
30-4' 3:!(37%) 
" 45-$9 11 (13%) 
" 
'"-" 
= (26%) 
" 
";::7$ $(6%) 7 
"'' Male $4(63%) 
" Education: 
Minimum schooling 37(43%) 55 
Intermediate 3.4(4{1%) 
" Higher/degree level 15(17%) 
" M"oS:lins 0(0%) 
Main Activity: 
Employ<:d 46($4%) 
Reured 19(:::!%) 
Housework 15 (17%) 
Student 1(1%) 
ln.;:apacnated 4(5%) 
Sc:<:kmg work 1(1%) 
Mi,.,.ing 0(0%) 
Rating oi own heallh: 
<SO 18(21%) 
80-90 29 (34%) 
>90 32(37%) 
Mi"inr; 7(8%) 
"For definition = text. 
The results of the valuation of the 16 elected health 
states are summ::uized in Table 4. The ordering of the 
states is according to the medians.. as at least ordinal 
measuring level may be assumed. Ordering accorcling 
to the arithmetical means does not result in any 
change in ranking. however. 
The clispersion of the attributed values is rather 
large, especially for 'bad' health states. 'Being dead' 
yields a heterogeneous response. the range of at-
tributed values ranging from 0 to 100. Seven of 80 
respondents (9%) valuated 'being dead' equal to or 
higher than 50. Two health states were presented 
twice (112222 and 'being dead'). Scores were com-
pared for both pairs. Individual correlation was high 
Table 4. Valuauons for 14 health states 
Health "ate" Mode M<d. LQ.t M= so 
111111 .00 95 5 
" " 
86 
1 I 11~1 so 
"' " "' " " 111!12 85 78 
" 
73 
" 
., 
111122 ;o 70 
" 
69 
" 
86 
112121 
"' 
65 
" 
., 
" " 112131 65 80 
" 
55 
" 
S3 
ll2:::!2{a)t 30 ,, 
" " " 
86 
112212{b) 
"' "' " " " 
S2 
112232~ 
" " " 
37 
" 
8> 
211232 20 20 8 
" 
20 86 
Being de;Jd {a): 0 5 
" " " 
80 
Being de~d (b) 0 20 19
" 
n 
~2 
' 
6 
" " 
8S 
232232 0
" " " 322232 0 
'" " " 33123.:: 0 7 
" 
8S
•For c!aniic.Hion of repr=ntalion of health state. by win~ of 
numbers >eo: Methods and Table 1 o.nd .::. 
tMed. ,., median 'core. I.Q. = interquartile range. 
:Thc:;e two Mat~ "1121::2" and "b<:>ngd.ad") were presented twio:: in 
the questionnarie. 
9The string "11223Z" rep,-.,nts the scenario pmented in Table .::. 
Table 5. Consis~ ao;:ordin& to item-rank 
differences 1:>etw=1 pairs of I=Jtb stat=; 
Distance 
' 
' 6 
ToW 
" 
" B 
" 
Inconsistent 
(%) 
16.3 
5.9 
1$ 
LS 
L7 
L7 
,, 
r..:: 
>2 
5.0 
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(Spearman's rank correlation coefficient 0.76 and 
0.95 respectlvely; Pearsons's correlation coefficient 
0.69 and 0.94 respectively). though small. insignifi-
cant (P > 0.05 for both pairs) differences of the 
means were found (see Table 4). The influence of 
background vari::tbles (e.g. age. sex. level of edu· 
cation) on the resulting valuations appeared to be 
insignificant. 
Next we tested the logical consistency of valu-
ations.. both on a group level ::md on an inclivldual 
level. Consistency of valuations may be checked by 
comparison of values attached to pairs of scenario's 
which can be logic::illy ordered according to their 
description. For instance 112222 might be expected to 
show a higher score than 212232. When a dimension 
description varies in two clirections.. e.g. I 12131 and 
1122"'..2. with in this case the first scenario on two 
dimensions better and one dimension worse. no 
logical rank order can be established. 'Being dead' 
was excluded from this analysis. The mcclian answers 
(group level) do not exhibit any inconsistency (see 
Table 4). However, on an inclividuallevcl inconsisten-
cies occurred. The 14 health states account for 82 
pairs of logically ranked scenario's. Overall, only 5% 
of the answers proved to be inconsistent on the indi-
vidual level. TIJogical ranking oceurrcd more often as 
pairs of health states were more alike (see Table 5). 
The next item to be addressed is consensus between 
respondents. This was first tested by comparing indi-
vidual ranlcings with the group ranking. as the meas· 
uring level is assumed to be at least orclinal. As 
carclinal measuring properties arc conceivable, a 
comparison of individual values with the group means 
was also carried out. The results are shown in Fig. 2. 
DISCliSSION 
The feasibility of a measurement instrument to 
elicit valuations for various complex health states 
from the genernl public was investigated. The device 
of this instrument was based on previous experience 
and supporting pilot studies by a collaborative group 
of European researchers [19-21]. Essentially it con-
sists of valuation by VAS of six-dimensional health 
state descriptions in an unsupported situation (postal 
questionnaire). Some of the arguments favouring its 
feasibility are: 
-the relatively high response. taking into account 
the demanding character of the questionnaire: 
-the acceptable level of experienced difficulty: 
-the interpretability of the results. 
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'oor--------------------,---------------------, 
I : 
0 
~ 40 
• ~ 20 
Spearman rark. 
corr. coeff. 
Fig. 2. Correlation of individual scales with group scale (n = 74). 
Thus mting of health states on a VAS by postal 
questionnaire appears to be feasible. However. inap-
propriate response of those returning the question-
naire did occur (20%). and was related to age and 
level of education.. This is probably of little import-
ance. as further analysis of our data did not reveal 
significant influence of the level of any of the socio-
demographic variables. Improvement of the instruc-
tion paragraph probably will enhance completion 
rates. A thorough non-response study will be under-
taken to answer the question directly whether persons 
who would generally not respond differ from respon-
dents in their valuation of health states. 
Judging from the response--quality and the logical 
consistency. the v:iluation task was generally well 
understood. Also the fact that respondents who 
classified their own health logically hlgher also rated 
it significantly higher. may lead to the conclusion that 
the laymen interpreted the judgement task correctly. 
The dispersion of the attributed values is fairly large. 
However. psychophysical methods typically yield 
highly variable observations [12). 
The consensus found among respondents with 
respect to the ranking of the scenario's is of import-
ance [22]. It is a support for the validity of the 
questionnaire. as well as for earlier evidence of hom-
ogeneity of society with regard to health state prefer-
ences [1 0. 22]. However. the possibililty of biases 
introduced by the response rate should be kept in 
mind. A comparison of results of this survey with 
preliminary results in other European countries 
shows virtually the same ranking order of health 
states (data to be published). 
Though these provisional results seem to warrant 
extended use of the measurement instrument. there 
remain additional questions to be answered. In the 
first place the reliability and the validity of the 
questionnaire should be determined. For the validity 
this concerns the content validity (are we measuring 
health state valuations?) as well as external validity 
(can we generalize results to subgroups of the popu-
lation. e.g. patients. health care workers etc?). 
Secondly the measurement level of the produced 
values should be established. Are respondents merely 
ranking the states., or are the numbers on the scale 
interpreted quantitatively? Research on measuring 
properties of a VAS in this context implies compari-
son with other valuation methods [time trade off 
(TTO). standard gamble (SG)]. from which also 
conclusions about the validity of the measurement 
procedure (are we measuring health state prefer-
ences?) might be drawn. Methods like TTO and SG 
can not be operationalized on a postal questionnaire 
base. so a more structured interview format will be 
necessary. Also. results of the VAS with and without 
a structured interview setting should be compared. 
For application of the health state valuations in 
cost-utility analysis. at least interval measuring level 
is necessary [6, 23]. If the health states appear to be 
only ranked by the respondents. a scaling procedure 
could be performed in order to achieve cardinal 
values. Even if the measurement level is interval, the 
vah,1es res\llting from the measurement procedure 
should probably not be used directly as a quality 
index in the computation of QAL Y's. The relation 
between the elicited valuations to health state 
preferences as measured by time trade off or 
standard gamble may be. e.g. logarithmic or linear 
[6. 24, 25]. Probably a transformation procedure 
should be employed before use of the results in 
cost-utility analysis [26). More generally. the way to 
apply the results in QALY -calculations should be 
determined. 
Problems remain with the valuation of 'being 
dead'. Controversy exists whether it should be incor-
porated in a system of health states. For application 
in computations of quality-adjusted life-years 
(QAL Y's) it is not necessary to elicit values for 'being 
dead', as 'being dead' in this context means ·o life 
years·. Also presentation of 'being dead' as a health 
state encounters opposition of respondents. This 
might be the result of assignment of two conflicting 
meanings to 'being dead'. viz. 'lack of life years' and 
·something very bad'. In the last intepretation, 'being 
dead' serves as a point of reference on the scale. This 
double-interpretation might be the cause of cognitive 
problems in the comparison of 'being dead' with 
health states. 
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Another remaining question regards response pat-
terns. We observed. e.g. 'dlchotomous' response pat-
terns: :ill states were valuated '100' except the very 
worst, or all states were rated ·o· except some (nearly) 
optimal ones. Such response patterns may in fact 
reflect a cognitive difficulty to distinguish more 
'shades' than 'healthy' and 'unhealthy'. Another 
possibility is that they reflect extremes of unknown 
individual distribution rules. We think this is the 
same phenomenon as Llewellyn-Thomas found in her 
analysis of standard gamble validlty [13]. McNeil also 
describes this response pattern, as well as a formal 
way to apply such results as utility weights [27]. 
Routine implementation of an improved version of 
the present measurement instrument o.Iso requires 
systematiC:J.l research on methods to describe health 
states of patients (steps 1 and 2). Utility instruments 
described earlier do not provide unequivocal algor-
ithms to C:J.tegorize patients [10. 11]. 
Though many questions are yet to be answered. the 
first results with this instrument are encouraging 
enough to continue the search for a universally 
appliC:J.ble utility measurement instrument for health 
states. 
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Abstract 
The need for liver transplantation (liver transplantation) in the Netherlands was 
determined as part of a medical technology assessment. W c aimed at estimation of 
the need for liver transplantation following medical standards. Due to the absence 
of longitudinal studies of end-stage and congenital liver diseases three indirect 
methods were used. 
The practice-based method extrapolates current transplantation activities, account-
ing for incomplete referral, relaxation of contraindications, inclusion of acute 
hepatic failure and retransplantations. The monality-based method starts from 
national age and sex-specific mortality data on the relevant liver diseases. Adjusting 
factors were estimated to express the quantitative association between death due to 
a specific liver disease and suitability for liver transplantation. This method enables 
to estimate the impact of inclusion of older patients. 
The incidence-based method applies available epidemiological data on living 
patients Vli.th specific liver diseases. 
The three methods yielded corresponding results suggesting an annual need of at 
least 25 liver transplantations. Without change of upper age limit (60 year) and 
inclusion criteria (no alcoholic cirrhosis) this number may rise to a maximum of 
about 70 transplantations in the near future. The actual number of transplantations 
and the uneven distn"bution of referred patients suggests the existence of unmet 
need. 
International application of Dutch ·results, i.e. a normative need for liver trans-
plantation of 2 to 5 per 106 inhabitants, is only justified in countries with com-
parable epidemiological structure and similar selection criteria. 
1 Introduction 
Liver transplantation, though never assessed for efficacy in a controlled trial, is 
performed in a continuously growing number of centres all over the world1• As the 
costs of the procedure are impressive, ranging from $180.000 to $ 460.000, health 
insurance companies have been reluctant to incorporate liver transplantation into 
their insurance schemes23.4. In the Netherlands orthotopic liver transplantations 
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have been performed since 1979 in the Academisch Ziekenhuis of Groningen 
(AZG). The Dutch government and the Dutch health insurance companies agreed 
in subsidizing this liver transplantation-programme, excluding the procedure from 
regular reimbursement. From 1985 to 1988 a comprehensive medical technology 
assessment of liver transplantation was carried out to assess the costs and effects of 
the procedure and to determine the future need for liver transplantation5• The re-
sults would be used for health policy decisions on the national level. 
This article presents three empirically based procedures to estimate the need 
for liver transplantation to answer the following questions: 
does the present situation show any unmct need for liver transplantation in 
the Netherlands ? 
what is the future need for liver transplantation in the Netherlands ? 
is generali7..ation of our estimations of need to other countries justified ? 
2 Definitions, methods and data 
21 Patient definition 
Criteria for patient selection are described in the protocol of the liver transplanta-
tion-programme and elsewhere1A 7• Patients should suffer from some irreversible 
non-alcoholic liver disease without complications or accompanying diseases, which 
might affect transplantation results. 
Most contraindications are relative i.e. their potential influence is balanced 
against other favourable and unfavourable circumstances. Further improvement of 
the results may decrease the weight of contraindications, leading to an increasing 
proportion of suitable candidates among patients with irreversible liver disease. 
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22 Definition of need 
Tnree types of need" may be distinguisbed89'10: 
normative or medical need 
felt need 
latent need 
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Normative need is defined as the need for health services according to standards of 
professional care, if existent. It is related to the expected benefits of a particular 
health service. Felt need is defined as the need experienced by the population. 
Media and other sources of professional and non-professional information may 
exert great influence on felt need. If need is not accommodated sufficiently by 
supply of medical services, latent need exists. Need may be latent as defined by 
medical standards, from the viev.rpoint of a patient, or both. In our case we were 
primary interested in normative need. 
A maximally valid estimation of the frequencies of particular disease-stages 
and their change over time on the national level, would imply a nation-wide 
longitudinal epidemiological programme. However, given limited resources other, 
indirect methods must be applied10J 1•12• 
Evans estimated the 'true" need for heart transplantation in the United States with 
population-based epidemiological data and with utili7.ation-based data ('true' need 
was defined nearly identical to normative needY0• The use of utiii7.ation-based data 
assumes a firm relation between need and supply. This method overestimates 'true' 
need if unjustified supply is substantial but underestimates 'true need' if latent need 
from a medical point of view is present. 
Except for acute hepatic failure, we tried to estimate normative need of liver 
transplantation irrespective of availability of resources (number of centres, available 
donors and the degree of reimbursement). Both population-based epidemiological 
data and utilization-based data were used, supplemented by various data from the 
AZG. 
We do not take economically defined need into account. 
Appendix 9 314 
23 Methods for empirical estimation of normative need 
Three methods were used to determine the normative need: a practice-based, a 
mortality-based and an incidence-based method. 
The first method takes the lG-year transplantation experience of the AZG 
(1978-1987) as point of departure. We regarded the annual volume of liver trans-
plantations in the AZG to be a valid proxy for the normative need in the Nether-
lands provided that: 
patient selection has been unchanged in the AZG-programme 
the AZG·programme has not been limited by exterual constraints (financial 
resources, donors, incomplete referral, etc.) 
the transplantation-programme has been in a steady state 
None of these conditions were perfectly satisfied. As a considerable average lag-
time was observed between candidacy and transplantation, we used the annual 
number of definitively accepted patients as the basic proxy of future transplantation 
volume, which was subsequently refmed for known sources of distortion. 
The second method started from national mortality statistics and should be 
regarded as a population-based method. We assumed that in the absence of a liver 
transplantation programme, transplantation candidates may be found among those 
who died due to specific chronic liver diseases. We regarded the use of mortality 
data to be justified if: 
the medical condition for which the procedure is indicated can be properly 
classified according to the current International Classification of Deaths (I CD 
9u. revision) 
the interval between supposed application of the medical procedure and death 
due to the specific disease is reasonably small 
data are derived from a period, in which no effect of the application of the 
medical procedure may be expected 
Though in the case of liver transplantation these three conditions seemed sufficient-
ly be satisfied. sensitivity-analysis was carried out to estimate the effects of age 
limits, contraindications and incomplete referral. Transplantations for quality of life 
improvement or replacement of a non-functioning graft were accounted for sepa-
rately. 
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The third method applies population-based epidemiological data on living 
patients with end-stage liver disease. This method needs additional information on 
the stage or severity of the particular disease. E.g. data on the incidence of histo-
logically proven primary biliary cirrhosis may only be useful if data on the distnou-
tion of age, clinical stage (Child-Pugh classification), comorbidity, and clinical 
course are also available. 
If information on the epidemiology of non-alcoholic liver diseases in the 
Netherlands was lacking, we projected epidemiological data from other countries 
on the Dutch population, provided that epidemiological comparability could be 
expected. Within Western Europe only comparability with the United Kingdom 
seemed sufficient for this purpose13J 4JS. However~ most data available originated 
from a comprehensive study of Vierling, who used data from American sources16• 
Eventually we compared the resulting projections with Dutch hospital admission 
data of 1982, provided by the Dutch registry of hospital activities (Stichting 
Informatiecentrum voor de Gezondheidszorg, SIG). No information about the re-
admission rate was available. With some diseases we compared the results of the 
incidence-based method with national mortality statistics. 
3 Results 
All results are presented as nonnative need for liver transplantation for the Nether-
lands. and as normative need per 106 inhabitants. The minimum level of an 
adjustment factor reflects the current state of affairs, the maximum level shows the 
largest expected change. 
3.1 Practice-based method 
Figure 1 shows the annual inflow and throughflow of patients in the liver transplan-
tation-programme. During 1978 to 1987 a total number of 145 patients was 
definitively accepted for liver transplantation. At the end of 1987 about half of 
these had been transplanted. Recently the annual number of definitively accepted 
patients has levelled off at about 20. which was taken as the basic number for 
further computations. 
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Figure 1 Annual number of patients in subsequent diagnostic stages. 1978-1987. 
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Below the correction factors are discussed, which were used to adjust this basic 
number for changing selection and suboptimal referral. 
Relaxation of contraindications 
Examination of the medical records of non accepted patients revealed 40 patients 
who might have been accepted when accepting policy would have been more 
liberal. In 34 cases liver dysfunction was considered too advanced to justify the risks 
which accompany the operation. An additional 6 HB.Ag-positive cirrhosis patients 
were rejected in accordance with the liver transplantation protocoL Tif all these pa-
tients are included a multiplication factor results of 13 ( = 185/145). 
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Figure 2 Regional distribution of def"mitively accepted patients for liver trans-
plantation. 197lH987 
Total number per 1~6 inhabiea.nts: 1978 • 19S7 
- 0.0 • 7.5 - 15.0 • 22.5 
- 7.5. 15.0 - > 22.5 
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Referral patterns 
Next we investigated referral patterns in the Netherlands by comparing the 
standardized number of definitively accepted patients in each province ('county'). 
The distribution of definitively accepted patients appeared to be rather uneven. 
Taking the four northern counties together, more definitively accepted patients 
originated from thls part of the country as compaired to the remaining counties 
(see Figure 2 on previous page). If all provinces would show the same level of 
referral as the northern provinces, a total of 'X74 definitively accepted patients 
should be expected. Thus a factor with a maximum level of 1.9 ( =274/145) should 
be applied to account for a complete change of the referral level of the western 
and southern provinces towards the level of the north. This estimation assumes no 
unjustified supply and no latent need in the north and no significant regional 
differences in the epidemiology of non-alcoholic liver diseases. 
J4~rional~agnoses 
We added an annual number of 2 to 10 patients with acute hepatic failure, based 
on the experience of all major centres in the Netherlands. The experience of the 
Rotterdam liver centre, which accepts this type of patients from all over the 
country for auxiliary partial liver transplantation, suggests that only in small number 
of cases of acute hepatic frulure transplantation can be performed 17•1s.19• 
Retransplantations 
The actual retransplantation rate is about 11%. Different centres have rapported 
retransplantation rates ranging from 10 to 25 %'SJ. An upper limit of 15% was 
chosen, based on European experience21• 
Final result 
Table 1 shows the final results of the practice-based method suggesting a normative 
need between 1.7 and 4.9 per 106 inhabitants. Chronic cirrhosis constitutes about 
two thirds of this number. Clearly effects of changes of the current age limit can 
not be shown with this method. 
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Table 1 Practice-based estimation of normative need for liver transplantation in 
the Netherlands. 
Definitively accepted patients (annual, AZG) 
Adjustment Factors 
- Relaxation contraindications 
- Even referral-patterns 
- Additional indications 
- Retransplantations 
Total per year in the Netherlands 
Normative need per year per 106 inhabitants 
3.2 Mortality-based method 
Minimum Maximum 
X 
X 
+ 
X 
20 
1.0 X 
1.0 X 
20 
2 + 
22 
1.10 X 
24 
1.7 
20 
13 
1.9 
49 
10 
59 
1.15 
68 
4.9 
National mortality data were made available by the Central Bureau of Statistics 
(CBS). Registration of causes of death in the Netherlands offers complete coverage 
of the country and is based on the ICD 91h revision22• Table 2 shows the selected 
disease-groups, together with the corresponding I.C.D.-codes and the average 
annual number of deaths in the Netherlands in the perind 1979·1984. 
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A problem exists v.ith regard to ICD 5715, 571.8, and 571.9. These codes are 
assigned to deaths due to cirrhosis or chronic liver disease without any indication of 
a specific cause. As the number of deaths in category 5715 accounts for 20% of the 
total number of deaths in ICD 571, the contn'bution of non~alcoholic deaths to !CD 
571.5, 571.8 and 571.9 should be estimated. After consultation of e:\-perts, applica-
tion of the proportion of non~alcoholic among all specified deaths in ICD 571 
seemed justified (19.6 I (239.7 + 19.6) = 0.08; rounded to 0.10). Nevertheless 
computations were repeated with a supposed non~alcoholic proportion of 0.25. 
Acute hepatic failure were excluded from analysis (see practice-based method). 
The effects of contraindications, upper age limit, referral patterns, quality of life 
and retransplantations are discussed below. 
Contraindications 
The potential impact of contraindications was estimated usi.ng medical data of 
referred, provisionally accepted and definitively accepted patients. Patients rejected 
because of age (mortality data are already age-specific) and those still under 
judgement were excluded from computations of the contraindication factor. 
The disease-specific ratio of definitively accepted patients to refen-ed patients was 
assumed to dcscn"be current selection policies6• The disease-specific ratio of provisi-
onally accepted to refe"ed patients was regarded to be an approximation of the 
effect of relaxed contraindications. 
On average 75% of all referred patients within the age limits are rejected for 
contraindications, with relaxed contraindications this fraction will be about 60% 
(overall suitability 25% and 40% respectively, see Table 3). Notice that these are 
weighted averages: the rejection fractions for carcinoma's are 94% and 81%, for 
biliary atresia 56% and 16% respectively. 
Upper age-limit 
The Dutch protocol provides for an upper age-limit of 60 year. The influence of a 
higher upper age-limit is described by three sets of disease-specific values. They re-
present 1he increa()e of the number of deaths within a specific disease category, 
when 65 or 70 year would be the upper age limit, relative to the total number of 
deaths to 60 year (see Table 3)23• 
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Table 2 Deaths due to "liver diseases amenable to liver transplantation. Upper age limit 60 year. 
Netherlands. 1979-1984. 
Disease category lCD Average Average Male/ %<60 yr 
'od"' annual annual female 
number number ratio 
of of 
deaths deaths 
(abs) U10') 
I Hepatocellular carcinoma 155.0 45.0 3.46 15 28% 
II Cirrhosis ( excl PBC) 571.4 13.6 1.05 0.9 37% 
Ill Primary biliary cirrhosis 571.6 6.0 0.46 02 23% 
IV Unspecified chronic liver 
disease 5715 571.9 645 0.50 2.0 24% 
571.8 
v Biliary atresia 751.6 11.4 0.88 0.6 100% 
VI Primary sclerosing cholangitis 576.1 2.8 022 1.8 7% 
VII Metabolic diseases 210.2 m.1 113 0.87 15 71% 
271.0 277.4 
275.0 277.6 
275.1 
VIII Other diseases 228.0 453.0 8.0 0.62 0.6 60% 
747.4 
Not included in mortality-based method 
IX Acute hepatic failure 570.0 7.1 055 0.3 44% 
X Alcoholic liver disease 571.0 571.2 ?39.7 18.44 2.6 59% 
571.1 5713 
Referral patterns 
As discussed before, inequalities e,Ost with regard to referral of patients from all 
provinces to the AZG. Accepting the referral pattern of the northern provinces as 
a standard, the referring level of the Netherlands is low. Half (145/274 • 53%) of 
the expected patients is referred. Future improvement to 100% may be expected. 
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Table 3 Disea~pecifie adjustment factors to acrount for rontraindications, qoali«y-of-lire consi-
derations, age limit and retransplantation rate. 
Disease category* I n m IV v VI vn vm 
HCC OR PBC UNSP BA PSC MIB OTHER 
Referral 
minimum level 053 053 053 053 053 053 053 053 
maximum level 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
No Contraindications j Suitability 
minimum level .. 0.06 0.41 0.60 0.41 0.44 0.40 0.26 0.26 
maximum level*'"* 0.19 0.49 050 0.49 0.84 050 039 039 
Quality-of-life 
minimum level 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
maximum level 1.00 1.10 !.10 !.10 1.00 1.00 1.10 1.10 
Age-limit 
60 year 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
65 year 156 1.33 156 1.40 1.00 1.82 1.10 132 
70 year 2.16 1.70 2.36 1.95 1.00 2.82 1.24 159 
Retransplantation 
minimum level Lll 1.11 1.11 1.11 1.11 1.11 1.11 1.11 
maximum level 1.15 1.15 1.15 1.15 1.15 1.15 1.15 1.15 
categories cf. Table 3 
weighted average (all diagnoses): 0.25 
weighted average (all diagnoses): 0.40 
Quality-of-life 
Analysis of the medical records of the transplanted patients revealed that occa-
sionally improvement of the quality-of-life was the predominant reason for trans-
plantation (intractable pruritus, intractable osteodystrophia?. Though it may be 
argued that the presence of such complaints is strongly related to a poor prognosis, 
we assume that patients who were primarily transplanted for quality-of-life reasons 
are not represented by disease specific deaths in mortality statistics. Therefore we 
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assumed an independent disease-specific multiplication factor to account for 
patients accepted primarily for quality-of-life reasons. Two sets of values were 
chosen, one reflecting no and one reflecting modest impact of this aspect (see 
Table 3). 
Retransplantation 
Fmally two retransplantation rates were chosen, 11% and 15% respectively (see 
practice-based method). 
Figure 3 Mortality-based need for liver transplantation in the Netherlands. 15% 
retransplantations, quality-of-life transplantations included, 100% refer-
ral, no acute hepatic failure. 
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Final result 
Combination of different levels of the adjustment factors allows for the presenta-
tion of many future scenario's of the total need for liver transplantation. In figure 3 
the effects of age-limit and suitability (i.e. the effect of contraindications) are 
shown. The remaining adjustment factors all are assumed to have their maximum 
value. Choosing a lower level of these ftxed adjustment factors will result in propor-
tional lowering of the estimates. Note that acute hepatic failure was excluded. 
3.3 Incidence-based method 
Below a description of the results of is given of each diagnosis group separately 
follo\Vi.ng the disease classification of Table 2. Results are summarized in Table 4. 
Hepato ceUular carcinoma (HCC) 
Only few reports exist with regard to the prevalence and incidence of this disease. Because the 
duration of illness is short and case-fatality rate is almost 1()0%. different measures of incidence and 
mortality should give comparable results. Vierling reported a yearly incidence of 10 to 70 per 106 
males in an American standard population and half of this number for females16. 
Projection on the Dutch population results in 100 to 700 eases.. The total number of ::sdmissions in 
1982 in the Netherlands was 314. Mortality statistics revealed 162 deaths of whom 70 aged younger 
than 60. Suitability ;~mong HCC-patients may be derived from a study of 600 consecutive patients with 
HCC 24. Only 98 could be regarded suitable for curative opemtion; 69 patients (12%) were in good 
clinical condition. This may serve as the upper level of the proportion of HCC-patients who might 
benefit from liver transplantation. Patients without apparent spread of disease often show recurrence 
of disease after curative treatment (either resection or transplantation) so a minimum level of about a 
third of 12% seems justified25. The AZG-experience shows a comparable low level of about 5% suita-
bility (see Table 3). 
Assuming 4 to 12% of the Vierling-projection suitable for liver transplantation results in an annual 
number of 4 to 85 patients. Starting with national mortality due to HCC of persons younger than 60 
years results in a normative need of about 3 to 10 patients, which seems the most likely estimate. 
Thus an essentially mortality-based normative need resulted between 0.23 and 0.77 per 106 inha-
bitants. 
Non-alcoholic cirrhosis (NAC) 
This diagnosis category contains types of chronic cirrhosis of quite heterogeneous etiology. Most 
information is available about viral hepatitis which predominantly deals with the distribution of 
seroconversion due to viral hepatitis.. The prevalence of hepatitis B carrier state. which is strongly 
related to the occurence of chronic cirrhosis, is supposed to be lesser than 1000 per 106 inhabitants of 
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the Western population26. However this information is of little help without a quantitative relation 
between serological evidence and clinical m~nifestations of the disease. Also little is known about pre-
valence and incidence of chronic cirrhosis of other etiology.Only Vierling provides for an estimate of 
the prevalence of all types of NAC (PBC excludedi6. Based on unknown sources a total nllmber of 
1800 - 9000 patients (all ages) per million inhabitants was projected for the United States. No infor-
mation about the distnOution of etiology and clinical stage of the disease was included. 
Projection of this prevalence on the Dutch population results in abot~t 23.000 to 117.000 patients. The 
SIG reported 675 {10% of the unspecified cirrhosis included) to m (25% of the unspecified cirrhosis 
included) hospital admissions of NAC in 1982 (all ages). We conclude that the American figures. if 
valid, do not seem realistic for the Dutch case. Dutch hospital data also do not yield a valid estimate 
because little is known about the re-admission rate and the severity of disease at admission. 
Primary biliary cinhosis (PBC) 
We could dispose on twO studies from the United Kingdom for an estimation of the frequency of 
PBC. Prevalence ranged from 40 to 54 per 106 inhabitants, incidence from 5.8 to 10.4 per 106 
inhabitant?.28. The projected prevalence in. the Netherlands is about 500 to 700 patients. In 1982 182 
admissions were counted for this disease. As the prognosis of asymptomatic patients does not differ 
from healthy controls, knowledge about the distnbution of disease states is mandatory for a valid 
estimation of the nonnative need for liver transplantation among PBC·patients29. Therefore the 
incidence·based method does not yield a valid estimate for primary biliary cirrhosis. 
Biliary atresia (BA) 
Vierling reported that biliary atresia occurred in about 0.6 to 1.0 of lOS living newborns 16. Epidemio--
logic investigation of congenital diseases in the United Kingdom yielded an incidence of BA of about 
0.8 per ICf living newborn?'. Finally Houwen conc\\lded form various epidemiological sources the 
incidence of BA in the Netherlands to be between the range of 0.4 to 0.7 per 1oS living newbom~1. 
The proportion of S\litable candidates among patients "With this congenital disorder is uncertain. 
AlthO\Igh primary liver transplantation may be a therapeutic option of the future, we assumed a maxi· 
mum of 50% of newborns "With BA to be a suitable candidate for liver transplantation. 
About 175.000 living newborns are born in the Netherlands each year, 8 to 12 of whom have BA. 
Eight deaths "With BA aged younger than 5 years were registered in 1982. This supports the above· 
mentioned epidemiological data, provided that casc·fatality was high before 1982. when children were 
not yet included in the liver transplantation·programme. 
We conclude a nonnative need for liver transplantation after BAjKasai of 4 to 6 each year, 
corresponding to 0.31 • 0.46 per 106 persons of a population "With comparable reproduction rate. 
Primary sclerosing cholangitis (PSC) 
No reliable epidemiological data are available for this relatively new diagnostic entit/2. The devel· 
opment of endoscopic techniques is responsible for the recent rapid increase of patients discovered. 
Although PSC is associated with chronic innammatory digestive disease (about 60%) no quantitative 
data are available of the proportion of "With chronic innammatory digestive disease with PSC'3. 
Hospital--data showed 379 admissions with ICD<ode 576.1. In 24 cases, 1 patient younger than 60 
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year. admission was followed by death due to the disease. National mortality statistics revealed on 
average 3 patients younger than 60 year dying in this disease category. 
Because these results date from the time before wide-spread use of endoscopic devices we conclude 
that no incidence--based estimates for PSC are available, although AZG-cxperience suggests PSC is of 
minor importance (less than 0.10 per 106 inhabitants per year). 
Metabolic diseases 
A large number of different metabolic diseases affect the liver. Some of them have their primary 
locus within in the liver. liver transplantation is a therapeutic option in a considerablo;:: number of rare 
metabolic diseases but as a rule no population-based estimations are available on ·the frequency of 
their occurencc. 
Alfa-1-antit:rypsin-deficiency (alfa-1-ATD) forms an exception, as population-based data are available 
from different sources. Genetically defined alfa-1-ATD occurs in 20 to 60 cases per 1if living new-
borns. Only 5 to 10% have clinical manifestations (cholestatic disease) and only 1 to 2% may benefit 
from liver transplantation (02 to 12 cases per 10S living newborns)34. 
Dick reported a comparable clinical incidence of alfa-1-AID of OS cases per loS living newborn.s30. 
Projection on the annual Dutch birth cohort results in a nonnative need of 0 to 2 cases each year, 
corresponding to 0.03 - 0.08 per 106 persons of a population with comparable reproduction rate. 
Compared to alfa-1-ATD other metabolic diseases are of neglegible quantitave importance. 
Acute hepalt.'c failure (AHF) 
The clinical course of acute hepatic failure is short, usually resulting in either death or full recovery. 
Although AHF was excluded as an indication for liver transplantation during the period we inves-
tigated (1978-1987). recent developments show a considerable improvement of results, with subsequent 
incorporation of AHF into the AZG-protocol18.19. 
Two problems deserve special attention. Fim, no consensus exist with regard to the optimal 
therapeutic strategy, because of the prior unpredictability of those who will survive. Donor-availability 
is a second uncertainty in the decision-process. An agressive strategy certainly leads to treatment of 
patients, who otherwise would have been recovered. Expectant strategies lead to treatment of 
subacute hepatic failure only. with considerable loss of patients with an ovetwhelming course of their 
disease. Although it has been argued that auxiliary partial liver transplantation would be the surgical 
technique of choice. as a temporary support for those patients who recover, this outcome has not 
been observed yet. Most authors seem to agree on limited application of liver transplantation for 
AHF, for those who are ·healthy enough to survive diagnostic check-up and donor-procurement and 
sick enough to be sure of a substantial probability of dying•. 
Epidemiological infonnation on AHF is scarce. The number of 8.5 cases each year per 106 inhabitants 
of Vierling descend from an oral communication of Mosley and includes AHF of all causes (e.g. 
exacerbations of chronic infectious hepatitis) and all age?. Comparison of this estimate with the 
actual admission rate in 1982 (117) gives similar results. Almost 20% died after admission, half of 
them being younger than 60 year. As the question remains which part of all admissions should be 
transplanted to prevent the major part of these deaths and which part of projected transplantations 
actually will be executed, the incidence-based method can not be used. 
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Table 4 Incidence-based estimation or the annual need for liver transplantation in the NefherJands. 
No retransplantation. 
Disease categocy 
v 
VI 
vn 
Hepatocellular carcinoma 
Biliary atresia 
Primary sclerosing cholangitis 
Metabolic diseases (alfa-1-AID) 
4 Discussion 
Netherlands per 106 inhabitants 
3- 10 
4- 6 
0- 1 
0- 2 
0.23- 0.77 
0.31 - 0.46 
0.00- 0.08 
O.Q3- 0.16 
We applied three methods to determine the need for liver transplantation. For 
those disease categories, where comparison was feasible we arrived at similar re-
sults (see Table 5). Given current selection criteria and 15% rctransplantations, the 
annual normative need in the Netherlands ranges from about 25 to 70, correspon-
ding to 2 to 5 per 106 persons. 
Table 5 Annual number of expected transplants in the Netherlands for three 
diagnosis groups, 15% retransplantations included (number per 106 
inhabitants between parentheses). Three methods. 
Disease category Practice- Monality- Incidence-
bo>ed bo>ed baud 
Non-alcoholic cirrhosis and PBC 15-37 14 - 17 NA 
(II. IlL IV) (1.15 - 2.85) (1.08- 131) 
Acute hepatic failure 2- 11 NA NA 
(IX) (0.15 - 0.84) 
Other diseases 8- 19 16-32 7- 19" 
(!. v. VI. vn. VIIl) (0.62 - 1.40) (1.23 - 2.46) (0.54 - 1.40) 
* Disease category VIII assumed to be of neglegiblc importance. 
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Though results are roughly similar, this type of analysis may suffer from sources of 
uncorrectable bias and uncertainties. with regard to future development. Historical 
data may not account for future trends of the epidemiology of diseases (from the 
period 1978 - 1984). E.g. the incidence of hepatitis-B related chronic cirrhosis may 
be expected to fall due to the prevention of AIDS. For the larger part of the 
disease categories no short term change in incidence may be expected. 
Three sources of uncertainty are related to changing inclusion and exclusion 
criteria. Increased effectivity of conventional therapy or the introduction of new 
therapeutic approaches may decrease the need for liver transplantation. Examples 
are various drug regimes for hepatitis-B, prostaglandines for acute hepatic failure, 
ursodeoxycholic acid for the treatment of PBC and PSC"'.J7. Application of liver cell 
transplantation may not be expected in the next future and will probably only affect 
the need for some minor diagnostic categories (metabolic diseases). At the other 
side improved results of liver transplantation in acute hepatic failure and formerly 
too ill regarded patients will increase the need for liver transplantation. For short 
term forecasts these are neglible compared to the impact of changing the age limits 
or indicationa (alcohic cirrhosis), sec Table 2 and 3. 
In addition to these general remarks some method-specific questions remain. 
Though the practice-based method accounts for regional differences of referral 
practices, it assumes complete referral in the northern provinces. This assumption 
seems valid as the AZG is the only hepatological centre in the northern and 
adjacent provinces, with traditionally complete adherence of patients. 
Questions may remain with regard to the validity of the use of mortality data with 
an upper age limit of 60 year (mainly for non-alcoholic and primary biliary 
cirrhosis). Their use assumes a neglcgiblc time interval between supposed applica~ 
tion of the medical procedure and death due to the specific disease. The value of 
the 65-year adjustment factor for non-alcoholic and primary biliary cirrhosis may be 
used as an indicator for the magnitude of bias when transplantation would take 
place on average 5 year before death. After intrapolation a time lag of 1 year 
turned out to result in an underestimation of need for non-alcoholic and primary 
biliary cirrhosis of 5% to 10%. Coding errors are another source of uncertainty. If 
25% instead of 10% of unspecified cirrhosis is supposed to be non~alcoholic, 
normative-need raises about 15%; 0% leads to a decrease of 11%. 
Provided that gross alteration of inclusion criteria does not occur, our 
estimations seem valid enough to support governmental decisions for the next few 
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years. The number of liver transplantation, which actually will be performed de-
pends on the availability of resources. Lack of donor organs generally (children 
excluded) may not be expected in the next few years38• In absence of financial con-
straints only one liver transplantation centre with a capacity of 50 transplantations 
annually will suffice in the Netherlands in the near future. Our study showed the 
existence of considerable regional differences in referral pattern.. Patient's negative 
attitude towards high technology medicine, relative unawareness of the current 
effectivity of liver transplantation and unwillingness of specialists to refer patients 
to another hospital contributed to this undesirable state of affairs. Governmental 
strategies for optimizing application of liver transplantation should pay attention to 
this problem. 
Lastly, the application of our results in other countries is of interest. Though 
various transplant centres have published expectations of the need for liver 
transplantation, only O'Grady published an empirical estimation for chronic liver 
diseases and acute hepatic failure, using British mortality data2S. Obviously some 
minor disease-categories were excluded. About 30% of those who died from 
chronic liver disease were thought to be suitable for liver transplantation (1000 out 
of 2937), which is close to our estimates. However, O'Grady's ultimate nonnative 
need ranges from 4 to 20 per 106 persons, which far exceeds our estimates. Ap-
parently different inclusion criteria are responsible for this discrepancy. O'Grady 
included all deaths due to cirrhosis regardless of age and diagnosis. Only about 
15% of them meet both our age criterion (age below 60) and diagnosis criterion 
(no alcoholic cirrhosis), which explains the magnitude of the difference. 
Though evidence is limited, we believe our results are internationaliy applicable for 
disease categories without knov.rn causal origin. Alcoholic cirrhosis, hepatocellular 
carcinoma and viral hepatitis with its chronic sequelae show large international dif-
ferences n. 14" JS •• For most countries our estimates will be a serious underestimation 
when these disease-categories are included. 
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Whilst politicians are still arguing over the selection criteria for heart transplanta-
tion and while they are postponing a policy decision on liver transplantation until at 
least 1992, at the same time being trapped in the license policy concerning in vitro 
fertilization, the investigators look back in this article at the three evaluation 
studies, that the same politicians wanted to have performed for these decisions1.2.3. 
The reason for this retrospective is not a finished decision process, although the 
availability of the outcome of the study in 1988 would have implied a firm decision. 
The direct cause is the appearance of a report in January 1990, written by Van 
Rossum under the authority of the National Health Insurance Board4• In this re-
port the value of these three studies - usually indicated by Medical Technology 
Assessments - has been investigated from the client's point of view. This article 
describes the view of the institute for Medical Technology Assessment (iMT A) on 
this topic. The paper is structured by six questions pertinent to the issue: What are 
the criteria one should apply at an evaluation of evaluations? What has been the 
relevance of the evaluations at the political level? Have the studies produced new 
insights? What is the spin-off of the studies? Is a cheaper option available? Are 
there alternatives anyway? 
1. Criteria 
The selection of the criteria to judge the value of the evaluation studies is, obvious-
ly, crucial. The value of the studies as perceived by their users has been selected as 
the primary criterion in the report-Van Rossum. This value was determined by 
interviewing the relevant decision-makers in the summer of 1989, asking them to 
adress the following question: what was, according to your experience, the role of 
the evaluation studies in the advising and provisional decision-making on the 
inclusion of the evaluated interventions in the insurance package? It may be argued 
that the actual or the pretended utilization of information by health politicians 
depends on more than on the quality of information. Therefore we think a second 
criterion has to be app1icd if we evaluate these evaluations, vi7_ the question if the 
information, which was asked for by the clients, has really become available. That 
question to the value of infonnation hardly comes up in the previously mentioned 
report. However, an essential condition for rational policy choices is the availability 
of objective and reliable information. 
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Whether such information will actually be used depends ultimately on the rational-
ity of this process of choice itself. 
Thus, a specific definition of what valuable information from a medical technology 
assessment consists of, is necessary. In our opinion, this definition includes a.o. that 
information should be non-distorted, reliable, unweighted, comprehensive and 
ready available at the time it is needed. This listing looks trivial, but we will 
illustrate that the search for suitable information as defmed above (criterion 2) and 
the promotion of the utilization of these studies in health policy decisions (criterion 
1) may be at conflict. 
The report-Van Rossum makes some recommendations for promoting utilization 
(criterion 1): the involvement of the health policy makers in the initiation, design 
and execution of an MTA-investigation should be even greater than it already v.ras 
in the three MTA-studies mentioned above; a small distance between policy maker 
and investigators should be the aim. In the extreme case that would imply that the 
research team functions within the policy body. These recommendations of Van 
Rossum follow from the dominant position of the user in his definition of the value 
of information: this value was operationalized as the actual utili7..ation as perceived 
by those who instituted the MTA. To fulfil the demands of good information 
(criterion 2) some other conditions has to be satisfied. Three of them are: 
1. the assignment of an independent role to the investigator in designing the study; 
2. the opportunity to collect primary data, if secondary sources appears to be 
insufficient; 
3. the execution of the study within an universitary setting, which implies political 
independence of the research team. 
Ad 1. The separate responsibility of MTA-investigators with regard to the defini-
tion of study objectives and study design should be acknowledged. This responsibil-
ity turns into a major role on some occasions. Two examples are given. 
In the transplantation studies we remember lengthy discussions about the 
necessity of estimating survival -without transplantation and the necessity of 
estimating the quality of life changes. 
In a cost-effectiveness analysis of a new cholesterol lowering drug under 
authorization of a pharmaceutical industry, some time had to be spent discussing 
the fact whether or not to include certain (standard) costs and effects in the 
analysis. 
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Ad 2. Another two examples illustrate problems with respect to the second 
condition. 
The relation between the research team at the IVF study and the secretariat of 
the NHIB initially provoked problems with regard to the data collection: at the 
start of the IVF study few observations were known on male subfertility. This was a 
registration-artifact due to the fact that this indication was not qualified by the 
NHIB for subsidy of the participating IVF centres. 
Data collection for cost registration in all studies was influenced demonstrably 
by the presumed application of cost results at tariff negotiations. 
Ad 3. The scientific independency of the MTA team could be endangered if policy 
goals guide the investigations too much. Independency is necessary, be the client a 
governmental agency, or a pharmaceutical company. Consequently, free publication 
by the MTA-team is a key instrument to establish their independence. If this 
freedom leads to impassable objections from the side of the client or the investi-
gated patients, the study may be withdraVID.. 
In the case of the Dutch MTA's the investigators think aU the abovementioned 
conditions were satisfied, hence there is no reason to recommend, like Van 
Rossum, a shift in responsibilities between MTA-investigators and policy body to 
attain another balance between conditions for good research and conditions for the 
utilization of results. 
We agree with the report-Van Rossum that in some cases the actual use of 
information by health policy makers has been to some extent insufficient. We might 
think of their rather slow reaction and of the occasional presence of a non-decision 
policy. Three examples may illustrate the judgment. 
The large inter-hospital variation of in vitro fertilization results was an excellent 
pretext for the license policy of Article 18 of the Hospital Provisions Act; despite 
this variation, health policy failed to device a rational regulation, as been memoriz-
ed recently by Rigter'. 
In heart transplantation age limits are currently employed, which certainly do 
not back up the results of our MT A. 
Fmally, liver transplantation is still not regularly compensated to children with 
biliary atresia, although the results of liver transplantation indicate transplantation 
to be the optimal option available. Paradoxically, no continued research was 
considered essential for the decision making on transplantation in these children 
(contrarily to the adults). 
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2. Policy relevance 
Have the evaluations been used for policy-making? This question is thoroughly 
answered in the report-Van Rossum. The results appear to be applied rather 
quickly and e).tensively by both the National Health Insurance Board and the 
Health Council 
In our experience, the health politicians sometimes disliked the obvious lack of 
pre-arranged decisions in our reports. Van Rossum also considers this to be a 
disadvantage; he speaks of 'solely indirect use' from the advisory boards and the 
health care authorities. However, in our opinion this 'disadvantage' is the result of 
an intentional separation of responsibilities. Following this intention, the apparent 
absence of other information (for example on ethical aspects) is no real in-
adequacy, because the client explicitly provided his need for that information in 
another way. This deliberate efficiency of information generation succeeded as can 
be illustrated in the case of heart transplantation. 
In the medical technology assessment of heart transplantation the socalled sce-
nario analysis clearly showed that for optimal utilization of all donor hearts offered 
a large waiting list would be profitable. However, the price for this optimal 
utilization is a considerable number of patients dying on the waiting list - not quite 
equivalent with the situation that the same patients dy unaware of being a cand.i-
date for transplantation - and a grinding selection issue. The ethical aspects of such 
problems indeed were thoroughly discussed by the Health Council. No duplication 
of research efforts happened2-6. 
3. New information 
The question is :relevant whether these studies have contributed new information 
as, in the dinicians perception, they have been conducted by relative outsiders. 
Although the answer is not the single criterion to measure the quality or the 
benefit of the research the answer is important as a justification towards the clinical 
investigators. In our opinion, information is new, if it 1. considerably differs from 
present scientific knowledge, 2. it fills up an information void, 3. it restructures 
present and/or new knowledge. Two dates are important in this respect: the 
starting (summer 1985) and the finishing date of the studies (summer 1988). 
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In general, one may state safely that at the completion of the studies in 1988 details 
of the costs, the effectiveness and the throughput of the programme were unavail-
able elsewhere. The cost~effectivcness analysis, which we presented, and, in the 
case of heart transplantation, the detailed future forecasting (scenario's), offered a 
new structure to the information available. 
If the focus is on clinically knowledge, especially on the effectiveness of transpla."lta-
tion, our experience is interesting. 
In the case of heart transplantation the MTA results didn't differ from a priori 
expectations and from the publications of one of the centres involved. This was 
maybe due to the fact that in all centres one protocol was used and, apparently, 
care of the same high quality was supplied. 
The picture was completely different in the liver transplantation and in the vitro 
fertilization study. The one- and five year survival probabilities after liver transplan-
tation were, according to literature, appro:cimately 80% and 75% in 1985 (in 1988 
even higher), but in the Dutch programme these probabilities appeared to be 
lower, 68% and 58% respectively. Not a bad clinical performance, but inferior 
statistics (uncontrollable 'case-selection, combination of children and adults, and 
other forms of publication bias) explained these differences. The MTA-estimates of 
expected survival without transplantation (all forms of cirrhosis: one year survival 
51%) was to such an extent different from clinical expectations (cirrhosis: at last 
three months survival, one year survival < 10%) that many people doubted the 
validity of the MT A-results. On1y when the two biggest transp]antation centres in 
the world published a similar analysis in the New England Journal of Medicine and 
now that the Dutch analyses has appeared in the Lancet, more people accept the 
MTA-results on effectiveness of liver transplantation7.s. Results on other aspects of 
liver transplantation also showed large discrepancies between scientific sources of 
information and our empirical MTA-rcport. Two examples of discrepancies are 
given, starting with the costs of liver transplantation. The business economics 
department of the Academic Hospital Groningen estimated these costs more than 
twice higher than we later calculated. The costs of liver transplantation i."l the U.S. 
as they have appeared in several reports, arc also much higher, even if we assume 
that one Dutch florin spent at health care in the Netherlands corresponds with one 
US dollar spent at health care in the U.S. Secondly, the need for liver transplanta-
tion in the American literature is estimated at 20-250/106 inhibitors, in the English 
literature at 4-20/106 and in the Netherlands at 2-5/106 inhibitors. 
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Lastly, we shall present some evidence of the in vitro fertilization study. At the start 
of the MTA, success rates of 20% to 30% per in vitro fertilization treatment were 
reported. In vitro fertilization appeared to be clearly superior over tuba surgery. 
The advisory committee on IVF of the NHIB, proposed to accept only those 
hospitals for participation in the MTA only, which could show at least a 10% 
success rate per IVF-procedure. This criterion apparently was generous, consider-
ing the prior information about success rates. Fortunately that criterium was not 
effectuated: in the long run only two out of five participating hospitals did show a 
success rate over 10%, whilst two out of five hospitals were just below and one was 
far below the percentage. At this moment, one of the centres communicates 
through the newspaper that the effectiveness of IVF treatments could at least 
double by application of a new method of hormone stimulation. In our view only 
primary data collection in a controlled way can prove this bold prediction. 
According to the report-Van Rossum the studies were not valid, partly because 
of the fact that no randomi7gd clinical trial was performed. We disagree with this 
global judgment, though some research issues were particu]arly difficult to address 
due to pathological complexities (for example the prediction of survival of patients 
suffering from heart failure) or due to the fact that a research effort was acquired 
that was far beyond this medical technology assessment (for example the determi-
nation of the number of persons in the Netherlands with severe heart failure of 
severe liver dysfunction). 
It has been proved though, that the studies can stand the comparison with cost-
effectiveness studies abroad. This is found to be true according to the resulting 
publications, but also according to the requests transfer of the applied methodology 
to other places in the Netherlands and abroad. 
Nevertheless, we are aware of the fact that further devdopment and, especially, 
standardization of the applied methodology is necessarY. Lack of standardization is 
partly responsible for the above mentioned differences in results. Consensus on a 
uniform protocol for the execution of medical technology assessments is urgently 
needed. Thus the results of various studies will become comparable and they will 
consequently constitute a better point of action for policy-making. 
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4. Spin-off 
The studies clearly produced considerable spin-off. 
Frrst, the impact of the studies for settling the expertise in this area in the 
Netherlands cannot be underestimated. This effect may well be to the credit of the 
Health Insurance Executive Board, the Health Council and the Ministry of Wel-
fare, Public Health and Cultural Affairs. These agencies were at the start of the 
studies and committed themselves to take account of the results in their policy-
making. After the assignments of the MTA to the centres in Rotterdam and Maas-
tricht, these centres acquired a lot of new contracting research, sometimes after 
competition with reputable institutes in the U.K. and the U.S. This development 
has given rise to a national centre for MTA, which is supported by the parties 
which conducted the evaluation studies. Moreover, the MTA-investigators esta-
blished an informal communication network, to which many international MTA-
centres participate. 
A second spin-off effect is the increased knowledge on methods, possibilities and 
limitations of medical technology assessment, and of problems concerning its inter-
pretation. This side effect is visible in both health politicians and the investigators. 
The effect results from their intensive communication. The Dutch policy-maker is 
at the frontier of MT A, at least in Europe. This position contributes to the 
responsible application of MTA research. 
Thirdly, we denominate the increased interest for the methods of cost-effective-
ness analysis, at least by some clinicians. This interest is of significance as the 
simultaneous development of a clinical research programme and its associated 
MTA offers the best opportunity for a cost-effectiveness analysis. Regarding the 
developmental medicine· it is important that clinical investigators are aware of the 
relatively low marginal costs of performing a complete evaluation study instead of 
an effectiveness study only. The future must prove whether the dangers of publica-
tion bias and the heterogeneity of methods for the determination of effects and 
costs will negatively influence the results of developmental medicine studies. 
In the Netherlands the National Health Insurance Board has insituted a fund ('Ontwikkelings-
geneeskunde', tr.: Developmental medicine) to support the new medical technologies at the 
stage they are introduced for clinical use. The application of a grant depends a.o. on the 
inclusion of a fonnal evaluation study in the design. 
Appendix 10 342 
5. Is there a cheaper option? 
From an absolute point of view, the MTA-studies have been rather expensive: the 
costs ranged from Hfl. 1,5 million (IVF) to Hfl. 1,9 million (heart transplantati.on4 ) 
(total costs include the data management of the participating institutes!). It can be 
cheaper on next occasions, of course. The experience with the design and the 
execution of empirical research in this area will lead to a more efficient approach 
in future. For example, the already developed instruments regarding quality of life 
and utility measurement can be applied in new studies. 
'Whether an alternative exists, which is indeed cheaper, depends on the question 
whether primary data collection is required and to which degree information is 
already available in hospitals or outside. 
Sometimes primary data collection is not possible or even unnecessary. 
Data collection is difficult if a new drug still has to be or just has been registered. 
Usually, available time for investigation meaningful primary data collection 
according to scientific standards. A modelling approach, like we adopted for the 
evaluation of the new drug simvastatine is more appropriate in that case. More 
time for evaluation would result if the onus of proof rests with the producer. After 
all, the producer is responsible for the developments at an early stage, when data 
on its security and its effectiveness are collected. 
Secondly, primary data collection is unnecessary if a meta analysis of published 
studies provides enough evidence on the effectiveness of a technology and if the 
estimation of the costs in the Netheriands is possible by adaption of costs figures 
from abroad. However, one must be aware of publication bias and unduly optimism 
in first papers on innovations. Our institute is involved in the meta-analysis of 
several issues. For example the transfer of the Dutch model for heart transplanta-
tion evaluation to the Spanish situation and, at an earlier stage, the application of 
the methods and results the American and the English studies on heart transplanta-
tion in the Netherlands. Sofar the evidence is somewhat equivocal. 
Ample knowledge of and long experience with MTA research appears to be neces-
sary to conclude a 'quick and dirty' medical technology assessment successfully, 
particularly if, unlike the heart transplanation case, predecessors on the topic are 
absent. Particularly the estimation of the global magnitude of effects in absence of 
empirical data is demanding. 
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If primary data collection and subsequent analysis is indeed necessary, one its 
costs should be related to the expenses of the evaluated technology. If we consider 
the expenses of in vitro fertilization over five years, only 1% of the expenses has 
been applied for evaluation. For the liver transplantation study this is approximately 
4%. 
6. Are there alternatives any how? 
Evaluation of new medical technologies may take various forms. In the Netherlands 
the calling in of the Health Council often appears to be the best option available. 
The increasing professionalization of this unique institute and the continuing loyal 
cooperation of medical experts guarantees a useful a..1swcr on many occasions. 
Another form is the institution of a project on developmental medicine, which 
should be the responsibility of the clinical experts themselves. Future will show 
which balance between the information from such research and that of an indepen-
dent technology assessment should be preferred. 
Some people, amongst who Van Rossum, have claimed that a technology assess-
ment should enhance more than data collection only. They suggest that e}..1emal 
steering of medical technologies is feasible by means of the utilization of existing 
information and by the application of societal criteria (constructive TA). Thus, a 
constructive technology assessment not only requires that the technical aspects are 
known at an early stage of the development of a technology, but it also considers 
the social aspects of the introduction of the technology. Three remarks given. 
Developmental medicine could, in some cases, be considered as a constructive 
medical technology assessment, particularly if the obtained insights improve the 
performance of a new technology or the circumstances under which these arc 
performed. We think the relevance of constructive technology assessment depends 
on the type of technology and its developmental stage. 
In general the relevance should not be overestimated. Many medical techno-
logies arc introduced from outside our country, for example new drugs and new 
medical equipments. Constructive MTA is not useful to evaluate these mature 
technologies. Policy-makers, who are confronted with these technologies, have only 
to make a rather simple decision about allowance on the market and subsequent 
coverage by health insurance companies. Therefore, a constructive TA is no 
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alternative for the type of MTA-studies which are finished now. Our previous 
remark applies i.e. the shift of the onus of proving the effectiveness of a product 
from the health care authorities to the producer. This policy change probably will 
influence the development of a product by a producer in a way resembling the 
presumed influence of constructive technology assessment. 
Anyway, constructive technology assessment assumes that the technological 
development by the medical profession may be guided externally, an assumption 
which has been challenged10• 
7. Conclusion 
We conclude with the foliowing remarks. 
Frrst, obviously the report-Van Rossum did not address some important questions. 
Secondly, after re-reading the report, one is left with too much a feeling of the 
infallible excellence of our advisory bodies. More distance from the evaluator to the 
client would possibly have made the report as tempting for him as it was for us. 
Finally, we sincerely hope that the atmosphere of collaboration, which has been 
built up with clinicians in the past, will be continued in the future, be it in the 
context of studies of developmental medicine or, in the context of MTA studies 
initiated by policy-makers on any level in health care. 
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